
<html lang="en"     class="pb-page"  data-request-id="afb622b5-b932-433c-9fba-a3776690ddec"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b01188;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-5"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structure–Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability" /></meta><meta name="dc.Creator" content="Rachel D.  Slack" /></meta><meta name="dc.Creator" content="Therese C.  Ku" /></meta><meta name="dc.Creator" content="Jianjing  Cao" /></meta><meta name="dc.Creator" content="JoLynn B.  Giancola" /></meta><meta name="dc.Creator" content="Alessandro  Bonifazi" /></meta><meta name="dc.Creator" content="Claus J.  Loland" /></meta><meta name="dc.Creator" content="Alexandra  Gadiano" /></meta><meta name="dc.Creator" content="Jenny  Lam" /></meta><meta name="dc.Creator" content="Rana  Rais" /></meta><meta name="dc.Creator" content="Barbara S.  Slusher" /></meta><meta name="dc.Creator" content="Mark  Coggiano" /></meta><meta name="dc.Creator" content="Gianluigi  Tanda" /></meta><meta name="dc.Creator" content="Amy Hauck  Newman" /></meta><meta name="dc.Description" content="Atypical dopamine transporter (DAT) inhibitors have shown therapeutic potential in preclinical models of psychostimulant abuse. In rats, 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)-piperazi..." /></meta><meta name="Description" content="Atypical dopamine transporter (DAT) inhibitors have shown therapeutic potential in preclinical models of psychostimulant abuse. In rats, 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)-piperazi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 29, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01188" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01188" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01188" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01188" /></link>
        
    
    

<title>Structure–Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01188" /></meta><meta property="og:title" content="Structure–Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0012.jpeg" /></meta><meta property="og:description" content="Atypical dopamine transporter (DAT) inhibitors have shown therapeutic potential in preclinical models of psychostimulant abuse. In rats, 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)-piperazin-1-yl)-propan-2-ol (3b) was effective in reducing the reinforcing effects of both cocaine and methamphetamine but did not exhibit psychostimulant behaviors itself. While further development of 3b is ongoing, diastereomeric separation, as well as improvements in potency and pharmacokinetics were desirable for discovering pipeline drug candidates. Thus, a series of bis(4-fluorophenyl)methyl)sulfinyl)alkyl alicyclic amines, where the piperazine-2-propanol scaffold was modified, were designed, synthesized, and evaluated for binding affinities at DAT, as well as the serotonin transporter and σ1 receptors. Within the series, 14a showed improved DAT affinity (Ki = 23 nM) over 3b (Ki = 230 nM), moderate metabolic stability in human liver microsomes, and a hERG/DAT affinity ratio = 28. While 14a increased locomotor activity relative to vehicle, it was significantly lower than activity produced by cocaine. These results support further investigation of 14a as a potential treatment for psychostimulant use disorders." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01188"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01188">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01188&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01188&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01188&amp;href=/doi/10.1021/acs.jmedchem.9b01188" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2343-2357</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01130" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01136" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure–Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Rachel D. Slack</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rachel D. Slack</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rachel+D.++Slack">Rachel D. Slack</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Therese C. Ku</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Therese C. Ku</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Therese+C.++Ku">Therese C. Ku</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8353-4985" title="Orcid link">http://orcid.org/0000-0002-8353-4985</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianjing Cao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianjing Cao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianjing++Cao">Jianjing Cao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">JoLynn B. Giancola</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">JoLynn B. Giancola</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=JoLynn+B.++Giancola">JoLynn B. Giancola</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alessandro Bonifazi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alessandro Bonifazi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alessandro++Bonifazi">Alessandro Bonifazi</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7306-0114" title="Orcid link">http://orcid.org/0000-0002-7306-0114</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Claus J. Loland</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claus J. Loland</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claus+J.++Loland">Claus J. Loland</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexandra Gadiano</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexandra Gadiano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div><div class="loa-info-affiliations-info">Department of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, Maryland 21205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexandra++Gadiano">Alexandra Gadiano</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jenny Lam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jenny Lam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div><div class="loa-info-affiliations-info">Department of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, Maryland 21205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jenny++Lam">Jenny Lam</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rana Rais</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rana Rais</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, Maryland 21205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rana++Rais">Rana Rais</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4059-2453" title="Orcid link">http://orcid.org/0000-0003-4059-2453</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Barbara S. Slusher</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Barbara S. Slusher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, Maryland 21205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Barbara+S.++Slusher">Barbara S. Slusher</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9814-4157" title="Orcid link">http://orcid.org/0000-0001-9814-4157</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark Coggiano</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Coggiano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Coggiano">Mark Coggiano</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gianluigi Tanda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gianluigi Tanda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gianluigi++Tanda">Gianluigi Tanda</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Amy Hauck Newman</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amy Hauck Newman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#23424d46544e424d634a4d5751420d4d4a47420d4d4a4b0d444c55"><span class="__cf_email__" data-cfemail="c0a1aea5b7ada1ae80a9aeb4b2a1eeaea9a4a1eeaea9a8eea7afb6">[email protected]</span></a>. Phone: (443) 740-2887. Fax: (443) 740-2111.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amy+Hauck++Newman">Amy Hauck Newman</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9065-4072" title="Orcid link">http://orcid.org/0000-0001-9065-4072</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01188&amp;href=/doi/10.1021%2Facs.jmedchem.9b01188" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2343–2357</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 29, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 July 2019</li><li><span class="item_label"><b>Published</b> online</span>29 October 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 March 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01188" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01188</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2343%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRachel%2BD.%2BSlack%252C%2BTherese%2BC.%2BKu%252C%2BJianjing%2BCao%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D5%26contentID%3Dacs.jmedchem.9b01188%26title%3DStructure%25E2%2580%2593Activity%2BRelationships%2Bfor%2Ba%2BSeries%2Bof%2B%2528Bis%25284-fluorophenyl%2529methyl%2529sulfinyl%2BAlkyl%2BAlicyclic%2BAmines%2Bat%2Bthe%2BDopamine%2BTransporter%253A%2BFunctionalizing%2Bthe%2BTerminal%2BNitrogen%2BAffects%2BAffinity%252C%2BSelectivity%252C%2Band%2BMetabolic%2BStability%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2357%26publicationDate%3DMarch%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01188"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">919</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01188" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure–Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Rachel&quot;,&quot;last_name&quot;:&quot;D. Slack&quot;},{&quot;first_name&quot;:&quot;Therese&quot;,&quot;last_name&quot;:&quot;C. Ku&quot;},{&quot;first_name&quot;:&quot;Jianjing&quot;,&quot;last_name&quot;:&quot;Cao&quot;},{&quot;first_name&quot;:&quot;JoLynn&quot;,&quot;last_name&quot;:&quot;B. Giancola&quot;},{&quot;first_name&quot;:&quot;Alessandro&quot;,&quot;last_name&quot;:&quot;Bonifazi&quot;},{&quot;first_name&quot;:&quot;Claus&quot;,&quot;last_name&quot;:&quot;J. Loland&quot;},{&quot;first_name&quot;:&quot;Alexandra&quot;,&quot;last_name&quot;:&quot;Gadiano&quot;},{&quot;first_name&quot;:&quot;Jenny&quot;,&quot;last_name&quot;:&quot;Lam&quot;},{&quot;first_name&quot;:&quot;Rana&quot;,&quot;last_name&quot;:&quot;Rais&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;S. Slusher&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Coggiano&quot;},{&quot;first_name&quot;:&quot;Gianluigi&quot;,&quot;last_name&quot;:&quot;Tanda&quot;},{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;Hauck Newman&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;2343-2357&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01188&quot;},&quot;abstract&quot;:&quot;Atypical dopamine transporter (DAT) inhibitors have shown therapeutic potential in preclinical models of psychostimulant abuse. In rats, 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)-piperazin-1-yl)-propan-2-ol (3b) was effective in reducing the reinforcing effects of both cocaine and methamphetamine but did not exhibit psychostimulant behaviors itself. While further development of 3b is ongoing, diastereomeric separation, as well as improvements in potency and pharmacokinetics were desirable for discovering pipeline drug candidates. Thus, a series of bis(4-fluorophenyl)methyl)sulfinyl)alkyl alicyclic amines, where the piperazine-2-propanol scaffold was modified, were designed, synthesized, and evaluated for binding affinities at DAT, as well as the serotonin transporter and σ1 receptors. Within the series, 14a showed improved DAT affinity (Ki = 23 nM) over 3b (Ki = 230 nM), moderate metabolic stability in human liver microsomes, and a hERG/DAT affinity ratio = 28. While 14a increased locomotor activity&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01188&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01188" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01188&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01188" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01188&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01188" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01188&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01188&amp;href=/doi/10.1021/acs.jmedchem.9b01188" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01188" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01188" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01188%26sid%3Dliteratum%253Aachs%26pmid%3D31661268%26genre%3Darticle%26aulast%3DSlack%26date%3D2020%26atitle%3DStructure%25E2%2580%2593Activity%2BRelationships%2Bfor%2Ba%2BSeries%2Bof%2B%2528Bis%25284-fluorophenyl%2529methyl%2529sulfinyl%2BAlkyl%2BAlicyclic%2BAmines%2Bat%2Bthe%2BDopamine%2BTransporter%253A%2BFunctionalizing%2Bthe%2BTerminal%2BNitrogen%2BAffects%2BAffinity%252C%2BSelectivity%252C%2Band%2BMetabolic%2BStability%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D5%26spage%3D2343%26epage%3D2357%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291650" title="Alcohols">Alcohols</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/jmcmar.2020.63.issue-5/20200312/jmcmar.2020.63.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Atypical dopamine transporter (DAT) inhibitors have shown therapeutic potential in preclinical models of psychostimulant abuse. In rats, 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)-piperazin-1-yl)-propan-2-ol (<b>3b</b>) was effective in reducing the reinforcing effects of both cocaine and methamphetamine but did not exhibit psychostimulant behaviors itself. While further development of <b>3b</b> is ongoing, diastereomeric separation, as well as improvements in potency and pharmacokinetics were desirable for discovering pipeline drug candidates. Thus, a series of bis(4-fluorophenyl)methyl)sulfinyl)alkyl alicyclic amines, where the piperazine-2-propanol scaffold was modified, were designed, synthesized, and evaluated for binding affinities at DAT, as well as the serotonin transporter and σ<sub>1</sub> receptors. Within the series, <b>14a</b> showed improved DAT affinity (<i>K</i><sub>i</sub> = 23 nM) over <b>3b</b> (<i>K</i><sub>i</sub> = 230 nM), moderate metabolic stability in human liver microsomes, and a hERG/DAT affinity ratio = 28. While <b>14a</b> increased locomotor activity relative to vehicle, it was significantly lower than activity produced by cocaine. These results support further investigation of <b>14a</b> as a potential treatment for psychostimulant use disorders.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/5"><issue-title>Women in Medicinal Chemistry</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71308" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71308" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Deaths related to drug overdose within the United States are rising rapidly, with less than 17,000 deaths in 1999, and reaching 70,237 deaths in 2017.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Despite warnings by the Drug Enforcement Agency (DEA) of a national rebound in cocaine initiates and cocaine poisoning deaths, it has now become the third highest-killing illicit substance, behind synthetic opioids, such as fentanyl and heroin.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Regrettably, pharmacotherapeutic treatments for those addicted to psychostimulants, like cocaine and methamphetamine, have yet to be approved by the FDA, and thus, psychostimulant use disorders are currently treated exclusively with behavioral therapies.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> An overwhelming need for the development of a medication-assisted treatment (MAT) for psychostimulant use disorders has been exemplified by the superior outcomes in MAT programs for opioid users versus solely behaviorally based treatments.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4−7)</a></div><div class="NLM_p">Cocaine binds to the dopamine transporter (DAT), blocking the reuptake of dopamine (DA), enhancing dopaminergic neurotransmission, and resulting in feelings of euphoria and reward that can lead to abuse.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11 ref12 ref13">(8−13)</a> Drug development efforts to design a small molecule that competitively blocks cocaine at DAT, while possessing low abuse potential, have led to once promising compounds like JHW007<a onclick="showRef(event, 'ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17">(14−17)</a> and GBR12909 (vanoxerine).<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a> Owing to its favorable results in animal models of cocaine use disorders, GBR12909 was advanced into Phase I clinical trials before failing, due to rate-dependent QTc elongation in healthy subjects.<a onclick="showRef(event, 'ref18 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref18 ref21 ref22 ref23">(18,21−23)</a></div><div class="NLM_p">Modafinil (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and its (<i>R</i>)-enantiomer are FDA approved as prescription medications to promote wakefulness in those suffering from narcolepsy, shift work sleep disorder, and obstructive sleep apnea.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> Modafinil is a DA uptake blocker but does not exhibit cocaine-like abuse potential in animal models.<a onclick="showRef(event, 'ref25 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref27">(25,27)</a> Similar to treatment of attention deficit hyperactivity disorder (ADHD) using DAT ligands (amphetamine and methylphenidate), <b>1</b> is used off-label as a cognitive enhancer but exhibits limited addiction liability in humans.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Results of studies investigating <b>1</b> as a treatment for psychostimulant use disorders in humans have shown mixed results. When cocaine-dependent subjects were treated with <b>1</b> coupled to cognitive behavioral therapy vs placebo, a reduction in cocaine use was observed, as measured by cocaine-negative urine samples; however, in a larger study, there were no significant differences between <b>1</b> and placebo.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> More recently, a large clinical trial in cocaine-dependent subjects showed no significant difference between <b>1</b> and placebo; however, a subpopulation of nonalcohol abusing cocaine-dependent subjects exhibited an increase in cocaine-free days and an overall reduction in cocaine cravings when treated with <b>1</b>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> For these reasons, our group has focused on chemically modifying modafinil in the search for a safe and more effective pharmacotherapy for the treatment of psychostimulant use disorders.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> Of note, others have also expanded on DAT SAR with thiazole analogues of modafinil and are investigating them in rodent models of memory enhancement.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of atypical DAT inhibitors (±)-modafinil and recently discovered analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Two compounds resulting from our efforts, <b>2b</b> and <b>3b</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), were found to bind with higher affinity both at rat and human DAT (rDAT and hDAT, respectively) compared to <b>1</b>.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Binding assays with a Y156F mutant of hDAT confirmed that both compounds bind DAT differently than cocaine, showing a binding profile more similar to JHW007.<a onclick="showRef(event, 'ref27 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref27 ref35 ref36 ref37">(27,35−37)</a> Curiously, in rodent models, <b>2b</b> displayed a cocaine-like behavioral profile, whereas <b>3b</b> did not.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In addition, pretreating rodents with <b>3b</b> decreased self-administration of cocaine and reduced cocaine-induced reinstatement to drug seeking behaviors.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> Based on these findings,<a onclick="showRef(event, 'ref27 ref31 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref27 ref31 ref39 ref40">(27,31,39,40)</a><b>2b</b> and <b>3b</b> were characterized for their binding modes in the central ligand binding site of hDAT using molecular dynamics (MD) simulations<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Interestingly, DAT preferred an outward open conformation in the presence of <b>2b</b>, similar to cocaine, whereas DAT preferred a more occluded conformation when <b>3b</b> was bound, providing an explanation, at the molecular level, for the observed behavioral profiles.<a onclick="showRef(event, 'ref32 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref32 ref41 ref42 ref43">(32,41−43)</a></div><div class="NLM_p">While inhibition of DAT has hitherto been our strategy in developing potential psychostimulant use disorders, dual inhibition of sigma1  receptors (σ1R) and DAT has been shown to significantly reduce cocaine’s reinforcing effects in animal models of cocaine abuse.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> One hypothesis posits that this is the result of σ1R modulation of DAT conformation.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> DAT inhibitors with high affinity for σ1R have also been reported to attenuate the reinforcing actions of methamphetamine measured in self-administration tests.<a onclick="showRef(event, 'ref37 ref47'); return false;" href="javascript:void(0);" class="ref ref37 ref47">(37,47)</a> Moreover, a recent study reported that methamphetamine might activate σ1R, leading to oxidation of a cysteine residue on VMAT2, which would be responsible for a reduction in the vesicular transport of DA, thus potentiating the dopaminergic actions of methamphetamine.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> However, another study found that activation (not blockade) of σ1R would attenuate methamphetamine induced ambulatory activity, motivated behaviors, and enhancement of brain reward stimulation.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> As there are evident relationships between DAT and σ1R, assessing how our compounds bind σ1R will prove beneficial in our overall understanding of mechanism.</div><div class="NLM_p">Generally, within the bis(4-fluorophenyl)methyl)sulfinyl)ethylpiperazines series,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> the sulfoxide analogues have lower affinity for DAT than their sulfide counterparts. For example, the sulfide analogue of <b>3b</b>, <b>3a</b>, has higher DAT affinity than <b>3b</b> (DAT <i>K</i><sub>i</sub> = 37.8 ± 8.72 nM vs 230 ± 40.5 nM); however, <b>3a</b> was determined to be metabolically unstable, with a half-life of 14 min in rat liver microsomes, whereas <b>3b</b> had a half-life of 126 min.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Hence, our focus has primarily been on the development of sulfoxides. Furthermore, the sulfoxide analogues tend to possess lower potency at hERG,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> a highly beneficial characteristic for drugs vying for clinical trials.<a onclick="showRef(event, 'ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52 ref53">(50−53)</a></div><div class="NLM_p">hERG, the human <i>ether-à-go-go-related</i> potassium channel, is involved in the repolarization of the cardiac action potential.<a onclick="showRef(event, 'ref21 ref50 ref51 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref21 ref50 ref51 ref52 ref53 ref54">(21,50−54)</a> Mutation or drug inhibition of this channel leads to delays in repolarization, which then leads to prolonged QT syndrome and the lethal cardiac arrhythmia torsade de pointes.<a onclick="showRef(event, 'ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53">(51−53)</a> The hERG channel is highly promiscuous and binds a wide range of molecules, including those that possess aromatic groups, primarily because of its tyrosine 652 and phenylalanine 656 residues, and those with positively charged groups (e.g., protonatable amines), due to the strong electrostatic environment within the pore.<a onclick="showRef(event, 'ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53">(51−53)</a> Numerous drugs have been withdrawn from the market due to cardiotoxicity related to hERG inhibition, and although not all hERG blockers lead to lethal cardiotoxicity, there are strong correlations.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Thus, it is a metric that the FDA mandates reporting prior to progressing to clinical trials.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><div class="NLM_p">While <b>3b</b> is currently being developed as a medication candidate for psychostimulant use disorder, we sought to improve its DAT affinity, metabolic stability, and hERG profiles through chemical modifications of the N-terminus. The objective of this series was to find analogues of <b>2a</b>, <b>2b</b>, <b>3a</b>, and <b>3b</b> that displayed higher affinity for DAT and potentially σ1R, were metabolically stable, and showed an acceptable hERG/DAT affinity ratio.<named-content content-type="anchor" rid="fig2" type="simple"></named-content></div><div class="NLM_p">While the piperazine scaffold is a widely used and effective building block in drug design, it is also highly vulnerable to various drug metabolizing enzymes and often binds to hERG, due to its electron-rich nature.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> To potentially bypass these problems, while attempting to preserve high DAT affinity, we set out to explore the effects imparted by (1) the amidation of the terminal piperazine nitrogen (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, red), (2) the oxidation and reduction of the terminal alcohol moiety (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, pink), (3) varying the substitution on the terminal phenyl group of <b>2</b> with electron donating and withdrawing groups (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, green), (4) varying the alicyclic amine linker (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, orange), and (5) resolving the secondary alcohol chiral center (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, pink). The <i>cis</i>-2,6-dimethylpiperazine and 2,8-diazaspiro[4.5]decane scaffolds inspired by compounds listed in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> were introduced as alternative alicyclic amine moieties. The <i>cis</i>-2,6-dimethylpiperazine group of rimcazole (<b>5</b>) was chosen to attenuate the p<i>K</i><sub>a</sub> of the terminal tertiary amine on the piperazine, which should decrease hERG affinity. As rimcazole is a good DAT inhibitor (<i>K</i><sub>i</sub> = 97.7 ± 12 nM), the additional methyl groups were not anticipated to decrease binding of the new compounds at DAT. The 2,8-diazaspiro[4.5]decane group, shown recently in a series of highly selective D<sub>3</sub> receptor antagonists (<b>6</b>),<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> not only decreases lipophilicity, thus potentially decreasing hERG affinity,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> but also increases metabolic stability as the piperazine scaffold is replaced.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Sites of modifications made to <b>2</b> and <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of compounds possessing other alicyclic amine linkers.<a onclick="showRef(event, 'ref57 ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref57 ref58 ref59 ref60">(57−60)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All final compounds were evaluated for DAT and SERT binding in rat brain (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>; NET binding for select compounds is reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_001.pdf" class="ext-link">Table S3</a>). σ1R binding in guinea pig brain was also evaluated for continued investigation of a previous hypothesis, that compounds with dual DAT/σ1R inhibitor profiles may be more therapeutically beneficial over DAT selective inhibitors.<a onclick="showRef(event, 'ref44 ref59 ref60 ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref44 ref59 ref60 ref61 ref62 ref63">(44,59−63)</a> In addition, a subset of compounds were tested for their hERG binding profile. Furthermore, a subset of analogues was also tested on cell lines overexpressing DAT and the Y156F mutant. The affinity ratio between the binding affinity to WT DAT and its Y156F mutant has previously been used to predict if a compound demonstrates a classical or more atypical DAT binding profile, as reported for (<i>R</i>)-modafinil, <b>2b</b>, and <b>3b</b>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Based on these findings, the stereoisomers of <b>2b</b>, <b>3b</b>, and several of the analogues described herein were evaluated for metabolic stability in mouse liver microsomes, as well as hERG affinity. Finally, compound <b>14a</b> and its diastereomers (<b>14b,c</b>), were chosen as new lead compounds and compared to cocaine for their effects on locomotor activity in mice.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Binding Data for Sulfenyl- and Sulfinylalkylamine Analogues<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0010.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0011.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Each <i>K</i><sub>i</sub> value represents data from at least three independent experiments, each performed in triplicate. <i>K</i><sub>i</sub> values were analyzed by PRISM. Binding assay procedures are described in detail in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Methods">Experimental Methods</a>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Concentration (log) response curves were fitted to a logistic equation (three parameters assuming complete block of the current at very high test compound concentrations) to generate estimates of the 50% inhibitory concentration (IC<sub>50</sub>). The concentration–response relationship of each compound was constructed from the percentage reductions of current amplitude by sequential concentrations. NT; not tested.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Data from ref <a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a>.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Data from ref <a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a>.</p></div></div><div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36740" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36740" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Syntheses of novel sulfenylalkylamine (<b>8a–8g</b>, <b>11a–11d</b>) and sulfinylalkylamine analogues (<b>9a–9e</b>, <b>12a–12c</b>) were achieved as depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Epoxide ring opening using the appropriate oxiranes with 1-(2-((bis(4-fluorophenyl)methyl)thio)ethyl)piperazine <b>7</b> gave alcohols <b>8a</b>–<b>8c</b> in quantitative yield.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Alkylation of <b>7</b> with the appropriate halides provided compounds <b>8d</b>, <b>8e</b>, and <b>8g</b> in 66%–84% yield. Amidation of the appropriate carboxylic acids using 1,1′-carbonyldiimidazole (CDI) gave amide <b>8f</b> in 86% yield. To understand the effect of stereochemistry on DAT, the stereoisomers of <b>2b</b> were resolved using commercially available (2<i>S</i>)- or (2<i>R</i>)-1-chloro-3-phenylpropan-2-ol to give <b>9d</b> and <b>9e</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>8a</b>–<b>g</b> and <b>9a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate oxirane, isopropyl alcohol, reflux, overnight; (b) appropriate halide, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux; (c) CDI, 3-phenylpropanoic acid, THF, RT, overnight; (d) H<sub>2</sub>O<sub>2</sub>, CH<sub>3</sub>COOH/CH<sub>3</sub>OH, 40 °C, overnight.</p></p></figure><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>11a</b>–<b>d</b> and <b>12a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate piperazine, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux, overnight; (b) H<sub>2</sub>O<sub>2</sub>, CH<sub>3</sub>COOH/CH<sub>3</sub>OH, 40 °C, overnight.</p></p></figure><div class="NLM_p">Synthesis of compound <b>10b</b> was achieved using methods similar to <b>10a</b>.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Dehydration of bis(4-fluorophenyl)methanol with 3-mercaptopropan-1-ol in the presence of trifluoroacetic acid, followed by treatment with K<sub>2</sub>CO<sub>3</sub> in H<sub>2</sub>O/acetone provided the sulfide alcohol in quantitative yield. Bromination via Appel conditions gave <b>10b</b> in 98% yield. Alkylation of bromides <b>10a</b><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and <b>10b</b>, with the appropriate piperazines provided compounds <b>11a</b>–<b>11d</b>. Lastly, oxidation of all sulfenylamine compounds (<b>8a</b>–<b>8e</b>, <b>11a</b>–<b>11c</b>) using hydrogen peroxide in an acetic acid/methanol solution gave the sulfinylamine compounds (<b>9a</b>–<b>9e</b>, <b>12a</b>–<b>12c</b>) in 35–60% yield. Similarly, the stereoisomers of <b>3b</b> (<b>12a</b> and <b>12b</b>) were synthesized using either commercially available (<i>S</i>)- or (<i>R</i>)-propylene oxide.</div><div class="NLM_p">The <i>cis</i>-dimethylpiperazine series was achieved through similar methods as the piperazine analogues (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Alkylation of <i>cis</i>-2,6-dimethylpiperazine with <b>10a</b> afforded intermediate <b>13</b>, and the sulfenyl products <b>14a</b>–<b>14d</b> were obtained through ring epoxide opening with the appropriate oxiranes. Subsequent oxidation of the sulfenyl compounds into the sulfinyl products gave <b>15a</b> and <b>15b</b>. As <b>14a</b> showed promising pharmacological properties for our purposes, its stereoisomers <b>14b</b> and <b>14c</b> were also synthesized using commercially available (<i>S</i>)- or (<i>R</i>)-propylene oxide for comparison.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>14a</b>–<b>d</b> and <b>15a</b>–<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>cis</i>-2,6-dimethylpiperazine, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux, overnight; (b) appropriate oxirane, isopropyl alcohol, reflux, overnight; (c) H<sub>2</sub>O<sub>2</sub>, CH<sub>3</sub>COOH/CH<sub>3</sub>OH, RT, 48 h.</p></p></figure><div class="NLM_p">As for the diazaspiro compounds (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>), the sulfenyl products <b>18a</b> and <b>18b</b> were again obtained through similar methods as previous products. Alkylation of <b>10a</b> with <i>tert</i>-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate, followed by Boc deprotection afforded <b>17</b>. The terminal alcohol moieties were installed using the appropriate oxiranes to afford <b>18a</b> and <b>18b</b>, and final oxidation of <b>18a</b> gave the sulfinyl product <b>19</b>.</div><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Diazaspiro Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux, overnight; (b) TFA, DCM, RT, 5 h; (c) appropriate oxirane, isopropyl alcohol, reflux, 18–48 h; (d) H<sub>2</sub>O<sub>2</sub>, CH<sub>3</sub>COOH/CH<sub>3</sub>OH, RT, 48 h.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Biological Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32667" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32667" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> SAR at DAT, SERT, and σ1R</h3><div class="NLM_p">All final compounds (<b>8</b>, <b>9</b>, <b>11</b>, <b>12</b>, <b>14</b>, <b>15</b>, <b>18</b>, and <b>19</b>) were evaluated for binding at DAT and SERT in rat brain (striatum and midbrain, respectively) membranes and σ1R in guinea pig brain (cortex) membranes, and compared to known DAT inhibitors <b>1</b>–<b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The binding affinities (<i>K</i><sub>i</sub> values) are presented in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_p">In general, the sulfinylamine compounds were less potent DAT inhibitors than their sulfenylamine precursors, with the exception of <b>8b</b> and <b>9b</b>, although the difference between the two was negligible. Unsurprisingly, the compounds with a phenyl-2-propanol terminus had the lowest DAT <i>K</i><sub>i</sub> values and higher affinity when compared to their nonaromatic counterparts, similar to <b>2</b> versus <b>3</b>. Compounds <b>8b</b> and <b>9b</b> had the lowest DAT affinities within that group, likely because of the compounding bulk and electron withdrawing effects of the <i>p</i>-CF<sub>3</sub> group, whereas <b>8a</b>, <b>8c</b>, <b>8d</b>, and <b>8e</b> were comparable to <b>2a</b>, and <b>9a</b>, <b>9c</b>, <b>9d</b>, and <b>9e</b> were comparable to <b>2b</b>. Modifying the terminal amine of the piperazine to an amide, with or without a phenyl terminus (<b>8f</b> and <b>11d</b> respectively), resulted in DAT <i>K</i><sub>i</sub> values in the low micromolar range, confirming the MD simulation findings that the terminal tertiary amine is crucial for DAT binding.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Oxidizing the 2-propanol of <b>3</b> to 2-propanone (<b>8g</b>) increased the DAT <i>K</i><sub>i</sub>, decreasing DAT affinity by ∼5-fold compared to <b>3a</b>, which also agreed with the MD simulation of <b>3b</b> in DAT, where the hydroxyl group in the 2-propanol end participates in binding.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Converting the piperazine linker to the <i>cis</i>-2,6-dimethylpiperazine scaffold did not alter the DAT <i>K</i><sub>i</sub>s significantly, as anticipated.</div><div class="NLM_p">As our goal in modifying the alicyclic amine linker was aimed at lowering the rate of metabolism and decreasing hERG affinity, the lack of change in DAT binding was ideal. The diazaspiro compounds (<b>18b</b> and <b>19</b>), however, showed relatively lower DAT binding affinities compared to their parent analogues (<b>3a</b> and <b>3b</b>, respectively) and were not selective for DAT over SERT. Interestingly, both compounds showed a binding preference for σ1R over either DAT or SERT. The extension of the alkyl chain between the sulfur and piperazine and removal of the alcohol (<b>11c</b> and <b>12c</b>) increased DAT <i>K</i><sub>i</sub> values when compared to <b>2a</b> and <b>2b</b>.</div><div class="NLM_p">The resolved diastereomers of <b>3b</b> (<b>12a</b> and <b>12b</b>) showed no appreciable enantioselectivity at DAT or SERT, and the same was observed for the diastereomers of <b>2b</b> and <b>14a</b>, <b>9d</b> and <b>9e</b>, and <b>14b</b> and <b>14c</b>, respectively. Although the (<i>S</i>)-diastereomer in all cases (<b>8d</b>, <b>9d</b>, <b>11a</b>, <b>12a</b>, and <b>14b</b>) had lower <i>K</i><sub>i</sub>s than the (<i>R</i>)-diastereomers (<b>8e</b>, <b>9e</b>, <b>11b</b>, <b>12b</b>, and <b>14c</b>), the differences were minimal.</div><div class="NLM_p">In most cases, these novel analogues were highly DAT selective when compared to SERT, with the exception of (as mentioned) amides <b>8f</b> and <b>11d</b>, and diazaspiro compounds <b>18b</b> and <b>19</b>, where DAT and SERT <i>K</i><sub>i</sub>s were equivalent.</div><div class="NLM_p">With respect to σ1R binding, compounds without a phenyl terminus showed high affinity binding, which is the reverse trend when compared to DAT binding; however, in general the sulfides had higher affinities for σ1R than the sulfoxides, as seen at DAT. Compounds <b>8f</b>, <b>11d</b>, and <b>8g</b> were σ1R selective compared to either monoamine transporter, with <b>8g</b> being the best σ1R inhibitor among all the compounds shown (<i>K</i><sub>i</sub> = 1.08 nM). Interestingly, while stereochemistry had very little effect on DAT binding, a significant difference between the σ1R <i>K</i><sub>i</sub> of sulfoxides <b>9e</b> and <b>9d</b> and, to a lesser extent, <b>12b</b> and <b>12a</b> was observed. This difference was not observed between the stereoisomers of their sulfide precursors.</div><div class="NLM_p last">Compounds <b>14a</b>, <b>15a</b>, and <b>15b</b> were tested for their potencies in blocking hERG. As predicted, the <i>cis</i>-2,6-dimethylpiperazine analogue of <b>3b</b>, <b>15a</b>, had the lowest affinity for hERG among this series of compounds, while <b>15b</b> had the highest, reflecting the literature and hERG results of their predecessors.<a onclick="showRef(event, 'ref21 ref32 ref50 ref51 ref52 ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref21 ref32 ref50 ref51 ref52 ref53 ref54 ref55">(21,32,50−55)</a> Importantly, the hERG/DAT affinity ratio of the sulfenyl compound <b>14a</b> was much higher than that of its parent compound <b>3a</b> (<b>28</b> and <b>3</b>, respectively) and comparable to <b>15a</b> (<b>30</b>). Fortuitously, compounds with an affinity ratio >30-fold are unlikely to produce a QT prolongation effect.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> With a significantly higher DAT affinity than <b>3b</b> and an acceptable hERG/DAT affinity ratio, <b>14a</b> has development potential as a MAT for psychostimulant use disorders.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Molecular Pharmacology and Mutagenesis Studies</h3><div class="NLM_p">We next evaluated the binding ratios of compounds <b>14a</b>, <b>15a</b>, <b>15b</b>, and <b>18b</b> in DAT wildtype (WT) and the Y156F mutant to preliminarily assess the nature of DAT binding <i>in vitro</i>, as has been done previously with earlier generation analogues of benztropine and modafinil.<a onclick="showRef(event, 'ref27 ref32 ref40'); return false;" href="javascript:void(0);" class="ref ref27 ref32 ref40">(27,32,40)</a> In DAT WT, the OH-group of Tyr156 is suggested to generate an H-bond to Asp79, which initiates occlusion of the binding site to the extracellular environment after substrate binding. Molecular docking simulations<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> and X-ray crystallography<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> have suggested that cocaine prefers to bind DAT in an outward facing conformation that does not interfere with the H-bond formation. Hence, there is little binding affinity difference between the WT and Y156F mutant DAT for cocaine and cocaine-like compounds.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In contrast, binding of the atypical DAT inhibitors induce a more occluded conformation, which depends on the Tyr156-Asp79 H-bond formation.<a onclick="showRef(event, 'ref27 ref38 ref39 ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref27 ref38 ref39 ref65 ref66">(27,38,39,65,66)</a> Hence, mutation of Y156 typically decreases the binding affinity of atypical DAT inhibitors resulting in a >2-fold decrease in <i>K</i><sub>i</sub> between DAT WT and the DAT Y156F mutation (see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, affinity ratio).<a onclick="showRef(event, 'ref27 ref36'); return false;" href="javascript:void(0);" class="ref ref27 ref36">(27,36)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>K</i><sub>i</sub> Values for Inhibition of [<sup>3</sup>H]WIN35,428 Binding by Indicated Compounds to DAT WT and the Y156F Mutant<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">WT <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>n</i></th><th class="colsep0 rowsep0" align="center">Y156F <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>n</i></th><th class="colsep0 rowsep0" align="center">affinity ratio</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cocaine<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">450 [340;590]</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">350 [280; 450]</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WIN35,428<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">13 [12;14]</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">13 [9.6–17]</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14a</b></td><td class="colsep0 rowsep0" align="left">58.3 [48.6; 69.9]</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">269 [251; 289]</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15a</b></td><td class="colsep0 rowsep0" align="left">406 [398; 414]</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">3030 [2390; 3830]</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">7.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15b</b></td><td class="colsep0 rowsep0" align="left">3.83 [3.02; 4.87]</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">19.1 [12.2; 29.9]</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">5.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18b</b></td><td class="colsep0 rowsep0" align="left">104 [88; 123]</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">239 [199; 288]</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">2.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">[<sup>3</sup>H]WIN35,428 binding is performed on intact COS7 cells transiently expressing DAT WT or the Y156F mutant. Data are shown as mean [SE interval] and are calculated from pIC<sub>50</sub> and the SE interval from pIC<sub>50</sub> ± SE.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Data from ref <a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>.</p></div></div></div><div class="NLM_p last">Inhibition of [<sup>3</sup>H]WIN35,428 binding on COS7 cells transiently expressing WT DAT or Y156F was determined. All tested analogues showed a significant decrease in binding affinity for Y156F relative to WT DAT in contrast to cocaine or its higher affinity analogue, WIN35,428 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). We have previously reported that <b>2b</b>, based on the Y156F binding assay assessment, may be an atypical DAT inhibitor; however, preclinical behavioral evaluation demonstrated it had a more cocaine-like behavioral profile.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Thus, although the Y156F/WT DAT ratio suggests that these compounds bind differently than cocaine, it does not always predict their behavioral profiles. Of note, <i>K</i><sub>i</sub> values (nM) for inhibition of [<sup>3</sup>H]DA uptake were obtained in this same cell line for <b>14a</b> = 100 [79.9; 125]; <b>15a</b> = 552 [490; 621]; <b>15b</b> = 11.1 [5.70; 21.8]; and <b>18b</b> = 268 [228;315] using methods previously described.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> These data closely correspond to the <i>K</i><sub>i</sub> values found in the WT DAT binding assay (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.)</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Metabolic Stability in Mouse Microsomes</h3><div class="NLM_p">A subset of analogues (<b>8a</b>, <b>8d</b>, <b>8e</b>, <b>9a</b>–<b>e</b>, <b>12c</b>, <b>14a</b>, <b>15a</b>, <b>15b</b>, and <b>18b</b>) were tested for phase I metabolism following procedures previously described<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> to predict the susceptibility to Phase I metabolism following <i>in vivo</i> administration. As seen in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_001.pdf" class="ext-link">Table S2</a>, similar to <b>2b</b>, compounds with a phenyl-propanol terminus (<b>8a</b>, <b>8d</b>, <b>8e</b>, <b>9a</b>–<b>e</b>, <b>12c</b>, and <b>15b</b>) were highly susceptible to phase I metabolism, with almost no compound present after 60 min. In contrast, the stereoisomers of <b>3b</b>, <b>12a</b>, and <b>12b</b>, both exhibit exceptional and similar metabolic stability, more so than <b>3b</b> (<i>t</i><sub>1/2</sub> = 126 min).</div><div class="NLM_p">Within the modified alicyclic amine compound series (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_001.pdf" class="ext-link">Table S2 and Figure S1</a>), compounds <b>15a</b> and <b>18b</b> exhibited moderate stability with 30–44% of both compounds remaining in mouse microsomes fortified with NADPH. In contrast, compound <b>14a</b> and <b>15b</b> underwent substantial phase I metabolism with <10% remaining in microsomes fortified with NADPH at 1 h, suggesting CYP-dependent metabolism of the compounds and relatively short <i>in vitro t</i><sub>1/2</sub>. Since <b>18b</b> contains a diazaspiro linker instead of the classic piperazine, the metabolism result was not surprising as the typical piperazine degrading phase I metabolic enzymes would be ineffective against that moiety.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Furthermore, the sulfinyl compound <b>15a</b> was more stable than its sulfenyl counterpart <b>14a</b>, a preserved trend when compared to <b>2b</b> and <b>3b</b> versus <b>2a</b> and <b>3a</b>. However, the <i>cis</i>-2,6-dimethylpiperazine scaffold did not improve metabolic stability in mice as observed with <b>14a</b> and <b>15a</b>.</div><div class="NLM_p">At a glance, the poor metabolic stability of <b>14a</b> seems problematic (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>); however, further metabolite identification studies revealed <b>13</b> as one of the major metabolites for <b>14a</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_001.pdf" class="ext-link">Figure S1</a>). Interestingly, <b>13</b> is an active metabolite with moderately high affinity for DAT and σ1R (<i>K</i><sub>i</sub> = 92.3 ± 5.6 and 111 ± 4.76 nM, respectively); hence, this rapid metabolism may not be disadvantageous. Furthermore, the (<i>R</i>)-enantiomer (<b>14c</b>) showed higher stability than the (<i>S</i>)-enantiomer (<b>14b</b>) at 30% and 10%, respectively (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_001.pdf" class="ext-link">Table S2</a>). Additionally, metabolism in mice is typically quite rapid and not necessarily a reflection of higher species. Indeed, human liver microsome studies showed modest stability >30% of <b>14a</b> and its enantiomers (<b>14b</b>, <b>14c</b>) remaining after 60 min suggesting that <b>14a</b>, <b>14b</b>, and <b>14c</b> remain useful tools for <i>in vivo</i> studies (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_001.pdf" class="ext-link">Figure S2</a>).</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Metabolic stability in mouse microsomes. Compounds <b>14a</b> and <b>15b</b> showed susceptibility to phase I metabolism in mouse liver microsomes. Compounds <b>15a</b> and <b>18b</b> showed modest stability, with <b>18b</b> being the most stable with 44% remaining after 60 min incubation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Locomotor Activity of <b>14a–c</b> Compared to Cocaine in Mice</h3><div class="NLM_p">While <b>15b</b> had the highest DAT affinity in this subset, with a Y156F/WT DAT affinity ratio of 5.8, our recent discovery that its parent compound, <b>2b</b>, despite a similarly high Y156F/WT DAT ratio, was indeed cocaine-like behaviorally<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> dampened our enthusiasm for further evaluating this compound <i>in vivo</i>. Thus, based on the overall profiles <i>in vitro</i>, <b>14a</b>–<b>c</b> were chosen as the best candidates for <i>in vivo</i> characterization, starting with locomotor activity studies in mice. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> shows the effects of <b>14a</b>–<b>c</b> on locomotor activity compared to cocaine and <b>3b</b> (data for <b>3b</b> were reanalyzed from Keighron et al. 2019,<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> see <a class="ref internalNav" href="#sec5" aria-label="Experimental Methods">Experimental Methods</a> for details). Systemic administration (i.p.) of cocaine (3, 10, 17, and 30 mg/kg) produced an increase in ambulatory activity, measured as maximum distance traveled in 30 min, that was significantly higher from that produced by <b>14a</b> (1, 3, 10, and 30 mg/kg) and <b>3b</b> (3, 10, 30, and 56 mg/kg) (two-way ANOVA, main effect drug: F2,75 = 53.18, <i>p</i> < 0.01; main effect dose: F4,75 = 12.87, <i>p</i> < 0.01; drug by dose interaction: F8,75 = 6.41, <i>p</i> < 0.01). Mice injected with <b>14a</b> showed an increase in locomotion that was significantly higher than the effect exhibited by <b>3b</b> (<i>p</i> < 0.05), but not significantly different than vehicle (<i>p</i> > 0.05). The enantiomers of <b>14a</b>, <b>14b</b> and <b>14c</b>, showed similar effects when compared to <b>14a</b> (two-way ANOVA, main effect drug, F2,45 = 0.08, NS; main effect dose, F2,45 = 3.1, NS; drug by dose interaction, F4,45 = 0.16, NS). It is worth noting that compound <b>14a</b> and its enantiomers showed levels of behavioral activity similar to those reported by Desai et al.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> and Schmeichel et al.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> for an atypical DAT inhibitor with potential therapeutic efficacy for ADHD. In the latter report, administration of the benztropine analogue AHN 2-005 (<i>N</i>-allyl-3α-[bis(4′-fluorophenyl)methoxy]tropane) did not significantly increase quadrant entering (an index of ambulatory activity) or rearing, but only modestly increased quiet wake.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of <b>14a</b>–<b>c</b> compared to <b>3b</b> and cocaine on mouse locomotion. Data are expressed as the maximum distance traveled in 30 min during a 2 h observation period, as a function of drug dose. * = <i>p</i> < 0.05 vs vehicle (VEH) treated mice. <i>N</i> = 6 for all groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16413" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16413" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, herein we have synthesized a series of novel analogues of <b>2</b> and <b>3</b> that have a range of DAT affinities and selectivities over SERT. Specifically, we have extended SAR at the DAT by manipulating the ethylpiperazine linker, propanol terminus, and substitution on the phenyl ring of <b>2</b>. All compounds were tested for binding to DAT and SERT, as well as σ1R. In addition, a subset of compounds (<b>3b</b>, <b>14a</b>, <b>15a</b>, and <b>15b</b>) were tested for NET and other off-target binding interactions (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_001.pdf" class="ext-link">Tables S3–S9</a>). There were no significant interactions observed at a concentration of 100 nM for any of these compounds at any off target tested, and most of these analogues were also inactive at 10 μM. When tested against hERG, <b>15a</b> had the lowest affinity, whereas <b>15b</b> had the highest (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Interestingly, the hERG/DAT affinity ratio of <b>14a</b> was similar to that of <b>15a</b> (28 and 30, respectively). We tested a subset of analogues (<b>14a</b>, <b>14d</b>, <b>15a</b>, and <b>18b</b>) in binding assays for affinities at both the WT and Y156F DAT mutant to determine if they demonstrated atypical binding profiles, as previously reported for (±)-modafinil, <b>2b</b> and <b>3b</b>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> These data suggest that <b>14a</b> did indeed bind the DAT in a conformation that was more similar to atypical DAT inhibitors (affinity ratio = 4.6) supporting further development.</div><div class="NLM_p last">Phase I metabolism studies showed that <b>14a</b> was rapidly metabolized in mouse liver microsomes (<i>t</i><sub>1/2</sub> ≈ 20 min), although its major metabolite (<b>13</b>) was also a DAT inhibitor. However, <b>14a</b> and its enantiomers were more stable in human liver microsomes (<i>t</i><sub>1/2</sub> > 40 min). Given that the major metabolite is also active at DAT and based on these collective <i>in vitro</i> data, compound <b>14a</b> was chosen as the lead candidate for further <i>in vivo</i> investigation. We discovered that, similar to previously reported atypical DAT inhibitors,<a onclick="showRef(event, 'ref15 ref26 ref32 ref69 ref70 ref71 ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref15 ref26 ref32 ref69 ref70 ref71 ref72 ref73 ref74">(15,26,32,69−74)</a> compound <b>14a</b> produced only moderate locomotor stimulation in mice and was substantially less efficacious than cocaine. These results are consistent with an atypical DAT inhibitor profile and suggest that <b>14a</b> may be a potential lead for development as a therapeutic for psychostimulant abuse. Further investigations of this compound in rodent models of cocaine abuse are underway to extend testing of the atypical DAT inhibitor hypothesis, as well as to further investigate the role of σ1 receptors in the behavioral profile of these agents.<a onclick="showRef(event, 'ref32 ref37'); return false;" href="javascript:void(0);" class="ref ref32 ref37">(32,37)</a> As <b>14a</b> also binds with high affinity to σ1 receptors (<i>K</i><sub>i</sub> = 5.62 nM) and has ∼4-fold higher binding affinity than at DAT, its dual DAT/σ1 receptor targeting may prove to be an important mechanistic underpinning of its potential therapeutic profile.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36776" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36776" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Synthesis</h3><div class="NLM_p">All chemicals and solvents were purchased from chemical suppliers unless otherwise stated and used without further purification. <sup>1</sup>H and <sup>13</sup>C NMR spectra were acquired using a Varian Mercury Plus 400 spectrometer at 400 and 100 MHz, respectively. Chemical shifts are reported in parts per million (ppm) and referenced according to deuterated solvent for <sup>1</sup>H NMR spectra (CDCl<sub>3</sub>, 7.26, CD<sub>3</sub>OD, 3.31 or acetone-<i>d</i><sub>6</sub>, 2.05) and <sup>13</sup>C NMR spectra (CDCl<sub>3</sub>, 77.2, CD<sub>3</sub>OD, 49.03 or acetone-<i>d</i><sub>6</sub>, 29.8 and 206.0). Gas chromatography–mass spectrometry (GC/MS) data were acquired (where obtainable) using an Agilent Technologies (Santa Clara, CA) 7890B GC equipped with an HP-5MS column (cross-linked 5% PH ME siloxane, 30 m × 0.25 mm i.d. × 0.25 μm film thickness) and a 5977B mass-selective ion detector in electron-impact mode. Ultrapure grade helium was used as the carrier gas at a flow rate of 1.2 mL/min. The injection port and transfer line temperatures were 250 and 280 °C, respectively, and the oven temperature gradient used was as follows: the initial temperature (70 °C) was held for 1 min and then increased to 300 °C at 20 °C/min over 11.5 min, and finally maintained at 300 °C for 4 min. All column chromatography was performed using a Teledyne Isco CombiFlash RF flash chromatography system. Combustion analyses were performed by Atlantic Microlab, Inc. (Norcross, GA) and agree with ±0.4% of calculated values. All melting points were determined on an OptiMelt automated melting point system and are uncorrected. On the basis of NMR and combustion data, all final compounds are >95% pure.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)piperazin-1-yl)-3-(4-fluorophenyl)propan-2-ol (<b>8a</b>)</h4><div class="NLM_p last">Compound <b>8a</b> was prepared using the method that was previously described<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using <b>7</b> (455 mg, 1.3 mmol) and 2-(4-fluorobenzyl)oxirane (198 mg, 1.3 mmol) to give the product (650 mg, 100% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.33–7.36 (m, 4H), 7.12–7.19 (m, 2H), 6.94–7.02 (m, 6H), 5.18 (s, 1H), 2.75–3.88 (m, 1H), 2.45–2.73 (m, 16H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.1, 162.8, 160.6, 160.4, 137.0, 136.9, 133.9, 130.7, 130.6, 129.8, 129.7, 115.7, 115.4, 115.2, 115.0, 67.1, 63.3, 57.8, 53.1, 52.9, 40.4, 29.4. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 210–211 °C. Anal. Calcd. (C<sub>28</sub>H<sub>31</sub>F<sub>3</sub>N<sub>2</sub>OS·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·0.25H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)piperazin-1-yl)-3-(4-(trifluoromethyl)phenyl)propan-2-ol (<b>8b</b>)</h4><div class="NLM_p last">Compound <b>8b</b> was prepared as described for <b>8a</b> using <b>7</b> (455 mg, 1.3 mmol) and 2-(4-(trifluoromethyl)benzyl)oxirane (264 mg, 1.3 mmol) to give the product <b>8b</b> (700 mg, 98% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.53–7.55 (m, 2H), 7.33–7.36 (m, 6H), 6.96–7.10 (m, 4H), 5.18 (s, 1H), 2.82–3.92 (m, 1H), 2.27–2.79 (m, 16H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.2, 163.1, 142.5, 137.0, 136.7, 129.8, 129.7, 129.6, 125.3, 125.2, 125.2, 122.9, 115.7, 115.6, 115.5, 115.4, 66.7, 63.3, 57.7, 53.1, 52.9, 52.8, 41.0, 29.4, 29.3. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 209–210 °C. Anal. Calcd. (C<sub>29</sub>H<sub>31</sub>F<sub>5</sub>N<sub>2</sub>OS·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)piperazin-1-yl)-3-(4-methoxyphenyl)propan-2-ol (<b>8c</b>)</h4><div class="NLM_p last">Compound <b>8c</b> was prepared as described for <b>8a</b> using <b>7</b> (455 mg, 1.3 mmol) and 2-(4-methoxybenzyl)oxirane (195 mg, 1.3 mmol) to give the product (650 mg, 98% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34–7.36 (m, 4H), 7.12–7.14 (m, 2H), 7.97–7.02 (m, 4H), 6.82–6.84 (m, 2H), 5.18 (s, 1H), 3.82–3.86 (m, 1H), 3.78 (s, 3H), 2.25–2.75 (m, 16H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.1, 160.6, 158.1, 137.0, 136.9, 130.2, 129.8, 129.7, 115.7, 115.6, 115.4, 113.8, 67.3, 63.3, 57.8, 55.2, 53.1, 52.9, 40.4, 29.4. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 207–208 °C. Anal. Calcd. (C<sub>29</sub>H<sub>34</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·0.25H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (<i>S</i>)-1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)piperazin-1-yl)-3-phenylpropan-2-ol (<b>8d</b>)</h4><div class="NLM_p last">A mixture of <b>7</b> (348 mg, 1.00 mmol), commercially available (<i>S</i>)-1-chloro-3-phenylpropan-2-ol (204 mg, 1.20 mmol), K<sub>2</sub>CO<sub>3</sub> (552 mg, 4.0 mmol), and KI (catalytic) in acetonitrile (30 mL) was refluxed overnight. The solvent was removed, H<sub>2</sub>O (50 mL) was added to the residue, and the aqueous mixture was extracted with ethyl acetate (3 × 50 mL). The organic layer was dried over MgSO<sub>4</sub>, the solvent was removed <i>in vacuo</i>, and the crude product was purified by flash column chromatography (ethyl acetate/TEA = 95:5) to give <b>8d</b> (320 mg, 66% yield) as a yellow oil. [α]<sub class="stack">D</sub><sup class="stack">26</sup> +24.79 (MeOH, <i>c</i> = 0.73); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.18–7.36 (m, 9H), 6.96–7.01 (m, 4H), 5.18 (s, 1H), 3.85–3.92(m, 1H), 2.76–2.82 (m, 1H), 2.56–2.68 (m, 3H), 2.26–2.54 (m, 12H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.1, 160.6, 138.2, 137.0, 129.8, 129.7, 129.3, 128.3, 126.3, 115.6, 115.3, 67.2, 63.4, 57.8, 53.1, 52.9, 41.3, 29.4. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 208–209 °C. Anal. Calcd. (C<sub>28</sub>H<sub>32</sub>F<sub>2</sub>N<sub>2</sub>OS·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·0.25H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (<i>R</i>)-1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)piperazin-1-yl)-3-phenylpropan-2-ol (<b>8e</b>)</h4><div class="NLM_p last">Compound <b>8e</b> was prepared as described for <b>8d</b> using <b>7</b> (348 mg, 1.00 mmol) and commercially available (<i>R</i>)-1-chloro-3-phenylpropan-2-ol (204 mg, 1.20 mmol) to give the product (350 mg, 73% yield) as a yellow oil. [α]<sub class="stack">D</sub><sup class="stack">25</sup> −24.80 (MeOH, <i>c</i> = 0.75). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.19–7.36 (m, 9H), 6.95–7.01 (m, 4H), 5.18 (s, 1H), 3.87–3.91(m, 1H), 2.77–2.82 (m, 1H), 2.27–2.69 (m, 15H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.1, 160.6, 138.2, 137.0, 129.8, 129.7, 129.3, 128.3, 126.3, 115.7,115.6, 115.4,115.3, 67.2, 63.4, 57.8, 53.1, 52.9, 41.3, 29.4. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 208–209 °C. Anal. Calcd. (C<sub>28</sub>H<sub>32</sub>F<sub>2</sub>N<sub>2</sub>OS·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·0.25H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)piperazin-1-yl)-2-phenylethan-1-one (<b>8f</b>)</h4><div class="NLM_p last">A mixture of CDI (243 mg, 1.50 mmol) and 3-phenylpropanoic acid (225 mg, 1.50 mmol) in THF (12 mL) was stirred at room temperature under argon. After 2 h, <b>7</b> (523 mg, 1.50 mmol) in THF (7 mL) was added, and the reaction mixture was stirred overnight at room temperature. Solvent was removed, and the reaction residue was purified by flash column chromatography (ethyl acetate/TEA = 95:5) to give <b>8f</b> (620 mg, 86% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.18–7.36 (m, 9H), 6.97–7.01 (m, 4H), 5.16 (s, 1H) 3.58–3.59 (m, 2H), 3.34–3.35 (m, 2H), 2.92–2.95 (m, 2H), 2.49–2.60 (m, 6H), 2.22–2.33 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 170.5, 163.1, 160.7, 141.2, 136.9, 136.8, 129.8, 129.7, 128.5, 128.4, 126.2, 115.7, 115.6, 115.5, 115.4, 57.5, 53.0, 52.9, 52.5, 45.3, 41.3, 34.9, 31.5, 29.3. The free base was converted to the oxalate salt and recrystallized from hot isopropanol to give a white solid. Mp 190–191 °C. Anal. Calcd. (C<sub>28</sub>H<sub>30</sub>F<sub>2</sub>N<sub>2</sub>OS·C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)piperazin-1-yl)propan-2-one (<b>8g</b>)</h4><div class="NLM_p last">Compound <b>8g</b> was prepared as <b>8d</b> using 1-bromopropan-2-one (137.0 mg, 0.73 mmol) to give the product (340 mg, 84% yield) as yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.36 (m, 4H), 6.96–7.00 (m, 4H), 5.18 (s, 1H), 3.12–3.17 (m, 2H), 2.46–2.56 (m, 12H), 2.12–2.13 (m, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 206.3, 163.1, 160.6, 137.0, 129.8, 129.7, 115.7, 115.6, 115.5, 115.4, 68.1, 58.3, 57.8, 53.3, 52.9, 52.8, 52.7, 32.4, 32.3, 32.0, 29.3, 29.2, 27.7. The free base was converted to the oxalate salt and recrystallized from hot isopropanol to give a white solid. Mp 222–223 °C. Anal. Calcd. (C<sub>22</sub>H<sub>26</sub>F<sub>2</sub>N<sub>2</sub>OS·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)-3-(4-fluorophenyl)propan-2-ol (<b>9a</b>)</h4><div class="NLM_p last">Compound <b>9a</b> was prepared as previously described<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using <b>8a</b> (360 mg, 0.72 mmol) to give the product (140 mg, 38% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35–7.42 (m, 4H), 6.93–7.12 (m, 8H), 4.91 (s, 1H), 3.82–3.88 (m, 1H), 2.25–2.82 (m, 16H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.0, 163.7, 162.0, 161.5, 161.3, 160.4, 133.9, 131.7, 131.0, 130.9, 130.7, 130.5, 130.3, 116.4, 116.2, 115.8, 115.6, 115.2, 115.0, 69.8, 67.1, 63.3, 53.1, 50.8, 48.2, 40.4. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 199–200 °C (dec.). Anal. Calcd. (C<sub>28</sub>H<sub>31</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)-3-(4-(trifluoromethyl)phenyl)propan-2-ol (<b>9b</b>)</h4><div class="NLM_p last">Compound <b>9b</b> was prepared as previously described<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using <b>8b</b> (360 mg, 0.72 mmol) to give the product (150 mg, 41% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.52–7.55 (m, 2H), 7.33–7.42 (m, 6H), 7.04–7.11 (m, 4H), 4.91 (s, 1H), 3.87–3.93 (m, 1H), 2.31–2.78 (m, 16H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.0, 163.8, 161.6, 161.3, 142.5, 131.7, 131.0, 130.9, 130.5, 130.3, 130.0, 129.1, 129.1, 128.8, 128.5, 116.4, 116.2, 116.1, 115.9, 115.6, 69.8, 66.8, 63.3, 53.1, 50.8, 48.2, 41.1, 41.0, 40.9. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 198–199 °C (dec.). Anal. Calcd. (C<sub>29</sub>H<sub>31</sub>F<sub>5</sub>N<sub>2</sub>O<sub>2</sub>S·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·0.25H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)-3-(4-methoxyphenyl)propan-2-ol (<b>9c</b>)</h4><div class="NLM_p last">Compound <b>9c</b> was prepared as previously described<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using <b>8c</b> (340 mg, 0.66 mmol) to give the product (160 mg, 59% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.42 (m, 4H), 7.04–7.13 (m, 6H), 6.82–6.84 (m, 2H), 4.92 (s, 1H), 3.79–3.86 (m, 1H), 3.78 (s, 3H), 2.29–2.77 (m, 16H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.0, 163.7, 161.6, 161.3, 158.2, 131.7, 131.0, 130.9, 130.5, 130.3, 130.2, 116.4, 116.2, 115.8, 115.6, 113.8, 69.7, 67.4, 63.3, 55.2, 53.1, 50.8, 48.2, 40.3. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 197–198 °C (dec.). Anal. Calcd. (C<sub>29</sub>H<sub>34</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·0.25H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>S</i>)-1-(4-(2-((Bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)-3-phenylpropan-2-ol (<b>9d</b>)</h4><div class="NLM_p last">Compound <b>9d</b> was prepared as previously described<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using <b>8d</b> (430 mg, 0.89 mmol) to give the product (160 mg, 36% yield) as a yellow oil. [α]<sub class="stack">D</sub><sup class="stack">29</sup> +21.29 (MeOH, <i>c</i> = 0.70). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.19–7.42 (m, 9H), 7.04–7.11 (m, 4H), 4.93 (s, 1H), 3.88–3.92 (m, 1H), 2.28–2.83 (m, 16H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.0, 163.8, 161.5, 161.3, 138.2, 131.8, 131.0, 130.9, 130.6, 130.5, 130.3, 129.3, 128.4, 126.3, 116.4, 116.2, 115.9, 115.6, 69.8, 67.3, 63.4, 53.1, 50.8, 48.2, 41.3. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 196–197 °C. Anal. Calcd. (C<sub>28</sub>H<sub>32</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>R</i>)-1-(4-(2-((Bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)-3-phenylpropan-2-ol (<b>9e</b>)</h4><div class="NLM_p last">Compound <b>9e</b> was prepared as previously described<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using <b>8e</b> (740 mg, 1.53 mmol) to give the product (360 mg, 47% yield) as a yellow oil. [α]<sub class="stack">D</sub><sup class="stack">29</sup> −22.75 (MeOH, <i>c</i> = 0.80). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.20–7.42 (m, 9H), 7.05–7.11 (m, 4H), 4.92 (s, 1H), 3.88–3.92 (m, 1H), 2.32–2.84 (m, 16H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.0, 163.8, 131.0, 130.9, 130.5, 130.3, 129.3, 128.4, 126.3, 116.4, 116.2, 115.9, 115.6, 69.8, 67.3, 63.4, 53.1, 50.8, 48.2, 41.3. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 196–197 °C. Anal. Calcd. (C<sub>28</sub>H<sub>32</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·0.25H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (Bis(4-fluorophenyl)methyl)(3-bromopropyl)sulfane (<b>10b</b>)</h4><div class="NLM_p last">Compound <b>10b</b> was prepared as <b>10a</b>, which was previously published<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using 3-mercaptopropan-1-ol to give the product as yellow oil. The product yield over two steps is 98%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.38 (m, 4H), 6.99–7.03 (m, 4H), 5.13 (s, 1H), 3.44–3.47 (m, 2H), 2.51–2.55 (m, 2H), 2.03–2.07 (m, 2H); GC/MS (EI) <i>m</i>/<i>z</i> 358 (M<sup>+</sup>)</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>S</i>)-1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)piperazin-1-yl)propan-2-ol (<b>11a</b>)</h4><div class="NLM_p last">Compound <b>11a</b> was prepared as described for <b>8d</b> using <b>10a</b> (1.05 g, 3.00 mmol) and commercially available 1-(<i>S</i>)-(piperazin-1-yl)propan-2-ol (433 mg, 3 mmol) to give the product (1.07 g, 88% yield) as a yellow oil. [α]<sub class="stack">D</sub><sup class="stack">25</sup> +24.56 (MeOH, <i>c</i> = 0.90). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.37 (m, 4H), 6.96–7.02 (m, 4H), 5.19 (s, 1H), 3.77–3.82 (m, 1H), 2.18–2.68 (m, 14H), 1.10–1.13 (m, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.1, 160.7, 137.0, 129.8, 129.7, 115.7, 115.5, 115.4, 65.5, 62.2, 57.8, 53.2, 53.1, 53.0, 52.8, 29.4, 29.3, 20.0. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 213-214 °C. Anal. Calcd. (C<sub>22</sub>H<sub>28</sub>F<sub>2</sub>N<sub>2</sub>OS·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·0.75H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>R</i>)-1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)piperazin-1-yl)propan-2-ol (<b>11b</b>)</h4><div class="NLM_p last">Compound <b>11b</b> was prepared as described for <b>8d</b> using <b>10a</b> (1.05 g, 3.00 mmol), commercially available 1-(<i>R</i>)-(piperazin-1-yl)propan-2-ol (433 mg, 3 mmol) to give the product (680 mg, 56% yield) as a yellow oil. [α]<sub class="stack">D</sub><sup class="stack">25</sup> −24.77 (MeOH, <i>c</i> = 0.90). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.31–7.37 (m, 4H), 6.94–7.02 (m, 4H), 5.19 (s, 1H), 3.78–3.82 (m, 1H), 2.18–2.70 (m, 14H), 1.11–1.16 (m, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.1, 160.7, 137.0, 129.8, 129.7, 115.7, 115.5, 115.4, 65.5, 62.2, 57.8, 53.2, 53.1, 52.8, 52.9, 29.4, 20.0. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 200–201 °C. Anal. Calcd. (C<sub>22</sub>H<sub>28</sub>F<sub>2</sub>N<sub>2</sub>OS·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 1-(3-((Bis(4-fluorophenyl)methyl)thio)propyl)-4-(3-phenylpropyl)piperazine (<b>11c</b>)</h4><div class="NLM_p last">Compound <b>11c</b> was prepared as described for <b>8d</b> using <b>10b</b> (985 mg, 2.76 mmol) and commercially available 1-(3-phenylpropyl)piperazine (564 mg, 2.76 mmol) to give the product (1.1 g, 83% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.33–7.37 (m, 4H), 7.25–7.29 (m, 2H), 7.17–7.19 (m, 3H), 6.98–7.01 (m, 4H), 5.13 (s, 1H), 2.61–2.65 (m, 2H), 2.36–2.40 (m, 14H), 1.71–1.86 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.1, 160.6, 142.0, 137.0, 129.8, 129.7, 128.4, 128.3, 125.8, 115.5, 115.3, 58.0, 57.2, 53.0, 52.5, 33.7, 30.1, 28.5, 26.2. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 202–203 °C (dec.). Anal. Calcd. (C<sub>29</sub>H<sub>34</sub>F<sub>2</sub>N<sub>2</sub>S·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)piperazin-1-yl)propan-1-one (<b>11d</b>)</h4><div class="NLM_p last">Compound <b>11d</b> was prepared as <b>11a</b>, using <b>10b</b> (515 mg, 1.5 mmol) and commercially available 1-(piperazin-1-yl)propan-1-one (213.0 mg, 1.50 mmol) to give the product (600 mg, 100% yield) as yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.36 (4H, m), 6.96–7.10 (m, 4H), 5.16 (s, 1H), 3.56–3.59 (m, 2H), 3.40–3.58 (m, 2H), 2.47–2.55 (m, 4H), 2.27–2.36 (m, 6H), 1.09–1.13 (m, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 172.2, 163.1, 160.7, 136.9, 129.8, 129.7, 115.7, 115.6, 115.4, 57.6, 53.2, 52.9, 52.6, 45.2, 41.4, 29.4, 26.4, 9.4. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 168–170 °C. Anal. Calcd. (C<sub>22</sub>H<sub>26</sub>F<sub>2</sub>N<sub>2</sub>OS·C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·0.25H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>S</i>)-1-(4-(2-((Bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)propan-2-ol (<b>12a</b>)</h4><div class="NLM_p last">Compound <b>12a</b> was prepared as previously described<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using <b>11a</b> (420 mg, 1.03 mmol) to give the product (220 mg, 51% yield) as a yellow oil. [α]<sub class="stack">D</sub><sup class="stack">25</sup> +22.00 (MeOH, <i>c</i> = 1.00). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.42 (m, 4H), 7.04–7.11 (m, 4H), 4.93 (s, 1H), 3.78–3.83 (m, 1H), 2.19–2.83 (m, 14H), 1.11–1.12 (m, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.0, 163.8, 161.6, 161.3, 131.8, 131.7, 131.0, 130.9, 130.5, 130.4, 130.3, 116.4, 116.2, 115.9, 115.6, 69.8, 65.5, 62.3, 53.1, 50.8, 48.2, 20.0. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 194–195 °C. Anal. Calcd. (C<sub>22</sub>H<sub>28</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>R</i>)-1-(4-(2-((Bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)propan-2-ol (<b>12b</b>)</h4><div class="NLM_p last">Compound <b>12b</b> was prepared as previously described<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using <b>11b</b> (470 mg, 1.16 mmol) to give the product (170 mg, 35% yield) as a yellow oil. [α]<sub class="stack">D</sub><sup class="stack">25</sup> −23.06 (MeOH, <i>c</i> = 0.85). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38–7.43 (m, 4H), 7.05–7.12 (m, 4H), 4.93 (s, 1H), 3.78–3.83 (m, 1H), 2.19–2.84 (m, 14H), 1.11–1.16 (m, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.0, 163.8, 161.6, 161.3, 131.8, 131.7, 131.0, 130.9, 130.5, 130.4, 130.3, 116.4, 116.2, 115.9, 115.6, 69.8, 65.5, 62.2, 53.1, 50.8, 48.2, 20.0. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 188–190 °C (dec.). Anal. Calcd. (C<sub>22</sub>H<sub>28</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-(3-((Bis(4-fluorophenyl)methyl)sulfinyl)propyl)-4-(3-phenylpropyl)piperazine (<b>12c</b>)</h4><div class="NLM_p last">Compound <b>12c</b> was prepared as previously described<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using <b>11c</b> (600 mg, 1.25 mmol) to give the product (370 mg, 60% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.41 (m, 4H), 7.25–7.29 (m, 2H), 7.16–7.19 (m, 3H), 7.05–7.11 (m, 4H), 4.77 (s, 1H), 2.32–2.65 (m, 16H), 1.76–1.96 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.0, 163.7, 161.5, 161.3, 142.1, 131.8, 131.0, 130.9, 130.5, 130.3, 130.2, 128.4, 128.3, 125.7, 116.4, 116.2, 115.9, 115.6, 70.1, 58.0, 56.6, 53.1, 53.0, 48.8, 33.7, 28.6, 19.9. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 213–214 °C. Anal. Calcd. (C<sub>29</sub>H<sub>34</sub>F<sub>2</sub>N<sub>2</sub>OS·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 1-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)-3,5-<i>cis</i>-dimethylpiperazine (<b>13</b>)</h4><div class="NLM_p last">A mixture of <b>10a</b> (750 mg, 2.19 mmol), <i>cis</i>-2,6-dimethylpiperazine (1.00 g, 8.75 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.21 g, 8.76 mmol) in acetonitrile (43.8 mL) was refluxed overnight. The solvent was removed and resuspended in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and water (20 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 8 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed <i>in vacuo</i>. The crude product was purified by flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH = 100:0:0–85:13.5:1.5) to give <b>13</b> (666 mg, 81%) as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.53–7.50 (m, 4H), 7.12–7.08 (m, 4H), 5.49 (s, 1H), 2.80–2.75 (m, 2H), 2.62 (d, <i>J</i> = 10.4 Hz, 2H), 2.50 (s, 4H), 1.46 (m, 2H), 0.93 (d, <i>J</i> = 6.0 Hz, 6H).</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)-2,6-<i>cis</i>-dimethylpiperazin-1-yl)propan-2-ol (<b>14a</b>)</h4><div class="NLM_p last">A mixture of <b>13</b> (200 mg, 0.53 mmol) and commercially available propylene oxide (372 μL, 5.31 mmol) in <i>i</i>PrOH (5.3 mL) was refluxed overnight. The solvent was removed and the crude oil was purified by flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH = 100:0:0–85:13.5:1.5) to give <b>14a</b> (179 mg, 78%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.28 (m, 4H), 7.03–6.87 (m, 4H), 5.18 (s, 1H), 3.63 (dq, <i>J</i> = 7.6, 6.1 Hz, 1H), 2.57 (m, 4H), 2.50–2.33 (m, 6H), 1.85–1.65 (m, 2H), 1.07 (d, <i>J</i> = 6.1 Hz, 3H), 0.99 (dd, <i>J</i> = 6.2, 2.6 Hz, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.0, 160.6, 137.0, 137.0, 129.8, 129.7, 115.5, 115.3, 65.4, 60.8, 58.5, 58.3, 57.6, 56.2, 52.8, 29.2, 20.4, 19.3, 19.1. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 148–149 °C. Anal. Calcd. (C<sub>24</sub>H<sub>32</sub>F<sub>2</sub>N<sub>2</sub>OS·2.5C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·0.5H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>S</i>)-1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)-2,6-<i>cis</i>-dimethylpiperazin-1-yl)propan-2-ol (<b>14b</b>)</h4><div class="NLM_p last">Compound <b>14b</b> was prepared as described for <b>14a</b>, using commercially available (<i>S</i>)-propylene oxide (610 μL, 8.76 mmol) to give <b>14b</b> (124 mg, 32%) as a colorless oil. [α]<sub class="stack">D</sub><sup class="stack">25</sup> 11.105 (MeOH, <i>c</i> = 8.10). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.34 (m, 4H), 7.02–6.97 (m, 4H), 5.20 (s, 1H), 3.69–3.61 (m, 1H), 2.64–2.55 (m, 4H), 2.47 (s, 4H), 2.41 (d, J = 6.8 Hz, 2H), 1.80–1.73 (m, 2H), 1.09 (d, <i>J</i> = 6.0 Hz, 3H), 1.02 (t, <i>J</i> = 2.8 Hz, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.1, 160.7, 137.0, 137.0, 129.8, 129.7, 115.6, 115.4, 65.4, 60.9, 58.5, 58.4, 57.6, 56.2, 52.9, 29.3, 20.3, 19.4, 19.1. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 133–134 °C. Anal. Calcd. (C<sub>24</sub>H<sub>32</sub>F<sub>2</sub>N<sub>2</sub>OS·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·2H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>R</i>)-1-(4-(2-((bis(4-fluorophenyl)methyl)thio)ethyl)-2,6-<i>cis</i>-dimethylpiperazin-1-yl)propan-2-ol (<b>14c</b>)</h4><div class="NLM_p last">Compound <b>14c</b> was prepared as described for <b>14a</b>, using commercially available (<i>R</i>)-propylene oxide (420 μL, 6.02 mmol) to give <b>14c</b> (278 mg, 53%) as a colorless oil. [α]<sub class="stack">D</sub><sup class="stack">25</sup> −11.187 (MeOH, <i>c</i> = 7.15). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.33 (m, 4H), 7.00–6.96 (m, 4H), 5.19 (s, 1H), 3.69–3.61 (m, 1H), 2.63–2.54 (m, 4H), 2.46 (s, 4H), 2.41 (d, <i>J</i> = 6.4 Hz, 2H), 1.79–1.73 (m, 2H), 1.08 (d, <i>J</i> = 5.2 Hz, 3H), 1.01 (t, <i>J</i> = 2.8 Hz, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.1, 160.6, 137.0, 137.0, 129.8, 129.7, 115.6, 115.3, 65.4, 60.8, 58.5, 58.4, 57.6, 56.2, 52.9, 29.3, 20.4, 19.3, 19.1. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 132–134 °C. Anal. Calcd. (C<sub>24</sub>H<sub>32</sub>F<sub>2</sub>N<sub>2</sub>OS·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·2H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)-2,6-<i>cis</i>-dimethylpiperazin-1-yl)-3-phenylpropan-2-ol (<b>14d</b>)</h4><div class="NLM_p last">Compound <b>14d</b> was prepared as described for <b>14a</b>, using commercially available (2,3-epoxypropyl)benzene (1.95 mL, 5.31 mmol) to give <b>14d</b> (124 mg, 45%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35 (dd, <i>J</i> = 8.4, 5.4 Hz, 4H), 7.25 (m, 5H), 6.99 (t, <i>J</i> = 8.5 Hz, 4H), 5.20 (s, 1H), 3.78 (dq, <i>J</i> = 10.5, 5.5 Hz, 1H), 3.54 (bs, 1H), 2.80 (dd, <i>J</i> = 13.7, 6.9 Hz, 1H), 2.76–2.53 (m, 7H), 2.51–2.35 (m, 4H), 1.74 (dd, <i>J</i> = 10.4, 7.6 Hz, 2H), 0.99–0.97 (m, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.1, 160.6, 138.4, 137.0, 137.0, 129.9, 129.8, 129.4, 129.3, 128.4, 128.4, 126.2, 115.6, 115.4, 70.1, 60.9, 60.8, 58.1, 57.6, 56.1, 52.9, 41.9, 29.2, 19.2, 19.0. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 150–152 °C. Anal. Calcd. (C<sub>30</sub>H<sub>36</sub>F<sub>2</sub>N<sub>2</sub>OS·2.5C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·0.5H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)sulfinyl)ethyl)-2,6-<i>cis</i>-dimethylpiperazin-1-yl)propan-2-ol (<b>15a</b>)</h4><div class="NLM_p last">Compound <b>15a</b> was prepared as previously described<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using <b>14a</b> (47.1 mg, 0.10 mmol) to give the product (36.9 mg, 82% yield) as a colorless oil (82% yield, 0.082 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.58–7.50 (m, 4H), 7.24–7.15 (m 4H), 5.07 (s, 1H), 3.84–3.77 (m, 1H), 3.58 (bs, 1H), 3.87–2.63 (m, 8H), 2.57 (s, 2H), 2.06–1.95 (m, 2H), 1.23–1.20 (m, 3H), 1.18–1.13 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.9, 163.7, 161.4, 161.2, 131.0, 130.9, 130.3, 130.3, 116.3, 116.1, 115.8, 115.5, 69.6, 65.3, 60.9, 60.2, 58.2, 56.1, 50.5, 48.2, 48.1, 20.4. The free base was converted to the oxalate salt and recrystallized from methanol to give an amorphous solid. Anal. Calcd. (C<sub>24</sub>H<sub>32</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-(4-(2-((Bis(4-fluorophenyl)methyl)sulfinyl)ethyl)-2,6-<i>cis</i>-dimethylpiperazin-1-yl)-3-phenylpropan-2-ol (<b>15b</b>)</h4><div class="NLM_p last">Compound <b>15b</b> was prepared as previously described<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using <b>14d</b> (34.3 mg, 0.067 mmol) to give the product (33.2 mg, 94% yield) as a colorless oil (82% yield, 0.082 mmol). The free base was converted to the oxalate salt and recrystallized from methanol to give an amorphous solid. Anal. Calcd. (C<sub>30</sub>H<sub>36</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·2H<sub>2</sub>O) C, H, N. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.55–7.52 (m, 4H), 7.32–7.21 (m, 5H), 7.17–7.09 (m, 4H), 5.10 (s, 1H), 4.22–4.16 (m, 1H), 3.75–3.65 (m, 1H), 3.53–3.42 (m, 1H), 3.31–3.16 (m, 3H), 3.01–2.84 (m, 5H), 2.79–2.72 (m, 2H), 2.69–2.62 (m, 1H), 2.47–2.32 (m, 2H), 1.29–1.06 (m, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.6, 161.6, 161.4, 137.0, 131.4, 131.3, 130.5, 130.4, 129.2, 128.4, 126.5, 115.9, 115.7, 115.3, 115.1, 69.5, 68.7, 67.7, 67.7, 60.0, 60.0, 58.1, 49.5, 49.5, 41.9, 23.9, 23.8, 23.8, 20.5, 14.1, 14.0, 13.9, 13.8.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>tert</i>-Butyl-8-(2-((bis(4-fluorophenyl)methyl)thio)ethyl)-2,8-diazaspiro[4.5]decane-2-carboxylate (<b>16</b>)</h4><div class="NLM_p last">A mixture of <b>10a</b> (428 mg, 1.25 mmol), commercially available <i>tert</i>-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate (300 mg, 1.25 mmol), and K<sub>2</sub>CO<sub>3</sub> (2.59 g, 1.88 mmol) in acetonitrile (6.25 mL) was refluxed overnight. The solvent was removed and resuspended in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and water (8 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed <i>in vacuo</i>. The crude product was purified by flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH = 100:0:0–85:13.5:1.5) to give <b>16</b> (577 mg, 89%) as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.41–7.32 (m, 4H), 7.04–6.92 (m, 4H), 5.22 (s, 1H), 3.35 (dt, <i>J</i> = 20.6, 7.0 Hz, 2H), 3.17 (s, 1H), 3.09. (s, 1H), 2.51 (s, 4H), 2.46–2.32 (m, 2H), 2.29–2.18 (m, 2H), 1.66–1.61 (m, 2H), 1.59–1.49 (m, 4H), 1.46 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 162.9, 160.5, 154.5, 137.1, 137.0, 129.8, 129.7, 115.4, 115.2, 78.9, 78.8, 77.5, 58.0, 52.7, 50.7, 44.1, 43.8, 40.3, 39.4, 34.6, 29.6, 29.4, 28.4.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 8-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)-2,8-diazaspiro[4.5]decane (<b>17</b>)</h4><div class="NLM_p last">A mixture of <b>16</b> (800 mg, 1.59 mmol) and trifluoroacetic acid (1.5 mL) in CH<sub>2</sub>Cl<sub>2</sub> (7 mL) was stirred for 5 h at room temperature. The mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (8 mL) and neutralized with 15% NH<sub>4</sub>OH (aq, 10 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed <i>in vacuo</i>. The crude product was purified by flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH = 100:0:0–85:13.5:1.5) to give <b>17</b> (589 mg, 92%) as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.35 (m, 4H), 7.01–6.96 (m, 4H), 5.21 (s, 1H), 3.37–3.33 (m, 4H), 2.93–2.89 (m, 2H), 2.65 (s, 2H), 2.32 (s, 4H), 1.56–1.50 (m, 4H), 1.55–1.51 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 162.7, 162.6, 160.2, 136.7, 129.5, 129.4, 129.3, 115.1, 114.9, 57.7, 57.7, 52.4, 50.9, 49.4, 45.5, 40.7, 40.7, 37.5, 35.7, 29.1.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 2-(8-(2-((Bis(4-fluorophenyl)methyl)thio)ethyl)-2,8-diazaspiro[4.5]decan-2-yl)-1-phenylethan-1-ol (<b>18b</b>)</h4><div class="NLM_p last">Compound <b>18b</b> was prepared as described for <b>14a</b>, using commercially available styrene oxide (5.22 mL, 75.6 mmol) to give <b>18b</b> (149 mg, 38%) as a pale yellow oil. The free base was converted to the oxalate salt and recrystallized from methanol to give an amorphous solid. Anal. Calcd. (C<sub>31</sub>H<sub>36</sub>F<sub>2</sub>N<sub>2</sub>OS·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>·0.5H<sub>2</sub>O) C, H, N. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.46–7.43 (m, 4H), 7.31–7.19 (m, 5H), 7.07–7.03 (m, 4H), 5.37 (s, 1H), 4.19–4.13 (m, 1H), 3.55–3.43 (m, 2H), 3.42–3.15 (m, 9H), 2.80–2.2.77 (m, 2H), 2.75–2.71 (m, 2H), 2.04–2.00 (t, <i>J</i> = 6.8 Hz, 2H), 2.01–1.87 (m, 4H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 165.2, 163.2, 160.8, 137.0, 136.8, 136.7, 129.8, 129.8.9, 129.2, 128.2, 126.3, 115.2, 115.0, 67.3, 60.2, 55.3, 53.7, 51.6, 49.6, 49.5, 41.4, 38.7, 32.2, 25.3.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 1-(8-(2-((Bis(4-fluorophenyl)methyl)sulfinyl)ethyl)-2,8-diazaspiro[4.5]decan-2-yl)propan-2-ol (<b>19</b>)</h4><div class="NLM_p last">Compound <b>19</b> was prepared as described for <b>14a</b> followed by <b>15a</b>, using commercially available propylene oxide (2 mL) to give <b>19</b> (24.0 mg, 21% yield over two steps) as a colorless oil. The free base was converted to the oxalate salt and recrystallized from methanol to give a white solid. Mp 166–167 °C. Anal. Calcd. (C<sub>26</sub>H<sub>34</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S·2C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.48–7.44 (m, 4H), 7.08–7.34 (m, 4H), 5.38 (s, 1H), 4.10–4.07 (m, 1H), 3.54–3.08 (m, 12H), 2.77–2.72 (m, 2H), 2.07–1.94 (m, 6H), 1.20 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 165.2, 163.3, 160.8, 136.8, 136.7, 129.9, 129.8, 115.2, 115.0, 62.4, 61.8, 55.3, 53.4, 51.6, 49.6, 49.5, 38.8, 32.2, 25.3, 20.0.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Radioligand Binding Studies</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> DAT Binding Assay</h4><div class="NLM_p last">Frozen striatum membranes dissected from male Sprague–Dawley rat brains (supplied on ice by Bioreclamation, Hicksville, NY) were homogenized in 20 volumes (w/v) of ice cold modified sucrose phosphate buffer (0.32 M sucrose, 7.74 mM Na<sub>2</sub>HPO<sub>4</sub>, and 2.26 mM NaH<sub>2</sub>PO<sub>4</sub>, pH adjusted to 7.4) using a Brinkman Polytron (Setting 6 for 20 s) and centrifuged at 48,400<i>g</i> for 10 min at 4 °C. The resulting pellet was resuspended in buffer, recentrifuged, and suspended in ice cold buffer again to a concentration of 20 mg/mL, original wet weight (OWW). Experiments were conducted in 96-well polypropylene plates containing 50 μL of various concentrations of the inhibitor, diluted using 30% DMSO vehicle, 300 μL of sucrose phosphate buffer, 50 μL of [<sup>3</sup>H]WIN 35,428<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> (final concentration 1.5 nM; <i>K</i><sub>d</sub> = 28.2 nM; PerkinElmer Life Sciences, Waltham, MA), and 100 μL of tissue (2.0 mg/well OWW). All compound dilutions were tested in triplicate and the competition reactions started with the addition of tissue, and the plates were incubated for 120 min at 0–4 °C. Nonspecific binding was determined using 10 μM indatraline.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> SERT Binding Assay</h4><div class="NLM_p last">Frozen stem membranes dissected from male Sprague–Dawley rat brains (supplied on ice by Bioreclamation, Hicksville, NY) were homogenized in 20 volumes (w/v) of 50 mM Tris buffer (120 mM NaCl and 5 mM KCl, adjusted to pH 7.4) at 25 °C using a Brinkman Polytron (at setting 6 for 20 s) and centrifuged at 48,400<i>g</i> for 10 min at 4 °C. The resulting pellet was resuspended in buffer, recentrifuged, and suspended in buffer again to a concentration of 20 mg/mL, OWW. Experiments were conducted in 96-well polypropylene plates containing 50 μL of various concentrations of the inhibitor, diluted using 30% DMSO vehicle, 300 μL of Tris buffer, 50 μL of [<sup>3</sup>H]citalopram (final concentration 1.5 nM; <i>K</i><sub>d</sub> = 6.91 nM; PerkinElmer Life Sciences, Waltham, MA), and 100 μL of tissue (2.0 mg/well OWW). All compound dilutions were tested in triplicate, and the competition reactions started with the addition of tissue, and the plates were incubated for 60 min at room temperature. Nonspecific binding was determined using 10 μM fluoxetine.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> σ1 Receptor Binding Assay</h4><div class="NLM_p">σ1R binding was performed as previously reported.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Frozen cortex membranes dissected from male guinea pig brains (supplied on ice by Bioreclamation, Hicksville, NY) were homogenized in 10 volumes (w/v) of ice cold modified sucrose Tris buffer (10 mM Tris-HCl with 0.32 M sucrose, adjusted to pH 7.4) with a glass and Teflon homogenizer. The homogenate was centrifuged at 1,240<i>g</i> for 10 min at 4 °C. The supernatant was collected into a clean centrifuge tube, and the remaining pellet was resuspended in 10 volumes (w/v) of buffer and centrifuged again at 48,400<i>g</i> for 15 min at 4 °C. The resulting pellet was resuspended in ice cold buffer to 50 mg/mL, OWW. Experiments were conducted in 96-well polypropylene plates containing 50 μL of various concentrations of the inhibitor, diluted using 30% DMSO vehicle, 300 μL of modified sucrose Tris buffer, 50 μL of [<sup>3</sup>H](+)-pentazocine (final concentration 3 nM; <i>K</i><sub><i>d</i></sub> = 5.18 nM; PerkinElmer Life and Analytical Sciences, Waltham, MA), and 100 μL of tissue (5.0 mg/well OWW). All compound dilutions were tested in triplicate and the competition reactions started with the addition of tissue, and the plates were incubated for 120 min at room temperature. Nonspecific binding was determined using 10 μM of either PRE084 or (+)-pentazocine.</div><div class="NLM_p last">For all binding assays, incubations were terminated by rapid filtration through PerkinElmer Uni-Filter-96 GF/B (DAT, SERT and σ1R) or Whatman GF/B filters (NET), presoaked in either 0.3% (SERT and NET) or 0.05% (DAT and σ1R) polyethylenimine, using a Brandel 96-Well Plates Harvester Manifold or Brandel R48 filtering manifold (Brandel Instruments, Gaithersburg, MD). The filters were washed a total of three times with 3 mL (3 × 1 mL/well or 3 × 1 mL/tube) of ice cold binding buffer. For DAT, SERT, and σ1R binding experiments, 65 μL of PerkinElmer MicroScint 20 Scintillation Cocktail was added to each filter well. For NET binding experiment, the filters were transferred in 24-well scintillation plates, and 600 μL of CytoScint was added to each well. All the plates/filters were counted using a PerkinElmer MicroBeta Microplate Counter. IC<sub>50</sub> values for each compound were determined from inhibition curves, and <i>K</i><sub>i</sub> values were calculated using the Cheng–Prusoff equation.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> When a complete inhibition could not be achieved at the highest tested concentrations, <i>K</i><sub>i</sub> values have been extrapolated by constraining the bottom of the dose–response curves (= 0% residual specific binding) in the nonlinear regression analysis. These analyses were performed using GraphPad Prism version 8.00 for Macintosh (GraphPad Software, San Diego, CA). <i>K</i><sub>d</sub> values for the radioligands were determined via separate homologous competitive binding or radioligand binding saturation experiments. <i>K</i><sub>i</sub> values were determined from at least three independent experiments performed in triplicate and are reported as mean ± SEM, and the results were rounded to the third significant figure.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Molecular Pharmacology</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Site-Directed Mutagenesis</h4><div class="NLM_p last">The Y156F mutation was introduced with QuickChange (adapted from Stratagene, La Jolla, CA) on DAT WT cDNA cloned into the pcDNA3 expression vector. Clones carrying the mutation were detected by DNA sequencing (Eurofins Genomics, DE), and plasmids were amplified by transformation (XL1 blue cells (Stratagene)) and harvested using the maxi prep kit (Qiagen) according to the manufacturer’s manual.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Cell Culture and Transfection</h4><div class="NLM_p last">COS7 cells were grown in Dulbecco’s modified Eagle’s medium 041 01885 supplemented with 10% fetal calf serum, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 0.01 mg/mL gentamicin at 37 °C in 10% CO<sub>2</sub>. DAT WT and Y156F were transiently transfected into COS7 cells with Lipo2000 (Invitrogen) according to the manufacturer’s manual using a cDNA:Lipo2000 ratio of 3:6.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> [<sup>3</sup>H]WIN35,428 Binding Experiments</h4><div class="NLM_p">Binding assays were carried out essentially as described.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Transfected COS7 cells were plated in 24-well dishes (10<sup>5</sup> cells/well) coated with poly-ornithine (Sigma). Forty-eight hours after transfection, cells were washed with 500 μL of uptake buffer (UB) (25 mM HEPES, 130 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl<sub>2</sub>, 1.2 mM MgSO<sub>4</sub>, 1 mM <span class="smallcaps smallerCapital">l</span>-ascorbic acid, 5 mM <span class="smallcaps smallerCapital">d</span>-glucose, and 1 μM catechol-<i>O</i>-methyltransferase inhibitor Ro 41-0960 (Sigma), pH 7.4), and the nonlabeled compound was added to the cells in a total volume of 500 μL UB. The assay was initiated by the addition of 10 nM [<sup>3</sup>H]WIN35,428 (82 Ci/mmol) (Novandi Chemistry, SE). The reactions were incubated at 5°C until equilibrium was obtained (>90 min). Then cells were washed twice with 500 μL of ice cold UB, lysed in 250 μL of 1% SDS, and left for >30 min at RT on gentle shaking. All experiments were carried out with 10 concentrations of unlabeled ligand within a concentration range from 1 nM to 1 mM, performed in triplicates.</div><div class="NLM_p last">All samples were transferred to 24-well counting plates (PerkinElmer, Waltham, MA), and 500 μL (24 well) of Opti-phase Hi Safe 3 scintillation fluid (PerkinElmer) was added followed by counting of the plates in a Wallac Tri-Lux β-scintillation counter (PerkinElmer).</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Phase I Metabolism in Mouse Liver Microsomes</h3><div class="NLM_p">The phase I metabolic stability assay was conducted in mouse liver microsomes as previously described with minor modifications.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> In brief, the reaction was carried out with 100 mM potassium phosphate buffer, pH 7.4, in the presence of the NADPH regenerating system (compound final concentration was 10 μM; and 0.5 mg/mL microsomes). Positive controls for phase I metabolism (buprenorphine) were also evaluated. Compound disappearance was monitored over time using a liquid chromatography and tandem mass spectrometry (LC/MS/MS) method. All reactions were performed in triplicate.</div><div class="NLM_p last">Chromatographic analysis was performed using an Accela ultrahigh-performance system consisting of an analytical pump and an autosampler coupled with a TSQ Vantage mass spectrometer (Thermo Fisher Scientific Inc., Waltham, MA). Chromatographic separation was achieved at ambient temperature using Agilent Eclipse Plus column (100 × 2.1 mm i.d.) packed with a 1.8 μm C18 stationary phase. The mobile phase consisted of 0.1% formic acid in acetonitrile and 0.1% formic acid in H<sub>2</sub>O with gradient elution, starting with 10% (organic) linearly increasing to 99% (0–2 min), maintaining at 99% (2–2.5 min), and re-equilibrating to 10% by 2.7 min. The total run time for each analyte was 4.5 min. The mass transitions used for compounds for LC/MS/MS analysis are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Metabolite Identification in Mouse Liver Microsomes</h3><div class="NLM_p last">Metabolite identification (MET-ID) was performed on a Dionex ultra high-performance LC system coupled with Q Exactive Focus orbitrap mass spectrometer (Thermo Fisher Scientific Inc., Waltham MA). Separation was achieved using Agilent Eclipse Plus column (100 × 2.1 mm i.d.; maintained at 35 °C) packed with a 1.8 μm C18 stationary phase. The mobile phase consisted of 0.1% formic acid in water and 0.1% formic acid in acetonitrile. Pumps were operated at a flow rate of 0.3 mL/min for 7 min using gradient elution. The mass spectrometer controlled by Xcalibur software 4.0.27.13 (Thermo Scientific) was operated with a HESI ion source in positive ionization mode. Metabolites were identified in the full-scan mode (from <i>m</i>/<i>z</i> 50 to 1600) by comparing <i>t</i> = 0 samples with <i>t</i> = 60 min samples, and structures were proposed based on the accurate mass information.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Locomotor Activity Studies in Mice</h3><div class="NLM_p last">Approximately two hours before the behavioral test, animals were transferred from the animal facility vivarium to the behavioral laboratory. After the acclimatization period, mice were injected i.p. with test compounds or vehicle and then immediately placed into the open field cages. These were clear acrylic testing chambers (40 cm<sup>3</sup>) (Med Associates, St. Albans, VT) provided with infrared light beam sources spaced 2.5 cm apart along two perpendicular walls directed at light sensitive detectors mounted on the opposing walls of the open field. Ambulatory activity in mice was detected by interruption of the light beams, where the occurrence during a 2 h session was automatically recorded and then transformed in distance traveled. The data obtained for each animal and dose of compounds (cocaine, 3, 10, 17, and 30 mg/kg; <b>14a</b>, 1, 3, 10, 30 mg/kg; <b>14b</b>, 1, 3, 10 mg/kg; <b>14c</b>, 1, 3, 10 mg/kg; <b>3b</b>, 3, 10, 30, 56 mg/kg) was averaged to obtain the group mean (<i>n</i> = 6 for all groups) and corresponding SEM. In <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, data have been expressed as the maximum distance traveled in cm/30 min over a 2 h session, as a function of drug and dose. Data were analyzed by two-way ANOVA with “Dose” and “Drug” as factors. Tukey’s posthoc test was employed to compare the activity produced by administration of different drugs and also to compare differences in activity between different doses of test compounds and vehicle. Mice were used only once. Data for <b>3b</b> were reanalyzed from results shown in Keighron et al. 2019,<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> which were obtained under identical conditions and with the same open field chambers used to assess the behavioral activity shown in the present study.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01188" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40207" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40207" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b01188" class="ext-link">10.1021/acs.jmedchem.9b01188</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Microanalysis data on all final compounds, phase I metabolic stability data in mouse liver microsomes, metabolite ID, metabolic stability data in human liver microsomes, and off target binding data on selected compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_001.pdf">jm9b01188_si_001.pdf (320.13 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_002.csv">jm9b01188_si_002.csv (3.37 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01188" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56316" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56316" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy Hauck Newman</span> - <span class="hlFld-Affiliation affiliation">Molecular
Targets and Medications Discovery Branch, National Institute on Drug
Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9065-4072" title="Orcid link">http://orcid.org/0000-0001-9065-4072</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#24454a415349454a644d4a5056450a4a4d40450a4a4d4c0a434b52"><span class="__cf_email__" data-cfemail="92f3fcf7e5fff3fcd2fbfce6e0f3bcfcfbf6f3bcfcfbfabcf5fde4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rachel D. Slack</span> - <span class="hlFld-Affiliation affiliation">Molecular
Targets and Medications Discovery Branch, National Institute on Drug
Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Therese C. Ku</span> - <span class="hlFld-Affiliation affiliation">Molecular
Targets and Medications Discovery Branch, National Institute on Drug
Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8353-4985" title="Orcid link">http://orcid.org/0000-0002-8353-4985</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianjing Cao</span> - <span class="hlFld-Affiliation affiliation">Molecular
Targets and Medications Discovery Branch, National Institute on Drug
Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">JoLynn B. Giancola</span> - <span class="hlFld-Affiliation affiliation">Molecular
Targets and Medications Discovery Branch, National Institute on Drug
Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alessandro Bonifazi</span> - <span class="hlFld-Affiliation affiliation">Molecular
Targets and Medications Discovery Branch, National Institute on Drug
Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7306-0114" title="Orcid link">http://orcid.org/0000-0002-7306-0114</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claus J. Loland</span> - <span class="hlFld-Affiliation affiliation">Molecular
Neuropharmacology and Genetics Laboratory, Department of Neuroscience
and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexandra Gadiano</span> - <span class="hlFld-Affiliation affiliation">Molecular
Targets and Medications Discovery Branch, National Institute on Drug
Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, Maryland 21205, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jenny Lam</span> - <span class="hlFld-Affiliation affiliation">Molecular
Targets and Medications Discovery Branch, National Institute on Drug
Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, Maryland 21205, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rana Rais</span> - <span class="hlFld-Affiliation affiliation">Department
of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, Maryland 21205, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4059-2453" title="Orcid link">http://orcid.org/0000-0003-4059-2453</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara S. Slusher</span> - <span class="hlFld-Affiliation affiliation">Department
of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, Maryland 21205, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9814-4157" title="Orcid link">http://orcid.org/0000-0001-9814-4157</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Coggiano</span> - <span class="hlFld-Affiliation affiliation">Molecular
Targets and Medications Discovery Branch, National Institute on Drug
Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gianluigi Tanda</span> - <span class="hlFld-Affiliation affiliation">Molecular
Targets and Medications Discovery Branch, National Institute on Drug
Abuse−Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>R.D.S., T.K., and J.C. contributed equally to this work. R.D.S. and A.H.N. designed the project; R.D.S., T.K., and A.H.N. wrote the manuscript with input of all authors; R.D.S., T.K., J.C., J.G., A.B., C.J.L., A.G., J.L., R.R., B.S.S., M.C., G.T., and A.H.N. designed and/or supervised the experiments and data analyses; R.D.S., T.K., J.C., J.G., A.B., A.G., J.L., and M.C. performed experiments.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e4627-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17886" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17886" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Support for this research was provided by the National Institute on Drug Abuse - Intramural Research Program (Z1A DA000389). C.J.L. is supported by the Danish Council for Independent Research (0602-02100B and 4183-00581). Care of the animals was in accordance with the guidelines of the National Institutes of Health and the National Institute on Drug Abuse Intramural Research Program Animal Care and Use Program, which is fully accredited by AAALAC International.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">ABBREVIATIONS</td></tr><tr><td class="NLM_term">ADHD</td><td class="NLM_def"><p class="first last">attention-deficit/hyperactivity disorder</p></td></tr><tr><td class="NLM_term">ANOVA</td><td class="NLM_def"><p class="first last">analysis of variance</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyloxycarbonyl</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CFT</td><td class="NLM_def"><p class="first last">β-carbomethoxy-3-β-(4-fluorophenyl)tropane</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DA</td><td class="NLM_def"><p class="first last">dopamine</p></td></tr><tr><td class="NLM_term">DAT</td><td class="NLM_def"><p class="first last">dopamine transporter</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DEA</td><td class="NLM_def"><p class="first last">Drug Enforcement Administration</p></td></tr><tr><td class="NLM_term">dec.</td><td class="NLM_def"><p class="first last">decomposed</p></td></tr><tr><td class="NLM_term">DMPK</td><td class="NLM_def"><p class="first last">drug metabolism and pharmacokinetics</p></td></tr><tr><td class="NLM_term">EI</td><td class="NLM_def"><p class="first last">electron ionization</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">GC</td><td class="NLM_def"><p class="first last">gas chromatography</p></td></tr><tr><td class="NLM_term">hDAT</td><td class="NLM_def"><p class="first last">human dopamine transporter</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">HESI</td><td class="NLM_def"><p class="first last">heated electrospray ionization</p></td></tr><tr><td class="NLM_term">i.p.</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term"><i>K</i><sub><i>d</i></sub></td><td class="NLM_def"><p class="first last">dissociation constant</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub></td><td class="NLM_def"><p class="first last">inhibitor constant</p></td></tr><tr><td class="NLM_term">LC</td><td class="NLM_def"><p class="first last">liquid chromatography</p></td></tr><tr><td class="NLM_term">MAT</td><td class="NLM_def"><p class="first last">medication-assisted treatment</p></td></tr><tr><td class="NLM_term">MD</td><td class="NLM_def"><p class="first last">molecular dynamics</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">MET-ID</td><td class="NLM_def"><p class="first last">metabolite identification</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">NET</td><td class="NLM_def"><p class="first last">norepinephrine transporter</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">NT</td><td class="NLM_def"><p class="first last">not tested</p></td></tr><tr><td class="NLM_term">OWW</td><td class="NLM_def"><p class="first last">original wet weight</p></td></tr><tr><td class="NLM_term">ppm</td><td class="NLM_def"><p class="first last">parts per million</p></td></tr><tr><td class="NLM_term">rDAT</td><td class="NLM_def"><p class="first last">rat dopamine transporter</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">σ1R</td><td class="NLM_def"><p class="first last">sigma 1 receptor</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term"><i>t</i><sub><i>1/2</i></sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TSQ</td><td class="NLM_def"><p class="first last">triple quadrupole</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild type</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 78 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">NIDA</span>. Overdose Death Rates. <a href="https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates" class="extLink">https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates</a> (accessed Apr 10, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIDA.+Overdose+Death+Rates.+https%3A%2F%2Fwww.drugabuse.gov%2Frelated-topics%2Ftrends-statistics%2Foverdose-death-rates+%28accessed+Apr+10%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">DEA</span>. <span class="NLM_year">2017</span> National Drug
Threat Assessment. <a href="https://www.dea.gov/documents/2017/10/01/2017-national-drug-threat-assessment" class="extLink">https://www.dea.gov/documents/2017/10/01/2017-national-drug-threat-assessment</a> (accessed Apr 15, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DEA.+2017+National+Drug%0AThreat+Assessment.+https%3A%2F%2Fwww.dea.gov%2Fdocuments%2F2017%2F10%2F01%2F2017-national-drug-threat-assessment+%28accessed+Apr+15%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoops, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, C. R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the “pipeline″ for development of medications for cocaine use disorder: A review of translational preclinical, human laboratory, and clinical trial research</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1124/pr.115.011668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fpr.115.011668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=27255266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFCktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=533-562&author=P.+W.+Czotyauthor=W.+W.+Stoopsauthor=C.+R.+Rush&title=Evaluation+of+the+%E2%80%9Cpipeline%E2%80%B3+for+development+of+medications+for+cocaine+use+disorder%3A+A+review+of+translational+preclinical%2C+human+laboratory%2C+and+clinical+trial+research&doi=10.1124%2Fpr.115.011668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the "pipeline" for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research</span></div><div class="casAuthors">Czoty, Paul W.; Stoops, William W.; Rush, Craig R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">533-562</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cocaine use disorder is a persistent public health problem for which no widely effective medications exist.  Self-administration procedures,which have shown good predictive validity in estg. the abuse potential of drugs, have been used in rodent, nonhuman primate, and human lab. studies to screen putative medications.  This review assessed the effectiveness of the medications development process regarding pharmacotherapies for cocaine use disorder.  The primary objective was to det. whether data from animal and human lab. self-administration studies predicted the results of clin. trials.  Inaddn., the concordance between lab. studies in animals and humans was assessed.  More than 100 blinded, randomized, fully placebo-controlled studies of putative medications for cocaine use disorder were identified.  Of the 64 drugs tested in these trials, only 10 had been examd. in both human and well-controlled animal lab. studies.  Within all three stages, few studies had been conducted for each drug and when multiple studies had been conducted conclusions were sometimes contradictory.  Overall, however, there was good concordance between animal and human lab. results when the former assessed chronic drug treatment.  Although only seven of the ten reviewed drugs showed fully concordant results across all three types of studies reviewed, the anal. revealed several subject-related, procedural, and environmental factors that differ between the lab. and clin. trial settings that help explain the disagreement for other drugs.  The review closes with several recommendations to enhance translation and communication across stages of the medications development process that will ultimately speed the progress toward effective pharmacotherapeutic strategies for cocaine use disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBBhIuhvG6aLVg90H21EOLACvtfcHk0lhqV84UKlhuPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFCktr8%253D&md5=dad28b6d0c2cb2d9f91e77cf74684021</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1124%2Fpr.115.011668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.115.011668%26sid%3Dliteratum%253Aachs%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DStoops%26aufirst%3DW.%2BW.%26aulast%3DRush%26aufirst%3DC.%2BR.%26atitle%3DEvaluation%2520of%2520the%2520%25E2%2580%259Cpipeline%25E2%2580%25B3%2520for%2520development%2520of%2520medications%2520for%2520cocaine%2520use%2520disorder%253A%2520A%2520review%2520of%2520translational%2520preclinical%252C%2520human%2520laboratory%252C%2520and%2520clinical%2520trial%2520research%26jtitle%3DPharmacol.%2520Rev.%26date%3D2016%26volume%3D68%26spage%3D533%26epage%3D562%26doi%3D10.1124%2Fpr.115.011668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattick, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoli, M.</span></span> <span> </span><span class="NLM_article-title">Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence</span>. <i>Cochrane Db. Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_fpage">CD002209</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD002209.pub2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1002%2F14651858.CD002209.pub2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=19588333" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=CD002209&author=R.+P.+Mattickauthor=C.+Breenauthor=J.+Kimberauthor=M.+Davoli&title=Methadone+maintenance+therapy+versus+no+opioid+replacement+therapy+for+opioid+dependence&doi=10.1002%2F14651858.CD002209.pub2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD002209.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD002209.pub2%26sid%3Dliteratum%253Aachs%26aulast%3DMattick%26aufirst%3DR.%2BP.%26aulast%3DBreen%26aufirst%3DC.%26aulast%3DKimber%26aufirst%3DJ.%26aulast%3DDavoli%26aufirst%3DM.%26atitle%3DMethadone%2520maintenance%2520therapy%2520versus%2520no%2520opioid%2520replacement%2520therapy%2520for%2520opioid%2520dependence%26jtitle%3DCochrane%2520Db.%2520Syst.%2520Rev.%26date%3D2009%26spage%3DCD002209%26doi%3D10.1002%2F14651858.CD002209.pub2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattick, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoli, M.</span></span> <span> </span><span class="NLM_article-title">Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence</span>. <i>Cochrane Db. Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_fpage">CD002207</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD002207.pub4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1002%2F14651858.CD002207.pub4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=24500948" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=CD002207&author=R.+P.+Mattickauthor=C.+Breenauthor=J.+Kimberauthor=M.+Davoli&title=Buprenorphine+maintenance+versus+placebo+or+methadone+maintenance+for+opioid+dependence&doi=10.1002%2F14651858.CD002207.pub4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD002207.pub4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD002207.pub4%26sid%3Dliteratum%253Aachs%26aulast%3DMattick%26aufirst%3DR.%2BP.%26aulast%3DBreen%26aufirst%3DC.%26aulast%3DKimber%26aufirst%3DJ.%26aulast%3DDavoli%26aufirst%3DM.%26atitle%3DBuprenorphine%2520maintenance%2520versus%2520placebo%2520or%2520methadone%2520maintenance%2520for%2520opioid%2520dependence%26jtitle%3DCochrane%2520Db.%2520Syst.%2520Rev.%26date%3D2014%26spage%3DCD002207%26doi%3D10.1002%2F14651858.CD002207.pub4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gryczynski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Grady, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharfstein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, J. H.</span></span> <span> </span><span class="NLM_article-title">Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009</span>. <i>Am. J. Public Health</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.2105/AJPH.2012.301049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.2105%2FAJPH.2012.301049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=23488511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A280%3ADC%252BC3svmtVWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2013&pages=917-922&author=R.+P.+Schwartzauthor=J.+Gryczynskiauthor=K.+E.+O%E2%80%99Gradyauthor=J.+M.+Sharfsteinauthor=G.+Warrenauthor=Y.+Olsenauthor=S.+G.+Mitchellauthor=J.+H.+Jaffe&title=Opioid+agonist+treatments+and+heroin+overdose+deaths+in+Baltimore%2C+Maryland%2C+1995%E2%80%932009&doi=10.2105%2FAJPH.2012.301049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009</span></div><div class="casAuthors">Schwartz Robert P; Gryczynski Jan; O'Grady Kevin E; Sharfstein Joshua M; Warren Gregory; Olsen Yngvild; Mitchell Shannon G; Jaffe Jerome H</div><div class="citationInfo"><span class="NLM_cas:title">American journal of public health</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">917-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  We examined the association between the expansion of methadone and buprenorphine treatment and the prevalence of heroin overdose deaths in Baltimore, Maryland from 1995 to 2009.  METHODS:  We conducted a longitudinal time series analysis of archival data using linear regression with the Newey-West method to correct SEs for heteroscedasticity and autocorrelation, adjusting for average heroin purity.  RESULTS:  Overdose deaths attributed to heroin ranged from a high of 312 in 1999 to a low of 106 in 2008.  While mean heroin purity rose sharply (1995-1999), the increasing number of patients treated with methadone was not associated with a change in the number of overdose deaths, but starting in 2000 expansion of opioid agonist treatment was associated with a decline in overdose deaths.  Adjusting for heroin purity and the number of methadone patients, there was a statistically significant inverse relationship between heroin overdose deaths and patients treated with buprenorphine (P = .002).  CONCLUSIONS:  Increased access to opioid agonist treatment was associated with a reduction in heroin overdose deaths.  Implementing policies that support evidence-based medication treatment of opiate dependence may decrease heroin overdose deaths.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrsDQJcRzzexFwe7cAcrfPfW6udTcc2eZLozKljWVFmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svmtVWitQ%253D%253D&md5=8753afe14d97538cee99ec110ea6c1ab</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2105%2FAJPH.2012.301049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2105%252FAJPH.2012.301049%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DR.%2BP.%26aulast%3DGryczynski%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Grady%26aufirst%3DK.%2BE.%26aulast%3DSharfstein%26aufirst%3DJ.%2BM.%26aulast%3DWarren%26aufirst%3DG.%26aulast%3DOlsen%26aufirst%3DY.%26aulast%3DMitchell%26aufirst%3DS.%2BG.%26aulast%3DJaffe%26aufirst%3DJ.%2BH.%26atitle%3DOpioid%2520agonist%2520treatments%2520and%2520heroin%2520overdose%2520deaths%2520in%2520Baltimore%252C%2520Maryland%252C%25201995%25E2%2580%25932009%26jtitle%3DAm.%2520J.%2520Public%2520Health%26date%3D2013%26volume%3D103%26spage%3D917%26epage%3D922%26doi%3D10.2105%2FAJPH.2012.301049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span> <span> </span><span class="NLM_article-title">Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">107609</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2019.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.neuropharm.2019.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=31009632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosFWisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2019&pages=107609&author=C.+J.+Jordanauthor=J.+Caoauthor=A.+H.+Newmanauthor=Z.+X.+Xi&title=Progress+in+agonist+therapy+for+substance+use+disorders%3A+Lessons+learned+from+methadone+and+buprenorphine&doi=10.1016%2Fj.neuropharm.2019.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine</span></div><div class="casAuthors">Jordan, Chloe J.; Cao, Jianjing; Newman, Amy Hauck; Xi, Zheng-Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107609</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Substance use disorders (SUD) are serious public health problems worldwide.  Although significant progress has been made in understanding the neurobiol. of drug reward and the transition to addiction, effective pharmacotherapies for SUD remain limited and a majority of drug users relapse even after a period of treatment.  The United States Food and Drug Administration (FDA) has approved several medications for opioid, nicotine, and alc. use disorders, whereas none are approved for the treatment of cocaine or other psychostimulant use disorders.  The medications approved by the FDA for the treatment of SUD can be divided into two major classes - agonist replacement therapies, such as methadone and buprenorphine for opioid use disorders (OUD), nicotine replacement therapy (NRT) and varenicline for nicotine use disorders (NUD), and antagonist therapies, such as naloxone for opioid overdose and naltrexone for promoting abstinence.  In the present review, we primarily focus on the pharmacol. rationale of agonist replacement strategies in treatment of opioid dependence, and the potential translation of this rationale to new therapies for cocaine use disorders.  We begin by describing the neural mechanisms underlying opioid reward, followed by preclin. and clin. findings supporting the utility of agonist therapies in the treatment of OUD.  We then discuss recent progress of agonist therapies for cocaine use disorders based on lessons learned from methadone and buprenorphine.  We contend that future studies should identify agonist pharmacotherapies that can facilitate abstinence in patients who are motivated to quit their illicit drug use.  Focusing on those that are able to achieve abstinence from cocaine will provide a platform to broaden the effectiveness of medication and psychosocial treatment strategies for this underserved population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFbQUGhmBexbVg90H21EOLACvtfcHk0lgUk8rsj3z5AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosFWisb4%253D&md5=87d3c94b52fb376a0ae6beddb14b62ef</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2019.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2019.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DC.%2BJ.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26atitle%3DProgress%2520in%2520agonist%2520therapy%2520for%2520substance%2520use%2520disorders%253A%2520Lessons%2520learned%2520from%2520methadone%2520and%2520buprenorphine%26jtitle%3DNeuropharmacology%26date%3D2019%26volume%3D158%26spage%3D107609%26doi%3D10.1016%2Fj.neuropharm.2019.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balster, R. L.</span>; <span class="NLM_string-name">Kuhar, M. J.</span>; <span class="NLM_string-name">Schuster, C. R.</span></span> <i>Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach</i>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1996</span>; Vol.  <span class="NLM_volume">xxv</span>, p  <span class="NLM_fpage">658</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&pages=658&author=R.+L.+Balster&author=M.+J.+Kuhar&author=C.+R.+Schuster&title=Pharmacological+Aspects+of+Drug+Dependence%3A+Toward+an+Integrated+Neurobehavioral+Approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBalster%26aufirst%3DR.%2BL.%26btitle%3DPharmacological%2520Aspects%2520of%2520Drug%2520Dependence%253A%2520Toward%2520an%2520Integrated%2520Neurobehavioral%2520Approach%26pub%3DSpringer%26date%3D1996%26volume%3Dxxv%26spage%3D658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E. A.</span></span> <span> </span><span class="NLM_article-title">Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wildtype and mutant human dopamine transporters: molecular features that differentially determine antagonist binding properties</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2008.05667.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1111%2Fj.1471-4159.2008.05667.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ejurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=296-296&author=K.+C.+Schmittauthor=J.+Zhenauthor=P.+Kharkarauthor=M.+Mishraauthor=N.+Chenauthor=A.+K.+Duttaauthor=M.+E.+A.+Reith&title=Interaction+of+cocaine-%2C+benztropine-%2C+and+GBR12909-like+compounds+with+wildtype+and+mutant+human+dopamine+transporters%3A+molecular+features+that+differentially+determine+antagonist+binding+properties&doi=10.1111%2Fj.1471-4159.2008.05667.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties. [Erratum to document cited in CA150:113703]</span></div><div class="casAuthors">Schmitt, Kyle C.; Zhen, Juan; Kharkar, Prashant; Mishra, Manoj; Chen, Nianhang; Dutta, Aloke K.; Reith, Maarten E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">296</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tables 1 (page 934) and 2 (page 935), were incorrectly given; the correct version of the tables, are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHQ_6f_PmRirVg90H21EOLACvtfcHk0lgUk8rsj3z5AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ejurjF&md5=47d05a0a49ad406302ee50cf19056cbe</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2008.05667.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2008.05667.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DK.%2BC.%26aulast%3DZhen%26aufirst%3DJ.%26aulast%3DKharkar%26aufirst%3DP.%26aulast%3DMishra%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DN.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26aulast%3DReith%26aufirst%3DM.%2BE.%2BA.%26atitle%3DInteraction%2520of%2520cocaine-%252C%2520benztropine-%252C%2520and%2520GBR12909-like%2520compounds%2520with%2520wildtype%2520and%2520mutant%2520human%2520dopamine%2520transporters%253A%2520molecular%2520features%2520that%2520differentially%2520determine%2520antagonist%2520binding%2520properties%26jtitle%3DJ.%2520Neurochem.%26date%3D2010%26volume%3D115%26spage%3D296%26epage%3D296%26doi%3D10.1111%2Fj.1471-4159.2008.05667.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E. A.</span></span> <span> </span><span class="NLM_article-title">Regulation of the dopamine transporter Aspects relevant to psychostimulant drugs of abuse</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1187</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.05148.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1111%2Fj.1749-6632.2009.05148.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=20201860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3cXks1Smsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1187&publication_year=2010&pages=316-340&author=K.+C.+Schmittauthor=M.+E.+A.+Reith&title=Regulation+of+the+dopamine+transporter+Aspects+relevant+to+psychostimulant+drugs+of+abuse&doi=10.1111%2Fj.1749-6632.2009.05148.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse</span></div><div class="casAuthors">Schmitt, Kyle C.; Reith, Maarten E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1187</span>
        (<span class="NLM_cas:issue">Addiction Reviews 2</span>),
    <span class="NLM_cas:pages">316-340</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Dopaminergic signaling in the brain is primarily modulated by dopamine transporters (DATs), which actively translocate extraneuronal dopamine back into dopaminergic neurons.  Transporter proteins are highly dynamic, continuously trafficking between plasmalemmal and endosomal membranes.  Changes in DAT membrane trafficking kinetics can rapidly regulate dopaminergic tone by altering the no. of transporters present at the cell surface.  Various psychostimulant DAT ligands-acting either as amphetamine-like substrates or cocaine-like nontranslocated inhibitors-affect transporter trafficking, triggering rapid insertion or removal of plasmalemmal DATs.  In this review, we focus on the effects of psychostimulants of addiction (particularly D-methamphetamine and cocaine) on DAT regulation and membrane trafficking, with an emphasis on how these drugs may influence intracellular signaling cascades and transporter-assocd. scaffolding proteins to affect DAT regulation.  In addn., we consider involvement of presynaptic receptors for dopamine and other ligands in DAT regulation.  Finally, we discuss possible implications of transporter regulation to the putative toxicity of several substituted amphetamine derivs. commonly used as recreational drugs, as well as to the design of therapeutics for cocaine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKPcrkSAoXX7Vg90H21EOLACvtfcHk0lgUk8rsj3z5AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXks1Smsrk%253D&md5=31977cbff667a331923e279d4b1be89f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.05148.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.05148.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DK.%2BC.%26aulast%3DReith%26aufirst%3DM.%2BE.%2BA.%26atitle%3DRegulation%2520of%2520the%2520dopamine%2520transporter%2520Aspects%2520relevant%2520to%2520psychostimulant%2520drugs%2520of%2520abuse%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2010%26volume%3D1187%26spage%3D316%26epage%3D340%26doi%3D10.1111%2Fj.1749-6632.2009.05148.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fleckenstein, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddle, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibb, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. R.</span></span> <span> </span><span class="NLM_article-title">New insights into the mechanism of action of amphetamines</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.47.120505.105140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1146%2Fannurev.pharmtox.47.120505.105140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=17209801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1alurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=681-698&author=A.+E.+Fleckensteinauthor=T.+J.+Volzauthor=E.+L.+Riddleauthor=J.+W.+Gibbauthor=G.+R.+Hanson&title=New+insights+into+the+mechanism+of+action+of+amphetamines&doi=10.1146%2Fannurev.pharmtox.47.120505.105140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the mechanism of action of amphetamines</span></div><div class="casAuthors">Fleckenstein, Annette E.; Volz, Trent J.; Riddle, Evan L.; Gibb, James W.; Hanson, Glen R.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">681-698</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Amphetamine is a psychostimulant commonly used to treat several disorders, including attention deficit, narcolepsy, and obesity.  Plasmalemmal and vesicular monoamine transporters, such as the neuronal dopamine transporter and the vesicular monoamine transporter-2, are two of its principal targets.  This review focuses on new insights, obtained from both in vivo and in vitro studies, into the mol. mechanisms whereby amphetamine, and the closely related compds. methamphetamine and methylenedioxymethamphetamine, cause monoamine, and particularly dopamine, release.  These mechanisms include amphetamine-induced exchange diffusion, reverse transport, and channel-like transport phenomena as well as the weak base properties of amphetamine.  Addnl., amphetamine analogs may affect monoamine transporters through phosphorylation, transporter trafficking, and the prodn. of reactive oxygen and nitrogen species.  All of these mechanisms have potential implications for both amphetamine- and methamphetamine-induced neurotoxicity, as well as dopaminergic neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraPle7JPAeKrVg90H21EOLACvtfcHk0liUhh9rQXAW-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1alurs%253D&md5=ead84eb20c530d952c181a79122a1971</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.47.120505.105140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.47.120505.105140%26sid%3Dliteratum%253Aachs%26aulast%3DFleckenstein%26aufirst%3DA.%2BE.%26aulast%3DVolz%26aufirst%3DT.%2BJ.%26aulast%3DRiddle%26aufirst%3DE.%2BL.%26aulast%3DGibb%26aufirst%3DJ.%2BW.%26aulast%3DHanson%26aufirst%3DG.%2BR.%26atitle%3DNew%2520insights%2520into%2520the%2520mechanism%2520of%2520action%2520of%2520amphetamines%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2007%26volume%3D47%26spage%3D681%26epage%3D698%26doi%3D10.1146%2Fannurev.pharmtox.47.120505.105140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anagnostaras, S. G.</span></span> <span> </span><span class="NLM_article-title">Psychostimulants and cognition: A continuum of behavioral and cognitive activation</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1124/pr.112.007054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fpr.112.007054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=24344115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGnu73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=193-221&author=S.+Woodauthor=J.+R.+Sageauthor=T.+Shumanauthor=S.+G.+Anagnostaras&title=Psychostimulants+and+cognition%3A+A+continuum+of+behavioral+and+cognitive+activation&doi=10.1124%2Fpr.112.007054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Psychostimulants and cognition: a continuum of behavioral and cognitive activation</span></div><div class="casAuthors">Wood, Suzanne; Sage, Jennifer R.; Shuman, Tristan; Anagnostaras, Stephan G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">193-221, 29 pp.</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Psychostimulants such as cocaine have been used as performance enhancers throughout recorded history.  Although psychostimulants are commonly prescribed to improve attention and cognition, a great deal of literature has described their ability to induce cognitive deficits, as well as addiction.  How can a single drug class be known to produce both cognitive enhancement and impairment.  Properties of the particular stimulant drug itself and individual differences between users have both been suggested to dictate the outcome of stimulant use.  A more parsimonious alternative, which we endorse, is that dose is the crit. detg. factor in cognitive effects of stimulant drugs.  Herein, we review several popular stimulants (cocaine, amphetamine, methylphenidate, modafinil, and caffeine), outlining their history of use, mechanism of action, and use and abuse today.  One common graphic depiction of the cognitive effects of psychostimulants is an inverted U-shaped dose-effect curve.  Moderate arousal is beneficial to cognition, whereas too much activation leads to cognitive impairment.  In parallel to this schematic, we propose a continuum of psychostimulant activation that covers the transition from one drug effect to another as stimulant intake is increased.  Low doses of stimulants effect increased arousal, attention, and cognitive enhancement; moderate doses can lead to feelings of euphoria and power, as well as addiction and cognitive impairment; and very high doses lead to psychosis and circulatory collapse.  This continuum helps account for the seemingly disparate effects of stimulant drugs, with the same drug being assocd. with cognitive enhancement and impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKUCx_-Q7V6rVg90H21EOLACvtfcHk0liUhh9rQXAW-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGnu73E&md5=ec43a4e0babb213d36455c2a070ba16e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fpr.112.007054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.112.007054%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DS.%26aulast%3DSage%26aufirst%3DJ.%2BR.%26aulast%3DShuman%26aufirst%3DT.%26aulast%3DAnagnostaras%26aufirst%3DS.%2BG.%26atitle%3DPsychostimulants%2520and%2520cognition%253A%2520A%2520continuum%2520of%2520behavioral%2520and%2520cognitive%2520activation%26jtitle%3DPharmacol.%2520Rev.%26date%3D2014%26volume%3D66%26spage%3D193%26epage%3D221%26doi%3D10.1124%2Fpr.112.007054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madras, B.</span>; <span class="NLM_string-name">Kuhar, M. J.</span></span> <i>The Effects of Drug Abuse on the Human Nervous System</i>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">2014</span>; Vol.  <span class="NLM_volume">xiii</span>, p  <span class="NLM_fpage">609</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=609&author=B.+Madras&author=M.+J.+Kuhar&title=The+Effects+of+Drug+Abuse+on+the+Human+Nervous+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMadras%26aufirst%3DB.%26btitle%3DThe%2520Effects%2520of%2520Drug%2520Abuse%2520on%2520the%2520Human%2520Nervous%2520System%26pub%3DElsevier%26date%3D2014%26volume%3Dxiii%26spage%3D609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agoston, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izenwasser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel N-substituted 3 alpha-[bis(4′-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">4329</span>– <span class="NLM_lpage">4339</span>, <span class="refDoi"> DOI: 10.1021/jm970525a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970525a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK1cXjsFGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=4329-4339&author=G.+E.+Agostonauthor=J.+H.+Wuauthor=S.+Izenwasserauthor=C.+Georgeauthor=J.+Katzauthor=R.+H.+Klineauthor=A.+H.+Newman&title=Novel+N-substituted+3+alpha-%5Bbis%284%E2%80%B2-fluorophenyl%29methoxy%5Dtropane+analogues%3A+selective+ligands+for+the+dopamine+transporter&doi=10.1021%2Fjm970525a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Novel N-substituted 3α-[bis(4'-fluorophenyl)methoxy]tropane analogs: selective ligands for the dopamine transporter</span></div><div class="casAuthors">Agoston, Gregory E.; Wu, Jae H.; Izenwasser, Sari; George, Clifford; Katz, Jonathan; Kline, Richard; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4329-4339</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-substituted 3α-[bis(4'-fluorophenyl)methoxy]tropane analogs I [R = CH(C6H4-4-F)2, R1 = Ph(CH2)3, 2-(3-indolyl)ethyl, Ph(CH2)4, 4-NO2-C6H4(CH2)4, 4-F-C6H4(CH2)3, Bu, cyclopropylmethyl, allyl, benzyl, 4-fluorobenzyl, cinnamyl, (CH2)2OCH(C6H4-4-F)2, (CH2)2OCH(Ph)C6H4-4-NO2, acetyl, formyl, tolyl, mesyl, Me(MeI) (N-Me methiodide), H] were prepd. from I [R = CH(C6H4-4-F)2, R1 = H] via acylation followed by hydride redn. of the amide or by direct alkylation to function as dopamine uptake inhibitors.  The N-methylated analog of this series had a significantly higher affinity for the dopamine transporter than the parent compd., N-methyl-3α-(diphenylmethoxy)tropane (benztropine, Cogentin).  Yet like the parent compd., it retained high affinity for muscarinic receptors.  All compds. contg. a basic tropane nitrogen displaced [3H]-WIN 35,428 at the dopamine transporter (Ki range = 8.5-634 nM) and blocked dopamine uptake (IC50 range = 10-371 nM) in rat caudate putamen, whereas ligands with a nonbasic nitrogen were virtually inactive.  None of the compds. demonstrated high binding affinity at norepinephrine or serotonin transporters.  Importantly, a sepn. of binding affinities for the dopamine transporter vs. muscarinic m1 receptors was achieved by substitution of the N-Me group with other N-alkyl or arylalkyl substituents (eg. Bu, allyl, benzyl, 3-phenylpropyl, etc.).  Addnl., the most potent and selective analog in this series at the dopamine transporter, I [R = CH(C6H4-4-F)2, R1 = Ph(CH2)4], failed to substitute for cocaine in rats trained to discriminate cocaine from saline.  Potentially, new leads toward the development of a pharmacotherapeutic for cocaine abuse and other disorders affecting the dopamine transporter may be discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR293Qup6etbVg90H21EOLACvtfcHk0liUhh9rQXAW-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjsFGhug%253D%253D&md5=374e879e24e3934579993a40f8ff8de3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm970525a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970525a%26sid%3Dliteratum%253Aachs%26aulast%3DAgoston%26aufirst%3DG.%2BE.%26aulast%3DWu%26aufirst%3DJ.%2BH.%26aulast%3DIzenwasser%26aufirst%3DS.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DKatz%26aufirst%3DJ.%26aulast%3DKline%26aufirst%3DR.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520N-substituted%25203%2520alpha-%255Bbis%25284%25E2%2580%25B2-fluorophenyl%2529methoxy%255Dtropane%2520analogues%253A%2520selective%2520ligands%2520for%2520the%2520dopamine%2520transporter%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D4329%26epage%3D4339%26doi%3D10.1021%2Fjm970525a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koffarnus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1889</span>– <span class="NLM_lpage">1893</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4778-04.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1523%2FJNEUROSCI.4778-04.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=15728828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVSnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=1889-1893&author=R.+I.+Desaiauthor=T.+A.+Kopajticauthor=M.+Koffarnusauthor=A.+H.+Newmanauthor=J.+L.+Katz&title=Identification+of+a+dopamine+transporter+ligand+that+blocks+the+stimulant+effects+of+cocaine&doi=10.1523%2FJNEUROSCI.4778-04.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine</span></div><div class="casAuthors">Desai, Rajeev I.; Kopajtic, Theresa A.; Koffarnus, Mikhail; Newman, Amy Hauck; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1889-1893</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">There is a large unmet medical need for cocaine addiction treatments.  Studies have indicated that the dopamine transporter (DAT) is the primary biol. target of cocaine, and most drugs that have DAT affinity have behavioral effects like those of cocaine.  However, analogs of benztropine have high DAT affinity and behavioral effects that show varying degrees of similarity to cocaine.  The authors now report the discovery that a benztropine analog, JHW007, with high affinity for the DAT does not have cocaine-like behavioral effects and antagonizes the effects of cocaine.  JHW007 occupied the DAT in vivo more slowly than did cocaine and had not reached an apparent plateau up to 270 min after injection.  The in vivo binding of cocaine to the DAT suggested rate of DAT occupancy as an important contributor to its behavioral effects, and the slow assocn. with the DAT may provide an explanation for JHW007 being relatively devoid of cocaine-like behavioral effects.  The antagonism of cocaine suggests that DAT ligands with reduced cocaine-like activity can function as cocaine antagonists and suggests JHW007 as a lead for discovery of cocaine-abuse pharmacotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTattX-fVUNLVg90H21EOLACvtfcHk0lgezfLYhvDB3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVSnu7w%253D&md5=b0f46e7fd58fc31fb6d214a86fa874b5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4778-04.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4778-04.2005%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DR.%2BI.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DKoffarnus%26aufirst%3DM.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DIdentification%2520of%2520a%2520dopamine%2520transporter%2520ligand%2520that%2520blocks%2520the%2520stimulant%2520effects%2520of%2520cocaine%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D1889%26epage%3D1893%26doi%3D10.1523%2FJNEUROSCI.4778-04.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandy, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupica, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">106</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.208538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.113.208538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=24194528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=106-115&author=R.+I.+Desaiauthor=D.+K.+Grandyauthor=C.+R.+Lupicaauthor=J.+L.+Katz&title=Pharmacological+characterization+of+a+dopamine+transporter+ligand+that+functions+as+a+cocaine+antagonist&doi=10.1124%2Fjpet.113.208538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist</span></div><div class="casAuthors">Desai, Rajeev I.; Grandy, David K.; Lupica, Carl R.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">106-115, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">An N-Bu analog of benztropine, JHW007 [N-(n-butyl)-3α-[bis(4'-fluorophenyl)methoxy]-tropane], binds to dopamine transporters (DAT) but has reduced cocaine-like behavioral effects and antagonizes various effects of cocaine.  The present study further examd. mechanisms underlying these effects.  Cocaine dose-dependently increased locomotion, whereas JHW007 was minimally effective but increased activity 24 h after injection.  JHW007 (310 mg/kg) dose-dependently and fully antagonized the locomotor-stimulant effects of cocaine (560 mg/kg), whereas N-Me and N-allyl analogs and the dopamine (DA) uptake inhibitor GBR12909 [1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride] stimulated activity and failed to antagonize effects of cocaine.  JHW007 also blocked the locomotor-stimulant effects of the DAT inhibitor GBR12909 but not stimulation produced by the δ-opioid agonist SNC 80 [4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide], which increases activity through nondopaminergic mechanisms.  JHW007 blocked locomotor-stimulant effects of cocaine in both DA D2- and CB1-receptor knockout and wild-type mice, indicating a lack of involvement of these targets.  Furthermore, JHW007 blocked effects of cocaine on stereotyped rearing but enhanced stereotyped sniffing, suggesting that interference with locomotion by enhanced stereotypies is not responsible for the cocaine-antagonist effects of JHW007.  Time-course data indicate that administration of JHW007 antagonized the locomotor-stimulant effects of cocaine within 10 min of injection, whereas occupancy at the DAT, as detd. in vivo, did not reach a max. until 4.5 h after injection.  The σ1-receptor antagonist BD 1008 [N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine dihydrobromide] blocked the locomotor-stimulant effects of cocaine.  Overall, these findings suggest that JHW007 has cocaine-antagonist effects that are deviate from its DAT occupancy and that some other mechanism, possibly σ-receptor antagonist activity, may contribute to the cocaine-antagonist effect of JHW007 and like drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfQ7sAchYs97Vg90H21EOLACvtfcHk0lgezfLYhvDB3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKjtbk%253D&md5=70a97618d207991be1a3fe76f8d2d1d1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.208538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.208538%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DR.%2BI.%26aulast%3DGrandy%26aufirst%3DD.%2BK.%26aulast%3DLupica%26aufirst%3DC.%2BR.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DPharmacological%2520characterization%2520of%2520a%2520dopamine%2520transporter%2520ligand%2520that%2520functions%2520as%2520a%2520cocaine%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D106%26epage%3D115%26doi%3D10.1124%2Fjpet.113.208538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez-Sanchez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferragud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canales, J. J.</span></span> <span> </span><span class="NLM_article-title">The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2010.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.euroneuro.2010.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=20413276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslGns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=501-508&author=C.+Velazquez-Sanchezauthor=A.+Ferragudauthor=J.+Murgaauthor=M.+Cardaauthor=J.+J.+Canales&title=The+high+affinity+dopamine+uptake+inhibitor%2C+JHW+007%2C+blocks+cocaine-induced+reward%2C+locomotor+stimulation+and+sensitization&doi=10.1016%2Fj.euroneuro.2010.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization</span></div><div class="casAuthors">Velazquez-Sanchez, C.; Ferragud, A.; Murga, J.; Carda, M.; Canales, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">501-508</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery and evaluation of high affinity dopamine transport inhibitors with low abuse liability is an important step toward the development of efficacious medications for cocaine addiction.  We examd. in mice the behavioral effects of (N-(n-butyl)-3α-[bis(4'-fluorophenyl)methoxy]-tropane) (JHW 007), a benztropine (BZT) analog that blocks dopamine uptake, and assessed its potential to influence the actions of cocaine in clin.-relevant models of cocaine addiction.  In the conditioned place preference (CPP) paradigm, JHW 007 exposure did not produce place conditioning within an ample dose range but effectively blocked the CPP induced by cocaine administration.  Similarly, in the CPP app. JHW 007 treatment failed to stimulate locomotor activity at any dose but dose-dependently suppressed the hyperactivity evoked by cocaine treatment.  In locomotor sensitization assays performed in the open field, JHW 007 did not produce sensitized locomotor behavior when given alone, but it prevented the sensitized component of the locomotor response elicited by subchronic (8-day) cocaine exposure.  In the elevated plus maze (EPM), acute treatment with JHW 007, cocaine and combinations of the BZT analog and cocaine produced an anxiogenic-like profile.  Re-test in the EPM following subchronic (8-day) exposure enhanced the anxiogenic-like effect of the same drug treatments.  The present findings indicate that JHW 007 exposure counteracts some crit. behavioral correlates of cocaine treatment, including conditioned reward, locomotor stimulation and sensitization, and lend support to the further development of BZT analogs as potential replacement medications in cocaine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoms5tHHckmlbVg90H21EOLACvtfcHk0lgezfLYhvDB3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslGns7c%253D&md5=af7eee8a23e8a299aacb3a34dab539ab</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2010.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2010.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DVelazquez-Sanchez%26aufirst%3DC.%26aulast%3DFerragud%26aufirst%3DA.%26aulast%3DMurga%26aufirst%3DJ.%26aulast%3DCarda%26aufirst%3DM.%26aulast%3DCanales%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520high%2520affinity%2520dopamine%2520uptake%2520inhibitor%252C%2520JHW%2520007%252C%2520blocks%2520cocaine-induced%2520reward%252C%2520locomotor%2520stimulation%2520and%2520sensitization%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D20%26spage%3D501%26epage%3D508%26doi%3D10.1016%2Fj.euroneuro.2010.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Preti, A.</span></span> <span> </span><span class="NLM_article-title">New developments in the pharmacotherapy of cocaine abuse</span>. <i>Addict. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1111/j.1369-1600.2007.00061.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1111%2Fj.1369-1600.2007.00061.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=17508985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVOqur3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=133-151&author=A.+Preti&title=New+developments+in+the+pharmacotherapy+of+cocaine+abuse&doi=10.1111%2Fj.1369-1600.2007.00061.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">New developments in the pharmacotherapy of cocaine abuse</span></div><div class="casAuthors">Preti, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Addiction Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-151</span>CODEN:
                <span class="NLM_cas:coden">ADBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1355-6215</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite huge advances in the neuroscience of substance abuse and dependence in the past 20 years, no approved pharmacol. treatment exists for cocaine abuse.  The available drugs for the treatment of cocaine abuse are poorly effective, hence the need for new compds. to be screened and tested for efficacy: targeting symptoms might improve the effectiveness of the treatment of cocaine abuse and dependence.  On the basis of the known neurochem. of cocaine, some target compds. have been studied: among others.  BP-897, a D3 partial agonist: vanoxerine, a highly selective inhibitor of dopamine uptake: aripiprazole, a partial mixed-action agonist approved for the treatment of schizophrenia.  Recently modafinil, approved for the treatment of narcolepsy, proved effective in favoring cocaine abstinence in cocaine-abusing people.  Some placebo-controlled studies also reported the effectiveness of topiramate, a licensed antiepileptic drug, and of tiagabine, a gamma-aminobutyric acid (GABA) re-uptake inhibitor also approved as an anticonvulsant: both compds. increased cocaine abstinence with no serious adverse events.  Promising results came from two more compds. acting on the GABA circuits, baclofen and valproic acid.  Finally disulfiram, prescribed with active psychosocial therapy, was found to favor higher retention rates and longer abstinence periods from both alc. and cocaine in polydrug-abusing patients.  An alternative approach rests on the use of vaccines, to date in the exptl. stage still.  Psychosocial treatments are a useful companion in the pharmacotherapy of cocaine abuse, with group therapy and contingency management therapies improving motivation and social functioning, particularly in patients abusing alc. as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBg9wU-hybkLVg90H21EOLACvtfcHk0liXSQqYoJjuSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVOqur3N&md5=93b4725efc304ddaee04534fa1ecfa8c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1369-1600.2007.00061.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1369-1600.2007.00061.x%26sid%3Dliteratum%253Aachs%26aulast%3DPreti%26aufirst%3DA.%26atitle%3DNew%2520developments%2520in%2520the%2520pharmacotherapy%2520of%2520cocaine%2520abuse%26jtitle%3DAddict.%2520Biol.%26date%3D2007%26volume%3D12%26spage%3D133%26epage%3D151%26doi%3D10.1111%2Fj.1369-1600.2007.00061.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanderzee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koger, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gootjes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hespe, W.</span></span> <span> </span><span class="NLM_article-title">Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">370</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1980&pages=363-370&author=P.+Vanderzeeauthor=H.+S.+Kogerauthor=J.+Gootjesauthor=W.+Hespe&title=Aryl+1%2C4-dialk%28en%29ylpiperazines+as+selective+and+very+potent+inhibitors+of+dopamine+uptake"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVanderzee%26aufirst%3DP.%26aulast%3DKoger%26aufirst%3DH.%2BS.%26aulast%3DGootjes%26aufirst%3DJ.%26aulast%3DHespe%26aufirst%3DW.%26atitle%3DAryl%25201%252C4-dialk%2528en%2529ylpiperazines%2520as%2520selective%2520and%2520very%2520potent%2520inhibitors%2520of%2520dopamine%2520uptake%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1980%26volume%3D15%26spage%3D363%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akunne, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurkauf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decosta, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pert, A.</span></span> <span> </span><span class="NLM_article-title">GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1016/0091-3057(91)90570-R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2F0091-3057%2891%2990570-R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1839568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK38XhsFOgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1991&pages=387-397&author=R.+B.+Rothmanauthor=A.+Meleauthor=A.+A.+Reidauthor=H.+C.+Akunneauthor=N.+Greigauthor=A.+Thurkaufauthor=B.+R.+Decostaauthor=K.+C.+Riceauthor=A.+Pert&title=GBR12909+antagonizes+the+ability+of+cocaine+to+elevate+extracellular+levels+of+dopamine&doi=10.1016%2F0091-3057%2891%2990570-R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine</span></div><div class="casAuthors">Rothman, Richard B.; Mele, Andrea; Reid, Audrey A.; Akunne, Hyacinth C.; Greig, Nigel; Thurkauf, Andrew; De Costa, Brian R.; Rice, Kenner C.; Pert, Agu</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">387-97</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    </div><div class="casAbstract">Rats were administered various i.p. doses of the high-affinity dopamine (DA) reuptake inhibitor GBR12909.  The brain caudate nuclei were removed 60 min after drug administration and striatal membranes were prepd.  GBR12909 produced a dose-dependent decrease in the binding of [3H]GBR12935 to the DA transporter (ED50∼ 10 mg/kg).  Satn. binding studies with [3H]GBR12935 showed that this was due to increased residual drug, and decreased Bmax.  At 25 mg/kg i.p., GBR12909 produced a 50% decrease in Bmax and a 3.4-fold increase in Kd.  In microdialysis studies, GBR12909 (25 mg/kg i.p.) produced a modest, long-lasting, and stable elevation of extracellular DA.  Administration of cocaine through the microdialysis probe to rats pretreated with saline or GBR12909 (25 mg/kg i.p.) produced a dose-dependent increase in extracellular DA in both groups.  GBR12909 inhibited the cocaine-induced increases in extracellular DA by ∼ 50% at all doses.  At a dose sufficient to decrease by 50% the Bmax of [3H]GBR12935 binding sites, GBR12909 antagonizes the ability of cocaine to elevate extracellular DA by 50%.  GBR12909 may have a use in the medical treatment of cocaine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdR8WIxCGwGbVg90H21EOLACvtfcHk0liXSQqYoJjuSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhsFOgtQ%253D%253D&md5=d79867ab017e0a9837f8f074318636e7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2F0091-3057%2891%2990570-R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0091-3057%252891%252990570-R%26sid%3Dliteratum%253Aachs%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DMele%26aufirst%3DA.%26aulast%3DReid%26aufirst%3DA.%2BA.%26aulast%3DAkunne%26aufirst%3DH.%2BC.%26aulast%3DGreig%26aufirst%3DN.%26aulast%3DThurkauf%26aufirst%3DA.%26aulast%3DDecosta%26aufirst%3DB.%2BR.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DPert%26aufirst%3DA.%26atitle%3DGBR12909%2520antagonizes%2520the%2520ability%2520of%2520cocaine%2520to%2520elevate%2520extracellular%2520levels%2520of%2520dopamine%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D1991%26volume%3D40%26spage%3D387%26epage%3D397%26doi%3D10.1016%2F0091-3057%2891%2990570-R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obejero-Paz, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruening-Wright, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawryluk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatalovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittrich, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. M.</span></span> <span> </span><span class="NLM_article-title">Quantitative profiling of the effects of vanoxerine on human cardiac ion channels and its application to cardiac risk</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">17623</span>, <span class="refDoi"> DOI: 10.1038/srep17623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fsrep17623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=26616666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGisrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=17623&author=C.+A.+Obejero-Pazauthor=A.+Bruening-Wrightauthor=J.+Kramerauthor=P.+Hawrylukauthor=M.+Tatalovicauthor=H.+C.+Dittrichauthor=A.+M.+Brown&title=Quantitative+profiling+of+the+effects+of+vanoxerine+on+human+cardiac+ion+channels+and+its+application+to+cardiac+risk&doi=10.1038%2Fsrep17623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk</span></div><div class="casAuthors">Obejero-Paz, Carlos A.; Bruening-Wright, Andrew; Kramer, James; Hawryluk, Peter; Tatalovic, Milos; Dittrich, Howard C.; Brown, Arthur M.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17623</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Vanoxerine has been in clin. trials for Parkinsonism, depression and cocaine addiction but lacked efficacy.  Although a potent blocker of hERG, it produced no serious adverse events.  We attributed the unexpected result to offsetting Multiple Ion Channel Effects (MICE).  Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.  Vanoxerine terminated AF/AFL in an animal model and a dose-ranging clin. trial.  Reversion to normal rhythm was assocd. with QT prolongation yet absent proarrhythmia markers for Torsade de Pointes (TdP).  To understand the QT/TdP discordance, we used quant. profiling and compared vanoxerine with dofetilide, a selective hERG-blocking torsadogen used for intractable AF, verapamil, a non-torsadogenic MICE comparator and bepridil, a torsadogenic MICE comparator.  At clin. relevant concns., verapamil blocked hCav1.2 and hERG, as did vanoxerine and bepridil both of which also blocked hNav1.5.  In acute expts. and simulations, dofetilide produced early after depolarizations (EADs) and arrhythmias, whereas verapamil, vanoxerine and bepridil produced no proarrhythmia markers.  Of the MICE drugs only bepridil inhibited hERG trafficking following overnight exposure.  The results are consistent with the emphasis on MICE of the CiPA assay.  Addnl. we propose that trafficking inhibition of hERG be added to CiPA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4GOHVLsXMurVg90H21EOLACvtfcHk0liXSQqYoJjuSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGisrfJ&md5=b806a408dfc37d0a428c40c47c7867d3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fsrep17623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep17623%26sid%3Dliteratum%253Aachs%26aulast%3DObejero-Paz%26aufirst%3DC.%2BA.%26aulast%3DBruening-Wright%26aufirst%3DA.%26aulast%3DKramer%26aufirst%3DJ.%26aulast%3DHawryluk%26aufirst%3DP.%26aulast%3DTatalovic%26aufirst%3DM.%26aulast%3DDittrich%26aufirst%3DH.%2BC.%26aulast%3DBrown%26aufirst%3DA.%2BM.%26atitle%3DQuantitative%2520profiling%2520of%2520the%2520effects%2520of%2520vanoxerine%2520on%2520human%2520cardiac%2520ion%2520channels%2520and%2520its%2520application%2520to%2520cardiac%2520risk%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D17623%26doi%3D10.1038%2Fsrep17623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vocci, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkashef, A.</span></span> <span> </span><span class="NLM_article-title">Medication development for addictive disorders: the state of the science</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">1432</span>– <span class="NLM_lpage">1440</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.162.8.1432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1176%2Fappi.ajp.162.8.1432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=16055764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A280%3ADC%252BD2MzpsVOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2005&pages=1432-1440&author=F.+J.+Vocciauthor=J.+Acriauthor=A.+Elkashef&title=Medication+development+for+addictive+disorders%3A+the+state+of+the+science&doi=10.1176%2Fappi.ajp.162.8.1432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Medication development for addictive disorders: the state of the science</span></div><div class="casAuthors">Vocci Frank J; Acri Jane; Elkashef Ahmed</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1432-40</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">In 1989, the National Institute on Drug Abuse (NIDA) established its Medications Development Program.  This program has concentrated on developing pharmacotherapies for opiate and cocaine dependence and, more recently, for methamphetamine and cannabis dependence.  The major goals of this program are to optimize existing treatments and to expand treatment options for physicians and patients.  This review will concentrate on the development of pharmacotherapies for the following substance abuse disorders: opiate, cocaine, methamphetamine, and cannabis dependence.  Left untreated, opiate and stimulant dependence are responsible for significant morbidity and mortality.  For example, use of illicit opiates is associated with an increased risk of hepatitis C infection, HIV infection, and other medical consequences, e.g., an overdose.  The NIDA Medications Development Program has had success in developing, with pharmaceutical partners, levomethadyl acetate, buprenorphine, and buprenorphine/naloxone for opiate dependence.  Moreover, several marketed medications have shown promise in reducing cocaine use.  Of interest, these medications likely operate through diverse neurochemical mechanisms, suggesting that combination therapy may be a rational next step that could increase treatment gains further in cocaine-dependent patients.  The Medications Development Program has also identified multiple neuronal mechanisms that are altered by chronic administration of drugs of abuse.  Advances in neuroscience have identified changes in conditioned cueing, drug priming, stress-induced increases in drug intake, and reduced frontal inhibitory mechanisms as all being possible for the development of, maintenance of, and possible relapse to, addiction.  Potential medications that modulate these mechanisms are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUliEMvgh98dLIORRPd5lbfW6udTcc2eZrZE7ueRpY5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzpsVOjsw%253D%253D&md5=2f5eb76c767d85475af267948c401033</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.162.8.1432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.162.8.1432%26sid%3Dliteratum%253Aachs%26aulast%3DVocci%26aufirst%3DF.%2BJ.%26aulast%3DAcri%26aufirst%3DJ.%26aulast%3DElkashef%26aufirst%3DA.%26atitle%3DMedication%2520development%2520for%2520addictive%2520disorders%253A%2520the%2520state%2520of%2520the%2520science%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2005%26volume%3D162%26spage%3D1432%26epage%3D1440%26doi%3D10.1176%2Fappi.ajp.162.8.1432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2007.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.bcp.2007.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=17897630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCksLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2008&pages=2-16&author=R.+B.+Rothmanauthor=M.+H.+Baumannauthor=T.+E.+Prisinzanoauthor=A.+H.+Newman&title=Dopamine+transport+inhibitors+based+on+GBR12909+and+benztropine+as+potential+medications+to+treat+cocaine+addiction&doi=10.1016%2Fj.bcp.2007.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction</span></div><div class="casAuthors">Rothman, Richard B.; Baumann, Michael H.; Prisinzano, Thomas E.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-16</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The discovery and development of medications to treat addiction and notably, cocaine addiction, have been frustrated by both the complexity of the disorder and the lack of target validation in human subjects.  The dopamine transporter has historically been a primary target for cocaine abuse medication development, but addictive liability and other confounds of such inhibitors of dopamine uptake have limited clin. evaluation and validation.  Herein we describe efforts to develop analogs of the dopamine uptake inhibitors GBR 12909 and benztropine that show promising profiles in animal models of cocaine abuse that contrast to that of cocaine.  Their unique pharmacol. profiles have provided important insights into the reinforcing actions of cocaine and we propose that clin. investigation of novel dopamine uptake inhibitors will facilitate the discovery of cocaine-abuse medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyk01dVAiBsLVg90H21EOLACvtfcHk0ljC8BJJNgB0PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCksLjK&md5=98fbd67bb986dc0557788d219a760a80</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2007.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2007.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DDopamine%2520transport%2520inhibitors%2520based%2520on%2520GBR12909%2520and%2520benztropine%2520as%2520potential%2520medications%2520to%2520treat%2520cocaine%2520addiction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2008%26volume%3D75%26spage%3D2%26epage%3D16%26doi%3D10.1016%2Fj.bcp.2007.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. R.</span></span> <span> </span><span class="NLM_article-title">Modafinil in the treatment of excessive sleepiness</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S2377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.2147%2FDDDT.S2377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFSnsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=71-85&author=J.+R.+Schwartz&title=Modafinil+in+the+treatment+of+excessive+sleepiness&doi=10.2147%2FDDDT.S2377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Modafinil in the treatment of excessive sleepiness</span></div><div class="casAuthors">Schwartz, Jonathan R. L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">71-85</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  The wake-promoting agent modafinil is approved for the treatment of excessive sleepiness assocd. with obstructive sleep apnea (OSA), shift work disorder (SWD), and narcolepsy.  In OSA, modafinil is recommended for use as an adjunct to std. therapies that treat the underlying airway obstruction.  This article reviews the literature on modafinil (pharmacol., pharmacokinetics, efficacy, tolerability, and abuse potential), with emphasis on use of modafinil in the treatment of excessive sleepiness in patients with OSA, SWD, and narcolepsy.  In large-scale, double-blind, placebo-controlled studies, modafinil improved objectively detd. sleep latency, improved overall clin. condition related to severity of sleepiness, and reduced patient-reported sleepiness.  Improvements in wakefulness were accompanied by improvements in behavioral alertness, functional status, and health-related quality of life.  In patients with SWD, diary data showed modafinil reduced the max. level of sleepiness during night shift work, level of sleepiness during the commute home, and incidence of accidents or near-accidents during the commute home when compared with placebo.  Modafinil was well tolerated, without adversely affecting cardiovascular parameters or scheduled sleep.  These findings and those of extension studies which reported improvements were maintained suggest modafinil has a beneficial effect on daily life and well-being in patients with excessive sleepiness assocd. with OSA, SWD, or narcolepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5cn8TrnR09bVg90H21EOLACvtfcHk0ljC8BJJNgB0PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFSnsrjL&md5=c9d13fef0083d172b1cf69dbc7d298a5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S2377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S2377%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DJ.%2BR.%26atitle%3DModafinil%2520in%2520the%2520treatment%2520of%2520excessive%2520sleepiness%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2008%26volume%3D2%26spage%3D71%26epage%3D85%26doi%3D10.2147%2FDDDT.S2377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mereu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span> <span> </span><span class="NLM_article-title">The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>229</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1007/s00213-013-3232-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1007%2Fs00213-013-3232-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=23934211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CrsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=2013&pages=415-434&author=M.+Mereuauthor=A.+Bonciauthor=A.+H.+Newmanauthor=G.+Tanda&title=The+neurobiology+of+modafinil+as+an+enhancer+of+cognitive+performance+and+a+potential+treatment+for+substance+use+disorders&doi=10.1007%2Fs00213-013-3232-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders</span></div><div class="casAuthors">Mereu, Maddalena; Bonci, Antonello; Newman, Amy Hauck; Tanda, Gianluigi</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">415-434</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Rationale and objectives: Modafinil (MOD) and its R-enantiomer (R-MOD) are approved medications for narcolepsy and other sleep disorders.  They have also been used, off-label, as cognitive enhancers in populations of patients with mental disorders, including substance abusers that demonstrate impaired cognitive function.  A debated nonmedical use of MOD in healthy individuals to improve intellectual performance is raising questions about its potential abuse liability in this population.  Results and conclusions: MOD has low micromolar affinity for the dopamine transporter (DAT).  Inhibition of dopamine (DA) reuptake via the DAT explains the enhancement of DA levels in several brain areas, an effect shared with psychostimulants like cocaine, methylphenidate, and the amphetamines.  However, its neurochem. effects and anatomical pattern of brain area activation differ from typical psychostimulants and are consistent with its beneficial effects on cognitive performance processes such as attention, learning, and memory.  At variance with typical psychostimulants, MOD shows very low, if any, abuse liability, in spite of its use as a cognitive enhancer by otherwise healthy individuals.  Finally, recent clin. studies have focused on the potential use of MOD as a medication for treatment of drug abuse, but have not shown consistent outcomes.  However, pos. trends in several result measures suggest that medications that improve cognitive function, like MOD or R-MOD, may be beneficial for the treatment of substance use disorders in certain patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk7rhhVPs1w7Vg90H21EOLACvtfcHk0lh99jBAYQUV9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CrsLvN&md5=65a22f87cf0588b5050f1a8993392990</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00213-013-3232-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-013-3232-4%26sid%3Dliteratum%253Aachs%26aulast%3DMereu%26aufirst%3DM.%26aulast%3DBonci%26aufirst%3DA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DTanda%26aufirst%3DG.%26atitle%3DThe%2520neurobiology%2520of%2520modafinil%2520as%2520an%2520enhancer%2520of%2520cognitive%2520performance%2520and%2520a%2520potential%2520treatment%2520for%2520substance%2520use%2520disorders%26jtitle%3DPsychopharmacology%26date%3D2013%26volume%3D229%26spage%3D415%26epage%3D434%26doi%3D10.1007%2Fs00213-013-3232-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blough, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partilla, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.drugalcdep.2014.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.drugalcdep.2014.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=25548026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Oqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2015&pages=1-19&author=M.+E.+Reithauthor=B.+E.+Bloughauthor=W.+C.+Hongauthor=K.+T.+Jonesauthor=K.+C.+Schmittauthor=M.+H.+Baumannauthor=J.+S.+Partillaauthor=R.+B.+Rothmanauthor=J.+L.+Katz&title=Behavioral%2C+biological%2C+and+chemical+perspectives+on+atypical+agents+targeting+the+dopamine+transporter&doi=10.1016%2Fj.drugalcdep.2014.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter</span></div><div class="casAuthors">Reith, Maarten E. A.; Blough, Bruce E.; Hong, Weimin C.; Jones, Kymry T.; Schmitt, Kyle C.; Baumann, Michael H.; Partilla, John S.; Rothman, Richard B.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug and Alcohol Dependence</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-19</span>CODEN:
                <span class="NLM_cas:coden">DADEDV</span>;
        ISSN:<span class="NLM_cas:issn">0376-8716</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Treatment of stimulant-use disorders remains a formidable challenge, and the dopamine transporter (DAT) remains a potential target for antagonist or agonist-like substitution therapies, so this review focuses on DAT ligands, such as benztropine, GBR 12909, modafinil, and DAT substrates derived from phenethylamine or cathinone that have atypical DAT-inhibitor effects, either in vitro or in vivo.  The compds. are described from a mol. mechanistic, behavioral, and medicinal-chem. perspective.Possible mechanisms for atypicality at the mol. level can be deduced from the conformational cycle for substrate translocation.  For each conformation, a crystal structure of a bacterial homolog is available, with a possible role of cholesterol, which is also present in the crystal of Drosophila DAT.  Although there is a direct relationship between behavioral potencies of most DAT inhibitors and their DAT affinities, a no. of compds. bind to the DAT and inhibit dopamine uptake but do not share cocaine-like effects.  Such atypical behavior, depending on the compd., may be related to slow DAT assocn., combined sigma-receptor actions, or bias for cytosol-facing DAT.  Some structures are sterically small enough to serve as DAT substrates but large enough to also inhibit transport.  Such compds. may display partial DA releasing effects, and may be combined with release or uptake inhibition at other monoamine transporters.  Mechanisms of atypical DAT inhibitors may serve as targets for the development of treatments for stimulant abuse.  These mechanisms are novel and their further exploration may produce compds. with unique therapeutic potential as treatments for stimulant abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGsfVrk5h43rVg90H21EOLACvtfcHk0lh99jBAYQUV9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Oqs74%253D&md5=d6f46c4fd505810f64eafc748702d299</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2014.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2014.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DBlough%26aufirst%3DB.%2BE.%26aulast%3DHong%26aufirst%3DW.%2BC.%26aulast%3DJones%26aufirst%3DK.%2BT.%26aulast%3DSchmitt%26aufirst%3DK.%2BC.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DPartilla%26aufirst%3DJ.%2BS.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DBehavioral%252C%2520biological%252C%2520and%2520chemical%2520perspectives%2520on%2520atypical%2520agents%2520targeting%2520the%2520dopamine%2520transporter%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2015%26volume%3D147%26spage%3D1%26epage%3D19%26doi%3D10.1016%2Fj.drugalcdep.2014.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mereu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okunola, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">R-Modafinil (Armodafinil): A unique dopamine uptake inhibitor and potential medication for psychostimulant abuse</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2012.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.biopsych.2012.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=22537794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFelt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=405-413&author=C.+J.+Lolandauthor=M.+Mereuauthor=O.+M.+Okunolaauthor=J.+Caoauthor=T.+E.+Prisinzanoauthor=S.+Mazierauthor=T.+Kopajticauthor=L.+Shiauthor=J.+L.+Katzauthor=G.+Tandaauthor=A.+H.+Newman&title=R-Modafinil+%28Armodafinil%29%3A+A+unique+dopamine+uptake+inhibitor+and+potential+medication+for+psychostimulant+abuse&doi=10.1016%2Fj.biopsych.2012.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">R-Modafinil (Armodafinil): A Unique Dopamine Uptake Inhibitor and Potential Medication for Psychostimulant Abuse</span></div><div class="casAuthors">Loland, Claus J.; Mereu, Maddalena; Okunola, Oluyomi M.; Cao, Jianjing; Prisinzano, Thomas E.; Mazier, Sonia; Kopajtic, Theresa; Shi, Lei; Katz, Jonathan L.; Tanda, Gianluigi; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">405-413</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">(±)-Modafinil has piqued interest as a treatment for attention-deficit/hyperactivity disorder and stimulant dependence.  The R-enantiomer of modafinil might have unique pharmacol. properties that should be further investigated.  (±)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [3H] dopamine (DA) uptake and [3H]WIN 35428 binding in human dopamine transporter (DAT) wild-type and mutants with altered conformational equil.  Data were compared with cocaine and the atypical DA uptake inhibitor, JHW 007.  R- and S-modafinil were also evaluated in microdialysis studies in the mouse nucleus accumbens shell and in a cocaine discrimination procedure.  (±)-, R-, and S-modafinil bind to the DAT and inhibit DA uptake less potently than cocaine, with R-modafinil having approx. threefold higher affinity than its S-enantiomer.  Mol. docking studies revealed subtle differences in binding modes for the enantiomers.  R-modafinil was significantly less potent in the DAT Y156F mutant compared with wild-type DAT, whereas S-modafinil was affected less.  Studies with the Y335A DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than cocaine, which was further supported by [2-(trimethylammonium)ethyl]-methanethiosulfonate reactivity on the DAT E2C I159C.  Microdialysis studies demonstrated that both R- and S-modafinil produced increases in extracellular DA concns. in the nucleus accumbens shell less efficaciously than cocaine and with a longer duration of action.  Both enantiomers fully substituted in mice trained to discriminate cocaine from saline.R-modafinil displays an in vitro profile different from cocaine.  Future trials with R-modafinil as a substitute therapy with the potential benefit of cognitive enhancement for psychostimulant addiction are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjL4KiRs4PUbVg90H21EOLACvtfcHk0lgQLhXu3g0Arw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFelt74%253D&md5=78808210fc68d2fbcdd97190f03b63d0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2012.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2012.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DMereu%26aufirst%3DM.%26aulast%3DOkunola%26aufirst%3DO.%2BM.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DMazier%26aufirst%3DS.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DR-Modafinil%2520%2528Armodafinil%2529%253A%2520A%2520unique%2520dopamine%2520uptake%2520inhibitor%2520and%2520potential%2520medication%2520for%2520psychostimulant%2520abuse%26jtitle%3DBiol.%2520Psychiatry%26date%3D2012%26volume%3D72%26spage%3D405%26epage%3D413%26doi%3D10.1016%2Fj.biopsych.2012.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dackis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plebani, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettinati, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparkman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C. P.</span></span> <span> </span><span class="NLM_article-title">A double-blind, placebo-controlled trial of modafinil for cocaine dependence</span>. <i>J. Subst. Abuse. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1016/j.jsat.2011.12.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.jsat.2011.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=22377391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A280%3ADC%252BC38vkvVWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2012&pages=303-312&author=C.+A.+Dackisauthor=K.+M.+Kampmanauthor=K.+G.+Lynchauthor=J.+G.+Plebaniauthor=H.+M.+Pettinatiauthor=T.+Sparkmanauthor=C.+P.+O%E2%80%99Brien&title=A+double-blind%2C+placebo-controlled+trial+of+modafinil+for+cocaine+dependence&doi=10.1016%2Fj.jsat.2011.12.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A double-blind, placebo-controlled trial of modafinil for cocaine dependence</span></div><div class="casAuthors">Dackis Charles A; Kampman Kyle M; Lynch Kevin G; Plebani Jennifer G; Pettinati Helen M; Sparkman Thorne; O'Brien Charles P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of substance abuse treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">303-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This is a randomized, double-blind, placebo-controlled study of modafinil treatment for cocaine dependence.  Patients (N = 210) who were actively using cocaine at baseline were randomized to 8 weeks of modafinil (0 mg/day, 200 mg/day, or 400 mg/day) combined with once-weekly cognitive-behavioral therapy.  Our primary efficacy measure was cocaine abstinence, based on urine benzoylecgonine (BE) levels, with secondary measures of craving, cocaine withdrawal, retention, and tolerability.  We found no significant differences between modafinil and placebo patients on any of these measures.  However, there was a significant gender difference in that male patients treated with 400 mg/day tended to be more abstinent than their placebo-treated counterparts (p = .06).  Our negative findings might be explained by gender differences and/or inadequate psychosocial treatment intensity in patients with severe cocaine dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfEuZhv9G9y9NTrvPZP1IpfW6udTcc2eanjneP4jf3nrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vkvVWmsw%253D%253D&md5=6f55dc91ebef9f89055a2352f241827f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.jsat.2011.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsat.2011.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DDackis%26aufirst%3DC.%2BA.%26aulast%3DKampman%26aufirst%3DK.%2BM.%26aulast%3DLynch%26aufirst%3DK.%2BG.%26aulast%3DPlebani%26aufirst%3DJ.%2BG.%26aulast%3DPettinati%26aufirst%3DH.%2BM.%26aulast%3DSparkman%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%2BP.%26atitle%3DA%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520modafinil%2520for%2520cocaine%2520dependence%26jtitle%3DJ.%2520Subst.%2520Abuse.%2520Treat.%26date%3D2012%26volume%3D43%26spage%3D303%26epage%3D312%26doi%3D10.1016%2Fj.jsat.2011.12.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shemanski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciraulo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dackis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roache, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloum, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urschel, H. C.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkashef, A. M.</span></span> <span> </span><span class="NLM_article-title">Modafinil for the treatment of cocaine dependence</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.drugalcdep.2009.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.drugalcdep.2009.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=19560290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosleiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2009&pages=133-9&author=A.+L.+Andersonauthor=M.+S.+Reidauthor=S.+H.+Liauthor=T.+Holmesauthor=L.+Shemanskiauthor=A.+Sleeauthor=E.+V.+Smithauthor=R.+Kahnauthor=N.+Chiangauthor=F.+Vocciauthor=D.+Cirauloauthor=C.+Dackisauthor=J.+D.+Roacheauthor=I.+M.+Salloumauthor=E.+Somozaauthor=H.+C.+Urschelauthor=A.+M.+Elkashef&title=Modafinil+for+the+treatment+of+cocaine+dependence&doi=10.1016%2Fj.drugalcdep.2009.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Modafinil for the treatment of cocaine dependence</span></div><div class="casAuthors">Anderson, Ann L.; Reid, Malcolm S.; Li, Shou-Hua; Holmes, Tyson; Shemanski, Lynn; Slee, April; Smith, Edwina V.; Kahn, Roberta; Chiang, Nora; Vocci, Frank; Ciraulo, Domenic; Dackis, Charles; Roache, John D.; Salloum, Ihsan M.; Somoza, Eugene; Urschel, Harold C., III; Elkashef, Ahmed M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug and Alcohol Dependence</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">133-139</span>CODEN:
                <span class="NLM_cas:coden">DADEDV</span>;
        ISSN:<span class="NLM_cas:issn">0376-8716</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Modafinil was tested for efficacy in facilitating abstinence in cocaine-dependent patients, compared to placebo.  This was a double-blind placebo-controlled study, with 12 wk of treatment and a 4-wk follow-up.  Six outpatient substance abuse treatment clinics participated in the study.  There were 210 treatment-seekers randomized, having a diagnosis of cocaine dependence; 72 participants were randomized to placebo, 69 to modafinil 200 mg, and 69 to modafinil 400 mg, taken once daily on awakening.  Participants came to the clinic three times per wk for assessments and urine drug screens, and had one hour of individual psychotherapy weekly.  The primary outcome measure was the weekly percentage of cocaine non-use days.  The GEE regression anal. showed that for the total sample, there was no significant difference between either modafinil group and placebo in the change in av. weekly percent of cocaine non-use days over the 12-wk treatment period (p > 0.79).  However, two secondary outcomes showed significant effects by modafinil 200 mg: the max. no. of consecutive non-use days for cocaine (p = 0.02), and a redn. in craving (p = 0.04).  Also, a post hoc anal. showed a significant effect of modafinil that increased the weekly percentage of non-use days in the subgroup of those cocaine patients who did not have a history of alc. dependence (p < 0.02).  These data suggest that modafinil, in combination with individual behavioral therapy, was effective for increasing cocaine non-use days in participants without co-morbid alc. dependence, and in reducing cocaine craving.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9pQ-oRIN93bVg90H21EOLACvtfcHk0lgQLhXu3g0Arw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosleiu7g%253D&md5=ff0d575a8b8e77162121c855de376554</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2009.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2009.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DA.%2BL.%26aulast%3DReid%26aufirst%3DM.%2BS.%26aulast%3DLi%26aufirst%3DS.%2BH.%26aulast%3DHolmes%26aufirst%3DT.%26aulast%3DShemanski%26aufirst%3DL.%26aulast%3DSlee%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DE.%2BV.%26aulast%3DKahn%26aufirst%3DR.%26aulast%3DChiang%26aufirst%3DN.%26aulast%3DVocci%26aufirst%3DF.%26aulast%3DCiraulo%26aufirst%3DD.%26aulast%3DDackis%26aufirst%3DC.%26aulast%3DRoache%26aufirst%3DJ.%2BD.%26aulast%3DSalloum%26aufirst%3DI.%2BM.%26aulast%3DSomoza%26aufirst%3DE.%26aulast%3DUrschel%26aufirst%3DH.%2BC.%26aulast%3DElkashef%26aufirst%3DA.%2BM.%26atitle%3DModafinil%2520for%2520the%2520treatment%2520of%2520cocaine%2520dependence%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2009%26volume%3D104%26spage%3D133%26epage%3D9%26doi%3D10.1016%2Fj.drugalcdep.2009.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okunola, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shook, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships at the monoamine transporters for a novel series of modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) analogues</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1021/ml1002025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1002025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12lt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=48-52&author=J.+Caoauthor=T.+E.+Prisinzanoauthor=O.+M.+Okunolaauthor=T.+Kopajticauthor=M.+Shookauthor=J.+L.+Katzauthor=A.+H.+Newman&title=Structure-activity+relationships+at+the+monoamine+transporters+for+a+novel+series+of+modafinil+%282-%5B%28diphenylmethyl%29sulfinyl%5Dacetamide%29+analogues&doi=10.1021%2Fml1002025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">SARs at the Monoamine Transporters for a Novel Series of Modafinil Analogues</span></div><div class="casAuthors">Cao, Jianjing; Prisinzano, Thomas E.; Okunola, Oluyomi M.; Kopajtic, Theresa; Shook, Matthew; Katz, Jonathan L.; Hauck Newman, Amy</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-52</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of modafinil (1) analogs were synthesized wherein (1) para-halo-substitutents were added to the aryl rings, (2) the sulfoxide function was removed, and (3) the primary amide group was replaced with secondary and tertiary amides and amines to investigate the effects of these chem. modifications on dopamine transporter, serotonin transporter, and norepinephrine transporter binding.  In addn., the locomotor-stimulant effects in mice of (±)-modafinil (1) (I), its R- and S-enantiomers, and its para-chloro sulfinylacetamide analog (5c) (II) were compared to those of cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDr9ac-J7nqbVg90H21EOLACvtfcHk0ljVvTa_eeWS8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12lt7bN&md5=660e546e8524b2e5e8b448ee5bf0e567</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fml1002025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1002025%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DOkunola%26aufirst%3DO.%2BM.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DShook%26aufirst%3DM.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DStructure-activity%2520relationships%2520at%2520the%2520monoamine%2520transporters%2520for%2520a%2520novel%2520series%2520of%2520modafinil%2520%25282-%255B%2528diphenylmethyl%2529sulfinyl%255Dacetamide%2529%2520analogues%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D48%26epage%3D52%26doi%3D10.1021%2Fml1002025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okunola-Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Elucidation of Structural Elements for Selectivity across Monoamine Transporters: Novel 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1000</span>– <span class="NLM_lpage">1013</span>, <span class="refDoi"> DOI: 10.1021/jm401754x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401754x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslyhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1000-1013&author=O.+M.+Okunola-Bakareauthor=J.+Caoauthor=T.+Kopajticauthor=J.+L.+Katzauthor=C.+J.+Lolandauthor=L.+Shiauthor=A.+H.+Newman&title=Elucidation+of+Structural+Elements+for+Selectivity+across+Monoamine+Transporters%3A+Novel+2-%5B%28Diphenylmethyl%29sulfinyl%5Dacetamide+%28Modafinil%29+Analogues&doi=10.1021%2Fjm401754x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Elucidation of Structural Elements for Selectivity across Monoamine Transporters: Novel 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues</span></div><div class="casAuthors">Okunola-Bakare, Oluyomi M.; Cao, Jianjing; Kopajtic, Theresa; Katz, Jonathan L.; Loland, Claus J.; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1000-1013</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-[(Diphenylmethyl)sulfinyl]acetamide (modafinil, (±)-1) is a unique dopamine uptake inhibitor that binds the dopamine transporter (DAT) differently than cocaine and may have potential for the treatment of psychostimulant abuse.  To further investigate structural requirements for this divergent binding mode, novel thio- and sulfinylacetamide and ethanamine analogs of (±)-1 were synthesized wherein (1) the di-Ph rings were substituted with Me, trifluoromethyl, and halogen substituents and (2) substituents were added to the terminal amide/amine nitrogen.  Halogen substitution of the di-Ph rings of (±)-1 gave several amide analogs with improved binding affinity for DAT and robust selectivity over the serotonin transporter (SERT), whereas affinity improved at SERT over DAT for the p-halo-substituted amine analogs.  Mol. docking studies, using a subset of analogs with DAT and SERT homol. models, and functional data obtained with DAT (A480T) and SERT (T497A) mutants defined a role for TM10 in the substrate/inhibitor S1 binding sites of DAT and SERT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjxRhiOBM-ErVg90H21EOLACvtfcHk0ljVvTa_eeWS8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslyhtrY%253D&md5=8c9679d83c0101e335bd59867b0c2863</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm401754x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401754x%26sid%3Dliteratum%253Aachs%26aulast%3DOkunola-Bakare%26aufirst%3DO.%2BM.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DElucidation%2520of%2520Structural%2520Elements%2520for%2520Selectivity%2520across%2520Monoamine%2520Transporters%253A%2520Novel%25202-%255B%2528Diphenylmethyl%2529sulfinyl%255Dacetamide%2520%2528Modafinil%2529%2520Analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1000%26epage%3D1013%26doi%3D10.1021%2Fjm401754x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel and high affinity 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues as atypical dopamine transporter inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10676</span>– <span class="NLM_lpage">10691</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFelu7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10676-10691&author=J.+Caoauthor=R.+D.+Slackauthor=O.+M.+Bakareauthor=C.+Burzynskiauthor=R.+Raisauthor=B.+S.+Slusherauthor=T.+Kopajticauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=H.+Yanoauthor=Y.+Heauthor=G.+H.+Biauthor=Z.+X.+Xiauthor=C.+J.+Lolandauthor=A.+H.+Newman&title=Novel+and+high+affinity+2-%5B%28diphenylmethyl%29sulfinyl%5Dacetamide+%28modafinil%29+analogues+as+atypical+dopamine+transporter+inhibitors&doi=10.1021%2Facs.jmedchem.6b01373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors</span></div><div class="casAuthors">Cao, Jianjing; Slack, Rachel D.; Bakare, Oluyomi M.; Burzynski, Caitlin; Rais, Rana; Slusher, Barbara S.; Kopajtic, Theresa; Bonifazi, Alessandro; Ellenberger, Michael P.; Yano, Hideaki; He, Yi; Bi, Guo-Hua; Xi, Zheng-Xiong; Loland, Claus J.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10676-10691</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of pharmacotherapeutic treatments of psychostimulant abuse has remained a challenge, despite significant efforts made toward relevant mechanistic targets, such as the dopamine transporter (DAT).  The atypical DAT inhibitors have received attention due to their promising pharmacol. profiles in animal models of cocaine and methamphetamine abuse.  Herein the authors report a series of modafinil analogs that have an atypical DAT inhibitor profile.  The authors extended SAR by chem. manipulating the oxidn. states of the sulfoxide and the amide functional groups, halogenating the Ph rings, and/or functionalizing the terminal nitrogen with substituted piperazines, resulting in several novel leads such as 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)-3-phenylpropan-2-ol (compd. 11b), which demonstrated high DAT affinity (Ki = 2.5 nM) and selectivity without producing concomitant locomotor stimulation in mice, as compared to cocaine.  These results are consistent with an atypical DAT inhibitor profile and suggest that 11b may be a potential lead for development as a psychostimulant abuse medication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL0BwESHNuRbVg90H21EOLACvtfcHk0ljVvTa_eeWS8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFelu7bP&md5=e912f256c764249ad606d83ac9c570fb</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01373%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DSlack%26aufirst%3DR.%2BD.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBi%26aufirst%3DG.%2BH.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520and%2520high%2520affinity%25202-%255B%2528diphenylmethyl%2529sulfinyl%255Dacetamide%2520%2528modafinil%2529%2520analogues%2520as%2520atypical%2520dopamine%2520transporter%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10676%26epage%3D10691%26doi%3D10.1021%2Facs.jmedchem.6b01373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalaba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragacevic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miklosi, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wackerlig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beryozkina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radoman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saroja, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakulev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leban, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitte, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubec, G.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic analogues of modafinil as novel, atypical dopamine transporter inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9330</span>– <span class="NLM_lpage">9348</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01313</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01313" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGnu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9330-9348&author=P.+Kalabaauthor=N.+Y.+Aherauthor=M.+Ilicauthor=V.+Dragacevicauthor=M.+Wiederauthor=A.+G.+Miklosiauthor=M.+Zehlauthor=J.+Wackerligauthor=A.+Rollerauthor=T.+Beryozkinaauthor=B.+Radomanauthor=S.+R.+Sarojaauthor=W.+Lindnerauthor=E.+P.+Gonzalezauthor=V.+Bakulevauthor=J.+J.+Lebanauthor=H.+H.+Sitteauthor=E.+Urbanauthor=T.+Langerauthor=G.+Lubec&title=Heterocyclic+analogues+of+modafinil+as+novel%2C+atypical+dopamine+transporter+inhibitors&doi=10.1021%2Facs.jmedchem.7b01313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Heterocyclic Analogues of Modafinil as Novel, Atypical Dopamine Transporter Inhibitors</span></div><div class="casAuthors">Kalaba, Predrag; Aher, Nilima Y.; Ilic, Marija; Dragacevic, Vladimir; Wieder, Marcus; Miklosi, Andras G.; Zehl, Martin; Wackerlig, Judith; Roller, Alexander; Beryozkina, Tetyana; Radoman, Bojana; Saroja, Sivaprakasam R.; Lindner, Wolfgang; Gonzalez, Eduardo Perez; Bakulev, Vasiliy; Leban, Johann Jakob; Sitte, Harald H.; Urban, Ernst; Langer, Thierry; Lubec, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9330-9348</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modafinil is a wake promoting compd. with high potential for cognitive enhancement.  It is targeting the dopamine transporter (DAT) with moderate selectivity, thereby leading to reuptake inhibition and increased dopamine levels in the synaptic cleft.  A series of modafinil analogs have been reported so far, but more target-specific analogs remain to be discovered.  It was the aim of this study to synthesize and characterize such analogs and, indeed, a series of compds. were showing higher activities on the DAT and a higher selectivity toward DAT vs. serotonin and norepinephrine transporters than modafinil.  This was achieved by substituting the amide moiety by five- and six-membered arom. heterocycles.  In vitro studies indicated binding to the cocaine pocket on DAT, although mol. dynamics revealed binding different from that of cocaine.  Moreover, no release of dopamine was obsd., ruling out amphetamine-like effects.  The absence of neurotoxicity of a representative analog may encourage further preclin. studies of the above-mentioned compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxI4zZzeCZg7Vg90H21EOLACvtfcHk0lgt-79BmDHu9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGnu7fP&md5=f391cc57a70ae320ae11961b00575633</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01313%26sid%3Dliteratum%253Aachs%26aulast%3DKalaba%26aufirst%3DP.%26aulast%3DAher%26aufirst%3DN.%2BY.%26aulast%3DIlic%26aufirst%3DM.%26aulast%3DDragacevic%26aufirst%3DV.%26aulast%3DWieder%26aufirst%3DM.%26aulast%3DMiklosi%26aufirst%3DA.%2BG.%26aulast%3DZehl%26aufirst%3DM.%26aulast%3DWackerlig%26aufirst%3DJ.%26aulast%3DRoller%26aufirst%3DA.%26aulast%3DBeryozkina%26aufirst%3DT.%26aulast%3DRadoman%26aufirst%3DB.%26aulast%3DSaroja%26aufirst%3DS.%2BR.%26aulast%3DLindner%26aufirst%3DW.%26aulast%3DGonzalez%26aufirst%3DE.%2BP.%26aulast%3DBakulev%26aufirst%3DV.%26aulast%3DLeban%26aufirst%3DJ.%2BJ.%26aulast%3DSitte%26aufirst%3DH.%2BH.%26aulast%3DUrban%26aufirst%3DE.%26aulast%3DLanger%26aufirst%3DT.%26aulast%3DLubec%26aufirst%3DG.%26atitle%3DHeterocyclic%2520analogues%2520of%2520modafinil%2520as%2520novel%252C%2520atypical%2520dopamine%2520transporter%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9330%26epage%3D9348%26doi%3D10.1021%2Facs.jmedchem.7b01313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kristofova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radoman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragacevic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leban, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhau, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitte, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubec, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aradska, J.</span></span> <span> </span><span class="NLM_article-title">A daily single dose of a novel modafinil analogue CE-123 improves memory acquisition and memory retrieval</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2018.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.bbr.2018.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=29410048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Ogsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2018&pages=83-94&author=M.+Kristofovaauthor=Y.+D.+Aherauthor=M.+Ilicauthor=B.+Radomanauthor=P.+Kalabaauthor=V.+Dragacevicauthor=N.+Y.+Aherauthor=J.+Lebanauthor=V.+Korzauthor=L.+Zanonauthor=W.+Neuhauauthor=M.+Wiederauthor=T.+Langerauthor=E.+Urbanauthor=H.+H.+Sitteauthor=H.+Hoegerauthor=G.+Lubecauthor=J.+Aradska&title=A+daily+single+dose+of+a+novel+modafinil+analogue+CE-123+improves+memory+acquisition+and+memory+retrieval&doi=10.1016%2Fj.bbr.2018.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A daily single dose of a novel modafinil analogue CE-123 improves memory acquisition and memory retrieval</span></div><div class="casAuthors">Kristofova, Martina; Aher, Yogesh D.; Ilic, Marija; Radoman, Bojana; Kalaba, Predrag; Dragacevic, Vladimir; Aher, Nilima Y.; Leban, Johann; Korz, Volker; Zanon, Lisa; Neuhaus, Winfried; Wieder, Marcus; Langer, Thierry; Urban, Ernst; Sitte, Harald H.; Hoeger, Harald; Lubec, Gert; Aradska, Jana</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-94</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dopamine reuptake inhibitors have been shown to improve cognitive parameters in various tasks and animal models.  We recently reported a series of modafinil analogs, of which the most promising, 5-((benzhydrylsulfinyl)methyl) thiazole (CE-123), was selected for further development.  The present study aims to characterize pharmacol. properties of CE-123 and to investigate the potential to enhance memory performance in a rat model.  In vitro transporter assays were performed in cells expressing human transporters.  CE-123 blocked uptake of [3H] dopamine (IC50 = 4.606 μM) while effects on serotonin (SERT) and the norepinephrine transporter (NET) were negligible.  Blood-brain barrier and pharmacokinetic studies showed that the compd. reached the brain and lower elimination than R-modafinil.  The Pro-cognitive effect was evaluated in a spatial hole-board task in male Sprague-Dawley rats and CE-123 enhances memory acquisition and memory retrieval, represented by significantly increased ref. memory indexes and shortened latency.  Since DAT blockers can be considered as indirect dopamine receptor agonists, western blotting was used to quantify protein levels of dopamine receptors D1R, D2R and D5R and DAT in the synaptosomal fraction of hippocampal subregions CA1, CA3 and dentate gyrus (DG).  CE-123 administration in rats increased total DAT levels and D1R protein levels were significantly increased in CA1 and CA3 in treated/trained groups.  The increase of D5R was obsd. in DG only.  Dopamine receptors, particularly D1R, seem to play a role in mediating CE-123-induced memory enhancement.  Dopamine reuptake inhibition by CE-123 may represent a novel and improved stimulant therapeutic for impairments of cognitive functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprz2p5563B_bVg90H21EOLACvtfcHk0lgt-79BmDHu9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Ogsbw%253D&md5=0f3059aab891533f96b28d3529310a77</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2018.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2018.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DKristofova%26aufirst%3DM.%26aulast%3DAher%26aufirst%3DY.%2BD.%26aulast%3DIlic%26aufirst%3DM.%26aulast%3DRadoman%26aufirst%3DB.%26aulast%3DKalaba%26aufirst%3DP.%26aulast%3DDragacevic%26aufirst%3DV.%26aulast%3DAher%26aufirst%3DN.%2BY.%26aulast%3DLeban%26aufirst%3DJ.%26aulast%3DKorz%26aufirst%3DV.%26aulast%3DZanon%26aufirst%3DL.%26aulast%3DNeuhau%26aufirst%3DW.%26aulast%3DWieder%26aufirst%3DM.%26aulast%3DLanger%26aufirst%3DT.%26aulast%3DUrban%26aufirst%3DE.%26aulast%3DSitte%26aufirst%3DH.%2BH.%26aulast%3DHoeger%26aufirst%3DH.%26aulast%3DLubec%26aufirst%3DG.%26aulast%3DAradska%26aufirst%3DJ.%26atitle%3DA%2520daily%2520single%2520dose%2520of%2520a%2520novel%2520modafinil%2520analogue%2520CE-123%2520improves%2520memory%2520acquisition%2520and%2520memory%2520retrieval%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2018%26volume%3D343%26spage%3D83%26epage%3D94%26doi%3D10.1016%2Fj.bbr.2018.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors</span>. <i>Adv. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1016/S1054-3589(08)57007-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2FS1054-3589%2808%2957007-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=20230764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmt1OltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2009&pages=253-289&author=G.+Tandaauthor=A.+H.+Newmanauthor=J.+L.+Katz&title=Discovery+of+drugs+to+treat+cocaine+dependence%3A+behavioral+and+neurochemical+effects+of+atypical+dopamine+transport+inhibitors&doi=10.1016%2FS1054-3589%2808%2957007-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors</span></div><div class="casAuthors">Tanda, Gianluigi; Newman, Amy H.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Pharmacology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">Contemporary Aspects of Biomedical Research: Drug Discovery</span>),
    <span class="NLM_cas:pages">253-289</span>CODEN:
                <span class="NLM_cas:coden">ADPHEL</span>;
        ISSN:<span class="NLM_cas:issn">1054-3589</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Stimulant drugs acting at the dopamine transporter (DAT), like cocaine, are widely abused, yet effective medical treatments for this abuse have not been found.  Analogs of benztropine (BZT) that, like cocaine, act at the DAT have effects that differ from cocaine and in some situations block the behavioral, neurochem., and reinforcing actions of cocaine.  Neurochem. studies of dopamine levels in brain and behavioral studies have demonstrated that BZT analogs have a relatively slow onset and reduced maximal effects compared to cocaine.  Pharmacokinetic studies, however, indicated that the BZT analogs rapidly access the brain at concns. above their in vitro binding affinities, while binding in vivo demonstrates apparent assocn. rates for BZT analogs lower than that for cocaine.  Addnl., the off-target effects of these compds. do not fully explain their differences from cocaine.  Initial structure-activity studies indicated that BZT analogs bind to DAT differently from cocaine and these differences have been supported by site-directed mutagenesis studies of the DAT.  In addn., BZT analog-mediated inhibition of uptake was more resistant to mutations producing inward conformational DAT changes than cocaine analogs.  The BZT analogs have provided new insights into the relation between the mol. and behavioral actions of cocaine and the diversity of effects produced by dopamine transport inhibitors.  Novel interactions of BZT analogs with the DAT suggest that these drugs may have a pharmacol. that would be useful in their development as treatments for cocaine abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzP1lulUWR6LVg90H21EOLACvtfcHk0lgt-79BmDHu9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmt1OltA%253D%253D&md5=f168272f328f6fe2849b3c651e55d30e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS1054-3589%2808%2957007-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1054-3589%252808%252957007-4%26sid%3Dliteratum%253Aachs%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DDiscovery%2520of%2520drugs%2520to%2520treat%2520cocaine%2520dependence%253A%2520behavioral%2520and%2520neurochemical%2520effects%2520of%2520atypical%2520dopamine%2520transport%2520inhibitors%26jtitle%3DAdv.%2520Pharmacol.%26date%3D2009%26volume%3D57%26spage%3D253%26epage%3D289%26doi%3D10.1016%2FS1054-3589%2808%2957007-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstbrein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitte, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gether, U.</span></span> <span> </span><span class="NLM_article-title">Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">823</span>, <span class="refDoi"> DOI: 10.1124/mol.107.039800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fmol.107.039800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=17978168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1egs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=813-823&author=C.+J.+Lolandauthor=R.+I.+Desaiauthor=M.+F.+Zouauthor=J.+Caoauthor=P.+Grundtauthor=K.+Gerstbreinauthor=H.+H.+Sitteauthor=A.+H.+Newmanauthor=J.+L.+Katzauthor=U.+Gether&title=Relationship+between+conformational+changes+in+the+dopamine+transporter+and+cocaine-like+subjective+effects+of+uptake+inhibitors&doi=10.1124%2Fmol.107.039800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors</span></div><div class="casAuthors">Loland, Claus J.; Desai, Rajeev I.; Zou, Mu-Fa; Cao, Jianjing; Grundt, Peter; Gerstbrein, Klaus; Sitte, Harald H.; Newman, Amy Hauck; Katz, Jonathan L.; Gether, Ulrik</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">813-823</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cocaine exerts its stimulatory effect by inhibiting the dopamine transporter (DAT).  However, novel benztropine- and rimcazole-based inhibitors show reduced stimulant effects compared with cocaine, despite higher affinity and selectivity for DAT.  To investigate possible mechanisms, we compared the subjective effects of different inhibitors with their mol. mode of interaction at the DAT.  We detd. how different inhibitors affected accessibility of the sulfhydryl-reactive reagent [2-(trimethylammonium)ethyl]-methanethiosulfonate to an inserted cysteine (I159C), which is accessible when the extracellular transporter gate is open but inaccessible when it is closed.  The data indicated that cocaine analogs bind an open conformation, whereas benztropine and rimcazole analogs bind a closed conformation.  Next, we investigated the changes in inhibition potency of [3H]dopamine uptake of the compds. at a mutant DAT (Y335A) characterized by a global change in the conformational equil.  We obsd. a close relationship between the decrease in potencies of inhibitors at this mutant and cocaine-like responding in rats trained to discriminate cocaine from saline injections.  Our data suggest that chem. different DAT inhibitors stabilize distinct transporter conformations and that this in turn affects the cocaine-like subjective effects of these compds. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryV1skqbjuE7Vg90H21EOLACvtfcHk0lgpscDSldI_7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1egs7Y%253D&md5=3371614fa985881d76d801d8d07442cf</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.039800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.039800%26sid%3Dliteratum%253Aachs%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DDesai%26aufirst%3DR.%2BI.%26aulast%3DZou%26aufirst%3DM.%2BF.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DGerstbrein%26aufirst%3DK.%26aulast%3DSitte%26aufirst%3DH.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DGether%26aufirst%3DU.%26atitle%3DRelationship%2520between%2520conformational%2520changes%2520in%2520the%2520dopamine%2520transporter%2520and%2520cocaine-like%2520subjective%2520effects%2520of%2520uptake%2520inhibitors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D73%26spage%3D813%26epage%3D823%26doi%3D10.1124%2Fmol.107.039800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tunstall, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendruscolo, J. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmeichel, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koob, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendruscolo, L. F.</span></span> <span> </span><span class="NLM_article-title">Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.neuropharm.2017.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=29217282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFykurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=96-103&author=B.+J.+Tunstallauthor=C.+P.+Hoauthor=J.+J.+Caoauthor=J.+C.+M.+Vendruscoloauthor=B.+E.+Schmeichelauthor=R.+D.+Slackauthor=G.+Tandaauthor=A.+J.+Gadianoauthor=R.+Raisauthor=B.+S.+Slusherauthor=G.+F.+Koobauthor=A.+H.+Newmanauthor=L.+F.+Vendruscolo&title=Atypical+dopamine+transporter+inhibitors+attenuate+compulsive-like+methamphetamine+self-administration+in+rats&doi=10.1016%2Fj.neuropharm.2017.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats</span></div><div class="casAuthors">Tunstall, Brendan J.; Ho, Chelsea P.; Cao, Jianjing; Vendruscolo, Janaina C. M.; Schmeichel, Brooke E.; Slack, Rachel D.; Tanda, Gianluigi; Gadiano, Alexandra J.; Rais, Rana; Slusher, Barbara S.; Koob, George F.; Newman, Amy H.; Vendruscolo, Leandro F.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">96-103</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Methamphetamine (METH) is a highly addictive drug, but no pharmacol. treatment is yet available for METH use disorders.  Similar to METH, the wake-promoting drug (R)-modafinil (R-MOD) binds to the dopamine transporter (DAT).  Unlike METH, R-MOD is not a substrate for transport by DAT and has low abuse potential.  We tested the hypothesis that the atypical DAT inhibitor R-MOD and compds. that are derived from modafinil would decrease METH intake by reducing the actions of METH at the DAT.  We tested the effects of systemic injections of R-MOD and four novel modafinil-derived ligands with increased DAT affinity (JJC8-016, JJC8-088, JJC8-089, and JJC8-091) on i.v. (i.v.) METH self-administration in rats that were allowed short access (ShA; 1 h) or long access (LgA; 6 h) to the drug.  ShA rats exhibited stable METH intake over sessions, whereas LgA rats exhibited an escalation of drug intake.  R-MOD decreased METH self-administration in ShA and LgA rats (in the 1st hour only).  JJC8-091 and JJC8-016 decreased METH self-administration in both ShA and LgA rats.  JJC8-089 decreased METH self-administration in LgA rats only, whereas JJC8-088 had no effect on METH self-administration in either ShA or LgA rats.  These findings support the potential of atypical DAT inhibitors for the treatment of METH use disorders and suggest several novel compds. as candidate drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovlYUD2STJo7Vg90H21EOLACvtfcHk0lgpscDSldI_7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFykurrJ&md5=e5d4b83aa9093b918b490ee8dd1ac0bd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DTunstall%26aufirst%3DB.%2BJ.%26aulast%3DHo%26aufirst%3DC.%2BP.%26aulast%3DCao%26aufirst%3DJ.%2BJ.%26aulast%3DVendruscolo%26aufirst%3DJ.%2BC.%2BM.%26aulast%3DSchmeichel%26aufirst%3DB.%2BE.%26aulast%3DSlack%26aufirst%3DR.%2BD.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DGadiano%26aufirst%3DA.%2BJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DVendruscolo%26aufirst%3DL.%2BF.%26atitle%3DAtypical%2520dopamine%2520transporter%2520inhibitors%2520attenuate%2520compulsive-like%2520methamphetamine%2520self-administration%2520in%2520rats%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D131%26spage%3D96%26epage%3D103%26doi%3D10.1016%2Fj.neuropharm.2017.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keighron, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avelar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschumi, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckstead, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span> <span> </span><span class="NLM_article-title">Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1435</span>, <span class="refDoi"> DOI: 10.1038/s41386-019-0366-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fs41386-019-0366-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=30858517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyru7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=1435&author=A.+H.+Newmanauthor=J.+Caoauthor=J.+D.+Keighronauthor=C.+J.+Jordanauthor=G.+H.+Biauthor=Y.+Liangauthor=A.+M.+Abramyanauthor=A.+J.+Avelarauthor=C.+W.+Tschumiauthor=M.+J.+Becksteadauthor=L.+Shiauthor=G.+Tandaauthor=Z.+X.+Xi&title=Translating+the+atypical+dopamine+uptake+inhibitor+hypothesis+toward+therapeutics+for+treatment+of+psychostimulant+use+disorders&doi=10.1038%2Fs41386-019-0366-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders</span></div><div class="casAuthors">Newman, Amy Hauck; Cao, Jianjing; Keighron, Jacqueline D.; Jordan, Chloe J.; Bi, Guo-Hua; Liang, Ying; Abramyan, Ara M.; Avelar, Alicia J.; Tschumi, Christopher W.; Beckstead, Michael J.; Shi, Lei; Tanda, Gianluigi; Xi, Zheng-Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1435-1444</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Medication-assisted treatments are unavailable to patients with cocaine use disorders.  Efforts to develop potential pharmacotherapies have led to the identification of a promising lead mol., JJC8-091, that demonstrates a novel binding mode at the dopamine transporter (DAT).  Here, JJC8-091 and a structural analog, JJC8-088, were extensively and comparatively assessed to elucidate neurochem. correlates to their divergent behavioral profiles.  Despite sharing significant structural similarity, JJC8-088 was more cocaine-like, increasing extracellular DA concns. in the nucleus accumbens shell (NAS) efficaciously and more potently than JJC8-091.  In contrast, JJC8-091 was not self-administered and was effective in blocking cocaine-induced reinstatement to drug seeking.  Electrophysiol. expts. confirmed that JJC8-091 was more effective than JJC8-088 at inhibiting cocaine-mediated enhancement of DA neurotransmission.  Further, when VTA DA neurons in DAT-cre mice were optically stimulated, JJC8-088 produced a significant leftward shift in the stimulation-response curve, similar to cocaine, while JJC8-091 shifted the curve downward, suggesting attenuation of DA-mediated brain reward.  Computational models predicted that JJC8-088 binds in an outward facing conformation of DAT, similar to cocaine.  Conversely, JJC8-091 steers DAT towards a more occluded conformation.  Collectively, these data reveal the underlying mol. mechanism at DAT that may be leveraged to rationally optimize leads for the treatment of cocaine use disorders, with JJC8-091 representing a compelling candidate for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAa-KR-A2MpbVg90H21EOLACvtfcHk0lg9gF_eAyPzKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyru7rI&md5=5105829a90c04a23b0406e8a209215e2</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fs41386-019-0366-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-019-0366-z%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DKeighron%26aufirst%3DJ.%2BD.%26aulast%3DJordan%26aufirst%3DC.%2BJ.%26aulast%3DBi%26aufirst%3DG.%2BH.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DAvelar%26aufirst%3DA.%2BJ.%26aulast%3DTschumi%26aufirst%3DC.%2BW.%26aulast%3DBeckstead%26aufirst%3DM.%2BJ.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26atitle%3DTranslating%2520the%2520atypical%2520dopamine%2520uptake%2520inhibitor%2520hypothesis%2520toward%2520therapeutics%2520for%2520treatment%2520of%2520psychostimulant%2520use%2520disorders%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D1435%26doi%3D10.1038%2Fs41386-019-0366-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisgaard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, M. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gether, U.</span></span> <span> </span><span class="NLM_article-title">The binding sites for benztropines and dopamine in the dopamine transporter overlap</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2010.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.neuropharm.2010.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=20816875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVaitLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=182-190&author=H.+Bisgaardauthor=M.+A.+B.+Larsenauthor=S.+Mazierauthor=T.+Beumingauthor=A.+H.+Newmanauthor=H.+Weinsteinauthor=L.+Shiauthor=C.+J.+Lolandauthor=U.+Gether&title=The+binding+sites+for+benztropines+and+dopamine+in+the+dopamine+transporter+overlap&doi=10.1016%2Fj.neuropharm.2010.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The binding sites for benztropines and dopamine in the dopamine transporter overlap</span></div><div class="casAuthors">Bisgaard, Heidi; Larsen, M. Andreas B.; Mazier, Sonia; Beuming, Thijs; Newman, Amy Hauck; Weinstein, Harel; Shi, Lei; Loland, Claus J.; Gether, Ulrik</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-190</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Analogs of benztropines (BZTs) are potent inhibitors of the dopamine transporter (DAT) but are less effective than cocaine as behavioral stimulants.  As a result, there have been efforts to evaluate these compds. as leads for potential medication for cocaine addiction.  Here we use computational modeling together with site-directed mutagenesis to characterize the binding site for BZTs in DAT.  Docking into mol. models based on the structure of the bacterial homolog LeuT supported a BZT binding site that overlaps with the substrate-binding pocket.  In agreement, mutations of residues within the pocket, including Val1523.46 to Ala or Ile, Ser4228.60 to Ala and Asn1573.51 to Cys or Ala, resulted in decreased affinity for BZT and the analog JHW007, as assessed in [3H]dopamine uptake inhibition assays and/or [3H]CFT competition binding assay.  A putative polar interaction of one of the Ph ring fluorine substituents in JHW007 with Asn1573.51 was used as a criterion for detg. likely binding poses and establish a structural context for the mutagenesis findings.  The anal. positioned the other fluorine-substituted Ph ring of JHW007 in close proximity to Ala47910.51/Ala48010.52 in transmembrane segment (TM) 10.  The lack of such an interaction for BZT led to a more tilted orientation, as compared to JHW007, bringing one of the Ph rings even closer to Ala47910.51/Ala48010.52.  Mutation of Ala47910.51 and Ala48010.52 to valines supported these predictions with a larger decrease in the affinity for BZT than for JHW007.  Summarized, our data suggest that BZTs display a classical competitive binding mode with binding sites overlapping those of cocaine and dopamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR-5LmnkQ4_7Vg90H21EOLACvtfcHk0lg9gF_eAyPzKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVaitLzM&md5=b601a5fa6abe86a35f84193ee45970a7</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2010.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2010.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DBisgaard%26aufirst%3DH.%26aulast%3DLarsen%26aufirst%3DM.%2BA.%2BB.%26aulast%3DMazier%26aufirst%3DS.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DGether%26aufirst%3DU.%26atitle%3DThe%2520binding%2520sites%2520for%2520benztropines%2520and%2520dopamine%2520in%2520the%2520dopamine%2520transporter%2520overlap%26jtitle%3DNeuropharmacology%26date%3D2011%26volume%3D60%26spage%3D182%26epage%3D190%26doi%3D10.1016%2Fj.neuropharm.2010.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanettini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthrie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship studies on a series of 3 alpha-[bis(4-fluorophenyl)methoxy]tropanes and 3 alpha-[bis(4-fluorophenyl)methylamino]tropanes as novel atypical dopamine transporter (DAT) inhibitors for the treatment of cocaine use disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10172</span>– <span class="NLM_lpage">10187</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01454</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01454" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCqt7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=10172-10187&author=M.+F.+Zouauthor=J.+Caoauthor=A.+M.+Abramyanauthor=T.+Kopajticauthor=C.+Zanettiniauthor=D.+A.+Guthrieauthor=R.+Raisauthor=B.+S.+Slusherauthor=L.+Shiauthor=C.+J.+Lolandauthor=A.+H.+Newman&title=Structure-activity+relationship+studies+on+a+series+of+3+alpha-%5Bbis%284-fluorophenyl%29methoxy%5Dtropanes+and+3+alpha-%5Bbis%284-fluorophenyl%29methylamino%5Dtropanes+as+novel+atypical+dopamine+transporter+%28DAT%29+inhibitors+for+the+treatment+of+cocaine+use+disorders&doi=10.1021%2Facs.jmedchem.7b01454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders</span></div><div class="casAuthors">Zou, Mu-Fa; Cao, Jianjing; Abramyan, Ara M.; Kopajtic, Theresa; Zanettini, Claudio; Guthrie, Daryl A.; Rais, Rana; Slusher, Barbara S.; Shi, Lei; Loland, Claus J.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10172-10187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of medications to treat cocaine use disorders has thus far defied success, leaving this patient population without pharmacotherapeutic options.  As the dopamine transporter (DAT) plays a prominent role in the reinforcing effects of cocaine that can lead to addiction, atypical DAT inhibitors have been developed that prevent cocaine from binding to DAT, but they themselves are not cocaine-like.  Herein, a series of novel DAT inhibitors were synthesized, and based on its pharmacol. profile, the lead compd. I was evaluated in phase I metabolic stability studies in mouse liver microsomes and compared to cocaine in locomotor activity and drug discrimination paradigms in mice.  A mol. dynamic simulation study supported the hypothesis that atypical DAT inhibitors have similar binding poses at DAT in a conformation that differs from that of cocaine.  Such differences may ultimately contribute to their unique behavioral profiles and potential for development as cocaine use disorder therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm08JwNTX1KbVg90H21EOLACvtfcHk0lg9gF_eAyPzKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCqt7fO&md5=e8f6fcbf17e227d9f5839049b6dd4dc5</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01454%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DM.%2BF.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DZanettini%26aufirst%3DC.%26aulast%3DGuthrie%26aufirst%3DD.%2BA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DStructure-activity%2520relationship%2520studies%2520on%2520a%2520series%2520of%25203%2520alpha-%255Bbis%25284-fluorophenyl%2529methoxy%255Dtropanes%2520and%25203%2520alpha-%255Bbis%25284-fluorophenyl%2529methylamino%255Dtropanes%2520as%2520novel%2520atypical%2520dopamine%2520transporter%2520%2528DAT%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cocaine%2520use%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D10172%26epage%3D10187%26doi%3D10.1021%2Facs.jmedchem.7b01454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolzenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">The isomeric preference of an atypical dopamine transporter inhibitor contributes to its selection of the transporter conformation</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1735</span>– <span class="NLM_lpage">1746</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.7b00094</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.7b00094" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXms1Wnt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1735-1746&author=A.+M.+Abramyanauthor=S.+Stolzenbergauthor=Z.+Liauthor=C.+J.+Lolandauthor=F.+Noeauthor=L.+Shi&title=The+isomeric+preference+of+an+atypical+dopamine+transporter+inhibitor+contributes+to+its+selection+of+the+transporter+conformation&doi=10.1021%2Facschemneuro.7b00094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The Isomeric Preference of an Atypical Dopamine Transporter Inhibitor Contributes to Its Selection of the Transporter Conformation</span></div><div class="casAuthors">Abramyan, Ara M.; Stolzenberg, Sebastian; Li, Zheng; Loland, Claus J.; Noe, Frank; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1735-1746</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cocaine, a widely abused psychostimulant, inhibits the dopamine transporter (DAT) by trapping the protein in an outward-open conformation, whereas atypical DAT inhibitors such as benztropine have low abuse liability and prefer less outward-open conformations.  Here, we use a spectrum of computational modeling and simulation approaches to obtain the underlying mol. mechanism in atomistic detail.  Interestingly, our quantum mech. calcns. and mol. dynamics (MD) simulations suggest that a benztropine deriv. JHW007 prefers a different stereoisomeric conformation of tropane in binding to DAT compared to that of a cocaine deriv., CFT.  To further investigate the different inhibition mechanisms of DAT, we carried out MD simulations in combination with Markov state modeling anal. of wild-type and Y156F DAT in the absence of any ligand or the presence of CFT or JHW007.  Our results indicate that the Y156F mutation and CFT shift the conformational equil. toward an outward-open conformation, whereas JHW007 prefers an inward-occluded conformation.  Our findings reveal the mechanistic details of DAT inhibition by JHW007 at the atomistic level, which provide clues for rational design of atypical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxNFlSEtAxMLVg90H21EOLACvtfcHk0lgzFaFLzmCqQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXms1Wnt7w%253D&md5=41117f8ff97f8c81d8e8bd9448bb72ed</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.7b00094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.7b00094%26sid%3Dliteratum%253Aachs%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DStolzenberg%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DNoe%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DThe%2520isomeric%2520preference%2520of%2520an%2520atypical%2520dopamine%2520transporter%2520inhibitor%2520contributes%2520to%2520its%2520selection%2520of%2520the%2520transporter%2520conformation%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D1735%26epage%3D1746%26doi%3D10.1021%2Facschemneuro.7b00094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Razavi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khelashvili, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span> <span> </span><span class="NLM_article-title">A Markov state-based quantitative kinetic model of sodium release from the dopamine transporter</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">40076</span>, <span class="refDoi"> DOI: 10.1038/srep40076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fsrep40076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=28059145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntlelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=40076&author=A.+M.+Razaviauthor=G.+Khelashviliauthor=H.+Weinstein&title=A+Markov+state-based+quantitative+kinetic+model+of+sodium+release+from+the+dopamine+transporter&doi=10.1038%2Fsrep40076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A Markov State-based Quantitative Kinetic Model of Sodium Release from the Dopamine Transporter</span></div><div class="casAuthors">Razavi, Asghar M.; Khelashvili, George; Weinstein, Harel</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40076</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The dopamine transporter (DAT) belongs to the neurotransmitter:sodium symporter (NSS) family of membrane proteins that are responsible for reuptake of neurotransmitters from the synaptic cleft to terminate a neuronal signal and enable subsequent neurotransmitter release from the presynaptic neuron.  The release of one sodium ion from the crystallog. detd. sodium binding site Na2 had been identified as an initial step in the transport cycle which preps. the transporter for substrate translocation by stabilizing an inward-open conformation.  We have constructed Markov State Models (MSMs) from extensive mol. dynamics simulations of human DAT (hDAT) to explore the mechanism of this sodium release.  Our results quantify the release process triggered by hydration of the Na2 site that occurs concomitantly with a conformational transition from an outward-facing to an inward-facing state of the transporter.  The kinetics of the release process are computed from the MSM, and transition path theory is used to identify the most probable sodium release pathways.  An intermediate state is discovered on the sodium release pathway, and the results reveal the importance of various modes of interaction of the N-terminus of hDAT in controlling the pathways of release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIuAYJ2vYiZrVg90H21EOLACvtfcHk0lgzFaFLzmCqQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntlelsg%253D%253D&md5=685a78ef27fb0588d16ebdbf4f52516b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fsrep40076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep40076%26sid%3Dliteratum%253Aachs%26aulast%3DRazavi%26aufirst%3DA.%2BM.%26aulast%3DKhelashvili%26aufirst%3DG.%26aulast%3DWeinstein%26aufirst%3DH.%26atitle%3DA%2520Markov%2520state-based%2520quantitative%2520kinetic%2520model%2520of%2520sodium%2520release%2520from%2520the%2520dopamine%2520transporter%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D40076%26doi%3D10.1038%2Fsrep40076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahar, I.</span></span> <span> </span><span class="NLM_article-title">Quantitative assessment of the energetics of dopamine translocation by human dopamine transporter</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">5336</span>– <span class="NLM_lpage">5346</span>, <span class="refDoi"> DOI: 10.1021/acs.jpcb.7b10340</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jpcb.7b10340" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOitbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2018&pages=5336-5346&author=M.+H.+Chengauthor=C.+Kayaauthor=I.+Bahar&title=Quantitative+assessment+of+the+energetics+of+dopamine+translocation+by+human+dopamine+transporter&doi=10.1021%2Facs.jpcb.7b10340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Assessment of the Energetics of Dopamine Translocation by Human Dopamine Transporter</span></div><div class="casAuthors">Cheng, Mary Hongying; Kaya, Cihan; Bahar, Ivet</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5336-5346</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-5207</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Computational evaluation of the energetics of substrate binding, transport, and release events of neurotransmitter transporters at the mol. level is a challenge, as the structural transitions of these membrane proteins involve coupled global and local changes that span time scales of several orders of magnitude, from nanoseconds to seconds.  Here, we provide a quant. assessment of the energetics of dopamine (DA) translocation through the human DA transporter (hDAT), using a combination of mol. modeling, simulation, and anal. tools.  DA-binding and -unbinding events, which generally involve local configurational changes, are evaluated using free-energy perturbation or adaptive biasing force methods.  The global transitions between the outward-facing state and the inward-facing state, on the other hand, require a dual-boost accelerated mol. dynamics simulation.  We present results on DA-binding/unbinding energetics under different conditions, as well as the conformational energy landscape of hDAT in both DA-bound and -unbound states.  The study provides a tractable method of approach for quant. evaluation of substrate-binding energetics and efficient estn. of conformational energy landscape, in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonsBnmjh64hLVg90H21EOLACvtfcHk0lgzFaFLzmCqQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOitbfP&md5=f6e825eed95c36287664349b3e176f36</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jpcb.7b10340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jpcb.7b10340%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%2BH.%26aulast%3DKaya%26aufirst%3DC.%26aulast%3DBahar%26aufirst%3DI.%26atitle%3DQuantitative%2520assessment%2520of%2520the%2520energetics%2520of%2520dopamine%2520translocation%2520by%2520human%2520dopamine%2520transporter%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2018%26volume%3D122%26spage%3D5336%26epage%3D5346%26doi%3D10.1021%2Facs.jpcb.7b10340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohut, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and Sigma receptors</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.185025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.111.185025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=21859929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFehtbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2011&pages=662-677&author=T.+Hiranitaauthor=P.+L.+Sotoauthor=S.+J.+Kohutauthor=T.+Kopajticauthor=J.+Caoauthor=A.+H.+Newmanauthor=G.+Tandaauthor=J.+L.+Katz&title=Decreases+in+cocaine+self-administration+with+dual+inhibition+of+the+dopamine+transporter+and+Sigma+receptors&doi=10.1124%2Fjpet.111.185025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and σ receptors</span></div><div class="casAuthors">Hiranita, Takato; Soto, Paul L.; Kohut, Stephen J.; Kopajtic, Theresa; Cao, Jianjing; Newman, Amy H.; Tanda, Gianluigi; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">662-677</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sigma receptor (σR) antagonists attenuate many behavioral effects of cocaine but typically not its reinforcing effects in self-administration procedures.  However, the σR antagonist rimcazole and its N-propylphenyl analogs, [3-(cis-3,5-dimethyl-4-[3-phenylpropyl]-1-piperazinyl)-propyl]diphenylamine hydrochloride (SH 3-24) and 9-[3-(cis-3,5-dimethyl-4-[3-phenylpropyl]-1-piperazinyl)-propyl]carbazole hydrobromide (SH 3-28), dose-dependently decreased the maximal rates of cocaine self-administration without affecting comparable responding maintained by food reinforcement.  In contrast, a variety of σR antagonists [N-phenethylpiperidine oxalate (AC927), N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine dihydrobromide (BD 1008), N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino) ethylamine dihydrobromide (BD 1047), N-[2-(3,4-dichlorophenyl) ethyl]-4-methylpiperazine dihydrochloride (BD 1063), and N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine monohydrochloride (NE-100)] had no effect on cocaine self-administration across the range of doses that decreased rates of food-maintained responding.  Rimcazole analogs differed from selective σR antagonists in their dual affinities for σRs and the dopamine transporter (DAT) assessed with radioligand binding.  Selective DAT inhibitors and σR antagonists were studied alone and in combination on cocaine self-administration to det. whether actions at both σRs and the DAT were sufficient to reproduce the effects of rimcazole analogs.  Typical DAT inhibitors [2β-carbomethoxy-3β-(4-fluorophenyl)tropane (WIN 35,428), methylphenidate, and nomifensine] dose-dependently shifted the cocaine dose-effect curve leftward.  Combinations of DAT inhibitor and σR antagonist doses that were behaviorally inactive alone decreased cocaine self-administration without effects on food-maintained responding.  In addn., whereas the DAT inhibitors were self-administered at rates similar to those of cocaine, neither rimcazole analogs nor typical σR antagonists (NE-100 and AC927) maintained responding above control levels across a wide range of doses.  These findings suggest that the unique effects of rimcazole analogs are due to dual actions at the DAT and σRs and that a combined target approach may have utility in development of medical treatments for cocaine abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs0gcxwJwV_LVg90H21EOLACvtfcHk0lgzFaFLzmCqQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFehtbvJ&md5=7be9d75e9be58be204e9f89e672f4a5a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.185025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.185025%26sid%3Dliteratum%253Aachs%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DSoto%26aufirst%3DP.%2BL.%26aulast%3DKohut%26aufirst%3DS.%2BJ.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DDecreases%2520in%2520cocaine%2520self-administration%2520with%2520dual%2520inhibition%2520of%2520the%2520dopamine%2520transporter%2520and%2520Sigma%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D339%26spage%3D662%26epage%3D677%26doi%3D10.1124%2Fjpet.111.185025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Sigma receptor effects of N-substituted benztropine analogs: implications for antagonism of cocaine self-administration</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.241109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.117.241109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=28442581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2017&pages=2-13&author=T.+Hiranitaauthor=W.+C.+Hongauthor=T.+Kopajticauthor=J.+L.+Katz&title=Sigma+receptor+effects+of+N-substituted+benztropine+analogs%3A+implications+for+antagonism+of+cocaine+self-administration&doi=10.1124%2Fjpet.117.241109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">σ receptor effects of N-substituted benztropine analogs: implications for antagonism of cocaine self-administration</span></div><div class="casAuthors">Hiranita, Takato; Hong, Weimin C.; Kopajtic, Theresa; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-13</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several N-substituted benztropine (BZT) analogs are atypical dopamine transport inhibitors as they have affinity for the dopamine transporter (DAT) but have minimal cocaine-like pharmacol. effects and can block numerous effects of cocaine, including its self-administration.  Among these compds., N-Me (AHN1-055), N-allyl (AHN2-005), and N-Bu (JHW007) analogs of 3α-[bis(4'-fluorophenyl)methoxy]-tropane were more potent in antagonizing self-administration of cocaine and d-methamphetamine than in decreasing food-maintained responding.  The antagonism of cocaine self-administration (0.03-1.0 mg/kg per injection) with the above BZT analogs was reproduced in the present study.  Further, the stimulant-antagonist effects resembled previously reported effects of pretreatments with combinations of std. DAT inhibitors and σ1-receptor (σ1R) antagonists.  Therefore, the present study examd. binding of the BZT analogs to σRs, as well as their in vivo σR antagonist effects.  Each of the BZT analogs displaced radiolabeled σR ligands with nanomolar affinity.  Further, self-administration of the σR agonist DTG (0.1-3.2 mg/kg/injection) was dose dependently blocked by AHN2-005 and JHW007 but potentiated by AHN1-055.  In contrast, none of the BZT analogs that were active against DTG self-administration was active against the self-administration of agonists at dopamine D1-like [R(+)-SKF 81297, (±)-SKF 82958 (0.00032-0.01 mg/kg per injection each)], D2-like [R(-)-NPA (0.0001-0.0032 mg/kg per injection), (-)-quinpirole (0.0032-0.1 mg/kg per injection)], or μ-opioid (remifentanil, 0.0001-0.0032 mg/kg per injection) receptors.  The present results indicate that behavioral antagonist effects of the N-substituted BZT analogs are specific for abused drugs acting at the DAT and further suggest that σR antagonism contributes to those actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUG3AyF6Z927Vg90H21EOLACvtfcHk0lgSv62mo8EQfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsbvF&md5=148e6177caf110e0a158f8cfc0803e95</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.241109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.241109%26sid%3Dliteratum%253Aachs%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.%2BC.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DSigma%2520receptor%2520effects%2520of%2520N-substituted%2520benztropine%2520analogs%253A%2520implications%2520for%2520antagonism%2520of%2520cocaine%2520self-administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D362%26spage%3D2%26epage%3D13%26doi%3D10.1124%2Fjpet.117.241109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">The Sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">11250</span>– <span class="NLM_lpage">11261</span>, <span class="refDoi"> DOI: 10.1074/jbc.M116.774075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1074%2Fjbc.M116.774075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=28495886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCisL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=11250-11261&author=W.+C.+Hongauthor=H.+Yanoauthor=T.+Hiranitaauthor=F.+T.+Chinauthor=C.+R.+McCurdyauthor=T.+P.+Suauthor=S.+G.+Amaraauthor=J.+L.+Katz&title=The+Sigma-1+receptor+modulates+dopamine+transporter+conformation+and+cocaine+binding+and+may+thereby+potentiate+cocaine+self-administration+in+rats&doi=10.1074%2Fjbc.M116.774075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats</span></div><div class="casAuthors">Hong, Weimin Conrad; Yano, Hideaki; Hiranita, Takato; Chin, Frederick T.; McCurdy, Christopher R.; Su, Tsung-Ping; Amara, Susan G.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">11250-11261</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The dopamine transporter (DAT) regulates dopamine (DA) neurotransmission by recapturing DA into the presynaptic terminals and is a principal target of the psychostimulant cocaine.  The sigma-1 receptor (σ1R) is a mol. chaperone, and its ligands have been shown to modulate DA neuronal signaling, although their effects on DAT activity are unclear.  Here, the authors report that the prototypical σ1R agonist (+)-pentazocine potentiated the dose response of cocaine self-administration in rats, consistent with the effects of the σR agonists PRE-084 and DTG (1,3-di-o-tolylguanidine) reported previously.  These behavioral effects appeared to be correlated with functional changes of DAT.  Preincubation with (+)-pentazocine or PRE-084 increased the Bmax values of [3H]WIN35428 binding to DAT in rat striatal synaptosomes and transfected cells.  A specific interaction between σ1R and DAT was detected by co-immunopptn. and bioluminescence resonance energy transfer assays.  Mutational analyses indicated that the transmembrane domain of σ1R likely mediated this interaction.  Furthermore, cysteine accessibility assays showed that σ1R agonist preincubation potentiated cocaine-induced changes in DAT conformation, which were blocked by the specific σ1R antagonist CM304.  Moreover, σ1R ligands had distinct effects on σ1R multimerization.  CM304 increased the proportion of multimeric σ1Rs, whereas (+)-pentazocine increased monomeric σ1Rs.  Together these results support the hypothesis that σ1R agonists promote dissocn. of σ1R multimers into monomers, which then interact with DAT to stabilize an outward-facing DAT conformation and enhance cocaine binding.  The authors propose that this novel mol. mechanism underlies the behavioral potentiation of cocaine self-administration by σ1R agonists in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9IZLHbohe7rVg90H21EOLACvtfcHk0lgSv62mo8EQfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCisL7F&md5=5366dbf409e7cbefeb52c79a3198023f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M116.774075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M116.774075%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DW.%2BC.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DAmara%26aufirst%3DS.%2BG.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520Sigma-1%2520receptor%2520modulates%2520dopamine%2520transporter%2520conformation%2520and%2520cocaine%2520binding%2520and%2520may%2520thereby%2520potentiate%2520cocaine%2520self-administration%2520in%2520rats%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26spage%3D11250%26epage%3D11261%26doi%3D10.1074%2Fjbc.M116.774075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohut, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.208264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.113.208264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=24194527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=174-191&author=T.+Hiranitaauthor=S.+J.+Kohutauthor=P.+L.+Sotoauthor=G.+Tandaauthor=T.+A.+Kopajticauthor=J.+L.+Katz&title=Preclinical+efficacy+of+N-substituted+benztropine+analogs+as+antagonists+of+methamphetamine+self-administration+in+rats&doi=10.1124%2Fjpet.113.208264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats</span></div><div class="casAuthors">Hiranita, Takato; Kohut, Stephen J.; Soto, Paul L.; Tanda, Gianluigi; Kopajtic, Theresa A.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-191, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Atypical dopamine-uptake inhibitors have low abuse potential and may serve as leads for development of cocaine-abuse treatments.  Among them, the benztropine (BZT) derivs., N-Bu (JHW007), N-allyl (AHN2-005), and N-Me (AHN1-055) analogs of 3α-[bis(4'-fluorophenyl)methoxy]-tropane dose-dependently decreased cocaine self-administration without effects on food-maintained responding.  Our study examd. selectivity by assessing their effects on self-administration of other drugs.  As with cocaine, each BZT analog (1.0-10.0 mg/kg i.p.) dose-dependently decreased maximal self-administration of d-methamphetamine (0.01-0.32 mg/kg/infusion) but was inactive against heroin (1.0-32.0 μg/kg/infusion) and ketamine (0.032-1.0 mg/kg/infusion) self-administration.  Further, std. dopamine indirect-agonists [WIN35,428 ((-)-3β-(4-fluorophenyl)-tropan-2-β-carboxylic acid Me ester tartrate), d-amphetamine (0.1-1.0 mg/kg i.p., each)] dose-dependently left-shifted self-administration dose-effect curves for d-methamphetamine, heroin, and ketamine.  Noncompetitive NMDA-glutamate receptor/channel antagonists [(+)-MK-801 (0.01-0.1 mg/kg i.p.), memantine (1.0-10.0 mg/kg i.p.)] also left-shifted dose-effect curves for d-methamphetamine and ketamine (but not heroin) self-administration.  The μ-agonists [dl-methadone and morphine (1.0-10.0 mg/kg i.p., each)] dose-dependently decreased maximal self-administration of μ-agonists (heroin, remifentanil) but not d-methamphetamine or ketamine self-administration.  The μ-agonist-induced decreases were similar to the effects of BZT analogs on stimulant self-administration and effects of food prefeeding on responding maintained by food reinforcement.  Radioligand-binding and behavioral studies suggested that inhibition of dopamine transporters and s receptors were crit. for blocking stimulant self-administration by BZT-analogs.  Thus, the present results suggest that the effects of BZT analogs on stimulant self-administration are similar to effects of μ-agonists on μ-agonist self-administration and food prefeeding on food-reinforced responding, which implicates behavioral mechanisms for these effects and further supports development of atypical dopamine uptake inhibitors as medications for stimulant abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoePjL_jLBq8LVg90H21EOLACvtfcHk0lgSv62mo8EQfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKjur4%253D&md5=5a67df57fd903d92e17c313203d9aebe</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.208264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.208264%26sid%3Dliteratum%253Aachs%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DKohut%26aufirst%3DS.%2BJ.%26aulast%3DSoto%26aufirst%3DP.%2BL.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DPreclinical%2520efficacy%2520of%2520N-substituted%2520benztropine%2520analogs%2520as%2520antagonists%2520of%2520methamphetamine%2520self-administration%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D174%26epage%3D191%26doi%3D10.1124%2Fjpet.113.208264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hedges, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obray, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yorgason, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerasekara, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uys, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellinger, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffensen, S. C.</span></span> <span> </span><span class="NLM_article-title">Methamphetamine induces dopamine release in the nucleus accumbens through a Sigma receptor-mediated pathway</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1405</span>– <span class="NLM_lpage">1414</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fnpp.2017.291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=29185481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12it78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=1405-1414&author=D.+M.+Hedgesauthor=J.+D.+Obrayauthor=J.+T.+Yorgasonauthor=E.+Y.+Jangauthor=V.+K.+Weerasekaraauthor=J.+D.+Uysauthor=F.+P.+Bellingerauthor=S.+C.+Steffensen&title=Methamphetamine+induces+dopamine+release+in+the+nucleus+accumbens+through+a+Sigma+receptor-mediated+pathway&doi=10.1038%2Fnpp.2017.291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Methamphetamine Induces Dopamine Release in the Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway</span></div><div class="casAuthors">Hedges, David M.; Obray, J. Daniel; Yorgason, Jordan T.; Jang, Eun Young; Weerasekara, Vajira K.; Uys, Joachim D.; Bellinger, Frederick P.; Steffensen, Scott C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1405-1414</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Methamphetamine (METH) is a drug with a high addictive potential that is widely abused across the world.  Although it is known that METH dysregulates both dopamine transmission and dopamine reuptake, the specific mechanism of action remains obscure.  One promising target of METH is the sigma receptor, a chaperone protein located on the membrane of the endoplasmic reticulum.  Using fast-scan cyclic voltammetry, we show that METH-enhancement of evoked dopamine release and basal efflux is dependent on sigma receptor activation.  METH-induced activation of sigma receptors results in oxidn. of a cysteine residue on VMAT2, which decreases transporter function.  Unilateral injections of the sigma receptor antagonist BD-1063 prior to METH administration increased dopamine-related ipsilateral circling behavior, indicating the involvement of sigma receptors.  These findings suggest that interactions between METH and the sigma receptor lead to oxidative species (most likely superoxide) that in turn oxidize VMAT2.  Altogether, these findings show that the sigma receptor has a key role in METH dysregulation of dopamine release and dopamine-related behaviors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4t7gheuDT2rVg90H21EOLACvtfcHk0lglE8qcccmSbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12it78%253D&md5=2f8cc2b1b8ea906e9f40b2f73a4586eb</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.291%26sid%3Dliteratum%253Aachs%26aulast%3DHedges%26aufirst%3DD.%2BM.%26aulast%3DObray%26aufirst%3DJ.%2BD.%26aulast%3DYorgason%26aufirst%3DJ.%2BT.%26aulast%3DJang%26aufirst%3DE.%2BY.%26aulast%3DWeerasekara%26aufirst%3DV.%2BK.%26aulast%3DUys%26aufirst%3DJ.%2BD.%26aulast%3DBellinger%26aufirst%3DF.%2BP.%26aulast%3DSteffensen%26aufirst%3DS.%2BC.%26atitle%3DMethamphetamine%2520induces%2520dopamine%2520release%2520in%2520the%2520nucleus%2520accumbens%2520through%2520a%2520Sigma%2520receptor-mediated%2520pathway%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26spage%3D1405%26epage%3D1414%26doi%3D10.1038%2Fnpp.2017.291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sambo, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagnarine, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriquez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Febo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruijnzeel, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daws, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoshbouei, H.</span></span> <span> </span><span class="NLM_article-title">The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2228</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02087-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fs41467-017-02087-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=29263318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A280%3ADC%252BC1MzjslSitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2228&author=D.+O.+Samboauthor=M.+Linauthor=A.+Owensauthor=J.+J.+Lebowitzauthor=B.+Richardsonauthor=D.+A.+Jagnarineauthor=M.+Shettyauthor=M.+Rodriquezauthor=T.+Alongeauthor=M.+Aliauthor=J.+Katzauthor=L.+Yanauthor=M.+Feboauthor=L.+K.+Henryauthor=A.+W.+Bruijnzeelauthor=L.+Dawsauthor=H.+Khoshbouei&title=The+sigma-1+receptor+modulates+methamphetamine+dysregulation+of+dopamine+neurotransmission&doi=10.1038%2Fs41467-017-02087-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission</span></div><div class="casAuthors">Sambo Danielle O; Lin Min; Lebowitz Joseph J; Richardson Ben; Alonge Taiwo; Ali Mishaal; Khoshbouei Habibeh; Owens Anthony; Daws Lynette; Jagnarine Darin A; Febo Marcelo; Bruijnzeel Adriaan W; Shetty Madhur; Rodriquez Meghan; Henry L Keith; Katz Jonathan; Yan Long</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2228</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dopamine neurotransmission is highly dysregulated by the psychostimulant methamphetamine, a substrate for the dopamine transporter (DAT).  Through interactions with DAT, methamphetamine increases extracellular dopamine levels in the brain, leading to its rewarding and addictive properties.  Methamphetamine also interacts with the sigma-1 receptor (σ1R), an inter-organelle signaling modulator.  Using complementary strategies, we identified a novel mechanism for σ1R regulation of dopamine neurotransmission in response to methamphetamine.  We found that σ1R activation prevents methamphetamine-induced, DAT-mediated increases in firing activity of dopamine neurons.  In vitro and in vivo amperometric measurements revealed that σ1R activation decreases methamphetamine-stimulated dopamine efflux without affecting basal dopamine neurotransmission.  Consistent with these findings, σ1R activation decreases methamphetamine-induced locomotion, motivated behavior, and enhancement of brain reward function.  Notably, we revealed that the σ1R interacts with DAT at or near the plasma membrane and decreases methamphetamine-induced Ca(2+) signaling, providing potential mechanisms.  Broadly, these data provide evidence for σ1R regulation of dopamine neurotransmission and support the σ1R as a putative target for the treatment of methamphetamine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREMjSSm_naSEHdcurJClFcfW6udTcc2ebmyP6YPZnHQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzjslSitA%253D%253D&md5=37e54a2f26bec8d60459b42df2e10602</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02087-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02087-x%26sid%3Dliteratum%253Aachs%26aulast%3DSambo%26aufirst%3DD.%2BO.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DOwens%26aufirst%3DA.%26aulast%3DLebowitz%26aufirst%3DJ.%2BJ.%26aulast%3DRichardson%26aufirst%3DB.%26aulast%3DJagnarine%26aufirst%3DD.%2BA.%26aulast%3DShetty%26aufirst%3DM.%26aulast%3DRodriquez%26aufirst%3DM.%26aulast%3DAlonge%26aufirst%3DT.%26aulast%3DAli%26aufirst%3DM.%26aulast%3DKatz%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DFebo%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DL.%2BK.%26aulast%3DBruijnzeel%26aufirst%3DA.%2BW.%26aulast%3DDaws%26aufirst%3DL.%26aulast%3DKhoshbouei%26aufirst%3DH.%26atitle%3DThe%2520sigma-1%2520receptor%2520modulates%2520methamphetamine%2520dysregulation%2520of%2520dopamine%2520neurotransmission%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D2228%26doi%3D10.1038%2Fs41467-017-02087-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+Highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lglE8qcccmSbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520Highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchel, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberg, J. I.</span></span> <span> </span><span class="NLM_article-title">Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go-related gene channels</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1443</span>– <span class="NLM_lpage">1452</span>, <span class="refDoi"> DOI: 10.1124/mol.108.049056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fmol.108.049056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=18701618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCnt77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1443-1452&author=M.+J.+Perrinauthor=P.+W.+Kuchelauthor=T.+J.+Campbellauthor=J.+I.+Vandenberg&title=Drug+binding+to+the+inactivated+state+is+necessary+but+not+sufficient+for+high-affinity+binding+to+human+ether-a-go-go-related+gene+channels&doi=10.1124%2Fmol.108.049056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go-related gene channels</span></div><div class="casAuthors">Perrin, Mark J.; Kuchel, Philip W.; Campbell, Terence J.; Vandenberg, Jamie I.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1443-1452</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drug block of the human ether-a-go-go-related gene K+ channel (hERG) is the most common cause of acquired long QT syndrome, a disorder of cardiac repolarization that may result in ventricular tachycardia and sudden cardiac death.  We investigated the open vs. inactivated state dependence of drug block by using hERG mutants N588K and N588E, which shift the voltage dependence of inactivation compared with wild-type but in which the mutated residue is remote from the drug-binding pocket in the channel pore.  Four high-affinity drugs (cisapride, dofetilide, terfenadine, and astemizole) demonstrated lower affinity for the inactivation-deficient N588K mutant hERG channel compared with N588E and wild-type hERG.  Three of four low-affinity drugs (erythromycin, perhexiline, and quinidine) demonstrated no preference for N588E over N588K channels, whereas dl-sotalol was an example of a low-affinity state-dependent blocker.  All five state-dependent blockers showed an even lower affinity for S620T mutant hERG (no inactivation) compared with N588K mutant hERG (greatly reduced inactivation).  Computer modeling indicates that the reduced affinity for S620T compared with N588K and wild-type channels can be explained by the relative kinetics of drug block and unblock compared with the kinetics of inactivation and recovery from inactivation.  We were also able to calc., for the first time, the relative affinities for the inactivated vs. the open state, which for the drugs tested here ranged from 4- to 70-fold.  Our results show that preferential binding to the inactivated state is necessary but not sufficient for high-affinity binding to hERG channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaHugsuGVEULVg90H21EOLACvtfcHk0lhLLY9sn3JhkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCnt77E&md5=fc04e3e6bef06a9ca27a5ed388150ef0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.049056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.049056%26sid%3Dliteratum%253Aachs%26aulast%3DPerrin%26aufirst%3DM.%2BJ.%26aulast%3DKuchel%26aufirst%3DP.%2BW.%26aulast%3DCampbell%26aufirst%3DT.%2BJ.%26aulast%3DVandenberg%26aufirst%3DJ.%2BI.%26atitle%3DDrug%2520binding%2520to%2520the%2520inactivated%2520state%2520is%2520necessary%2520but%2520not%2520sufficient%2520for%2520high-affinity%2520binding%2520to%2520human%2520ether-a-go-go-related%2520gene%2520channels%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26spage%3D1443%26epage%3D1452%26doi%3D10.1124%2Fmol.108.049056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gintant, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sager, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockbridge, N.</span></span> <span> </span><span class="NLM_article-title">Evolution of strategies to improve preclinical cardiac safety testing</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fnrd.2015.34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=26893184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVCju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=457-471&author=G.+Gintantauthor=P.+T.+Sagerauthor=N.+Stockbridge&title=Evolution+of+strategies+to+improve+preclinical+cardiac+safety+testing&doi=10.1038%2Fnrd.2015.34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of strategies to improve preclinical cardiac safety testing</span></div><div class="casAuthors">Gintant, Gary; Sager, Philip T.; Stockbridge, Norman</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">457-471</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The early and efficient assessment of cardiac safety liabilities is essential to confidently advance novel drug candidates.  This article discusses evolving mechanistically based preclin. strategies for detecting drug-induced electrophysiol. and structural cardiotoxicity using in vitro human ion channel assays, human-based in silico reconstructions and human stem cell-derived cardiomyocytes.  These strategies represent a paradigm shift from current approaches, which rely on simplistic in vitro assays that measure blockade of the Kv11.1 current (also known as the hERG current or IKr) and on the use of non-human cells or tissues.  These new strategies have the potential to improve sensitivity and specificity in the early detection of genuine cardiotoxicity risks, thereby reducing the likelihood of mistakenly discarding viable drug candidates and speeding the progression of worthy drugs into clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-kYgmcNzy-bVg90H21EOLACvtfcHk0lhLLY9sn3JhkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVCju7s%253D&md5=0a6fa907a6d85fa0a3b42188a22165b9</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.34%26sid%3Dliteratum%253Aachs%26aulast%3DGintant%26aufirst%3DG.%26aulast%3DSager%26aufirst%3DP.%2BT.%26aulast%3DStockbridge%26aufirst%3DN.%26atitle%3DEvolution%2520of%2520strategies%2520to%2520improve%2520preclinical%2520cardiac%2520safety%2520testing%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D457%26epage%3D471%26doi%3D10.1038%2Fnrd.2015.34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalyaanamoorthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barakat, K. H.</span></span> <span> </span><span class="NLM_article-title">Binding modes of hERG blockers: an unsolved mystery in the drug design arena</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1080/17460441.2018.1418319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1080%2F17460441.2018.1418319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=29240515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVSmtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=207-210&author=S.+Kalyaanamoorthyauthor=K.+H.+Barakat&title=Binding+modes+of+hERG+blockers%3A+an+unsolved+mystery+in+the+drug+design+arena&doi=10.1080%2F17460441.2018.1418319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Binding modes of hERG blockers: an unsolved mystery in the drug design arena</span></div><div class="casAuthors">Kalyaanamoorthy, Subha; Barakat, Khaled H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-210</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8rGFUuQD4ObVg90H21EOLACvtfcHk0lhLLY9sn3JhkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVSmtrzF&md5=9d0ea3eb1d621d890b8aed4cb11922a4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1080%2F17460441.2018.1418319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2018.1418319%26sid%3Dliteratum%253Aachs%26aulast%3DKalyaanamoorthy%26aufirst%3DS.%26aulast%3DBarakat%26aufirst%3DK.%2BH.%26atitle%3DBinding%2520modes%2520of%2520hERG%2520blockers%253A%2520an%2520unsolved%2520mystery%2520in%2520the%2520drug%2520design%2520arena%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2018%26volume%3D13%26spage%3D207%26epage%3D210%26doi%3D10.1080%2F17460441.2018.1418319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fant, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duff, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noskov, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Toward reducing hERG affinities for DAT inhibitors with a combined machine learning and molecular modeling approach</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">562a</span>– <span class="NLM_lpage">562a</span>, <span class="refDoi"> DOI: 10.1016/j.bpj.2018.11.3021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.bpj.2018.11.3021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=562a-562a&author=A.+D.+Fantauthor=S.+Wackerauthor=J.+Jungauthor=J.+Q.+Guoauthor=A.+M.+Abramyanauthor=H.+J.+Duffauthor=A.+H.+Newmanauthor=S.+Y.+Noskovauthor=L.+Shi&title=Toward+reducing+hERG+affinities+for+DAT+inhibitors+with+a+combined+machine+learning+and+molecular+modeling+approach&doi=10.1016%2Fj.bpj.2018.11.3021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2018.11.3021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2018.11.3021%26sid%3Dliteratum%253Aachs%26aulast%3DFant%26aufirst%3DA.%2BD.%26aulast%3DWacker%26aufirst%3DS.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DJ.%2BQ.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DDuff%26aufirst%3DH.%2BJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DNoskov%26aufirst%3DS.%2BY.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DToward%2520reducing%2520hERG%2520affinities%2520for%2520DAT%2520inhibitors%2520with%2520a%2520combined%2520machine%2520learning%2520and%2520molecular%2520modeling%2520approach%26jtitle%3DBiophys.%2520J.%26date%3D2019%26volume%3D116%26spage%3D562a%26epage%3D562a%26doi%3D10.1016%2Fj.bpj.2018.11.3021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johannesen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanabria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waite-Labott, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumb, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blinova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stohlman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockbridge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, D. G.</span></span> <span> </span><span class="NLM_article-title">Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1002/cpt.205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1002%2Fcpt.205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=26259627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVylsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2016&pages=214-223&author=L.+Johannesenauthor=J.+Vicenteauthor=J.+W.+Masonauthor=C.+Eratoauthor=C.+Sanabriaauthor=K.+Waite-Labottauthor=M.+Hongauthor=J.+Linauthor=P.+Guoauthor=A.+Mutlibauthor=J.+Wangauthor=W.+J.+Crumbauthor=K.+Blinovaauthor=D.+Chanauthor=J.+Stohlmanauthor=J.+Florianauthor=M.+Uganderauthor=N.+Stockbridgeauthor=D.+G.+Strauss&title=Late+sodium+current+block+for+drug-induced+long+QT+syndrome%3A+Results+from+a+prospective+clinical+trial&doi=10.1002%2Fcpt.205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial</span></div><div class="casAuthors">Johannesen, L.; Vicente, J.; Mason, J. W.; Erato, C.; Sanabria, C.; Waite-Labott, K.; Hong, M.; Lin, J.; Guo, P.; Mutlib, A.; Wang, J.; Crumb, W. J.; Blinova, K.; Chan, D.; Stohlman, J.; Florian, J.; Ugander, M.; Stockbridge, N.; Strauss, D. G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">214-223</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced long QT syndrome has resulted in many drugs being withdrawn from the market.  At the same time, the current regulatory paradigm for screening new drugs causing long QT syndrome is preventing drugs from reaching the market, sometimes inappropriately.  In this study, we report the results of a first-of-a-kind clin. trial studying late sodium (mexiletine and lidocaine) and calcium (diltiazem) current blocking drugs to counteract the effects of hERG potassium channel blocking drugs (dofetilide and moxifloxacin).  We demonstrate that both mexiletine and lidocaine substantially reduce heart-rate cor. QT (QTc) prolongation from dofetilide by 20 ms.  Furthermore, all QTc shortening occurs in the heart-rate cor. J-Tpeak (J-Tpeakc) interval, the biomarker we identified as a sign of late sodium current block.  This clin. trial demonstrates that late sodium blocking drugs can substantially reduce QTc prolongation from hERG potassium channel block and assessment of J-Tpeakc may add value beyond only assessing QTc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqKnezvy6cALVg90H21EOLACvtfcHk0liQeQT_lhS1mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVylsb0%253D&md5=b6f88fd121d50d4d32b1ab7ae6664d37</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fcpt.205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.205%26sid%3Dliteratum%253Aachs%26aulast%3DJohannesen%26aufirst%3DL.%26aulast%3DVicente%26aufirst%3DJ.%26aulast%3DMason%26aufirst%3DJ.%2BW.%26aulast%3DErato%26aufirst%3DC.%26aulast%3DSanabria%26aufirst%3DC.%26aulast%3DWaite-Labott%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DP.%26aulast%3DMutlib%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DCrumb%26aufirst%3DW.%2BJ.%26aulast%3DBlinova%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DD.%26aulast%3DStohlman%26aufirst%3DJ.%26aulast%3DFlorian%26aufirst%3DJ.%26aulast%3DUgander%26aufirst%3DM.%26aulast%3DStockbridge%26aufirst%3DN.%26aulast%3DStrauss%26aufirst%3DD.%2BG.%26atitle%3DLate%2520sodium%2520current%2520block%2520for%2520drug-induced%2520long%2520QT%2520syndrome%253A%2520Results%2520from%2520a%2520prospective%2520clinical%2520trial%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D99%26spage%3D214%26epage%3D223%26doi%3D10.1002%2Fcpt.205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolleddula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worboys, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassil, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdet, D. L.</span></span> <span> </span><span class="NLM_article-title">Biotransformation and bioactivation reactions of alicyclic amines in drug molecules</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.3109/03602532.2014.924962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.3109%2F03602532.2014.924962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=24909234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlagu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=379-419&author=J.+Bolleddulaauthor=K.+DeMentauthor=J.+P.+Driscollauthor=P.+Worboysauthor=P.+J.+Brassilauthor=D.+L.+Bourdet&title=Biotransformation+and+bioactivation+reactions+of+alicyclic+amines+in+drug+molecules&doi=10.3109%2F03602532.2014.924962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Biotransformation and bioactivation reactions of alicyclic amines in drug molecules</span></div><div class="casAuthors">Bolleddula, Jayaprakasam; DeMent, Kevin; Driscoll, James P.; Worboys, Philip; Brassil, Patrick J.; Bourdet, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">379-419</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Aliph. nitrogen heterocycles such as piperazine, piperidine, pyrrolidine, morpholine, aziridine, azetidine, and azepane are well known building blocks in drug design and important core structures in approved drug therapies.  These core units have been targets for metabolic attack by P450s and other drug metabolizing enzymes such as aldehyde oxidase and monoamine oxidase (MAOs).  The electron rich nitrogen and/or α-carbons are often major sites of metab. of alicyclic amines.  The most common biotransformations include N-oxidn., N-conjugation, oxidative N-dealkylation, ring oxidn., and ring opening.  In some instances, the metabolic pathways generate electrophilic reactive intermediates and cause bioactivation.  However, potential bioactivation related adverse events can be attenuated by structural modifications.  Hence it is important to understand the biotransformation pathways to design stable drug candidates that are devoid of metabolic liabilities early in the discovery stage.  The current review provides a comprehensive summary of biotransformation and bioactivation pathways of aliph. nitrogen contg. heterocycles and strategies to mitigate metabolic liabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgryPqDMy3f7Vg90H21EOLACvtfcHk0liQeQT_lhS1mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlagu7jO&md5=f20339b5306805f531cbd22f0640e8b6</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.3109%2F03602532.2014.924962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602532.2014.924962%26sid%3Dliteratum%253Aachs%26aulast%3DBolleddula%26aufirst%3DJ.%26aulast%3DDeMent%26aufirst%3DK.%26aulast%3DDriscoll%26aufirst%3DJ.%2BP.%26aulast%3DWorboys%26aufirst%3DP.%26aulast%3DBrassil%26aufirst%3DP.%2BJ.%26aulast%3DBourdet%26aufirst%3DD.%2BL.%26atitle%3DBiotransformation%2520and%2520bioactivation%2520reactions%2520of%2520alicyclic%2520amines%2520in%2520drug%2520molecules%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2014%26volume%3D46%26spage%3D379%26epage%3D419%26doi%3D10.3109%2F03602532.2014.924962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlholm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacome, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Highly selective dopamine D3 receptor antagonists with arylated diazaspiro alkane cores</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9905</span>– <span class="NLM_lpage">9910</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9905-9910&author=S.+W.+Reillyauthor=S.+Griffinauthor=M.+Taylorauthor=K.+Sahlholmauthor=C.+C.+Wengauthor=K.+Xuauthor=D.+A.+Jacomeauthor=R.+R.+Luedtkeauthor=R.+H.+Mach&title=Highly+selective+dopamine+D3+receptor+antagonists+with+arylated+diazaspiro+alkane+cores&doi=10.1021%2Facs.jmedchem.7b01248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores</span></div><div class="casAuthors">Reilly, Sean W.; Griffin, Suzy; Taylor, Michelle; Sahlholm, Kristoffer; Weng, Chi-Chang; Xu, Kuiying; Jacome, Daniel A.; Luedtke, Robert R.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9905-9910</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aryldiazaspirocyclylpropyl phenyltriazolyl thioethers such as I (R = 2-MeOC6H4, 4-FC6H4, 4-MeOC6H4, 2-pyridinyl, 3-NCC6H4, 2,3-Cl2C6H3) were prepd. as selective dopamine D3 receptor (D3R) antagonists; their selectivities for D3R over D2R and for selected compds. over 5-HT1a, 5-HT2a, and 5-HT2c receptors and adenylyl cyclase were detd.  I (R = 2-MeOC6H4, 4-FC6H4) showed favorable D3R affinities (Ki = 12-25.6 nM) and were 264- to 905-fold selective for D3R vs D2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHLC1nn5_14LVg90H21EOLACvtfcHk0lg2iEntdR-ovg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsbjL&md5=a60ed8b0524189901b7155e11025d3c6</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01248%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DS.%2BW.%26aulast%3DGriffin%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DSahlholm%26aufirst%3DK.%26aulast%3DWeng%26aufirst%3DC.%2BC.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DJacome%26aufirst%3DD.%2BA.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DHighly%2520selective%2520dopamine%2520D3%2520receptor%2520antagonists%2520with%2520arylated%2520diazaspiro%2520alkane%2520cores%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9905%26epage%3D9910%26doi%3D10.1021%2Facs.jmedchem.7b01248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlholm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacome, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanicolas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Leveraging a low-affinity diazaspiro orthosteric fragment to reduce dopamine D3 receptor (D3R) ligand promiscuity across highly conserved aminergic G-protein-coupled receptors (GPCRs)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5132</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00412</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00412" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1Sntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5132&author=S.+W.+Reillyauthor=A.+A.+Riadauthor=C.+J.+Hsiehauthor=K.+Sahlholmauthor=D.+A.+Jacomeauthor=S.+Griffinauthor=M.+Taylorauthor=C.+C.+Wengauthor=K.+Xuauthor=N.+Kirschnerauthor=R.+R.+Luedtkeauthor=C.+Parryauthor=S.+Malhotraauthor=J.+Karanicolasauthor=R.+H.+Mach&title=Leveraging+a+low-affinity+diazaspiro+orthosteric+fragment+to+reduce+dopamine+D3+receptor+%28D3R%29+ligand+promiscuity+across+highly+conserved+aminergic+G-protein-coupled+receptors+%28GPCRs%29&doi=10.1021%2Facs.jmedchem.9b00412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D3 Receptor (D3R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs)</span></div><div class="casAuthors">Reilly, Sean W.; Riad, Aladdin A.; Hsieh, Chia-Ju; Sahlholm, Kristoffer; Jacome, Daniel A.; Griffin, Suzy; Taylor, Michelle; Weng, Chi-Chang; Xu, Kuiying; Kirschner, Nathan; Luedtke, Robert R.; Parry, Christopher; Malhotra, Shipra; Karanicolas, John; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5132-5147</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previously, we reported a 3-(2-methoxyphenyl)-9-(3-((4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propyl)-3,9-diazaspiro[5.5]undecane (I) compd. with excellent dopamine D3 receptor (D3R) affinity (D3R Ki = 12.0 nM) and selectivity (D2R/D3R ratio = 905).  Herein, we present derivs. of I with comparable D3R affinity (II, D3R Ki = 3.2 nM, D2R/D3R ratio = 60) and selectivity (III, D3R Ki = 21.0 nM, D2R/D3R ratio = 934).  Fragmentation of I revealed orthosteric fragment IV to express an unusually low D3R affinity (Ki = 2.7 μM).  Compared to piperazine congener V, which retains a high-affinity orthosteric fragment (VI, D3R Ki = 23.9 nM), I was found to be more selective for the D3R among D1- and D2-like receptors and exhibited negligible off-target interactions at serotoninergic and adrenergic G-protein-coupled receptors (GPCRs), common off-target sites for piperazine-contg. D3R scaffolds.  This study provides a unique rationale for implementing weakly potent orthosteric fragments into D3R ligand systems to minimize drug promiscuity at other aminergic GPCR sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0AsYC3qYsr7Vg90H21EOLACvtfcHk0lg2iEntdR-ovg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1Sntrs%253D&md5=ce936e36f3007e1f5587edf9275479ff</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00412%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DS.%2BW.%26aulast%3DRiad%26aufirst%3DA.%2BA.%26aulast%3DHsieh%26aufirst%3DC.%2BJ.%26aulast%3DSahlholm%26aufirst%3DK.%26aulast%3DJacome%26aufirst%3DD.%2BA.%26aulast%3DGriffin%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DWeng%26aufirst%3DC.%2BC.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DKirschner%26aufirst%3DN.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DParry%26aufirst%3DC.%26aulast%3DMalhotra%26aufirst%3DS.%26aulast%3DKaranicolas%26aufirst%3DJ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DLeveraging%2520a%2520low-affinity%2520diazaspiro%2520orthosteric%2520fragment%2520to%2520reduce%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%2520ligand%2520promiscuity%2520across%2520highly%2520conserved%2520aminergic%2520G-protein-coupled%2520receptors%2520%2528GPCRs%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5132%26doi%3D10.1021%2Facs.jmedchem.9b00412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izenwasser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">4446</span>– <span class="NLM_lpage">4455</span>, <span class="refDoi"> DOI: 10.1021/jm9902943</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9902943" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK1MXmt12ltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=4446-4455&author=S.+M.+Husbandsauthor=S.+Izenwasserauthor=T.+Kopajticauthor=W.+D.+Bowenauthor=B.+J.+Vilnerauthor=J.+L.+Katzauthor=A.+H.+Newman&title=Structure-activity+relationships+at+the+monoamine+transporters+and+sigma+receptors+for+a+novel+series+of+9-%5B3-%28cis-3%2C+5-dimethyl-1-piperazinyl%29propyl%5Dcarbazole+%28rimcazole%29+analogues&doi=10.1021%2Fjm9902943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships at the Monoamine Transporters and σ Receptors for a Novel Series of 9-[3-(cis-3,5-Dimethyl-1-piperazinyl)- propyl]carbazole (Rimcazole) Analogues</span></div><div class="casAuthors">Husbands, Stephen M.; Izenwasser, Sari; Kopajtic, Theresa; Bowen, Wayne D.; Vilner, Bertold J.; Katz, Jonathan L.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4446-4455</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-[3-(Cis-3,5-Dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) has been characterized as a σ receptor antagonist that binds to the dopamine transporter with moderate affinity (Ki = 224 nM).  Although the binding affinities at the dopamine transporter of rimcazole and cocaine are comparable, rimcazole only depressed locomotor activity in mice and antagonized the stimulant effects produced by cocaine.  The neurochem. mechanisms underlying the attenuation of cocaine's effects are not understood, although interaction at a low affinity site/state of the dopamine transporter has been suggested.  To explore further this class of compds., a series of rimcazole analogs was designed and synthesized.  Displacement of [3H]WIN 35,428 binding at the dopamine transporter in rat caudate-putamen revealed that arom. substitutions on rimcazole were not well tolerated, generally, with significant redns. in affinity for a 3,6-dibromo deriv. (Ki = 3890 nM), 1,3,6-tribromo deriv.(Ki = 30300 nM), 3-amino deriv. (Ki = 2400 nM), and 3,6-dinitro deriv. (Ki = 174000 nM) analogs.  An N-phenylpropyl group was the only terminal piperazine nitrogen substituent that retained moderate affinity at the dopamine transporter (Ki = 263 nM).  Analogs in which the carbazole ring was replaced with a freely rotating diphenylamine moiety were also prepd.  Although the diphenylamino analog in which the terminal piperazine nitrogen was unsubstituted, as in rimcazole, demonstrated relatively low binding affinity at the dopamine transporter (Ki = 813 nM), an N-phenylpropyl analog was found to have the highest affinity for the dopamine transporter within the series (Ki = 61.0 nM).  All of the analogs that had affinity for the dopamine transporter inhibited [3H]dopamine uptake in synaptosomes, and potencies for these two effects showed a pos. correlation (r2 = 0.7731, p = 0.0018).  Several of the analogs displaced [3H]paroxetine from serotonin transporters with moderate to high affinity, with an N-phenylpropyl deriv. having the highest affinity (Ki = 44.5 nM).  In contrast, none of the analogs recognized the norepinephrine transporter with an affinity of <1.3 μM.  Binding affinities for σ1 and σ2 receptors were also detd., and several of the compds. were more potent than rimcazole with affinities ranging from 97 nM to >6 μM at σ1 sites and 145 to 1990 nM at σ2 sites.  A compd. with the highest affinity at σ1 sites was also the compd. with highest affinity at the dopamine transporter.  These novel rimcazole analogs may provide important tools with which to characterize the relationship between the low affinity site or state of the dopamine transporter, σ receptors, and their potential roles in modulating cocaine's psychostimulant actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC4bpCWt4m9bVg90H21EOLACvtfcHk0lg2iEntdR-ovg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmt12ltrw%253D&md5=cd8d2b8c55f0387873714af4b18b99a5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm9902943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9902943%26sid%3Dliteratum%253Aachs%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DIzenwasser%26aufirst%3DS.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DStructure-activity%2520relationships%2520at%2520the%2520monoamine%2520transporters%2520and%2520sigma%2520receptors%2520for%2520a%2520novel%2520series%2520of%25209-%255B3-%2528cis-3%252C%25205-dimethyl-1-piperazinyl%2529propyl%255Dcarbazole%2520%2528rimcazole%2529%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D4446%26epage%3D4455%26doi%3D10.1021%2Fjm9902943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izenwasser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeloff, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Isothiocyanate derivatives of 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]-carbazole (rimcazole): Irreversible ligands for the dopamine transporter</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">4340</span>– <span class="NLM_lpage">4346</span>, <span class="refDoi"> DOI: 10.1021/jm9705519</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9705519" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFKlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=4340-4346&author=S.+M.+Husbandsauthor=S.+Izenwasserauthor=R.+J.+Loeloffauthor=J.+L.+Katzauthor=W.+D.+Bowenauthor=B.+J.+Vilnerauthor=A.+H.+Newman&title=Isothiocyanate+derivatives+of+9-%5B3-%28cis-3%2C5-dimethyl-1-piperazinyl%29propyl%5D-carbazole+%28rimcazole%29%3A+Irreversible+ligands+for+the+dopamine+transporter&doi=10.1021%2Fjm9705519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Isothiocyanate derivatives of 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]carbazole (Rimcazole): irreversible ligands for the dopamine transporter</span></div><div class="casAuthors">Husbands, Stephen M.; Izenwasser, Sari; Loeloff, Richard J.; Katz, Jonathan L.; Bowen, Wayne D.; Vilner, Bertold J.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4340-4346</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cocaine has been reported to bind to the dopamine transporter in a biphasic fashion, and the low-affinity component may play a modulatory role in cocaine's psychomotor stimulant effects.  To study this further, the authors have prepd. a series of irreversible ligands based on rimcazole [I; 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]carbazole], a compd. that has been postulated to bind only to the low-affinity site.  The alkylating moiety, isothiocyanate, is attached to the distal nitrogen of the piperazine ring via alkyl chains of varying lengths or directly attached to one of the arom. groups.  It was found that substitution on the piperazine nitrogen caused an initial decrease in affinity that was recovered as the alkyl chain length increased.  Isothiocyanate deriv. II of rimcazole, with the highest affinity for the dopamine transporter (DAT), binds in a monophasic and irreversible manner, as evidenced by the greatly diminished binding of [3H]WIN 35,428 in tissue that had been preincubated with the ligand and then thoroughly washed using centrifugation.  The dose-dependent redn. in Bmax was accompanied by a concn.-related decrease in KD values.  This shift in KD to a lower value suggests that the preincubation with isothiocyanate II produced a preferential irreversible binding to the low-affinity [3H]WIN 35,428 site on the dopamine transporter.  These ligands may prove to be important tools with which to study the significance of the low-affinity site on the DAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJm0uovk7Z7LVg90H21EOLACvtfcHk0lglvlFD1twU6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFKlug%253D%253D&md5=b3d7f07a10569ea9be26b9bd324c4b31</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm9705519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9705519%26sid%3Dliteratum%253Aachs%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DIzenwasser%26aufirst%3DS.%26aulast%3DLoeloff%26aufirst%3DR.%2BJ.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DIsothiocyanate%2520derivatives%2520of%25209-%255B3-%2528cis-3%252C5-dimethyl-1-piperazinyl%2529propyl%255D-carbazole%2520%2528rimcazole%2529%253A%2520Irreversible%2520ligands%2520for%2520the%2520dopamine%2520transporter%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D4340%26epage%3D4346%26doi%3D10.1021%2Fjm9705519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Dual probes for the dopamine transporter and sigma(1) receptors: novel piperazinyl alkyl-bis(4′-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2589</span>– <span class="NLM_lpage">2598</span>, <span class="refDoi"> DOI: 10.1021/jm030008u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030008u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs12qt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2589-2598&author=J.+Caoauthor=S.+S.+Kulkarniauthor=S.+M.+Husbandsauthor=W.+D.+Bowenauthor=W.+Williamsauthor=T.+Kopajticauthor=J.+L.+Katzauthor=C.+Georgeauthor=A.+H.+Newman&title=Dual+probes+for+the+dopamine+transporter+and+sigma%281%29+receptors%3A+novel+piperazinyl+alkyl-bis%284%E2%80%B2-fluorophenyl%29amine+analogues+as+potential+cocaine-abuse+therapeutic+agents&doi=10.1021%2Fjm030008u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Probes for the Dopamine Transporter and σ1 Receptors: Novel Piperazinylalkylbis(4'-fluorophenyl)amine Analogues as Potential Cocaine-Abuse Therapeutic Agents</span></div><div class="casAuthors">Cao, Jianjing; Kulkarni, Santosh S.; Husbands, Stephen M.; Bowen, Wayne D.; Williams, Wanda; Kopajtic, Theresa; Katz, Jonathan L.; George, Clifford; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2589-2598</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Both dopamine uptake inhibitors and σ1 receptor antagonists have been implicated as potential pharmacotherapeutics for the treatment of cocaine abuse.  While the dopamine uptake inhibitors may share with cocaine neurochem. mechanisms underlying reinforcing properties, σ1 antagonists have been shown to attenuate some behavioral actions and toxic side effects assocd. with cocaine overdose.  Rimcazole, a σ1 receptor antagonist that binds to the DAT (Ki = 224 nM), is not behaviorally cocaine-like and attenuates some of the behavioral actions of cocaine.  To det. the roles of both DAT and σ1 receptors in the behavioral actions of rimcazole, a series of analogs was synthesized.  Initial studies identified two analogs that showed high to moderate affinities for both DAT and σ1 receptors and failed to show cocaine-like discriminative stimulus (DS) effects.  A second series of bis(4-fluorophenyl)amine analogs have now been prepd. in which the most potent DAT compd., I [R1 = CH2CH2CHPhOH, R2 = H] (Ki = 8.5 nM), was selective over serotonin transporter (SERT/DAT = 94), norepinephrine transporter (NET/DAT = 63), and σ1 receptor binding (σ1/DAT = 44).  In addn., I [R1 = CH2Ph, R2 = H; R1 = H, R2 = Me] showed superior selectivity for DAT over SERT (170- and 140-fold, resp.) and DAT over NET (219- and 190-fold, resp.) but were essentially equipotent at DAT and σ1 receptors (10; Ki = 77 and 124 nM, resp., 17; Ki = 28 and 13 nM, resp.).  CoMFA studies at both DAT and σ1 receptors were performed to examine structural requirements for optimal binding at these two targets as well as to assess differences between them.  Behavioral evaluation of analogs with varying affinities for both DAT and σ1 receptors may provide a novel approach toward designing medications for cocaine abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSk1ra5C_lfrVg90H21EOLACvtfcHk0lglvlFD1twU6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs12qt78%253D&md5=f00a3f570eb7723594810dc343ba64bd</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm030008u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030008u%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DKulkarni%26aufirst%3DS.%2BS.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DDual%2520probes%2520for%2520the%2520dopamine%2520transporter%2520and%2520sigma%25281%2529%2520receptors%253A%2520novel%2520piperazinyl%2520alkyl-bis%25284%25E2%2580%25B2-fluorophenyl%2529amine%2520analogues%2520as%2520potential%2520cocaine-abuse%2520therapeutic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2589%26epage%3D2598%26doi%3D10.1021%2Fjm030008u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Dual DAT/sigma 1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl) amino) propyl) piperazin-1-yl)-1-phenylpropan-1-ol</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5238</span>– <span class="NLM_lpage">5241</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.08.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.bmcl.2008.08.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=18774292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFert7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5238-5241&author=J.+Caoauthor=T.+Kopajticauthor=J.+L.+Katzauthor=A.+H.+Newman&title=Dual+DAT%2Fsigma+1+receptor+ligands+based+on+3-%284-%283-%28bis%284-fluorophenyl%29+amino%29+propyl%29+piperazin-1-yl%29-1-phenylpropan-1-ol&doi=10.1016%2Fj.bmcl.2008.08.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Dual DAT/σ1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol</span></div><div class="casAuthors">Cao, Jianjing; Kopajtic, Theresa; Katz, Jonathan L.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5238-5241</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ester analogs of (±)3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol were synthesized and evaluated for binding at DAT, SERT, NET, and σ1 receptors, and compared to GBR 12909 and several known σ1 receptor ligands.  Most of these compds. demonstrated high affinity (K i = 4.3-51 nM) and selectivity for the DAT among the monoamine transporters.  S- and R-1-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-3-phenylpropan-2-ol were also prepd. wherein modest enantioselectivity was demonstrated at the DAT.  However, no enantioselectivity at σ1 receptors was obsd. and most of the ester analogs of the more active S-enantiomer showed comparable binding affinities at both DAT and σ1 receptors with a maximal 16-fold DAT/σ1 selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps-GGvWyuyvrVg90H21EOLACvtfcHk0lglvlFD1twU6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFert7%252FL&md5=8a40cb7474dc768647f635535ea1b04b</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.08.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.08.065%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DDual%2520DAT%252Fsigma%25201%2520receptor%2520ligands%2520based%2520on%25203-%25284-%25283-%2528bis%25284-fluorophenyl%2529%2520amino%2529%2520propyl%2529%2520piperazin-1-yl%2529-1-phenylpropan-1-ol%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5238%26epage%3D5241%26doi%3D10.1016%2Fj.bmcl.2008.08.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">A role for sigma receptors in stimulant self-administration and addiction</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1097/FBP.0000000000000209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1097%2FFBP.0000000000000209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=26650253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=100-115&author=J.+L.+Katzauthor=W.+C.+Hongauthor=T.+Hiranitaauthor=T.+P.+Su&title=A+role+for+sigma+receptors+in+stimulant+self-administration+and+addiction&doi=10.1097%2FFBP.0000000000000209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">A role for sigma receptors in stimulant self-administration and addiction</span></div><div class="casAuthors">Katz, Jonathan L.; Hong, Weimin C.; Hiranita, Takato; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2 and 3</span>),
    <span class="NLM_cas:pages">100-115</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Sigma-1 receptors (σ1Rs) are structurally unique intracellular proteins that function as chaperones. σ1Rs translocate from the mitochondria-assocd. membrane to other subcellular compartments, and can influence a host of targets, including ion channels, G-protein-coupled receptors, lipids, and other signaling proteins.  Drugs binding to σRs can induce or block the actions of σRs.  Studies indicate that stimulant self-administration induces the reinforcing effects of σR agonists, because of dopamine transporter actions.  Once established, the reinforcing effects of σR agonists are independent of dopaminergic mechanisms traditionally thought to be crit. to the reinforcing effects of stimulants.  Self-administered doses of σR agonists do not increase dopamine concns. in the nucleus accumbens shell, a transmitter and brain region considered important for the reinforcing effects of abused drugs.  However, self-administration of σR agonists is blocked by σR antagonists.  Several effects of stimulants have been blocked by σR antagonists, including the reinforcing effects, assessed by a place-conditioning procedure.  However, the self-administration of stimulants is largely unaffected by σR antagonists, indicating fundamental differences in the mechanisms underlying these two procedures used to assess the reinforcing effects.  When σR antagonists are administered in combination with dopamine uptake inhibitors, an effective and specific blockade of stimulant self-administration is obtained.  Actions of stimulant drugs related to their abuse induce unique changes in σR activity and the changes induced potentially create redundant and, once established, independent reinforcement pathways.  Concomitant targeting of both dopaminergic pathways and σR proteins produces a selective antagonism of stimulant self-administration, suggesting new avenues for combination chemotherapies to specifically combat stimulant abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozieYVfrbwdLVg90H21EOLACvtfcHk0liEt2AxWjzv9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOht7o%253D&md5=262279d7e148fade608c21d7c6f87704</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1097%2FFBP.0000000000000209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0000000000000209%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DHong%26aufirst%3DW.%2BC.%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DA%2520role%2520for%2520sigma%2520receptors%2520in%2520stimulant%2520self-administration%2520and%2520addiction%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2016%26volume%3D27%26spage%3D100%26epage%3D115%26doi%3D10.1097%2FFBP.0000000000000209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Redfern, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palethorpe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegl, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camm, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T. G.</span></span> <span> </span><span class="NLM_article-title">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/S0008-6363(02)00846-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=12667944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&author=W.+S.+Redfernauthor=L.+Carlssonauthor=A.+S.+Davisauthor=W.+G.+Lynchauthor=I.+MacKenzieauthor=S.+Palethorpeauthor=P.+K.+Sieglauthor=I.+Strangauthor=A.+T.+Sullivanauthor=R.+Wallisauthor=A.+J.+Cammauthor=T.+G.+Hammond&title=Relationships+between+preclinical+cardiac+electrophysiology%2C+clinical+QT+interval+prolongation+and+torsade+de+pointes+for+a+broad+range+of+drugs%3A+evidence+for+a+provisional+safety+margin+in+drug+development&doi=10.1016%2FS0008-6363%2802%2900846-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span></div><div class="casAuthors">Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discussing attempts to det. the relative value of preclin. cardiac electrophysiol. data (in vitro and in vivo) for predicting risk of torsades de pointes (TdP) in clin. use.  Published data on human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG) (or IKr) activity, cardiac action potential duration (at 90% repolarization; APD90), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.  These data were set against the free plasma concns. attained during clin. use (effective therapeutic plasma concns.; ETPCunbound).  The drugs were divided into five categories: (1) Class Ia and III antiarrhythmics; (2) withdrawn from market due to TdP; (3) measurable incidence/numerous reports of TdP in humans; (4) isolated reports of TdP in humans; (5) no reports of TdP in humans.  Data from hERG (or IKr) assays in addn. to ETPCunbound data were available for 52 drugs.  For Category 1 drugs, data for hERG/IKr IC50, APD90, QTc in animals and QTc in humans were generally close to or superimposed on the ETPCunbound values.  This relationship was uncoupled in the other categories, with more complex relationships between the data.  In Category 1 (except amiodarone), the ratios between hERG/IKr IC50 and ETPCunbound (max) ranged 0.1-31-fold.  Similar ranges were obtained for drugs in Category 2 (0.31-13-fold) and Category 3 (0.03-35-fold).  A large spread was found for Category 4 drugs (0.13-35,700-fold); this category embraced an assortment of mechanisms ranging from drugs which may well be affecting IKr currents in clin. use (e.g., sparfloxacin) to others such as nifedipine (35,700-fold) where channel block is not involved.  Finally, for the majority of Category 5 drugs there was a >30-fold sepn. between hERG/IKr activity and ETPCunbound values, with the notable exception of verapamil (1.7-fold), which is free from QT prolongation in man; this is probably explained by its multiple interactions with cardiac ion channels.  The dataset confirms the widely held belief that most drugs assocd. with TdP in humans are also assocd. with hERG K+ channel block at concns. close to or superimposed upon the free plasma concns. found in clin. use.  A 30-fold margin between Cmax and hERG IC50 may suffice for drugs currently undergoing clin. evaluation, but for future drug discovery programs, pharmaceutical companies should consider increasing this margin, particularly for drugs aimed at nondebilitating diseases.  However, interactions with multiple cardiac ion channels can either mitigate or exacerbate the prolongation of APD and QT that would ensue from block of IKr currents alone, and delay of repolarization per se is not necessarily torsadogenic.  Clearly, an integrated assessment of in vitro and in vivo data is required in order to predict the torsadogenic risk of a new candidate drug in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkpRDUH0rhyrVg90H21EOLACvtfcHk0liEt2AxWjzv9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D&md5=a236c07febd2e05fe70e61604619bf2e</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%2BS.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BS.%26aulast%3DLynch%26aufirst%3DW.%2BG.%26aulast%3DMacKenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%26aulast%3DStrang%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DA.%2BT.%26aulast%3DWallis%26aufirst%3DR.%26aulast%3DCamm%26aufirst%3DA.%2BJ.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26atitle%3DRelationships%2520between%2520preclinical%2520cardiac%2520electrophysiology%252C%2520clinical%2520QT%2520interval%2520prolongation%2520and%2520torsade%2520de%2520pointes%2520for%2520a%2520broad%2520range%2520of%2520drugs%253A%2520evidence%2520for%2520a%2520provisional%2520safety%2520margin%2520in%2520drug%2520development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26spage%3D32%26epage%3D45%26doi%3D10.1016%2FS0008-6363%2802%2900846-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kniazeff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergmann, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raniszewska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gether, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span> <span> </span><span class="NLM_article-title">The binding sites for cocaine and dopamine in the dopamine transporter overlap</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">780</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1038/nn.2146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fnn.2146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=18568020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1Omsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=780-789&author=T.+Beumingauthor=J.+Kniazeffauthor=M.+L.+Bergmannauthor=L.+Shiauthor=L.+Graciaauthor=K.+Raniszewskaauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=H.+Weinsteinauthor=U.+Getherauthor=C.+J.+Loland&title=The+binding+sites+for+cocaine+and+dopamine+in+the+dopamine+transporter+overlap&doi=10.1038%2Fnn.2146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The binding sites for cocaine and dopamine in the dopamine transporter overlap</span></div><div class="casAuthors">Beuming, Thijs; Kniazeff, Julie; Bergmann, Marianne L.; Shi, Lei; Gracia, Luis; Raniszewska, Klaudia; Newman, Amy Hauck; Javitch, Jonathan A.; Weinstein, Harel; Gether, Ulrik; Loland, Claus J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">780-789</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Beuming and colleagues detd. that the binding site for cocaine overlaps with that of dopamine on the dopamine transporter.  Detailed modeling and mutagenesis expts. revealed that this site is deeply buried amongst several transmembrane domains.  Cocaine is a widely abused substance with psychostimulant effects that are attributed to inhibition of the dopamine transporter (DAT).  We present mol. models for DAT binding of cocaine and cocaine analogs constructed from the high-resoln. structure of the bacterial transporter homolog LeuT.  Our models suggest that the binding site for cocaine and cocaine analogs is deeply buried between transmembrane segments 1, 3, 6 and 8, and overlaps with the binding sites for the substrates dopamine and amphetamine, as well as for benztropine-like DAT inhibitors.  We validated our models by detailed mutagenesis and by trapping the radiolabeled cocaine analog [3H]CFT in the transporter, either by crosslinking engineered cysteines or with an engineered Zn2+-binding site that was situated extracellularly to the predicted common binding pocket.  Our data demonstrate the mol. basis for the competitive inhibition of dopamine transport by cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogCWenpzRZ47Vg90H21EOLACvtfcHk0liEt2AxWjzv9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1Omsrw%253D&md5=7f96344e92478939540d84a37eaf3a70</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fnn.2146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.2146%26sid%3Dliteratum%253Aachs%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DKniazeff%26aufirst%3DJ.%26aulast%3DBergmann%26aufirst%3DM.%2BL.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DGracia%26aufirst%3DL.%26aulast%3DRaniszewska%26aufirst%3DK.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DGether%26aufirst%3DU.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520binding%2520sites%2520for%2520cocaine%2520and%2520dopamine%2520in%2520the%2520dopamine%2520transporter%2520overlap%26jtitle%3DNat.%2520Neurosci.%26date%3D2008%26volume%3D11%26spage%3D780%26epage%3D789%26doi%3D10.1038%2Fnn.2146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penmatsa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">Neurotransmitter and psychostimulant recognition by the dopamine transporter</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>521</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1038/nature14431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fnature14431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=25970245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WltbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=521&publication_year=2015&pages=322-327&author=K.+H.+Wangauthor=A.+Penmatsaauthor=E.+Gouaux&title=Neurotransmitter+and+psychostimulant+recognition+by+the+dopamine+transporter&doi=10.1038%2Fnature14431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotransmitter and psychostimulant recognition by the dopamine transporter</span></div><div class="casAuthors">Wang, Kevin H.; Penmatsa, Aravind; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">521</span>
        (<span class="NLM_cas:issue">7552</span>),
    <span class="NLM_cas:pages">322-327</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Na+/Cl--coupled biogenic amine transporters are the primary targets of therapeutic and abused drugs, ranging from antidepressants to the psychostimulants cocaine and amphetamines, and to their cognate substrates.  Here we det. X-ray crystal structures of the Drosophila melanogaster dopamine transporter (dDAT) bound to its substrate dopamine, a substrate analog 3,4-dichlorophenethylamine, the psychostimulants D-amphetamine and methamphetamine, or to cocaine and cocaine analogs.  All ligands bind to the central binding site, located approx. halfway across the membrane bilayer, in close proximity to bound sodium and chloride ions.  The central binding site recognizes three chem. distinct classes of ligands via conformational changes that accommodate varying sizes and shapes, thus illustrating mol. principles that distinguish substrates from inhibitors in biogenic amine transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWbqTaT0RDD7Vg90H21EOLACvtfcHk0lhCZha5eEWQPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WltbbK&md5=1784d5fd0e7e1ddbe8346c96aaf98a00</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fnature14431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14431%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DK.%2BH.%26aulast%3DPenmatsa%26aufirst%3DA.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DNeurotransmitter%2520and%2520psychostimulant%2520recognition%2520by%2520the%2520dopamine%2520transporter%26jtitle%3DNature%26date%3D2015%26volume%3D521%26spage%3D322%26epage%3D327%26doi%3D10.1038%2Fnature14431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaaro-Peled, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strick, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engle, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2067</span>– <span class="NLM_lpage">2073</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.046482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fdmd.112.046482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=22837388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKkt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=2067-2073&author=R.+Raisauthor=A.+G.+Thomasauthor=K.+Wozniakauthor=Y.+Wuauthor=H.+Jaaro-Peledauthor=A.+Sawaauthor=C.+A.+Strickauthor=S.+J.+Engleauthor=N.+J.+Brandonauthor=C.+Rojasauthor=B.+S.+Slusherauthor=T.+Tsukamoto&title=Pharmacokinetics+of+oral+D-serine+in+D-amino+acid+oxidase+knockout+mice&doi=10.1124%2Fdmd.112.046482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice</span></div><div class="casAuthors">Rais, Rana; Thomas, Ajit G.; Wozniak, Krystyna; Wu, Ying; Jaaro-Peled, Hanna; Sawa, Akira; Strick, Christine A.; Engle, Sandra J.; Brandon, Nicholas J.; Rojas, Camilo; Slusher, Barbara S.; Tsukamoto, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2067-2073</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">D-Amino acid oxidase (DAAO) catalyzes the oxidative deamination of D-amino acids including D-serine, a full agonist at the glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor.  To evaluate the significance of DAAO-mediated metab. in the pharmacokinetics of oral D-serine, plasma D-serine levels were measured in both wild-type mice and transgenic mice lacking DAAO.  Although D-serine levels were rapidly diminished in wild-type mice (t1/2 = 1.2 h), sustained drug levels over the course of 4 h (t1/2 > 10 h) were obsd. in mice lacking DAAO.  Coadministration of D-serine with 6-chlorobenzo[d]isoxazol-3-ol (CBIO), a small-mol. DAAO inhibitor, in wild-type mice resulted in the enhancement of plasma D-serine levels, although CBIO seems to have only temporary effects on the plasma D-serine levels due to glucuronidation of the key hydroxyl group.  These findings highlight the predominant role of DAAO in the clearance of D-serine from the systemic circulation.  Thus, a potent DAAO inhibitor with a longer half-life should be capable of maintaining high plasma D-serine levels over a sustained period of time and might have therapeutic implications for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOnvR-tnwQ-rVg90H21EOLACvtfcHk0lhCZha5eEWQPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKkt73I&md5=c80a66d06d07cff75117790e0a927f84</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.046482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.046482%26sid%3Dliteratum%253Aachs%26aulast%3DRais%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DA.%2BG.%26aulast%3DWozniak%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DJaaro-Peled%26aufirst%3DH.%26aulast%3DSawa%26aufirst%3DA.%26aulast%3DStrick%26aufirst%3DC.%2BA.%26aulast%3DEngle%26aufirst%3DS.%2BJ.%26aulast%3DBrandon%26aufirst%3DN.%2BJ.%26aulast%3DRojas%26aufirst%3DC.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DTsukamoto%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520of%2520oral%2520D-serine%2520in%2520D-amino%2520acid%2520oxidase%2520knockout%2520mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D2067%26epage%3D2073%26doi%3D10.1124%2Fdmd.112.046482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keighron, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quarterman, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarco, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coggiano, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleaves, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanettini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span> <span> </span><span class="NLM_article-title">Effects of (R)-modafinil and modafinil analogues on dopamine dynamics assessed by voltammetry and microdialysis in the mouse nucleus accumbens shell</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2012</span>– <span class="NLM_lpage">2021</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00340</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00340" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVahtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2012-2021&author=J.+D.+Keighronauthor=J.+C.+Quartermanauthor=J.+Caoauthor=E.+M.+DeMarcoauthor=M.+A.+Coggianoauthor=A.+Gleavesauthor=R.+D.+Slackauthor=C.+Zanettiniauthor=A.+H.+Newmanauthor=G.+Tanda&title=Effects+of+%28R%29-modafinil+and+modafinil+analogues+on+dopamine+dynamics+assessed+by+voltammetry+and+microdialysis+in+the+mouse+nucleus+accumbens+shell&doi=10.1021%2Facschemneuro.8b00340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of (R)-Modafinil and Modafinil Analogues on Dopamine Dynamics Assessed by Voltammetry and Microdialysis in the Mouse Nucleus Accumbens Shell</span></div><div class="casAuthors">Keighron, Jacqueline D.; Quarterman, Juliana C.; Cao, Jianjing; De Marco, Emily M.; Coggiano, Mark A.; Gleaves, Apre; Slack, Rachel D.; Zanettini, Claudio; Newman, Amy Hauck; Tanda, Gianluigi</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2012-2021</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent discoveries have improved our understanding of the physiol. and pathol. roles of the dopamine transporter (DAT); however, only a few drugs are clin. available for DAT-implicated disorders.  Among those drugs, modafinil (MOD) and its (R)-enantiomer (R-MOD) have been used off-label as therapies for psychostimulant use disorders, but they have shown limited effectiveness in clin. trials.  Recent preclin. studies on MOD and R-MOD have led to chem. modified structures aimed toward improving their neurobiol. properties that might lead to more effective therapeutics for stimulant use disorders.  This study examines three MOD analogs (JJC8-016, JJC8-088, and JJC8-091) with improved DAT affinities compared to their parent compd.  These compds. were investigated for their effects on the neurochem. (brain microdialysis and FSCV) and behavior (ambulatory activity) of male Swiss-Webster mice.  Our data indicate that these compds. have dissimilar effects on tonic and phasic dopamine in the nucleus accumbens shell and variability in producing ambulatory activity.  These results suggest that small changes in the chem. structure of a DAT inhibitor can cause compds. such as JJC8-088 to produce effects similar to abused psychostimulants like cocaine.  In contrast, other compds. like JJC8-091 do not share cocaine-like effects and have a more atypical DAT-inhibitor profile, which may prove to be an advancement in the treatment of psychostimulant use disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOsciN_K_fZLVg90H21EOLACvtfcHk0lhCZha5eEWQPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVahtbw%253D&md5=8cf600df118f6a21c423e3b275007977</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00340%26sid%3Dliteratum%253Aachs%26aulast%3DKeighron%26aufirst%3DJ.%2BD.%26aulast%3DQuarterman%26aufirst%3DJ.%2BC.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DDeMarco%26aufirst%3DE.%2BM.%26aulast%3DCoggiano%26aufirst%3DM.%2BA.%26aulast%3DGleaves%26aufirst%3DA.%26aulast%3DSlack%26aufirst%3DR.%2BD.%26aulast%3DZanettini%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DTanda%26aufirst%3DG.%26atitle%3DEffects%2520of%2520%2528R%2529-modafinil%2520and%2520modafinil%2520analogues%2520on%2520dopamine%2520dynamics%2520assessed%2520by%2520voltammetry%2520and%2520microdialysis%2520in%2520the%2520mouse%2520nucleus%2520accumbens%2520shell%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D2012%26epage%3D2021%26doi%3D10.1021%2Facschemneuro.8b00340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl) methoxy]ethyl}-4-(3-phenylpropyl)piperazine], and benztropine analogs</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.091231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.105.091231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=16014753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOks7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=397-404&author=R.+I.+Desaiauthor=T.+A.+Kopajticauthor=D.+Frenchauthor=A.+H.+Newmanauthor=J.+L.+Katz&title=Relationship+between+in+vivo+occupancy+at+the+dopamine+transporter+and+behavioral+effects+of+cocaine%2C+GBR+12909+%5B1-%7B2-%5Bbis-%284-fluorophenyl%29+methoxy%5Dethyl%7D-4-%283-phenylpropyl%29piperazine%5D%2C+and+benztropine+analogs&doi=10.1124%2Fjpet.105.091231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between in Vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine],and benztropine analogs</span></div><div class="casAuthors">Desai, Rajeev I.; Kopajtic, Theresa A.; French, Dawn; Newman, Amy H.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">397-404</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Analogs of benztropine (BZT) bind to the dopamine (DA) transporter and inhibit DA uptake but often have behavioral effects that differ from those of cocaine and other DA-uptake inhibitors.  To better understand these differences, we examd. the relationship between locomotor-stimulant effects of cocaine, 1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)-piperazine (GBR 12909), and BZT analogs [(3α-[bis(4'-fluorophenyl)methoxy]-tropane) (AHN 1-055) and (N-allyl-3α-[bis(4'-fluorophenyl)methoxy]-tropane) (AHN 2-005)] and their in vivo displacement of the DA transporter ligand [125I]3β-(4-iodophenyl)-tropan-2β-carboxylic acid iso-Pr ester hydrochloride (RTI-121) in striatum.  Cocaine, GBR 12909, and BZT analogs each displaced [125I]RTI-121 and stimulated locomotor activity in a dose- and time-dependent manner.  The time course revealed a slower onset of both effects for AHN 1-055 and AHN 2-005 compared with cocaine and GBR 12909.  The BZT analogs were less effective than cocaine and GBR 12909 in stimulating locomotor activity.  Locomotor stimulant effects of cocaine were generally greater than predicted by the regression of displacement of [125I]RTI-121 and effect at short times after injection and less than predicted at longer times after injection.  This result suggests that the apparent rate of occupancy of the DA transporter, in addn. to percentage of sites occupied, contributes to the behavioral effects of cocaine.  The present results suggest that among drugs that act at the DA transporter, the slower apparent rates of occupancy with the DA transporter by the BZT analogs may contribute in an important way to differences in their effectiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjPuttHGNvq7Vg90H21EOLACvtfcHk0ljQ1bqaA23VBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOks7nI&md5=aa3d51cc833c446f5895f06bf1c28b99</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.091231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.091231%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DR.%2BI.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DFrench%26aufirst%3DD.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DRelationship%2520between%2520in%2520vivo%2520occupancy%2520at%2520the%2520dopamine%2520transporter%2520and%2520behavioral%2520effects%2520of%2520cocaine%252C%2520GBR%252012909%2520%255B1-%257B2-%255Bbis-%25284-fluorophenyl%2529%2520methoxy%255Dethyl%257D-4-%25283-phenylpropyl%2529piperazine%255D%252C%2520and%2520benztropine%2520analogs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D397%26epage%3D404%26doi%3D10.1124%2Fjpet.105.091231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmeichel, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zemlan, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berridge, C. W.</span></span> <span> </span><span class="NLM_article-title">A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.neuropharm.2012.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=22796428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFahsbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=321-328&author=B.+E.+Schmeichelauthor=F.+P.+Zemlanauthor=C.+W.+Berridge&title=A+selective+dopamine+reuptake+inhibitor+improves+prefrontal+cortex-dependent+cognitive+function%3A+potential+relevance+to+attention+deficit+hyperactivity+disorder&doi=10.1016%2Fj.neuropharm.2012.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: Potential relevance to attention deficit hyperactivity disorder</span></div><div class="casAuthors">Schmeichel, Brooke E.; Zemlan, Frank P.; Berridge, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">321-328</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Drugs used to treat attention deficit hyperactivity disorder (ADHD) improve prefrontal cortex (PFC)-dependent cognitive function.  The majority of ADHD-related treatments act either as dual norepinephrine (NE) and dopamine (DA) reuptake inhibitors (psychostimulants) or selective NE reuptake inhibitors (SNRIs).  Certain benztropine analogs act as highly selective DA reuptake inhibitors while lacking the reinforcing actions, and thus abuse potential, of psychostimulants.  To assess the potential use of these compds. in the treatment of ADHD, we examd. the effects of a well-characterized benztropine analog, AHN 2-005, on performance of rats in a PFC-dependent delayed-alternation task of spatial working memory.  Similar to that seen with all drugs currently approved for ADHD, AHN 2-005 dose-dependently improved performance in this task.  Clin.-relevant doses of psychostimulants and SNRIs elevate NE and DA preferentially in the PFC.  Despite the selectivity of this compd. for the DA transporter, addnl. microdialysis studies demonstrated that a cognition-enhancing dose of AHN 2-005 that lacked locomotor activating effects increased extracellular levels of both DA and NE in the PFC.  AHN 2-005 produced a larger increase in extracellular DA in the nucleus accumbens, although the magnitude of this was well below that seen with motor activating doses of psychostimulants.  Collectively, these observations suggest that benztropine analogs may be efficacious in the treatment of ADHD or other disorders assocd. with PFC dysfunction.  These studies provide a strong rationale for future research focused on the neural mechanisms contributing to the cognition-enhancing actions and the potential clin. utility of AHN 2-005 and related compds.This article is part of a Special Issue entitled 'Cognitive Enhancers'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcRRQhVm59OLVg90H21EOLACvtfcHk0lgWCyHRCLlmyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFahsbzJ&md5=02d22b902af8d4218bb0d228c2d5cc81</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DSchmeichel%26aufirst%3DB.%2BE.%26aulast%3DZemlan%26aufirst%3DF.%2BP.%26aulast%3DBerridge%26aufirst%3DC.%2BW.%26atitle%3DA%2520selective%2520dopamine%2520reuptake%2520inhibitor%2520improves%2520prefrontal%2520cortex-dependent%2520cognitive%2520function%253A%2520potential%2520relevance%2520to%2520attention%2520deficit%2520hyperactivity%2520disorder%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D64%26spage%3D321%26epage%3D328%26doi%3D10.1016%2Fj.neuropharm.2012.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izenwasser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Novel 3-alpha-(diphenylmethoxy) tropane analogs - Potent dopamine uptake inhibitors without cocaine-like behavioral profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2258</span>– <span class="NLM_lpage">2261</span>, <span class="refDoi"> DOI: 10.1021/jm00041a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00041a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK2cXkslejur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=2258-2261&author=A.+H.+Newmanauthor=A.+C.+Allenauthor=S.+Izenwasserauthor=J.+L.+Katz&title=Novel+3-alpha-%28diphenylmethoxy%29+tropane+analogs+-+Potent+dopamine+uptake+inhibitors+without+cocaine-like+behavioral+profiles&doi=10.1021%2Fjm00041a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 3α-(Diphenylmethoxy)tropane Analogs: Potent Dopamine Uptake Inhibitors without Cocaine-like Behavioral Profiles</span></div><div class="casAuthors">Newman, Amy Hauck; Allen, Andrew C.; Izenwasser, Sari; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2258-61</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The compd. I is the first tropane analog to be described that is structurally similar to cocaine and GBR 12909, binds with high affinity to the dopamine transporter, blocks the reuptake of dopamine, and yet is behaviorally distinct from all other compds. that share this structural and/or neurochem. profile.  Preliminary locomotor activity and drug discrimination data show that all of the compds. in this series appear to demonstrate the same behavioral profile as I.  The possibility that this compd. and others in this series may be potential cocaine antagonists is currently being investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsfTXfjcVNs7Vg90H21EOLACvtfcHk0lgWCyHRCLlmyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkslejur8%253D&md5=f817de033330e444c1aab347536f15db</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm00041a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00041a002%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DAllen%26aufirst%3DA.%2BC.%26aulast%3DIzenwasser%26aufirst%3DS.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DNovel%25203-alpha-%2528diphenylmethoxy%2529%2520tropane%2520analogs%2520-%2520Potent%2520dopamine%2520uptake%2520inhibitors%2520without%2520cocaine-like%2520behavioral%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D2258%26epage%3D2261%26doi%3D10.1021%2Fjm00041a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izenwasser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel 3 alpha-diphenylmethoxytropane analogs: Selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">315</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=9862785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK1MXisVyqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=1999&pages=302-315&author=J.+L.+Katzauthor=S.+Izenwasserauthor=R.+H.+Klineauthor=A.+C.+Allenauthor=A.+H.+Newman&title=Novel+3+alpha-diphenylmethoxytropane+analogs%3A+Selective+dopamine+uptake+inhibitors+with+behavioral+effects+distinct+from+those+of+cocaine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 3α-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine</span></div><div class="casAuthors">Katz, Jonathan L.; Izenwasser, Sari; Kline, Richard H.; Allen, Andrew C.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">302-315</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pharmacol. effects were assessed for a series of 3α-diphenylmethoxy-1αH,5αH-tropane analogs which have structural similarities to cocaine.  Like cocaine, these compds. displaced [3H]WIN 35,428 binding from rat caudate and had affinities ranging from approx. 10-fold greater than cocaine (Ki=11.8 nM) to relatively low affinity (Ki=2000 nM).  The compds. also inhibited dopamine uptake with potencies corresponding to their affinities for WIN 35,428 binding sites.  Like the parent compd., benztropine, the 3α-(diphenylmethoxy)tropane analogs displaced [3H]pirenzepine from muscarinic M1 receptors with affinities ranging from 2 to 120 nM.  Cocaine produced dose-related increases in locomotor activity (horizontal ambulation) in Swiss Webster mice, whereas the 3α-(diphenylmethoxy)tropane analogs generally had lower efficacy than cocaine.  Compds. with fluoro-substituents in the Ph rings generally were among those with efficacy approaching that of cocaine; those with chloro- and bromo-substituents were markedly less efficacious, despite having binding affinities comparable to those of the corresponding fluoro-substituted compds.  The 3α-(diphenylmethoxy)tropane analogs were also examd. in rats trained to discriminate saline from cocaine (10 mg/kg, i.p.).  Cocaine produced a dose-related increase in responding on the cocaine-appropriate lever, reaching 100% at 10 mg/kg.  Only the 4',4''-difluoro-substituted analog produced effects similar to those of cocaine; the other compds. showed markedly reduced efficacy compared to cocaine.  Drug interaction studies showed that the antimuscarinics, atropine and scopolamine, potentiated rather than attenuated the locomotor stimulant and cocaine-like discriminative-stimulus effects of cocaine, indicating that the antimuscarinic effects of the 3α-diphenylmethoxytropane analogs did not contribute to their diminished cocaine-like activity.  Studies of the time course of selected compds. indicated that their reduced cocaine-like efficacy was likely not due to behavioral observations being conducted at an inopportune time period.  Because none of the 3α-diphenylmethoxytropane analogs studied showed evidence that they were binding to more than one site, and because the structure activity relationships among these drugs are distinctly different from those obtained with cocaine, these data suggest that the 3α-diphenylmethoxytropane analogs are accessing a different binding domain than that accessed by cocaine.  Binding to this domain may produce a behavioral profile that is distinct from that of the cocaine-like dopamine uptake inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVv6SJkGAJDrVg90H21EOLACvtfcHk0lgWCyHRCLlmyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXisVyqug%253D%253D&md5=f2a3046324b849beee51eb2bd8bdac05</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DIzenwasser%26aufirst%3DS.%26aulast%3DKline%26aufirst%3DR.%2BH.%26aulast%3DAllen%26aufirst%3DA.%2BC.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%25203%2520alpha-diphenylmethoxytropane%2520analogs%253A%2520Selective%2520dopamine%2520uptake%2520inhibitors%2520with%2520behavioral%2520effects%2520distinct%2520from%2520those%2520of%2520cocaine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D288%26spage%3D302%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupica, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">2-Isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.212738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.113.212738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=24518035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVCmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2014&pages=297-309&author=T.+Hiranitaauthor=D.+S.+Wilkinsonauthor=W.+M.+C.+Hongauthor=M.+F.+Zouauthor=T.+A.+Kopajticauthor=P.+L.+Sotoauthor=C.+R.+Lupicaauthor=A.+H.+Newmanauthor=J.+L.+Katz&title=2-Isoxazol-3-phenyltropane+derivatives+of+cocaine%3A+molecular+and+atypical+system+effects+at+the+dopamine+transporter&doi=10.1124%2Fjpet.113.212738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">2-isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter</span></div><div class="casAuthors">Hiranita, Takato; Wilkinson, Derek S.; Hong, Weimin C.; Zou, Mu-Fa; Kopajtic, Theresa A.; Soto, Paul L.; Lupica, Carl R.; Newman, Amy H.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">297-309, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The present study examd. RTI-371 [3β-(4-methylphenyl)-2β-[3-(4-chlorophenyl)-isoxazol-5-yl]tropane], a phenyltropane cocaine analog with effects distinct from cocaine, and assessed potential mechanisms for those effects by comparison with its constitutional isomer, RTI-336 [3β-(4-chlorophenyl)-2β-[3-(4-methylphenyl)-isoxazol-5-yl]tropane].  In mice, RTI-371 was less effective than cocaine and RTI-336 in stimulating locomotion, and incompletely substituted (∼60% max. at 5 min or 1 h after injection) in a cocaine (10 mg/kg i.p.)/saline discrimination procedure; RTI-336 completely substituted.  In contrast to RTI-336, RTI-371 was not self-administered, and its pretreatment (1.0-10 mg/kg i.p.) dose-dependently decreased maximal cocaine self-administration more potently than food-maintained responding.  RTI-336 pretreatment dose-dependently left-shifted the cocaine self-administration dose-effect curve.  Both RTI-336 and RTI-371 displaced [3H]WIN35,428 [[3H](-)-3β-(4-fluorophenyl)-tropan-2β-carboxylic acid Me ester tartrate] binding to striatal dopamine transporters (DATs) with Ki values of 10.8 and 7.81 nM, resp., and had lower affinities at serotonin or norepinephrine transporters, or muscarinic and σ receptors.  The relative low affinity at these sites suggests the DAT as the primary target of RTI-371 with minimal contributions from these other targets.  In biochem. assays probing the outward-facing DAT conformation, both RTI-371 and RTI-336 had effects similar to cocaine, suggesting little contribution of DAT conformation to the unique pharmacol. of RTI-371.  The locomotor-stimulant effects of RTI-371 (3.0-30 mg/kg i.p.) were comparable in wild-type and knockout cannabinoid CB1 receptor (CB1R) mice, indicating that previously reported CB1 allosteric effects do not decrease cocaine-like effects of RTI-371.  DAT occupancy in vivo was most rapid with cocaine and least with RTI-371.  The slow apparent assocn. rate may allow compensatory actions that in turn dampen cocaine-like stimulation, and give RTI-371 its unique pharmacol. profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDwwGziyXAgbVg90H21EOLACvtfcHk0lhP4J4UNmxJxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVCmt7Y%253D&md5=0c4e7470799ae071011ab59b882e7165</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.212738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.212738%26sid%3Dliteratum%253Aachs%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DWilkinson%26aufirst%3DD.%2BS.%26aulast%3DHong%26aufirst%3DW.%2BM.%2BC.%26aulast%3DZou%26aufirst%3DM.%2BF.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DSoto%26aufirst%3DP.%2BL.%26aulast%3DLupica%26aufirst%3DC.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3D2-Isoxazol-3-phenyltropane%2520derivatives%2520of%2520cocaine%253A%2520molecular%2520and%2520atypical%2520system%2520effects%2520at%2520the%2520dopamine%2520transporter%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D349%26spage%3D297%26epage%3D309%26doi%3D10.1124%2Fjpet.113.212738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomenzo, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madura, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surratt, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudell, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">2-Substituted 3 beta-aryltropane cocaine analogs produce atypical effects without inducing inward-facing dopamine transporter conformations</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">624</span>– <span class="NLM_lpage">634</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.230722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.115.230722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=26769919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A280%3ADC%252BC28ngt1CitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2016&pages=624-634&author=W.+M.+C.+Hongauthor=T.+A.+Kopajticauthor=L.+F.+Xuauthor=S.+A.+Lomenzoauthor=B.+Jeanauthor=J.+D.+Maduraauthor=C.+K.+Surrattauthor=M.+L.+Trudellauthor=J.+L.+Katz&title=2-Substituted+3+beta-aryltropane+cocaine+analogs+produce+atypical+effects+without+inducing+inward-facing+dopamine+transporter+conformations&doi=10.1124%2Fjpet.115.230722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">2-Substituted 3β-Aryltropane Cocaine Analogs Produce Atypical Effects without Inducing Inward-Facing Dopamine Transporter Conformations</span></div><div class="casAuthors">Hong Weimin C; Kopajtic Theresa A; Xu Lifen; Lomenzo Stacey A; Jean Bernandie; Madura Jeffry D; Surratt Christopher K; Trudell Mark L; Katz Jonathan L</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">624-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Previous structure-activity relationship studies indicate that a series of cocaine analogs, 3β-aryltropanes with 2β-diarylmethoxy substituents, selectively bind to the dopamine transporter (DAT) with nanomolar affinities that are 10-fold greater than the affinities of their corresponding 2α-enantiomers.  The present study compared these compounds to cocaine with respect to locomotor effects in mice, and assessed their ability to substitute for cocaine (10 mg/kg, i.p.) in rats trained to discriminate cocaine from saline.  Despite nanomolar DAT affinity, only the 2β-Ph2COCH2-3β-4-Cl-Ph analog fully substituted for cocaine-like discriminative effects.  Whereas all of the 2β compounds increased locomotion, only the 2β-(4-ClPh)PhCOCH2-3β-4-Cl-Ph analog had cocaine-like efficacy.  None of the 2α-substituted compounds produced either of these cocaine-like effects.  To explore the molecular mechanisms of these drugs, their effects on DAT conformation were probed using a cysteine-accessibility assay.  Previous reports indicate that cocaine binds with substantially higher affinity to the DAT in its outward (extracellular)- compared with inward-facing conformation, whereas atypical DAT inhibitors, such as benztropine, have greater similarity in affinity to these conformations, and this is postulated to explain their divergent behavioral effects.  All of the 2β- and 2α-substituted compounds tested altered cysteine accessibility of DAT in a manner similar to cocaine.  Furthermore, molecular dynamics of in silico inhibitor-DAT complexes suggested that the 2-substituted compounds reach equilibrium in the binding pocket in a cocaine-like fashion.  These behavioral, biochemical, and computational results show that aryltropane analogs can bind to the DAT and stabilize outward-facing DAT conformations like cocaine, yet produce effects that differ from those of cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHUIt0a7sLpmx8TEN9K18QfW6udTcc2eaZZEf3P9TBdrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28ngt1CitA%253D%253D&md5=a21420fab70030162709440ede486173</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.230722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.230722%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DW.%2BM.%2BC.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DL.%2BF.%26aulast%3DLomenzo%26aufirst%3DS.%2BA.%26aulast%3DJean%26aufirst%3DB.%26aulast%3DMadura%26aufirst%3DJ.%2BD.%26aulast%3DSurratt%26aufirst%3DC.%2BK.%26aulast%3DTrudell%26aufirst%3DM.%2BL.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3D2-Substituted%25203%2520beta-aryltropane%2520cocaine%2520analogs%2520produce%2520atypical%2520effects%2520without%2520inducing%2520inward-facing%2520dopamine%2520transporter%2520conformations%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D356%26spage%3D624%26epage%3D634%26doi%3D10.1124%2Fjpet.115.230722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheffel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boja, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhar, M. J.</span></span> <span> </span><span class="NLM_article-title">Cocaine receptors - In vivo labeling with H-3 (−)cocaine, H-3 Win-35,065–2, and H-3 Win-35,428</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1002/syn.890040415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1002%2Fsyn.890040415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=2603151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK3cXptFKhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1989&pages=390-392&author=U.+Scheffelauthor=J.+W.+Bojaauthor=M.+J.+Kuhar&title=Cocaine+receptors+-+In+vivo+labeling+with+H-3+%28%E2%88%92%29cocaine%2C+H-3+Win-35%2C065%E2%80%932%2C+and+H-3+Win-35%2C428&doi=10.1002%2Fsyn.890040415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Cocaine receptors: in vivo labeling with 3H-(-)cocaine, 3H-WIN 35065-2, and 3H-WIN 35428</span></div><div class="casAuthors">Scheffel, Ursula; Boja, John W.; Kuhar, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (New York, NY, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">390-2</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    </div><div class="casAbstract">The binding of tritiated (-)-cocaine and its 2 title analogs to the brain striatum and cerebellum was studied in mice.  The analogs WIN-35065-2 and WIN-35428 showed a stronger binding than cocaine to cocaine-binding sites in the striatum presumably assocd. with dopamine transports.  Both analogs are less prone to metab. than cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2UAERaB5xILVg90H21EOLACvtfcHk0lhP4J4UNmxJxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXptFKhtA%253D%253D&md5=eed1a9ec1ddf6a054b5fc81045289b37</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fsyn.890040415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.890040415%26sid%3Dliteratum%253Aachs%26aulast%3DScheffel%26aufirst%3DU.%26aulast%3DBoja%26aufirst%3DJ.%2BW.%26aulast%3DKuhar%26aufirst%3DM.%2BJ.%26atitle%3DCocaine%2520receptors%2520-%2520In%2520vivo%2520labeling%2520with%2520H-3%2520%2528%25E2%2588%2592%2529cocaine%252C%2520H-3%2520Win-35%252C065%25E2%2580%25932%252C%2520and%2520H-3%2520Win-35%252C428%26jtitle%3DSynapse%26date%3D1989%26volume%3D4%26spage%3D390%26epage%3D392%26doi%3D10.1002%2Fsyn.890040415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Stimulants as specific inducers of dopamine-independent Sigma agonist self-administration in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.207522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.113.207522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=23908387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2ks7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=20-29&author=T.+Hiranitaauthor=P.+L.+Sotoauthor=G.+Tandaauthor=T.+A.+Kopajticauthor=J.+L.+Katz&title=Stimulants+as+specific+inducers+of+dopamine-independent+Sigma+agonist+self-administration+in+rats&doi=10.1124%2Fjpet.113.207522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulants as specific inducers of dopamine-independent σ agonist self-administration in rats</span></div><div class="casAuthors">Hiranita, Takato; Soto, Paul L.; Tanda, Gianluigi; Kopajtic, Theresa A.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-29</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A previous study showed that cocaine self-administration induced dopamine-independent reinforcing effects of σ agonists mediated by their selective actions at σ1 receptors (σ1Rs), which are intracellularly mobile chaperone proteins implicated in abuse-related effects of stimulants.  The present study assessed whether the induction was specific to self-administration of cocaine.  Rats were trained to self-administer the dopamine releaser, d-methamphetamine (0.01-0.32 mg/kg per injection), the μ-opioid receptor agonist, heroin (0.001-0.032 mg/kg per injection), and the noncompetitive N-methyl-D-aspartate receptor/channel antagonist ketamine (0.032-1.0 mg/kg per injection).  As with cocaine, self-administration of d-methamphetamine induced reinforcing effects of the selective σ1R agonists PRE-084 [2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate hydrochloride] and (+)-pentazocine (0.032-1.0 mg/kg per injection, each).  In contrast, neither self-administration of heroin nor ketamine induced PRE-084 or (+)-pentazocine (0.032-10 mg/kg per injection, each) self-administration.  Although the σ1R agonists did not maintain responding in subjects with histories of heroin or ketamine self-administration, substitution for those drugs was obtained with appropriate agonists (e.g., remifentanil, 0.1-3.2 μg/kg per injection, for heroin and (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine ((+)-MK 801; dizocilpine), 0.32-10.0 μg/kg per injection, for ketamine).  The σR antagonist N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine dihydrobromide (BD 1008; 1.0-10 mg/kg) dose-dependently blocked PRE-084 self-administration but was inactive against d-methamphetamine, heroin, and ketamine.  In contrast, PRE-084 self-administration was affected neither by the dopamine receptor antagonist (+)-butaclamol (10-100 μg/kg) nor by the opioid antagonist (-)-naltrexone (1.0-10 mg/kg), whereas these antagonists were active against d-methamphetamine and heroin self-administration, resp.  The results indicate that experience specifically with indirect-acting dopamine agonists induces reinforcing effects of previously inactive σ1R agonists.  It is further suggested that induced σ1R reinforcing mechanisms may play an essential role in treatment-resistant stimulant abuse, suggesting new approaches for the development of effective medications for its treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKYX262DkAL7Vg90H21EOLACvtfcHk0lg2JyBPZkAPFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2ks7zI&md5=3a6c50fc2758e9892cbe0c683b56b7d4</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207522%26sid%3Dliteratum%253Aachs%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DSoto%26aufirst%3DP.%2BL.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DStimulants%2520as%2520specific%2520inducers%2520of%2520dopamine-independent%2520Sigma%2520agonist%2520self-administration%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D20%26epage%3D29%26doi%3D10.1124%2Fjpet.113.207522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between inhibition constant (K1) and concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic-reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+inhibition+constant+%28K1%29+and+concentration+of+inhibitor+which+causes+50%25+inhibition+%28I50%29+of+an+enzymatic-reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lg2JyBPZkAPFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2525%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic-reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreassen, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span> <span> </span><span class="NLM_article-title">A conserved salt bridge between transmembrane segments 1 and 10 constitutes an extracellular gate in the dopamine transporter</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">35003</span>– <span class="NLM_lpage">35014</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.586982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1074%2Fjbc.M114.586982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=25339174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVSgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=35003-35014&author=A.+V.+Pedersenauthor=T.+F.+Andreassenauthor=C.+J.+Loland&title=A+conserved+salt+bridge+between+transmembrane+segments+1+and+10+constitutes+an+extracellular+gate+in+the+dopamine+transporter&doi=10.1074%2Fjbc.M114.586982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">A conserved salt bridge between transmembrane segments 1 and 10 constitutes an extracellular gate in the dopamine transporter</span></div><div class="casAuthors">Pedersen, Anders V.; Andreassen, Thorvald F.; Loland, Claus J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">35003-35014, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Neurotransmitter transporters play an important role in termination of synaptic transmission by mediating reuptake of neurotransmitter, but the mol. processes behind translocation are still unclear.  The crystal structures of the bacterial homolog, LeuT, provided valuable insight into the structural and dynamic requirements for substrate transport.  These structures support the existence of gating domains controlling access to a central binding site.  On the extracellular side, access is controlled by the "thin gate" formed by an interaction between Arg-30 and Asp-404.  In the human dopamine transporter (DAT), the corresponding residues are Arg-85 and Asp-476.  Here, we present results supporting the existence of a similar interaction in DAT.  The DAT R85D mutant has a complete loss of function, but the addnl. insertion of an arginine in opposite position (R85D/D476R), causing a charge reversal, results in a rescue of binding sites for the cocaine analog [3H]CFT.  Also, the coordination of Zn2+ between introduced histidines (R85H/D476H) caused a ∼2.5-fold increase in [3H]CFT binding (Bmax).  Importantly, Zn2+ also inhibited [3H]dopamine transport in R85H/D476H, suggesting that a dynamic interaction is required for the transport process.  Furthermore, cysteine-reactive chem. shows that mutation of the gating residues causes a higher proportion of transporters to reside in the outward facing conformation.  Finally, we show that charge reversal of the corresponding residues (R104E/E493R) in the serotonin transporter (SERT) also rescues [3H](S)-citalopram binding, suggesting a conserved feature.  Taken together, these data suggest that the extracellular thin gate is present in monoamine transporters and that a dynamic interaction is required for substrate transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob2g8cE5ScPrVg90H21EOLACvtfcHk0lg2JyBPZkAPFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVSgug%253D%253D&md5=8036920794dfc9fbf25a1f09f356cfaa</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.586982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.586982%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DA.%2BV.%26aulast%3DAndreassen%26aufirst%3DT.%2BF.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26atitle%3DA%2520conserved%2520salt%2520bridge%2520between%2520transmembrane%2520segments%25201%2520and%252010%2520constitutes%2520an%2520extracellular%2520gate%2520in%2520the%2520dopamine%2520transporter%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D35003%26epage%3D35014%26doi%3D10.1074%2Fjbc.M114.586982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Daryl A. Guthrie, Carmen Klein Herenbrink, Matthew Domenic Lycas, Therese Ku, Alessandro Bonifazi, Brian T. DeVree, Signe Mathiasen, Jonathan A. Javitch, Jonathan B. Grimm, Luke Lavis, Ulrik Gether, <span class="NLM_string-name hlFld-ContribAuthor">Amy Hauck Newman</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Fluorescent Ligands Enable Single-Molecule Localization Microscopy of the Dopamine Transporter. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (20)
                                     , 3288-3300. <a href="https://doi.org/10.1021/acschemneuro.0c00397" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00397</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00397%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DNovel%252BFluorescent%252BLigands%252BEnable%252BSingle-Molecule%252BLocalization%252BMicroscopy%252Bof%252Bthe%252BDopamine%252BTransporter%26aulast%3DGuthrie%26aufirst%3DDaryl%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26062020%26date%3D14092020%26date%3D01102020%26date%3D14092020%26volume%3D11%26issue%3D20%26spage%3D3288%26epage%3D3300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan-Fei  Sui</span>, <span class="hlFld-ContribAuthor ">Mohammad Fawad  Ansari</span>, <span class="hlFld-ContribAuthor ">Bo  Fang</span>, <span class="hlFld-ContribAuthor ">Shao-Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Cheng-He  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel purinylthiazolylethanone derivatives as anti-Candida albicans agents through possible multifaceted mechanisms. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113557. <a href="https://doi.org/10.1016/j.ejmech.2021.113557" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113557</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113557%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bpurinylthiazolylethanone%252Bderivatives%252Bas%252Banti-Candida%252Balbicans%252Bagents%252Bthrough%252Bpossible%252Bmultifaceted%252Bmechanisms%26aulast%3DSui%26aufirst%3DYan-Fei%26date%3D2021%26volume%3D221%26spage%3D113557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Hailan  Huang</span>, <span class="hlFld-ContribAuthor ">Ziheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiangkun  Yan</span>, <span class="hlFld-ContribAuthor ">Tianxiao  Wu</span>, <span class="hlFld-ContribAuthor ">Wenbo  Yin</span>, <span class="hlFld-ContribAuthor ">Yixiang  Sun</span>, <span class="hlFld-ContribAuthor ">Xinran  Wang</span>, <span class="hlFld-ContribAuthor ">Yanting  Gu</span>, <span class="hlFld-ContribAuthor ">Dongmei  Zhao</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113501. <a href="https://doi.org/10.1016/j.ejmech.2021.113501" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113501</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113501%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bbenzofuran%252Bderivatives%252Bas%252Bpotent%252BLSD1%252Binhibitors%26aulast%3DZhang%26aufirst%3DXiangyu%26date%3D2021%26volume%3D220%26spage%3D113501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aysel  Cetinkaya-Fisgin</span>, <span class="hlFld-ContribAuthor ">Jing  Zhu</span>, <span class="hlFld-ContribAuthor ">Xinghua  Luan</span>, <span class="hlFld-ContribAuthor ">Jun-Soon  Kim</span>, <span class="hlFld-ContribAuthor ">Byoungchol  Oh</span>, <span class="hlFld-ContribAuthor ">Cory  Brayton</span>, <span class="hlFld-ContribAuthor ">Jesse  Alt</span>, <span class="hlFld-ContribAuthor ">Rana  Rais</span>, <span class="hlFld-ContribAuthor ">Barbara  Slusher</span>, <span class="hlFld-ContribAuthor ">Ahmet  Höke</span>. </span><span class="cited-content_cbyCitation_article-title">Development of EQ-6, a Novel Analogue of Ethoxyquin to Prevent Chemotherapy-Induced Peripheral Neuropathy. </span><span class="cited-content_cbyCitation_journal-name">Neurotherapeutics</span><span> <strong>2021,</strong> <em>81 </em><a href="https://doi.org/10.1007/s13311-021-01093-8" title="DOI URL">https://doi.org/10.1007/s13311-021-01093-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13311-021-01093-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13311-021-01093-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurotherapeutics%26atitle%3DDevelopment%252Bof%252BEQ-6%25252C%252Ba%252BNovel%252BAnalogue%252Bof%252BEthoxyquin%252Bto%252BPrevent%252BChemotherapy-Induced%252BPeripheral%252BNeuropathy%26aulast%3DCetinkaya-Fisgin%26aufirst%3DAysel%26date%3D2021%26date%3D2021%26volume%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Melinda  Hersey</span>, <span class="hlFld-ContribAuthor ">Amanda K.  Bacon</span>, <span class="hlFld-ContribAuthor ">Lydia G.  Bailey</span>, <span class="hlFld-ContribAuthor ">Mark A.  Coggiano</span>, <span class="hlFld-ContribAuthor ">Amy H.  Newman</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Leggio</span>, <span class="hlFld-ContribAuthor ">Gianluigi  Tanda</span>. </span><span class="cited-content_cbyCitation_article-title">Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Neuroscience</span><span> <strong>2021,</strong> <em>15 </em><a href="https://doi.org/10.3389/fnins.2021.656475" title="DOI URL">https://doi.org/10.3389/fnins.2021.656475</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnins.2021.656475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnins.2021.656475%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Neuroscience%26atitle%3DPsychostimulant%252BUse%252BDisorder%25252C%252Ban%252BUnmet%252BTherapeutic%252BGoal%25253A%252BCan%252BModafinil%252BNarrow%252Bthe%252BGap%25253F%26aulast%3DHersey%26aufirst%3DMelinda%26date%3D2021%26date%3D2021%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gianluigi  Tanda</span>, <span class="hlFld-ContribAuthor ">Melinda  Hersey</span>, <span class="hlFld-ContribAuthor ">Briana  Hempel</span>, <span class="hlFld-ContribAuthor ">Zheng-Xiong  Xi</span>, <span class="hlFld-ContribAuthor ">Amy Hauck  Newman</span>. </span><span class="cited-content_cbyCitation_article-title">Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2021,</strong> <em>56 </em>, 13-21. <a href="https://doi.org/10.1016/j.coph.2020.07.007" title="DOI URL">https://doi.org/10.1016/j.coph.2020.07.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2020.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2020.07.007%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DModafinil%252Band%252Bits%252Bstructural%252Banalogs%252Bas%252Batypical%252Bdopamine%252Buptake%252Binhibitors%252Band%252Bpotential%252Bmedications%252Bfor%252Bpsychostimulant%252Buse%252Bdisorder%26aulast%3DTanda%26aufirst%3DGianluigi%26date%3D2021%26volume%3D56%26spage%3D13%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amy Hauck  Newman</span>, <span class="hlFld-ContribAuthor ">Therese  Ku</span>, <span class="hlFld-ContribAuthor ">Chloe J.  Jordan</span>, <span class="hlFld-ContribAuthor ">Alessandro  Bonifazi</span>, <span class="hlFld-ContribAuthor ">Zheng-Xiong  Xi</span>. </span><span class="cited-content_cbyCitation_article-title">New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Pharmacology and Toxicology</span><span> <strong>2021,</strong> <em>61 </em>
                                    (1)
                                     , 609-628. <a href="https://doi.org/10.1146/annurev-pharmtox-030220-124205" title="DOI URL">https://doi.org/10.1146/annurev-pharmtox-030220-124205</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-pharmtox-030220-124205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-pharmtox-030220-124205%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Pharmacology%2520and%2520Toxicology%26atitle%3DNew%252BDrugs%25252C%252BOld%252BTargets%25253A%252BTweaking%252Bthe%252BDopamine%252BSystem%252Bto%252BTreat%252BPsychostimulant%252BUse%252BDisorders%26aulast%3DNewman%26aufirst%3DAmy%2BHauck%26date%3D2021%26volume%3D61%26issue%3D1%26spage%3D609%26epage%3D628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Md  Ashraf-Uz-Zaman</span>, <span class="hlFld-ContribAuthor ">Sadisna  Shahi</span>, <span class="hlFld-ContribAuthor ">Racheal  Akwii</span>, <span class="hlFld-ContribAuthor ">Md Sanaullah  Sajib</span>, <span class="hlFld-ContribAuthor ">Mohammad Jodeiri  Farshbaf</span>, <span class="hlFld-ContribAuthor ">Raja Reddy  Kallem</span>, <span class="hlFld-ContribAuthor ">William  Putnam</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Ruiwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Karina  Alvina</span>, <span class="hlFld-ContribAuthor ">Paul C.  Trippier</span>, <span class="hlFld-ContribAuthor ">Constantinos M.  Mikelis</span>, <span class="hlFld-ContribAuthor ">Nadezhda A.  German</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112866. <a href="https://doi.org/10.1016/j.ejmech.2020.112866" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112866</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112866%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bstructure-activity%252Brelationship%252Bstudy%252Bof%252Bnovel%252Burea%252Bcompounds%252Bas%252BFGFR1%252Binhibitors%252Bto%252Btreat%252Bmetastatic%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DAshraf-Uz-Zaman%26aufirst%3DMd%26date%3D2021%26volume%3D209%26spage%3D112866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">JoLynn B.  Giancola</span>, <span class="hlFld-ContribAuthor ">Alessandro  Bonifazi</span>, <span class="hlFld-ContribAuthor ">Jianjing  Cao</span>, <span class="hlFld-ContribAuthor ">Therese  Ku</span>, <span class="hlFld-ContribAuthor ">Alexandra J.  Haraczy</span>, <span class="hlFld-ContribAuthor ">Jenny  Lam</span>, <span class="hlFld-ContribAuthor ">Rana  Rais</span>, <span class="hlFld-ContribAuthor ">Mark A.  Coggiano</span>, <span class="hlFld-ContribAuthor ">Gianluigi  Tanda</span>, <span class="hlFld-ContribAuthor ">Amy Hauck  Newman</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112674. <a href="https://doi.org/10.1016/j.ejmech.2020.112674" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112674%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-activity%252Brelationships%252Bfor%252Ba%252Bseries%252Bof%252B%252528Bis%2525284-fluorophenyl%252529methyl%252529sulfinylethyl-aminopiperidines%252Band%252B-piperidine%252Bamines%252Bat%252Bthe%252Bdopamine%252Btransporter%25253A%252BBioisosteric%252Breplacement%252Bof%252Bthe%252Bpiperazine%252Bimproves%252Bmetabolic%252Bstability%26aulast%3DGiancola%26aufirst%3DJoLynn%2BB.%26date%3D2020%26volume%3D208%26spage%3D112674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bridget  Duvall</span>, <span class="hlFld-ContribAuthor ">Sarah C.  Zimmermann</span>, <span class="hlFld-ContribAuthor ">Run-Duo  Gao</span>, <span class="hlFld-ContribAuthor ">Ajit G.  Thomas</span>, <span class="hlFld-ContribAuthor ">Filip  Kalčic</span>, <span class="hlFld-ContribAuthor ">Vijayabhaskar  Veeravalli</span>, <span class="hlFld-ContribAuthor ">Amira  Elgogary</span>, <span class="hlFld-ContribAuthor ">Rana  Rais</span>, <span class="hlFld-ContribAuthor ">Camilo  Rojas</span>, <span class="hlFld-ContribAuthor ">Anne  Le</span>, <span class="hlFld-ContribAuthor ">Barbara S.  Slusher</span>, <span class="hlFld-ContribAuthor ">Takashi  Tsukamoto</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl linker. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (20)
                                     , 115698. <a href="https://doi.org/10.1016/j.bmc.2020.115698" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115698%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAllosteric%252Bkidney-type%252Bglutaminase%252B%252528GLS%252529%252Binhibitors%252Bwith%252Ba%252Bmercaptoethyl%252Blinker%26aulast%3DDuvall%26aufirst%3DBridget%26date%3D2020%26volume%3D28%26issue%3D20%26spage%3D115698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of atypical DAT inhibitors (±)-modafinil and recently discovered analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Sites of modifications made to <b>2</b> and <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of compounds possessing other alicyclic amine linkers.<a onclick="showRef(event, 'ref57 ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref57 ref58 ref59 ref60">(57−60)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>8a</b>–<b>g</b> and <b>9a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate oxirane, isopropyl alcohol, reflux, overnight; (b) appropriate halide, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux; (c) CDI, 3-phenylpropanoic acid, THF, RT, overnight; (d) H<sub>2</sub>O<sub>2</sub>, CH<sub>3</sub>COOH/CH<sub>3</sub>OH, 40 °C, overnight.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>11a</b>–<b>d</b> and <b>12a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate piperazine, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux, overnight; (b) H<sub>2</sub>O<sub>2</sub>, CH<sub>3</sub>COOH/CH<sub>3</sub>OH, 40 °C, overnight.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>14a</b>–<b>d</b> and <b>15a</b>–<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>cis</i>-2,6-dimethylpiperazine, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux, overnight; (b) appropriate oxirane, isopropyl alcohol, reflux, overnight; (c) H<sub>2</sub>O<sub>2</sub>, CH<sub>3</sub>COOH/CH<sub>3</sub>OH, RT, 48 h.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Diazaspiro Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux, overnight; (b) TFA, DCM, RT, 5 h; (c) appropriate oxirane, isopropyl alcohol, reflux, 18–48 h; (d) H<sub>2</sub>O<sub>2</sub>, CH<sub>3</sub>COOH/CH<sub>3</sub>OH, RT, 48 h.</p></p></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Metabolic stability in mouse microsomes. Compounds <b>14a</b> and <b>15b</b> showed susceptibility to phase I metabolism in mouse liver microsomes. Compounds <b>15a</b> and <b>18b</b> showed modest stability, with <b>18b</b> being the most stable with 44% remaining after 60 min incubation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/medium/jm9b01188_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of <b>14a</b>–<b>c</b> compared to <b>3b</b> and cocaine on mouse locomotion. Data are expressed as the maximum distance traveled in 30 min during a 2 h observation period, as a function of drug dose. * = <i>p</i> < 0.05 vs vehicle (VEH) treated mice. <i>N</i> = 6 for all groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01188/20200306/images/large/jm9b01188_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01188&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27323" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27323" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 78 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">NIDA</span>. Overdose Death Rates. <a href="https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates" class="extLink">https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates</a> (accessed Apr 10, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIDA.+Overdose+Death+Rates.+https%3A%2F%2Fwww.drugabuse.gov%2Frelated-topics%2Ftrends-statistics%2Foverdose-death-rates+%28accessed+Apr+10%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">DEA</span>. <span class="NLM_year">2017</span> National Drug
Threat Assessment. <a href="https://www.dea.gov/documents/2017/10/01/2017-national-drug-threat-assessment" class="extLink">https://www.dea.gov/documents/2017/10/01/2017-national-drug-threat-assessment</a> (accessed Apr 15, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DEA.+2017+National+Drug%0AThreat+Assessment.+https%3A%2F%2Fwww.dea.gov%2Fdocuments%2F2017%2F10%2F01%2F2017-national-drug-threat-assessment+%28accessed+Apr+15%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoops, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, C. R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the “pipeline″ for development of medications for cocaine use disorder: A review of translational preclinical, human laboratory, and clinical trial research</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1124/pr.115.011668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fpr.115.011668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=27255266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFCktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=533-562&author=P.+W.+Czotyauthor=W.+W.+Stoopsauthor=C.+R.+Rush&title=Evaluation+of+the+%E2%80%9Cpipeline%E2%80%B3+for+development+of+medications+for+cocaine+use+disorder%3A+A+review+of+translational+preclinical%2C+human+laboratory%2C+and+clinical+trial+research&doi=10.1124%2Fpr.115.011668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the "pipeline" for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research</span></div><div class="casAuthors">Czoty, Paul W.; Stoops, William W.; Rush, Craig R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">533-562</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cocaine use disorder is a persistent public health problem for which no widely effective medications exist.  Self-administration procedures,which have shown good predictive validity in estg. the abuse potential of drugs, have been used in rodent, nonhuman primate, and human lab. studies to screen putative medications.  This review assessed the effectiveness of the medications development process regarding pharmacotherapies for cocaine use disorder.  The primary objective was to det. whether data from animal and human lab. self-administration studies predicted the results of clin. trials.  Inaddn., the concordance between lab. studies in animals and humans was assessed.  More than 100 blinded, randomized, fully placebo-controlled studies of putative medications for cocaine use disorder were identified.  Of the 64 drugs tested in these trials, only 10 had been examd. in both human and well-controlled animal lab. studies.  Within all three stages, few studies had been conducted for each drug and when multiple studies had been conducted conclusions were sometimes contradictory.  Overall, however, there was good concordance between animal and human lab. results when the former assessed chronic drug treatment.  Although only seven of the ten reviewed drugs showed fully concordant results across all three types of studies reviewed, the anal. revealed several subject-related, procedural, and environmental factors that differ between the lab. and clin. trial settings that help explain the disagreement for other drugs.  The review closes with several recommendations to enhance translation and communication across stages of the medications development process that will ultimately speed the progress toward effective pharmacotherapeutic strategies for cocaine use disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBBhIuhvG6aLVg90H21EOLACvtfcHk0lg1KHafm3fWiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFCktr8%253D&md5=dad28b6d0c2cb2d9f91e77cf74684021</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1124%2Fpr.115.011668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.115.011668%26sid%3Dliteratum%253Aachs%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DStoops%26aufirst%3DW.%2BW.%26aulast%3DRush%26aufirst%3DC.%2BR.%26atitle%3DEvaluation%2520of%2520the%2520%25E2%2580%259Cpipeline%25E2%2580%25B3%2520for%2520development%2520of%2520medications%2520for%2520cocaine%2520use%2520disorder%253A%2520A%2520review%2520of%2520translational%2520preclinical%252C%2520human%2520laboratory%252C%2520and%2520clinical%2520trial%2520research%26jtitle%3DPharmacol.%2520Rev.%26date%3D2016%26volume%3D68%26spage%3D533%26epage%3D562%26doi%3D10.1124%2Fpr.115.011668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattick, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoli, M.</span></span> <span> </span><span class="NLM_article-title">Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence</span>. <i>Cochrane Db. Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_fpage">CD002209</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD002209.pub2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1002%2F14651858.CD002209.pub2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=19588333" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=CD002209&author=R.+P.+Mattickauthor=C.+Breenauthor=J.+Kimberauthor=M.+Davoli&title=Methadone+maintenance+therapy+versus+no+opioid+replacement+therapy+for+opioid+dependence&doi=10.1002%2F14651858.CD002209.pub2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD002209.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD002209.pub2%26sid%3Dliteratum%253Aachs%26aulast%3DMattick%26aufirst%3DR.%2BP.%26aulast%3DBreen%26aufirst%3DC.%26aulast%3DKimber%26aufirst%3DJ.%26aulast%3DDavoli%26aufirst%3DM.%26atitle%3DMethadone%2520maintenance%2520therapy%2520versus%2520no%2520opioid%2520replacement%2520therapy%2520for%2520opioid%2520dependence%26jtitle%3DCochrane%2520Db.%2520Syst.%2520Rev.%26date%3D2009%26spage%3DCD002209%26doi%3D10.1002%2F14651858.CD002209.pub2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattick, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoli, M.</span></span> <span> </span><span class="NLM_article-title">Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence</span>. <i>Cochrane Db. Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_fpage">CD002207</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD002207.pub4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1002%2F14651858.CD002207.pub4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=24500948" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=CD002207&author=R.+P.+Mattickauthor=C.+Breenauthor=J.+Kimberauthor=M.+Davoli&title=Buprenorphine+maintenance+versus+placebo+or+methadone+maintenance+for+opioid+dependence&doi=10.1002%2F14651858.CD002207.pub4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD002207.pub4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD002207.pub4%26sid%3Dliteratum%253Aachs%26aulast%3DMattick%26aufirst%3DR.%2BP.%26aulast%3DBreen%26aufirst%3DC.%26aulast%3DKimber%26aufirst%3DJ.%26aulast%3DDavoli%26aufirst%3DM.%26atitle%3DBuprenorphine%2520maintenance%2520versus%2520placebo%2520or%2520methadone%2520maintenance%2520for%2520opioid%2520dependence%26jtitle%3DCochrane%2520Db.%2520Syst.%2520Rev.%26date%3D2014%26spage%3DCD002207%26doi%3D10.1002%2F14651858.CD002207.pub4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gryczynski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Grady, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharfstein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, J. H.</span></span> <span> </span><span class="NLM_article-title">Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009</span>. <i>Am. J. Public Health</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.2105/AJPH.2012.301049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.2105%2FAJPH.2012.301049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=23488511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A280%3ADC%252BC3svmtVWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2013&pages=917-922&author=R.+P.+Schwartzauthor=J.+Gryczynskiauthor=K.+E.+O%E2%80%99Gradyauthor=J.+M.+Sharfsteinauthor=G.+Warrenauthor=Y.+Olsenauthor=S.+G.+Mitchellauthor=J.+H.+Jaffe&title=Opioid+agonist+treatments+and+heroin+overdose+deaths+in+Baltimore%2C+Maryland%2C+1995%E2%80%932009&doi=10.2105%2FAJPH.2012.301049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009</span></div><div class="casAuthors">Schwartz Robert P; Gryczynski Jan; O'Grady Kevin E; Sharfstein Joshua M; Warren Gregory; Olsen Yngvild; Mitchell Shannon G; Jaffe Jerome H</div><div class="citationInfo"><span class="NLM_cas:title">American journal of public health</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">917-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  We examined the association between the expansion of methadone and buprenorphine treatment and the prevalence of heroin overdose deaths in Baltimore, Maryland from 1995 to 2009.  METHODS:  We conducted a longitudinal time series analysis of archival data using linear regression with the Newey-West method to correct SEs for heteroscedasticity and autocorrelation, adjusting for average heroin purity.  RESULTS:  Overdose deaths attributed to heroin ranged from a high of 312 in 1999 to a low of 106 in 2008.  While mean heroin purity rose sharply (1995-1999), the increasing number of patients treated with methadone was not associated with a change in the number of overdose deaths, but starting in 2000 expansion of opioid agonist treatment was associated with a decline in overdose deaths.  Adjusting for heroin purity and the number of methadone patients, there was a statistically significant inverse relationship between heroin overdose deaths and patients treated with buprenorphine (P = .002).  CONCLUSIONS:  Increased access to opioid agonist treatment was associated with a reduction in heroin overdose deaths.  Implementing policies that support evidence-based medication treatment of opiate dependence may decrease heroin overdose deaths.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrsDQJcRzzexFwe7cAcrfPfW6udTcc2eZC-s7zeP2MQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svmtVWitQ%253D%253D&md5=8753afe14d97538cee99ec110ea6c1ab</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2105%2FAJPH.2012.301049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2105%252FAJPH.2012.301049%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DR.%2BP.%26aulast%3DGryczynski%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Grady%26aufirst%3DK.%2BE.%26aulast%3DSharfstein%26aufirst%3DJ.%2BM.%26aulast%3DWarren%26aufirst%3DG.%26aulast%3DOlsen%26aufirst%3DY.%26aulast%3DMitchell%26aufirst%3DS.%2BG.%26aulast%3DJaffe%26aufirst%3DJ.%2BH.%26atitle%3DOpioid%2520agonist%2520treatments%2520and%2520heroin%2520overdose%2520deaths%2520in%2520Baltimore%252C%2520Maryland%252C%25201995%25E2%2580%25932009%26jtitle%3DAm.%2520J.%2520Public%2520Health%26date%3D2013%26volume%3D103%26spage%3D917%26epage%3D922%26doi%3D10.2105%2FAJPH.2012.301049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span> <span> </span><span class="NLM_article-title">Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">107609</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2019.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.neuropharm.2019.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=31009632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosFWisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2019&pages=107609&author=C.+J.+Jordanauthor=J.+Caoauthor=A.+H.+Newmanauthor=Z.+X.+Xi&title=Progress+in+agonist+therapy+for+substance+use+disorders%3A+Lessons+learned+from+methadone+and+buprenorphine&doi=10.1016%2Fj.neuropharm.2019.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine</span></div><div class="casAuthors">Jordan, Chloe J.; Cao, Jianjing; Newman, Amy Hauck; Xi, Zheng-Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107609</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Substance use disorders (SUD) are serious public health problems worldwide.  Although significant progress has been made in understanding the neurobiol. of drug reward and the transition to addiction, effective pharmacotherapies for SUD remain limited and a majority of drug users relapse even after a period of treatment.  The United States Food and Drug Administration (FDA) has approved several medications for opioid, nicotine, and alc. use disorders, whereas none are approved for the treatment of cocaine or other psychostimulant use disorders.  The medications approved by the FDA for the treatment of SUD can be divided into two major classes - agonist replacement therapies, such as methadone and buprenorphine for opioid use disorders (OUD), nicotine replacement therapy (NRT) and varenicline for nicotine use disorders (NUD), and antagonist therapies, such as naloxone for opioid overdose and naltrexone for promoting abstinence.  In the present review, we primarily focus on the pharmacol. rationale of agonist replacement strategies in treatment of opioid dependence, and the potential translation of this rationale to new therapies for cocaine use disorders.  We begin by describing the neural mechanisms underlying opioid reward, followed by preclin. and clin. findings supporting the utility of agonist therapies in the treatment of OUD.  We then discuss recent progress of agonist therapies for cocaine use disorders based on lessons learned from methadone and buprenorphine.  We contend that future studies should identify agonist pharmacotherapies that can facilitate abstinence in patients who are motivated to quit their illicit drug use.  Focusing on those that are able to achieve abstinence from cocaine will provide a platform to broaden the effectiveness of medication and psychosocial treatment strategies for this underserved population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFbQUGhmBexbVg90H21EOLACvtfcHk0li0pbRUiV8JUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosFWisb4%253D&md5=87d3c94b52fb376a0ae6beddb14b62ef</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2019.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2019.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DC.%2BJ.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26atitle%3DProgress%2520in%2520agonist%2520therapy%2520for%2520substance%2520use%2520disorders%253A%2520Lessons%2520learned%2520from%2520methadone%2520and%2520buprenorphine%26jtitle%3DNeuropharmacology%26date%3D2019%26volume%3D158%26spage%3D107609%26doi%3D10.1016%2Fj.neuropharm.2019.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balster, R. L.</span>; <span class="NLM_string-name">Kuhar, M. J.</span>; <span class="NLM_string-name">Schuster, C. R.</span></span> <i>Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach</i>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1996</span>; Vol.  <span class="NLM_volume">xxv</span>, p  <span class="NLM_fpage">658</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&pages=658&author=R.+L.+Balster&author=M.+J.+Kuhar&author=C.+R.+Schuster&title=Pharmacological+Aspects+of+Drug+Dependence%3A+Toward+an+Integrated+Neurobehavioral+Approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBalster%26aufirst%3DR.%2BL.%26btitle%3DPharmacological%2520Aspects%2520of%2520Drug%2520Dependence%253A%2520Toward%2520an%2520Integrated%2520Neurobehavioral%2520Approach%26pub%3DSpringer%26date%3D1996%26volume%3Dxxv%26spage%3D658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E. A.</span></span> <span> </span><span class="NLM_article-title">Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wildtype and mutant human dopamine transporters: molecular features that differentially determine antagonist binding properties</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2008.05667.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1111%2Fj.1471-4159.2008.05667.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ejurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=296-296&author=K.+C.+Schmittauthor=J.+Zhenauthor=P.+Kharkarauthor=M.+Mishraauthor=N.+Chenauthor=A.+K.+Duttaauthor=M.+E.+A.+Reith&title=Interaction+of+cocaine-%2C+benztropine-%2C+and+GBR12909-like+compounds+with+wildtype+and+mutant+human+dopamine+transporters%3A+molecular+features+that+differentially+determine+antagonist+binding+properties&doi=10.1111%2Fj.1471-4159.2008.05667.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties. [Erratum to document cited in CA150:113703]</span></div><div class="casAuthors">Schmitt, Kyle C.; Zhen, Juan; Kharkar, Prashant; Mishra, Manoj; Chen, Nianhang; Dutta, Aloke K.; Reith, Maarten E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">296</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tables 1 (page 934) and 2 (page 935), were incorrectly given; the correct version of the tables, are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHQ_6f_PmRirVg90H21EOLACvtfcHk0liX_DMcJo3L1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ejurjF&md5=47d05a0a49ad406302ee50cf19056cbe</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2008.05667.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2008.05667.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DK.%2BC.%26aulast%3DZhen%26aufirst%3DJ.%26aulast%3DKharkar%26aufirst%3DP.%26aulast%3DMishra%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DN.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26aulast%3DReith%26aufirst%3DM.%2BE.%2BA.%26atitle%3DInteraction%2520of%2520cocaine-%252C%2520benztropine-%252C%2520and%2520GBR12909-like%2520compounds%2520with%2520wildtype%2520and%2520mutant%2520human%2520dopamine%2520transporters%253A%2520molecular%2520features%2520that%2520differentially%2520determine%2520antagonist%2520binding%2520properties%26jtitle%3DJ.%2520Neurochem.%26date%3D2010%26volume%3D115%26spage%3D296%26epage%3D296%26doi%3D10.1111%2Fj.1471-4159.2008.05667.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E. A.</span></span> <span> </span><span class="NLM_article-title">Regulation of the dopamine transporter Aspects relevant to psychostimulant drugs of abuse</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1187</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.05148.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1111%2Fj.1749-6632.2009.05148.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=20201860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3cXks1Smsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1187&publication_year=2010&pages=316-340&author=K.+C.+Schmittauthor=M.+E.+A.+Reith&title=Regulation+of+the+dopamine+transporter+Aspects+relevant+to+psychostimulant+drugs+of+abuse&doi=10.1111%2Fj.1749-6632.2009.05148.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse</span></div><div class="casAuthors">Schmitt, Kyle C.; Reith, Maarten E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1187</span>
        (<span class="NLM_cas:issue">Addiction Reviews 2</span>),
    <span class="NLM_cas:pages">316-340</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Dopaminergic signaling in the brain is primarily modulated by dopamine transporters (DATs), which actively translocate extraneuronal dopamine back into dopaminergic neurons.  Transporter proteins are highly dynamic, continuously trafficking between plasmalemmal and endosomal membranes.  Changes in DAT membrane trafficking kinetics can rapidly regulate dopaminergic tone by altering the no. of transporters present at the cell surface.  Various psychostimulant DAT ligands-acting either as amphetamine-like substrates or cocaine-like nontranslocated inhibitors-affect transporter trafficking, triggering rapid insertion or removal of plasmalemmal DATs.  In this review, we focus on the effects of psychostimulants of addiction (particularly D-methamphetamine and cocaine) on DAT regulation and membrane trafficking, with an emphasis on how these drugs may influence intracellular signaling cascades and transporter-assocd. scaffolding proteins to affect DAT regulation.  In addn., we consider involvement of presynaptic receptors for dopamine and other ligands in DAT regulation.  Finally, we discuss possible implications of transporter regulation to the putative toxicity of several substituted amphetamine derivs. commonly used as recreational drugs, as well as to the design of therapeutics for cocaine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKPcrkSAoXX7Vg90H21EOLACvtfcHk0liX_DMcJo3L1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXks1Smsrk%253D&md5=31977cbff667a331923e279d4b1be89f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.05148.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.05148.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DK.%2BC.%26aulast%3DReith%26aufirst%3DM.%2BE.%2BA.%26atitle%3DRegulation%2520of%2520the%2520dopamine%2520transporter%2520Aspects%2520relevant%2520to%2520psychostimulant%2520drugs%2520of%2520abuse%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2010%26volume%3D1187%26spage%3D316%26epage%3D340%26doi%3D10.1111%2Fj.1749-6632.2009.05148.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fleckenstein, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddle, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibb, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. R.</span></span> <span> </span><span class="NLM_article-title">New insights into the mechanism of action of amphetamines</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.47.120505.105140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1146%2Fannurev.pharmtox.47.120505.105140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=17209801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1alurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=681-698&author=A.+E.+Fleckensteinauthor=T.+J.+Volzauthor=E.+L.+Riddleauthor=J.+W.+Gibbauthor=G.+R.+Hanson&title=New+insights+into+the+mechanism+of+action+of+amphetamines&doi=10.1146%2Fannurev.pharmtox.47.120505.105140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the mechanism of action of amphetamines</span></div><div class="casAuthors">Fleckenstein, Annette E.; Volz, Trent J.; Riddle, Evan L.; Gibb, James W.; Hanson, Glen R.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">681-698</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Amphetamine is a psychostimulant commonly used to treat several disorders, including attention deficit, narcolepsy, and obesity.  Plasmalemmal and vesicular monoamine transporters, such as the neuronal dopamine transporter and the vesicular monoamine transporter-2, are two of its principal targets.  This review focuses on new insights, obtained from both in vivo and in vitro studies, into the mol. mechanisms whereby amphetamine, and the closely related compds. methamphetamine and methylenedioxymethamphetamine, cause monoamine, and particularly dopamine, release.  These mechanisms include amphetamine-induced exchange diffusion, reverse transport, and channel-like transport phenomena as well as the weak base properties of amphetamine.  Addnl., amphetamine analogs may affect monoamine transporters through phosphorylation, transporter trafficking, and the prodn. of reactive oxygen and nitrogen species.  All of these mechanisms have potential implications for both amphetamine- and methamphetamine-induced neurotoxicity, as well as dopaminergic neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraPle7JPAeKrVg90H21EOLACvtfcHk0lhXPYvFpX1OBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1alurs%253D&md5=ead84eb20c530d952c181a79122a1971</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.47.120505.105140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.47.120505.105140%26sid%3Dliteratum%253Aachs%26aulast%3DFleckenstein%26aufirst%3DA.%2BE.%26aulast%3DVolz%26aufirst%3DT.%2BJ.%26aulast%3DRiddle%26aufirst%3DE.%2BL.%26aulast%3DGibb%26aufirst%3DJ.%2BW.%26aulast%3DHanson%26aufirst%3DG.%2BR.%26atitle%3DNew%2520insights%2520into%2520the%2520mechanism%2520of%2520action%2520of%2520amphetamines%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2007%26volume%3D47%26spage%3D681%26epage%3D698%26doi%3D10.1146%2Fannurev.pharmtox.47.120505.105140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anagnostaras, S. G.</span></span> <span> </span><span class="NLM_article-title">Psychostimulants and cognition: A continuum of behavioral and cognitive activation</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1124/pr.112.007054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fpr.112.007054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=24344115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGnu73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=193-221&author=S.+Woodauthor=J.+R.+Sageauthor=T.+Shumanauthor=S.+G.+Anagnostaras&title=Psychostimulants+and+cognition%3A+A+continuum+of+behavioral+and+cognitive+activation&doi=10.1124%2Fpr.112.007054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Psychostimulants and cognition: a continuum of behavioral and cognitive activation</span></div><div class="casAuthors">Wood, Suzanne; Sage, Jennifer R.; Shuman, Tristan; Anagnostaras, Stephan G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">193-221, 29 pp.</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Psychostimulants such as cocaine have been used as performance enhancers throughout recorded history.  Although psychostimulants are commonly prescribed to improve attention and cognition, a great deal of literature has described their ability to induce cognitive deficits, as well as addiction.  How can a single drug class be known to produce both cognitive enhancement and impairment.  Properties of the particular stimulant drug itself and individual differences between users have both been suggested to dictate the outcome of stimulant use.  A more parsimonious alternative, which we endorse, is that dose is the crit. detg. factor in cognitive effects of stimulant drugs.  Herein, we review several popular stimulants (cocaine, amphetamine, methylphenidate, modafinil, and caffeine), outlining their history of use, mechanism of action, and use and abuse today.  One common graphic depiction of the cognitive effects of psychostimulants is an inverted U-shaped dose-effect curve.  Moderate arousal is beneficial to cognition, whereas too much activation leads to cognitive impairment.  In parallel to this schematic, we propose a continuum of psychostimulant activation that covers the transition from one drug effect to another as stimulant intake is increased.  Low doses of stimulants effect increased arousal, attention, and cognitive enhancement; moderate doses can lead to feelings of euphoria and power, as well as addiction and cognitive impairment; and very high doses lead to psychosis and circulatory collapse.  This continuum helps account for the seemingly disparate effects of stimulant drugs, with the same drug being assocd. with cognitive enhancement and impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKUCx_-Q7V6rVg90H21EOLACvtfcHk0lhXPYvFpX1OBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGnu73E&md5=ec43a4e0babb213d36455c2a070ba16e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fpr.112.007054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.112.007054%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DS.%26aulast%3DSage%26aufirst%3DJ.%2BR.%26aulast%3DShuman%26aufirst%3DT.%26aulast%3DAnagnostaras%26aufirst%3DS.%2BG.%26atitle%3DPsychostimulants%2520and%2520cognition%253A%2520A%2520continuum%2520of%2520behavioral%2520and%2520cognitive%2520activation%26jtitle%3DPharmacol.%2520Rev.%26date%3D2014%26volume%3D66%26spage%3D193%26epage%3D221%26doi%3D10.1124%2Fpr.112.007054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madras, B.</span>; <span class="NLM_string-name">Kuhar, M. J.</span></span> <i>The Effects of Drug Abuse on the Human Nervous System</i>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">2014</span>; Vol.  <span class="NLM_volume">xiii</span>, p  <span class="NLM_fpage">609</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=609&author=B.+Madras&author=M.+J.+Kuhar&title=The+Effects+of+Drug+Abuse+on+the+Human+Nervous+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMadras%26aufirst%3DB.%26btitle%3DThe%2520Effects%2520of%2520Drug%2520Abuse%2520on%2520the%2520Human%2520Nervous%2520System%26pub%3DElsevier%26date%3D2014%26volume%3Dxiii%26spage%3D609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agoston, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izenwasser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel N-substituted 3 alpha-[bis(4′-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">4329</span>– <span class="NLM_lpage">4339</span>, <span class="refDoi"> DOI: 10.1021/jm970525a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970525a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK1cXjsFGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=4329-4339&author=G.+E.+Agostonauthor=J.+H.+Wuauthor=S.+Izenwasserauthor=C.+Georgeauthor=J.+Katzauthor=R.+H.+Klineauthor=A.+H.+Newman&title=Novel+N-substituted+3+alpha-%5Bbis%284%E2%80%B2-fluorophenyl%29methoxy%5Dtropane+analogues%3A+selective+ligands+for+the+dopamine+transporter&doi=10.1021%2Fjm970525a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Novel N-substituted 3α-[bis(4'-fluorophenyl)methoxy]tropane analogs: selective ligands for the dopamine transporter</span></div><div class="casAuthors">Agoston, Gregory E.; Wu, Jae H.; Izenwasser, Sari; George, Clifford; Katz, Jonathan; Kline, Richard; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4329-4339</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-substituted 3α-[bis(4'-fluorophenyl)methoxy]tropane analogs I [R = CH(C6H4-4-F)2, R1 = Ph(CH2)3, 2-(3-indolyl)ethyl, Ph(CH2)4, 4-NO2-C6H4(CH2)4, 4-F-C6H4(CH2)3, Bu, cyclopropylmethyl, allyl, benzyl, 4-fluorobenzyl, cinnamyl, (CH2)2OCH(C6H4-4-F)2, (CH2)2OCH(Ph)C6H4-4-NO2, acetyl, formyl, tolyl, mesyl, Me(MeI) (N-Me methiodide), H] were prepd. from I [R = CH(C6H4-4-F)2, R1 = H] via acylation followed by hydride redn. of the amide or by direct alkylation to function as dopamine uptake inhibitors.  The N-methylated analog of this series had a significantly higher affinity for the dopamine transporter than the parent compd., N-methyl-3α-(diphenylmethoxy)tropane (benztropine, Cogentin).  Yet like the parent compd., it retained high affinity for muscarinic receptors.  All compds. contg. a basic tropane nitrogen displaced [3H]-WIN 35,428 at the dopamine transporter (Ki range = 8.5-634 nM) and blocked dopamine uptake (IC50 range = 10-371 nM) in rat caudate putamen, whereas ligands with a nonbasic nitrogen were virtually inactive.  None of the compds. demonstrated high binding affinity at norepinephrine or serotonin transporters.  Importantly, a sepn. of binding affinities for the dopamine transporter vs. muscarinic m1 receptors was achieved by substitution of the N-Me group with other N-alkyl or arylalkyl substituents (eg. Bu, allyl, benzyl, 3-phenylpropyl, etc.).  Addnl., the most potent and selective analog in this series at the dopamine transporter, I [R = CH(C6H4-4-F)2, R1 = Ph(CH2)4], failed to substitute for cocaine in rats trained to discriminate cocaine from saline.  Potentially, new leads toward the development of a pharmacotherapeutic for cocaine abuse and other disorders affecting the dopamine transporter may be discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR293Qup6etbVg90H21EOLACvtfcHk0lhXPYvFpX1OBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjsFGhug%253D%253D&md5=374e879e24e3934579993a40f8ff8de3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm970525a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970525a%26sid%3Dliteratum%253Aachs%26aulast%3DAgoston%26aufirst%3DG.%2BE.%26aulast%3DWu%26aufirst%3DJ.%2BH.%26aulast%3DIzenwasser%26aufirst%3DS.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DKatz%26aufirst%3DJ.%26aulast%3DKline%26aufirst%3DR.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520N-substituted%25203%2520alpha-%255Bbis%25284%25E2%2580%25B2-fluorophenyl%2529methoxy%255Dtropane%2520analogues%253A%2520selective%2520ligands%2520for%2520the%2520dopamine%2520transporter%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D4329%26epage%3D4339%26doi%3D10.1021%2Fjm970525a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koffarnus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1889</span>– <span class="NLM_lpage">1893</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4778-04.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1523%2FJNEUROSCI.4778-04.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=15728828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVSnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=1889-1893&author=R.+I.+Desaiauthor=T.+A.+Kopajticauthor=M.+Koffarnusauthor=A.+H.+Newmanauthor=J.+L.+Katz&title=Identification+of+a+dopamine+transporter+ligand+that+blocks+the+stimulant+effects+of+cocaine&doi=10.1523%2FJNEUROSCI.4778-04.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine</span></div><div class="casAuthors">Desai, Rajeev I.; Kopajtic, Theresa A.; Koffarnus, Mikhail; Newman, Amy Hauck; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1889-1893</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">There is a large unmet medical need for cocaine addiction treatments.  Studies have indicated that the dopamine transporter (DAT) is the primary biol. target of cocaine, and most drugs that have DAT affinity have behavioral effects like those of cocaine.  However, analogs of benztropine have high DAT affinity and behavioral effects that show varying degrees of similarity to cocaine.  The authors now report the discovery that a benztropine analog, JHW007, with high affinity for the DAT does not have cocaine-like behavioral effects and antagonizes the effects of cocaine.  JHW007 occupied the DAT in vivo more slowly than did cocaine and had not reached an apparent plateau up to 270 min after injection.  The in vivo binding of cocaine to the DAT suggested rate of DAT occupancy as an important contributor to its behavioral effects, and the slow assocn. with the DAT may provide an explanation for JHW007 being relatively devoid of cocaine-like behavioral effects.  The antagonism of cocaine suggests that DAT ligands with reduced cocaine-like activity can function as cocaine antagonists and suggests JHW007 as a lead for discovery of cocaine-abuse pharmacotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTattX-fVUNLVg90H21EOLACvtfcHk0liNbL7TOtSe9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVSnu7w%253D&md5=b0f46e7fd58fc31fb6d214a86fa874b5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4778-04.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4778-04.2005%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DR.%2BI.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DKoffarnus%26aufirst%3DM.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DIdentification%2520of%2520a%2520dopamine%2520transporter%2520ligand%2520that%2520blocks%2520the%2520stimulant%2520effects%2520of%2520cocaine%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D1889%26epage%3D1893%26doi%3D10.1523%2FJNEUROSCI.4778-04.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandy, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupica, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">106</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.208538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.113.208538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=24194528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=106-115&author=R.+I.+Desaiauthor=D.+K.+Grandyauthor=C.+R.+Lupicaauthor=J.+L.+Katz&title=Pharmacological+characterization+of+a+dopamine+transporter+ligand+that+functions+as+a+cocaine+antagonist&doi=10.1124%2Fjpet.113.208538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist</span></div><div class="casAuthors">Desai, Rajeev I.; Grandy, David K.; Lupica, Carl R.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">106-115, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">An N-Bu analog of benztropine, JHW007 [N-(n-butyl)-3α-[bis(4'-fluorophenyl)methoxy]-tropane], binds to dopamine transporters (DAT) but has reduced cocaine-like behavioral effects and antagonizes various effects of cocaine.  The present study further examd. mechanisms underlying these effects.  Cocaine dose-dependently increased locomotion, whereas JHW007 was minimally effective but increased activity 24 h after injection.  JHW007 (310 mg/kg) dose-dependently and fully antagonized the locomotor-stimulant effects of cocaine (560 mg/kg), whereas N-Me and N-allyl analogs and the dopamine (DA) uptake inhibitor GBR12909 [1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride] stimulated activity and failed to antagonize effects of cocaine.  JHW007 also blocked the locomotor-stimulant effects of the DAT inhibitor GBR12909 but not stimulation produced by the δ-opioid agonist SNC 80 [4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide], which increases activity through nondopaminergic mechanisms.  JHW007 blocked locomotor-stimulant effects of cocaine in both DA D2- and CB1-receptor knockout and wild-type mice, indicating a lack of involvement of these targets.  Furthermore, JHW007 blocked effects of cocaine on stereotyped rearing but enhanced stereotyped sniffing, suggesting that interference with locomotion by enhanced stereotypies is not responsible for the cocaine-antagonist effects of JHW007.  Time-course data indicate that administration of JHW007 antagonized the locomotor-stimulant effects of cocaine within 10 min of injection, whereas occupancy at the DAT, as detd. in vivo, did not reach a max. until 4.5 h after injection.  The σ1-receptor antagonist BD 1008 [N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine dihydrobromide] blocked the locomotor-stimulant effects of cocaine.  Overall, these findings suggest that JHW007 has cocaine-antagonist effects that are deviate from its DAT occupancy and that some other mechanism, possibly σ-receptor antagonist activity, may contribute to the cocaine-antagonist effect of JHW007 and like drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfQ7sAchYs97Vg90H21EOLACvtfcHk0liNbL7TOtSe9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKjtbk%253D&md5=70a97618d207991be1a3fe76f8d2d1d1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.208538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.208538%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DR.%2BI.%26aulast%3DGrandy%26aufirst%3DD.%2BK.%26aulast%3DLupica%26aufirst%3DC.%2BR.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DPharmacological%2520characterization%2520of%2520a%2520dopamine%2520transporter%2520ligand%2520that%2520functions%2520as%2520a%2520cocaine%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D106%26epage%3D115%26doi%3D10.1124%2Fjpet.113.208538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez-Sanchez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferragud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canales, J. J.</span></span> <span> </span><span class="NLM_article-title">The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2010.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.euroneuro.2010.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=20413276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslGns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=501-508&author=C.+Velazquez-Sanchezauthor=A.+Ferragudauthor=J.+Murgaauthor=M.+Cardaauthor=J.+J.+Canales&title=The+high+affinity+dopamine+uptake+inhibitor%2C+JHW+007%2C+blocks+cocaine-induced+reward%2C+locomotor+stimulation+and+sensitization&doi=10.1016%2Fj.euroneuro.2010.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization</span></div><div class="casAuthors">Velazquez-Sanchez, C.; Ferragud, A.; Murga, J.; Carda, M.; Canales, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">501-508</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery and evaluation of high affinity dopamine transport inhibitors with low abuse liability is an important step toward the development of efficacious medications for cocaine addiction.  We examd. in mice the behavioral effects of (N-(n-butyl)-3α-[bis(4'-fluorophenyl)methoxy]-tropane) (JHW 007), a benztropine (BZT) analog that blocks dopamine uptake, and assessed its potential to influence the actions of cocaine in clin.-relevant models of cocaine addiction.  In the conditioned place preference (CPP) paradigm, JHW 007 exposure did not produce place conditioning within an ample dose range but effectively blocked the CPP induced by cocaine administration.  Similarly, in the CPP app. JHW 007 treatment failed to stimulate locomotor activity at any dose but dose-dependently suppressed the hyperactivity evoked by cocaine treatment.  In locomotor sensitization assays performed in the open field, JHW 007 did not produce sensitized locomotor behavior when given alone, but it prevented the sensitized component of the locomotor response elicited by subchronic (8-day) cocaine exposure.  In the elevated plus maze (EPM), acute treatment with JHW 007, cocaine and combinations of the BZT analog and cocaine produced an anxiogenic-like profile.  Re-test in the EPM following subchronic (8-day) exposure enhanced the anxiogenic-like effect of the same drug treatments.  The present findings indicate that JHW 007 exposure counteracts some crit. behavioral correlates of cocaine treatment, including conditioned reward, locomotor stimulation and sensitization, and lend support to the further development of BZT analogs as potential replacement medications in cocaine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoms5tHHckmlbVg90H21EOLACvtfcHk0liNbL7TOtSe9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslGns7c%253D&md5=af7eee8a23e8a299aacb3a34dab539ab</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2010.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2010.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DVelazquez-Sanchez%26aufirst%3DC.%26aulast%3DFerragud%26aufirst%3DA.%26aulast%3DMurga%26aufirst%3DJ.%26aulast%3DCarda%26aufirst%3DM.%26aulast%3DCanales%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520high%2520affinity%2520dopamine%2520uptake%2520inhibitor%252C%2520JHW%2520007%252C%2520blocks%2520cocaine-induced%2520reward%252C%2520locomotor%2520stimulation%2520and%2520sensitization%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D20%26spage%3D501%26epage%3D508%26doi%3D10.1016%2Fj.euroneuro.2010.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Preti, A.</span></span> <span> </span><span class="NLM_article-title">New developments in the pharmacotherapy of cocaine abuse</span>. <i>Addict. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1111/j.1369-1600.2007.00061.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1111%2Fj.1369-1600.2007.00061.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=17508985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVOqur3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=133-151&author=A.+Preti&title=New+developments+in+the+pharmacotherapy+of+cocaine+abuse&doi=10.1111%2Fj.1369-1600.2007.00061.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">New developments in the pharmacotherapy of cocaine abuse</span></div><div class="casAuthors">Preti, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Addiction Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-151</span>CODEN:
                <span class="NLM_cas:coden">ADBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1355-6215</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite huge advances in the neuroscience of substance abuse and dependence in the past 20 years, no approved pharmacol. treatment exists for cocaine abuse.  The available drugs for the treatment of cocaine abuse are poorly effective, hence the need for new compds. to be screened and tested for efficacy: targeting symptoms might improve the effectiveness of the treatment of cocaine abuse and dependence.  On the basis of the known neurochem. of cocaine, some target compds. have been studied: among others.  BP-897, a D3 partial agonist: vanoxerine, a highly selective inhibitor of dopamine uptake: aripiprazole, a partial mixed-action agonist approved for the treatment of schizophrenia.  Recently modafinil, approved for the treatment of narcolepsy, proved effective in favoring cocaine abstinence in cocaine-abusing people.  Some placebo-controlled studies also reported the effectiveness of topiramate, a licensed antiepileptic drug, and of tiagabine, a gamma-aminobutyric acid (GABA) re-uptake inhibitor also approved as an anticonvulsant: both compds. increased cocaine abstinence with no serious adverse events.  Promising results came from two more compds. acting on the GABA circuits, baclofen and valproic acid.  Finally disulfiram, prescribed with active psychosocial therapy, was found to favor higher retention rates and longer abstinence periods from both alc. and cocaine in polydrug-abusing patients.  An alternative approach rests on the use of vaccines, to date in the exptl. stage still.  Psychosocial treatments are a useful companion in the pharmacotherapy of cocaine abuse, with group therapy and contingency management therapies improving motivation and social functioning, particularly in patients abusing alc. as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBg9wU-hybkLVg90H21EOLACvtfcHk0lj0aqd1EZRCRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVOqur3N&md5=93b4725efc304ddaee04534fa1ecfa8c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1369-1600.2007.00061.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1369-1600.2007.00061.x%26sid%3Dliteratum%253Aachs%26aulast%3DPreti%26aufirst%3DA.%26atitle%3DNew%2520developments%2520in%2520the%2520pharmacotherapy%2520of%2520cocaine%2520abuse%26jtitle%3DAddict.%2520Biol.%26date%3D2007%26volume%3D12%26spage%3D133%26epage%3D151%26doi%3D10.1111%2Fj.1369-1600.2007.00061.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanderzee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koger, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gootjes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hespe, W.</span></span> <span> </span><span class="NLM_article-title">Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">370</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1980&pages=363-370&author=P.+Vanderzeeauthor=H.+S.+Kogerauthor=J.+Gootjesauthor=W.+Hespe&title=Aryl+1%2C4-dialk%28en%29ylpiperazines+as+selective+and+very+potent+inhibitors+of+dopamine+uptake"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVanderzee%26aufirst%3DP.%26aulast%3DKoger%26aufirst%3DH.%2BS.%26aulast%3DGootjes%26aufirst%3DJ.%26aulast%3DHespe%26aufirst%3DW.%26atitle%3DAryl%25201%252C4-dialk%2528en%2529ylpiperazines%2520as%2520selective%2520and%2520very%2520potent%2520inhibitors%2520of%2520dopamine%2520uptake%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1980%26volume%3D15%26spage%3D363%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akunne, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurkauf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decosta, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pert, A.</span></span> <span> </span><span class="NLM_article-title">GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1016/0091-3057(91)90570-R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2F0091-3057%2891%2990570-R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1839568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK38XhsFOgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1991&pages=387-397&author=R.+B.+Rothmanauthor=A.+Meleauthor=A.+A.+Reidauthor=H.+C.+Akunneauthor=N.+Greigauthor=A.+Thurkaufauthor=B.+R.+Decostaauthor=K.+C.+Riceauthor=A.+Pert&title=GBR12909+antagonizes+the+ability+of+cocaine+to+elevate+extracellular+levels+of+dopamine&doi=10.1016%2F0091-3057%2891%2990570-R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine</span></div><div class="casAuthors">Rothman, Richard B.; Mele, Andrea; Reid, Audrey A.; Akunne, Hyacinth C.; Greig, Nigel; Thurkauf, Andrew; De Costa, Brian R.; Rice, Kenner C.; Pert, Agu</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">387-97</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    </div><div class="casAbstract">Rats were administered various i.p. doses of the high-affinity dopamine (DA) reuptake inhibitor GBR12909.  The brain caudate nuclei were removed 60 min after drug administration and striatal membranes were prepd.  GBR12909 produced a dose-dependent decrease in the binding of [3H]GBR12935 to the DA transporter (ED50∼ 10 mg/kg).  Satn. binding studies with [3H]GBR12935 showed that this was due to increased residual drug, and decreased Bmax.  At 25 mg/kg i.p., GBR12909 produced a 50% decrease in Bmax and a 3.4-fold increase in Kd.  In microdialysis studies, GBR12909 (25 mg/kg i.p.) produced a modest, long-lasting, and stable elevation of extracellular DA.  Administration of cocaine through the microdialysis probe to rats pretreated with saline or GBR12909 (25 mg/kg i.p.) produced a dose-dependent increase in extracellular DA in both groups.  GBR12909 inhibited the cocaine-induced increases in extracellular DA by ∼ 50% at all doses.  At a dose sufficient to decrease by 50% the Bmax of [3H]GBR12935 binding sites, GBR12909 antagonizes the ability of cocaine to elevate extracellular DA by 50%.  GBR12909 may have a use in the medical treatment of cocaine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdR8WIxCGwGbVg90H21EOLACvtfcHk0lj0aqd1EZRCRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhsFOgtQ%253D%253D&md5=d79867ab017e0a9837f8f074318636e7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2F0091-3057%2891%2990570-R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0091-3057%252891%252990570-R%26sid%3Dliteratum%253Aachs%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DMele%26aufirst%3DA.%26aulast%3DReid%26aufirst%3DA.%2BA.%26aulast%3DAkunne%26aufirst%3DH.%2BC.%26aulast%3DGreig%26aufirst%3DN.%26aulast%3DThurkauf%26aufirst%3DA.%26aulast%3DDecosta%26aufirst%3DB.%2BR.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DPert%26aufirst%3DA.%26atitle%3DGBR12909%2520antagonizes%2520the%2520ability%2520of%2520cocaine%2520to%2520elevate%2520extracellular%2520levels%2520of%2520dopamine%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D1991%26volume%3D40%26spage%3D387%26epage%3D397%26doi%3D10.1016%2F0091-3057%2891%2990570-R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obejero-Paz, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruening-Wright, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawryluk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatalovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittrich, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. M.</span></span> <span> </span><span class="NLM_article-title">Quantitative profiling of the effects of vanoxerine on human cardiac ion channels and its application to cardiac risk</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">17623</span>, <span class="refDoi"> DOI: 10.1038/srep17623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fsrep17623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=26616666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGisrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=17623&author=C.+A.+Obejero-Pazauthor=A.+Bruening-Wrightauthor=J.+Kramerauthor=P.+Hawrylukauthor=M.+Tatalovicauthor=H.+C.+Dittrichauthor=A.+M.+Brown&title=Quantitative+profiling+of+the+effects+of+vanoxerine+on+human+cardiac+ion+channels+and+its+application+to+cardiac+risk&doi=10.1038%2Fsrep17623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk</span></div><div class="casAuthors">Obejero-Paz, Carlos A.; Bruening-Wright, Andrew; Kramer, James; Hawryluk, Peter; Tatalovic, Milos; Dittrich, Howard C.; Brown, Arthur M.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17623</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Vanoxerine has been in clin. trials for Parkinsonism, depression and cocaine addiction but lacked efficacy.  Although a potent blocker of hERG, it produced no serious adverse events.  We attributed the unexpected result to offsetting Multiple Ion Channel Effects (MICE).  Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.  Vanoxerine terminated AF/AFL in an animal model and a dose-ranging clin. trial.  Reversion to normal rhythm was assocd. with QT prolongation yet absent proarrhythmia markers for Torsade de Pointes (TdP).  To understand the QT/TdP discordance, we used quant. profiling and compared vanoxerine with dofetilide, a selective hERG-blocking torsadogen used for intractable AF, verapamil, a non-torsadogenic MICE comparator and bepridil, a torsadogenic MICE comparator.  At clin. relevant concns., verapamil blocked hCav1.2 and hERG, as did vanoxerine and bepridil both of which also blocked hNav1.5.  In acute expts. and simulations, dofetilide produced early after depolarizations (EADs) and arrhythmias, whereas verapamil, vanoxerine and bepridil produced no proarrhythmia markers.  Of the MICE drugs only bepridil inhibited hERG trafficking following overnight exposure.  The results are consistent with the emphasis on MICE of the CiPA assay.  Addnl. we propose that trafficking inhibition of hERG be added to CiPA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4GOHVLsXMurVg90H21EOLACvtfcHk0lj0aqd1EZRCRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGisrfJ&md5=b806a408dfc37d0a428c40c47c7867d3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fsrep17623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep17623%26sid%3Dliteratum%253Aachs%26aulast%3DObejero-Paz%26aufirst%3DC.%2BA.%26aulast%3DBruening-Wright%26aufirst%3DA.%26aulast%3DKramer%26aufirst%3DJ.%26aulast%3DHawryluk%26aufirst%3DP.%26aulast%3DTatalovic%26aufirst%3DM.%26aulast%3DDittrich%26aufirst%3DH.%2BC.%26aulast%3DBrown%26aufirst%3DA.%2BM.%26atitle%3DQuantitative%2520profiling%2520of%2520the%2520effects%2520of%2520vanoxerine%2520on%2520human%2520cardiac%2520ion%2520channels%2520and%2520its%2520application%2520to%2520cardiac%2520risk%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D17623%26doi%3D10.1038%2Fsrep17623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vocci, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkashef, A.</span></span> <span> </span><span class="NLM_article-title">Medication development for addictive disorders: the state of the science</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">1432</span>– <span class="NLM_lpage">1440</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.162.8.1432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1176%2Fappi.ajp.162.8.1432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=16055764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A280%3ADC%252BD2MzpsVOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2005&pages=1432-1440&author=F.+J.+Vocciauthor=J.+Acriauthor=A.+Elkashef&title=Medication+development+for+addictive+disorders%3A+the+state+of+the+science&doi=10.1176%2Fappi.ajp.162.8.1432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Medication development for addictive disorders: the state of the science</span></div><div class="casAuthors">Vocci Frank J; Acri Jane; Elkashef Ahmed</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1432-40</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">In 1989, the National Institute on Drug Abuse (NIDA) established its Medications Development Program.  This program has concentrated on developing pharmacotherapies for opiate and cocaine dependence and, more recently, for methamphetamine and cannabis dependence.  The major goals of this program are to optimize existing treatments and to expand treatment options for physicians and patients.  This review will concentrate on the development of pharmacotherapies for the following substance abuse disorders: opiate, cocaine, methamphetamine, and cannabis dependence.  Left untreated, opiate and stimulant dependence are responsible for significant morbidity and mortality.  For example, use of illicit opiates is associated with an increased risk of hepatitis C infection, HIV infection, and other medical consequences, e.g., an overdose.  The NIDA Medications Development Program has had success in developing, with pharmaceutical partners, levomethadyl acetate, buprenorphine, and buprenorphine/naloxone for opiate dependence.  Moreover, several marketed medications have shown promise in reducing cocaine use.  Of interest, these medications likely operate through diverse neurochemical mechanisms, suggesting that combination therapy may be a rational next step that could increase treatment gains further in cocaine-dependent patients.  The Medications Development Program has also identified multiple neuronal mechanisms that are altered by chronic administration of drugs of abuse.  Advances in neuroscience have identified changes in conditioned cueing, drug priming, stress-induced increases in drug intake, and reduced frontal inhibitory mechanisms as all being possible for the development of, maintenance of, and possible relapse to, addiction.  Potential medications that modulate these mechanisms are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUliEMvgh98dLIORRPd5lbfW6udTcc2eZk_UJXUkpqCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzpsVOjsw%253D%253D&md5=2f5eb76c767d85475af267948c401033</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.162.8.1432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.162.8.1432%26sid%3Dliteratum%253Aachs%26aulast%3DVocci%26aufirst%3DF.%2BJ.%26aulast%3DAcri%26aufirst%3DJ.%26aulast%3DElkashef%26aufirst%3DA.%26atitle%3DMedication%2520development%2520for%2520addictive%2520disorders%253A%2520the%2520state%2520of%2520the%2520science%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2005%26volume%3D162%26spage%3D1432%26epage%3D1440%26doi%3D10.1176%2Fappi.ajp.162.8.1432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2007.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.bcp.2007.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=17897630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCksLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2008&pages=2-16&author=R.+B.+Rothmanauthor=M.+H.+Baumannauthor=T.+E.+Prisinzanoauthor=A.+H.+Newman&title=Dopamine+transport+inhibitors+based+on+GBR12909+and+benztropine+as+potential+medications+to+treat+cocaine+addiction&doi=10.1016%2Fj.bcp.2007.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction</span></div><div class="casAuthors">Rothman, Richard B.; Baumann, Michael H.; Prisinzano, Thomas E.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-16</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The discovery and development of medications to treat addiction and notably, cocaine addiction, have been frustrated by both the complexity of the disorder and the lack of target validation in human subjects.  The dopamine transporter has historically been a primary target for cocaine abuse medication development, but addictive liability and other confounds of such inhibitors of dopamine uptake have limited clin. evaluation and validation.  Herein we describe efforts to develop analogs of the dopamine uptake inhibitors GBR 12909 and benztropine that show promising profiles in animal models of cocaine abuse that contrast to that of cocaine.  Their unique pharmacol. profiles have provided important insights into the reinforcing actions of cocaine and we propose that clin. investigation of novel dopamine uptake inhibitors will facilitate the discovery of cocaine-abuse medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyk01dVAiBsLVg90H21EOLACvtfcHk0lhUCLVdPTYJpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCksLjK&md5=98fbd67bb986dc0557788d219a760a80</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2007.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2007.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DDopamine%2520transport%2520inhibitors%2520based%2520on%2520GBR12909%2520and%2520benztropine%2520as%2520potential%2520medications%2520to%2520treat%2520cocaine%2520addiction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2008%26volume%3D75%26spage%3D2%26epage%3D16%26doi%3D10.1016%2Fj.bcp.2007.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. R.</span></span> <span> </span><span class="NLM_article-title">Modafinil in the treatment of excessive sleepiness</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S2377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.2147%2FDDDT.S2377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFSnsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=71-85&author=J.+R.+Schwartz&title=Modafinil+in+the+treatment+of+excessive+sleepiness&doi=10.2147%2FDDDT.S2377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Modafinil in the treatment of excessive sleepiness</span></div><div class="casAuthors">Schwartz, Jonathan R. L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">71-85</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  The wake-promoting agent modafinil is approved for the treatment of excessive sleepiness assocd. with obstructive sleep apnea (OSA), shift work disorder (SWD), and narcolepsy.  In OSA, modafinil is recommended for use as an adjunct to std. therapies that treat the underlying airway obstruction.  This article reviews the literature on modafinil (pharmacol., pharmacokinetics, efficacy, tolerability, and abuse potential), with emphasis on use of modafinil in the treatment of excessive sleepiness in patients with OSA, SWD, and narcolepsy.  In large-scale, double-blind, placebo-controlled studies, modafinil improved objectively detd. sleep latency, improved overall clin. condition related to severity of sleepiness, and reduced patient-reported sleepiness.  Improvements in wakefulness were accompanied by improvements in behavioral alertness, functional status, and health-related quality of life.  In patients with SWD, diary data showed modafinil reduced the max. level of sleepiness during night shift work, level of sleepiness during the commute home, and incidence of accidents or near-accidents during the commute home when compared with placebo.  Modafinil was well tolerated, without adversely affecting cardiovascular parameters or scheduled sleep.  These findings and those of extension studies which reported improvements were maintained suggest modafinil has a beneficial effect on daily life and well-being in patients with excessive sleepiness assocd. with OSA, SWD, or narcolepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5cn8TrnR09bVg90H21EOLACvtfcHk0lhUCLVdPTYJpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFSnsrjL&md5=c9d13fef0083d172b1cf69dbc7d298a5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S2377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S2377%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DJ.%2BR.%26atitle%3DModafinil%2520in%2520the%2520treatment%2520of%2520excessive%2520sleepiness%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2008%26volume%3D2%26spage%3D71%26epage%3D85%26doi%3D10.2147%2FDDDT.S2377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mereu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span> <span> </span><span class="NLM_article-title">The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>229</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1007/s00213-013-3232-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1007%2Fs00213-013-3232-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=23934211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CrsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=2013&pages=415-434&author=M.+Mereuauthor=A.+Bonciauthor=A.+H.+Newmanauthor=G.+Tanda&title=The+neurobiology+of+modafinil+as+an+enhancer+of+cognitive+performance+and+a+potential+treatment+for+substance+use+disorders&doi=10.1007%2Fs00213-013-3232-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders</span></div><div class="casAuthors">Mereu, Maddalena; Bonci, Antonello; Newman, Amy Hauck; Tanda, Gianluigi</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">415-434</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Rationale and objectives: Modafinil (MOD) and its R-enantiomer (R-MOD) are approved medications for narcolepsy and other sleep disorders.  They have also been used, off-label, as cognitive enhancers in populations of patients with mental disorders, including substance abusers that demonstrate impaired cognitive function.  A debated nonmedical use of MOD in healthy individuals to improve intellectual performance is raising questions about its potential abuse liability in this population.  Results and conclusions: MOD has low micromolar affinity for the dopamine transporter (DAT).  Inhibition of dopamine (DA) reuptake via the DAT explains the enhancement of DA levels in several brain areas, an effect shared with psychostimulants like cocaine, methylphenidate, and the amphetamines.  However, its neurochem. effects and anatomical pattern of brain area activation differ from typical psychostimulants and are consistent with its beneficial effects on cognitive performance processes such as attention, learning, and memory.  At variance with typical psychostimulants, MOD shows very low, if any, abuse liability, in spite of its use as a cognitive enhancer by otherwise healthy individuals.  Finally, recent clin. studies have focused on the potential use of MOD as a medication for treatment of drug abuse, but have not shown consistent outcomes.  However, pos. trends in several result measures suggest that medications that improve cognitive function, like MOD or R-MOD, may be beneficial for the treatment of substance use disorders in certain patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk7rhhVPs1w7Vg90H21EOLACvtfcHk0ljgxanAjN-2SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CrsLvN&md5=65a22f87cf0588b5050f1a8993392990</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00213-013-3232-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-013-3232-4%26sid%3Dliteratum%253Aachs%26aulast%3DMereu%26aufirst%3DM.%26aulast%3DBonci%26aufirst%3DA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DTanda%26aufirst%3DG.%26atitle%3DThe%2520neurobiology%2520of%2520modafinil%2520as%2520an%2520enhancer%2520of%2520cognitive%2520performance%2520and%2520a%2520potential%2520treatment%2520for%2520substance%2520use%2520disorders%26jtitle%3DPsychopharmacology%26date%3D2013%26volume%3D229%26spage%3D415%26epage%3D434%26doi%3D10.1007%2Fs00213-013-3232-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blough, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partilla, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.drugalcdep.2014.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.drugalcdep.2014.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=25548026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Oqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2015&pages=1-19&author=M.+E.+Reithauthor=B.+E.+Bloughauthor=W.+C.+Hongauthor=K.+T.+Jonesauthor=K.+C.+Schmittauthor=M.+H.+Baumannauthor=J.+S.+Partillaauthor=R.+B.+Rothmanauthor=J.+L.+Katz&title=Behavioral%2C+biological%2C+and+chemical+perspectives+on+atypical+agents+targeting+the+dopamine+transporter&doi=10.1016%2Fj.drugalcdep.2014.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter</span></div><div class="casAuthors">Reith, Maarten E. A.; Blough, Bruce E.; Hong, Weimin C.; Jones, Kymry T.; Schmitt, Kyle C.; Baumann, Michael H.; Partilla, John S.; Rothman, Richard B.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug and Alcohol Dependence</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-19</span>CODEN:
                <span class="NLM_cas:coden">DADEDV</span>;
        ISSN:<span class="NLM_cas:issn">0376-8716</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Treatment of stimulant-use disorders remains a formidable challenge, and the dopamine transporter (DAT) remains a potential target for antagonist or agonist-like substitution therapies, so this review focuses on DAT ligands, such as benztropine, GBR 12909, modafinil, and DAT substrates derived from phenethylamine or cathinone that have atypical DAT-inhibitor effects, either in vitro or in vivo.  The compds. are described from a mol. mechanistic, behavioral, and medicinal-chem. perspective.Possible mechanisms for atypicality at the mol. level can be deduced from the conformational cycle for substrate translocation.  For each conformation, a crystal structure of a bacterial homolog is available, with a possible role of cholesterol, which is also present in the crystal of Drosophila DAT.  Although there is a direct relationship between behavioral potencies of most DAT inhibitors and their DAT affinities, a no. of compds. bind to the DAT and inhibit dopamine uptake but do not share cocaine-like effects.  Such atypical behavior, depending on the compd., may be related to slow DAT assocn., combined sigma-receptor actions, or bias for cytosol-facing DAT.  Some structures are sterically small enough to serve as DAT substrates but large enough to also inhibit transport.  Such compds. may display partial DA releasing effects, and may be combined with release or uptake inhibition at other monoamine transporters.  Mechanisms of atypical DAT inhibitors may serve as targets for the development of treatments for stimulant abuse.  These mechanisms are novel and their further exploration may produce compds. with unique therapeutic potential as treatments for stimulant abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGsfVrk5h43rVg90H21EOLACvtfcHk0ljgxanAjN-2SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Oqs74%253D&md5=d6f46c4fd505810f64eafc748702d299</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2014.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2014.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DBlough%26aufirst%3DB.%2BE.%26aulast%3DHong%26aufirst%3DW.%2BC.%26aulast%3DJones%26aufirst%3DK.%2BT.%26aulast%3DSchmitt%26aufirst%3DK.%2BC.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DPartilla%26aufirst%3DJ.%2BS.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DBehavioral%252C%2520biological%252C%2520and%2520chemical%2520perspectives%2520on%2520atypical%2520agents%2520targeting%2520the%2520dopamine%2520transporter%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2015%26volume%3D147%26spage%3D1%26epage%3D19%26doi%3D10.1016%2Fj.drugalcdep.2014.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mereu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okunola, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">R-Modafinil (Armodafinil): A unique dopamine uptake inhibitor and potential medication for psychostimulant abuse</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2012.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.biopsych.2012.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=22537794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFelt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=405-413&author=C.+J.+Lolandauthor=M.+Mereuauthor=O.+M.+Okunolaauthor=J.+Caoauthor=T.+E.+Prisinzanoauthor=S.+Mazierauthor=T.+Kopajticauthor=L.+Shiauthor=J.+L.+Katzauthor=G.+Tandaauthor=A.+H.+Newman&title=R-Modafinil+%28Armodafinil%29%3A+A+unique+dopamine+uptake+inhibitor+and+potential+medication+for+psychostimulant+abuse&doi=10.1016%2Fj.biopsych.2012.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">R-Modafinil (Armodafinil): A Unique Dopamine Uptake Inhibitor and Potential Medication for Psychostimulant Abuse</span></div><div class="casAuthors">Loland, Claus J.; Mereu, Maddalena; Okunola, Oluyomi M.; Cao, Jianjing; Prisinzano, Thomas E.; Mazier, Sonia; Kopajtic, Theresa; Shi, Lei; Katz, Jonathan L.; Tanda, Gianluigi; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">405-413</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">(±)-Modafinil has piqued interest as a treatment for attention-deficit/hyperactivity disorder and stimulant dependence.  The R-enantiomer of modafinil might have unique pharmacol. properties that should be further investigated.  (±)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [3H] dopamine (DA) uptake and [3H]WIN 35428 binding in human dopamine transporter (DAT) wild-type and mutants with altered conformational equil.  Data were compared with cocaine and the atypical DA uptake inhibitor, JHW 007.  R- and S-modafinil were also evaluated in microdialysis studies in the mouse nucleus accumbens shell and in a cocaine discrimination procedure.  (±)-, R-, and S-modafinil bind to the DAT and inhibit DA uptake less potently than cocaine, with R-modafinil having approx. threefold higher affinity than its S-enantiomer.  Mol. docking studies revealed subtle differences in binding modes for the enantiomers.  R-modafinil was significantly less potent in the DAT Y156F mutant compared with wild-type DAT, whereas S-modafinil was affected less.  Studies with the Y335A DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than cocaine, which was further supported by [2-(trimethylammonium)ethyl]-methanethiosulfonate reactivity on the DAT E2C I159C.  Microdialysis studies demonstrated that both R- and S-modafinil produced increases in extracellular DA concns. in the nucleus accumbens shell less efficaciously than cocaine and with a longer duration of action.  Both enantiomers fully substituted in mice trained to discriminate cocaine from saline.R-modafinil displays an in vitro profile different from cocaine.  Future trials with R-modafinil as a substitute therapy with the potential benefit of cognitive enhancement for psychostimulant addiction are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjL4KiRs4PUbVg90H21EOLACvtfcHk0ljgxanAjN-2SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFelt74%253D&md5=78808210fc68d2fbcdd97190f03b63d0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2012.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2012.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DMereu%26aufirst%3DM.%26aulast%3DOkunola%26aufirst%3DO.%2BM.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DMazier%26aufirst%3DS.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DR-Modafinil%2520%2528Armodafinil%2529%253A%2520A%2520unique%2520dopamine%2520uptake%2520inhibitor%2520and%2520potential%2520medication%2520for%2520psychostimulant%2520abuse%26jtitle%3DBiol.%2520Psychiatry%26date%3D2012%26volume%3D72%26spage%3D405%26epage%3D413%26doi%3D10.1016%2Fj.biopsych.2012.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dackis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plebani, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettinati, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparkman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C. P.</span></span> <span> </span><span class="NLM_article-title">A double-blind, placebo-controlled trial of modafinil for cocaine dependence</span>. <i>J. Subst. Abuse. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1016/j.jsat.2011.12.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.jsat.2011.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=22377391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A280%3ADC%252BC38vkvVWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2012&pages=303-312&author=C.+A.+Dackisauthor=K.+M.+Kampmanauthor=K.+G.+Lynchauthor=J.+G.+Plebaniauthor=H.+M.+Pettinatiauthor=T.+Sparkmanauthor=C.+P.+O%E2%80%99Brien&title=A+double-blind%2C+placebo-controlled+trial+of+modafinil+for+cocaine+dependence&doi=10.1016%2Fj.jsat.2011.12.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A double-blind, placebo-controlled trial of modafinil for cocaine dependence</span></div><div class="casAuthors">Dackis Charles A; Kampman Kyle M; Lynch Kevin G; Plebani Jennifer G; Pettinati Helen M; Sparkman Thorne; O'Brien Charles P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of substance abuse treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">303-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This is a randomized, double-blind, placebo-controlled study of modafinil treatment for cocaine dependence.  Patients (N = 210) who were actively using cocaine at baseline were randomized to 8 weeks of modafinil (0 mg/day, 200 mg/day, or 400 mg/day) combined with once-weekly cognitive-behavioral therapy.  Our primary efficacy measure was cocaine abstinence, based on urine benzoylecgonine (BE) levels, with secondary measures of craving, cocaine withdrawal, retention, and tolerability.  We found no significant differences between modafinil and placebo patients on any of these measures.  However, there was a significant gender difference in that male patients treated with 400 mg/day tended to be more abstinent than their placebo-treated counterparts (p = .06).  Our negative findings might be explained by gender differences and/or inadequate psychosocial treatment intensity in patients with severe cocaine dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfEuZhv9G9y9NTrvPZP1IpfW6udTcc2eYTyOPNIcNjMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vkvVWmsw%253D%253D&md5=6f55dc91ebef9f89055a2352f241827f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.jsat.2011.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsat.2011.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DDackis%26aufirst%3DC.%2BA.%26aulast%3DKampman%26aufirst%3DK.%2BM.%26aulast%3DLynch%26aufirst%3DK.%2BG.%26aulast%3DPlebani%26aufirst%3DJ.%2BG.%26aulast%3DPettinati%26aufirst%3DH.%2BM.%26aulast%3DSparkman%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%2BP.%26atitle%3DA%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520modafinil%2520for%2520cocaine%2520dependence%26jtitle%3DJ.%2520Subst.%2520Abuse.%2520Treat.%26date%3D2012%26volume%3D43%26spage%3D303%26epage%3D312%26doi%3D10.1016%2Fj.jsat.2011.12.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shemanski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciraulo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dackis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roache, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloum, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urschel, H. C.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkashef, A. M.</span></span> <span> </span><span class="NLM_article-title">Modafinil for the treatment of cocaine dependence</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.drugalcdep.2009.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.drugalcdep.2009.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=19560290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosleiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2009&pages=133-9&author=A.+L.+Andersonauthor=M.+S.+Reidauthor=S.+H.+Liauthor=T.+Holmesauthor=L.+Shemanskiauthor=A.+Sleeauthor=E.+V.+Smithauthor=R.+Kahnauthor=N.+Chiangauthor=F.+Vocciauthor=D.+Cirauloauthor=C.+Dackisauthor=J.+D.+Roacheauthor=I.+M.+Salloumauthor=E.+Somozaauthor=H.+C.+Urschelauthor=A.+M.+Elkashef&title=Modafinil+for+the+treatment+of+cocaine+dependence&doi=10.1016%2Fj.drugalcdep.2009.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Modafinil for the treatment of cocaine dependence</span></div><div class="casAuthors">Anderson, Ann L.; Reid, Malcolm S.; Li, Shou-Hua; Holmes, Tyson; Shemanski, Lynn; Slee, April; Smith, Edwina V.; Kahn, Roberta; Chiang, Nora; Vocci, Frank; Ciraulo, Domenic; Dackis, Charles; Roache, John D.; Salloum, Ihsan M.; Somoza, Eugene; Urschel, Harold C., III; Elkashef, Ahmed M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug and Alcohol Dependence</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">133-139</span>CODEN:
                <span class="NLM_cas:coden">DADEDV</span>;
        ISSN:<span class="NLM_cas:issn">0376-8716</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Modafinil was tested for efficacy in facilitating abstinence in cocaine-dependent patients, compared to placebo.  This was a double-blind placebo-controlled study, with 12 wk of treatment and a 4-wk follow-up.  Six outpatient substance abuse treatment clinics participated in the study.  There were 210 treatment-seekers randomized, having a diagnosis of cocaine dependence; 72 participants were randomized to placebo, 69 to modafinil 200 mg, and 69 to modafinil 400 mg, taken once daily on awakening.  Participants came to the clinic three times per wk for assessments and urine drug screens, and had one hour of individual psychotherapy weekly.  The primary outcome measure was the weekly percentage of cocaine non-use days.  The GEE regression anal. showed that for the total sample, there was no significant difference between either modafinil group and placebo in the change in av. weekly percent of cocaine non-use days over the 12-wk treatment period (p > 0.79).  However, two secondary outcomes showed significant effects by modafinil 200 mg: the max. no. of consecutive non-use days for cocaine (p = 0.02), and a redn. in craving (p = 0.04).  Also, a post hoc anal. showed a significant effect of modafinil that increased the weekly percentage of non-use days in the subgroup of those cocaine patients who did not have a history of alc. dependence (p < 0.02).  These data suggest that modafinil, in combination with individual behavioral therapy, was effective for increasing cocaine non-use days in participants without co-morbid alc. dependence, and in reducing cocaine craving.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9pQ-oRIN93bVg90H21EOLACvtfcHk0lgYmU8WnbIu6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosleiu7g%253D&md5=ff0d575a8b8e77162121c855de376554</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2009.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2009.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DA.%2BL.%26aulast%3DReid%26aufirst%3DM.%2BS.%26aulast%3DLi%26aufirst%3DS.%2BH.%26aulast%3DHolmes%26aufirst%3DT.%26aulast%3DShemanski%26aufirst%3DL.%26aulast%3DSlee%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DE.%2BV.%26aulast%3DKahn%26aufirst%3DR.%26aulast%3DChiang%26aufirst%3DN.%26aulast%3DVocci%26aufirst%3DF.%26aulast%3DCiraulo%26aufirst%3DD.%26aulast%3DDackis%26aufirst%3DC.%26aulast%3DRoache%26aufirst%3DJ.%2BD.%26aulast%3DSalloum%26aufirst%3DI.%2BM.%26aulast%3DSomoza%26aufirst%3DE.%26aulast%3DUrschel%26aufirst%3DH.%2BC.%26aulast%3DElkashef%26aufirst%3DA.%2BM.%26atitle%3DModafinil%2520for%2520the%2520treatment%2520of%2520cocaine%2520dependence%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2009%26volume%3D104%26spage%3D133%26epage%3D9%26doi%3D10.1016%2Fj.drugalcdep.2009.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okunola, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shook, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships at the monoamine transporters for a novel series of modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) analogues</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1021/ml1002025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1002025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12lt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=48-52&author=J.+Caoauthor=T.+E.+Prisinzanoauthor=O.+M.+Okunolaauthor=T.+Kopajticauthor=M.+Shookauthor=J.+L.+Katzauthor=A.+H.+Newman&title=Structure-activity+relationships+at+the+monoamine+transporters+for+a+novel+series+of+modafinil+%282-%5B%28diphenylmethyl%29sulfinyl%5Dacetamide%29+analogues&doi=10.1021%2Fml1002025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">SARs at the Monoamine Transporters for a Novel Series of Modafinil Analogues</span></div><div class="casAuthors">Cao, Jianjing; Prisinzano, Thomas E.; Okunola, Oluyomi M.; Kopajtic, Theresa; Shook, Matthew; Katz, Jonathan L.; Hauck Newman, Amy</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-52</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of modafinil (1) analogs were synthesized wherein (1) para-halo-substitutents were added to the aryl rings, (2) the sulfoxide function was removed, and (3) the primary amide group was replaced with secondary and tertiary amides and amines to investigate the effects of these chem. modifications on dopamine transporter, serotonin transporter, and norepinephrine transporter binding.  In addn., the locomotor-stimulant effects in mice of (±)-modafinil (1) (I), its R- and S-enantiomers, and its para-chloro sulfinylacetamide analog (5c) (II) were compared to those of cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDr9ac-J7nqbVg90H21EOLACvtfcHk0lgYmU8WnbIu6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12lt7bN&md5=660e546e8524b2e5e8b448ee5bf0e567</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fml1002025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1002025%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DOkunola%26aufirst%3DO.%2BM.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DShook%26aufirst%3DM.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DStructure-activity%2520relationships%2520at%2520the%2520monoamine%2520transporters%2520for%2520a%2520novel%2520series%2520of%2520modafinil%2520%25282-%255B%2528diphenylmethyl%2529sulfinyl%255Dacetamide%2529%2520analogues%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D48%26epage%3D52%26doi%3D10.1021%2Fml1002025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okunola-Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Elucidation of Structural Elements for Selectivity across Monoamine Transporters: Novel 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1000</span>– <span class="NLM_lpage">1013</span>, <span class="refDoi"> DOI: 10.1021/jm401754x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401754x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslyhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1000-1013&author=O.+M.+Okunola-Bakareauthor=J.+Caoauthor=T.+Kopajticauthor=J.+L.+Katzauthor=C.+J.+Lolandauthor=L.+Shiauthor=A.+H.+Newman&title=Elucidation+of+Structural+Elements+for+Selectivity+across+Monoamine+Transporters%3A+Novel+2-%5B%28Diphenylmethyl%29sulfinyl%5Dacetamide+%28Modafinil%29+Analogues&doi=10.1021%2Fjm401754x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Elucidation of Structural Elements for Selectivity across Monoamine Transporters: Novel 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues</span></div><div class="casAuthors">Okunola-Bakare, Oluyomi M.; Cao, Jianjing; Kopajtic, Theresa; Katz, Jonathan L.; Loland, Claus J.; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1000-1013</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-[(Diphenylmethyl)sulfinyl]acetamide (modafinil, (±)-1) is a unique dopamine uptake inhibitor that binds the dopamine transporter (DAT) differently than cocaine and may have potential for the treatment of psychostimulant abuse.  To further investigate structural requirements for this divergent binding mode, novel thio- and sulfinylacetamide and ethanamine analogs of (±)-1 were synthesized wherein (1) the di-Ph rings were substituted with Me, trifluoromethyl, and halogen substituents and (2) substituents were added to the terminal amide/amine nitrogen.  Halogen substitution of the di-Ph rings of (±)-1 gave several amide analogs with improved binding affinity for DAT and robust selectivity over the serotonin transporter (SERT), whereas affinity improved at SERT over DAT for the p-halo-substituted amine analogs.  Mol. docking studies, using a subset of analogs with DAT and SERT homol. models, and functional data obtained with DAT (A480T) and SERT (T497A) mutants defined a role for TM10 in the substrate/inhibitor S1 binding sites of DAT and SERT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjxRhiOBM-ErVg90H21EOLACvtfcHk0liT2QnFIYcMNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslyhtrY%253D&md5=8c9679d83c0101e335bd59867b0c2863</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm401754x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401754x%26sid%3Dliteratum%253Aachs%26aulast%3DOkunola-Bakare%26aufirst%3DO.%2BM.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DElucidation%2520of%2520Structural%2520Elements%2520for%2520Selectivity%2520across%2520Monoamine%2520Transporters%253A%2520Novel%25202-%255B%2528Diphenylmethyl%2529sulfinyl%255Dacetamide%2520%2528Modafinil%2529%2520Analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1000%26epage%3D1013%26doi%3D10.1021%2Fjm401754x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel and high affinity 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues as atypical dopamine transporter inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10676</span>– <span class="NLM_lpage">10691</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFelu7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10676-10691&author=J.+Caoauthor=R.+D.+Slackauthor=O.+M.+Bakareauthor=C.+Burzynskiauthor=R.+Raisauthor=B.+S.+Slusherauthor=T.+Kopajticauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=H.+Yanoauthor=Y.+Heauthor=G.+H.+Biauthor=Z.+X.+Xiauthor=C.+J.+Lolandauthor=A.+H.+Newman&title=Novel+and+high+affinity+2-%5B%28diphenylmethyl%29sulfinyl%5Dacetamide+%28modafinil%29+analogues+as+atypical+dopamine+transporter+inhibitors&doi=10.1021%2Facs.jmedchem.6b01373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors</span></div><div class="casAuthors">Cao, Jianjing; Slack, Rachel D.; Bakare, Oluyomi M.; Burzynski, Caitlin; Rais, Rana; Slusher, Barbara S.; Kopajtic, Theresa; Bonifazi, Alessandro; Ellenberger, Michael P.; Yano, Hideaki; He, Yi; Bi, Guo-Hua; Xi, Zheng-Xiong; Loland, Claus J.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10676-10691</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of pharmacotherapeutic treatments of psychostimulant abuse has remained a challenge, despite significant efforts made toward relevant mechanistic targets, such as the dopamine transporter (DAT).  The atypical DAT inhibitors have received attention due to their promising pharmacol. profiles in animal models of cocaine and methamphetamine abuse.  Herein the authors report a series of modafinil analogs that have an atypical DAT inhibitor profile.  The authors extended SAR by chem. manipulating the oxidn. states of the sulfoxide and the amide functional groups, halogenating the Ph rings, and/or functionalizing the terminal nitrogen with substituted piperazines, resulting in several novel leads such as 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)-3-phenylpropan-2-ol (compd. 11b), which demonstrated high DAT affinity (Ki = 2.5 nM) and selectivity without producing concomitant locomotor stimulation in mice, as compared to cocaine.  These results are consistent with an atypical DAT inhibitor profile and suggest that 11b may be a potential lead for development as a psychostimulant abuse medication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL0BwESHNuRbVg90H21EOLACvtfcHk0liT2QnFIYcMNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFelu7bP&md5=e912f256c764249ad606d83ac9c570fb</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01373%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DSlack%26aufirst%3DR.%2BD.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBi%26aufirst%3DG.%2BH.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520and%2520high%2520affinity%25202-%255B%2528diphenylmethyl%2529sulfinyl%255Dacetamide%2520%2528modafinil%2529%2520analogues%2520as%2520atypical%2520dopamine%2520transporter%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10676%26epage%3D10691%26doi%3D10.1021%2Facs.jmedchem.6b01373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalaba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragacevic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miklosi, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wackerlig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beryozkina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radoman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saroja, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakulev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leban, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitte, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubec, G.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic analogues of modafinil as novel, atypical dopamine transporter inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9330</span>– <span class="NLM_lpage">9348</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01313</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01313" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGnu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9330-9348&author=P.+Kalabaauthor=N.+Y.+Aherauthor=M.+Ilicauthor=V.+Dragacevicauthor=M.+Wiederauthor=A.+G.+Miklosiauthor=M.+Zehlauthor=J.+Wackerligauthor=A.+Rollerauthor=T.+Beryozkinaauthor=B.+Radomanauthor=S.+R.+Sarojaauthor=W.+Lindnerauthor=E.+P.+Gonzalezauthor=V.+Bakulevauthor=J.+J.+Lebanauthor=H.+H.+Sitteauthor=E.+Urbanauthor=T.+Langerauthor=G.+Lubec&title=Heterocyclic+analogues+of+modafinil+as+novel%2C+atypical+dopamine+transporter+inhibitors&doi=10.1021%2Facs.jmedchem.7b01313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Heterocyclic Analogues of Modafinil as Novel, Atypical Dopamine Transporter Inhibitors</span></div><div class="casAuthors">Kalaba, Predrag; Aher, Nilima Y.; Ilic, Marija; Dragacevic, Vladimir; Wieder, Marcus; Miklosi, Andras G.; Zehl, Martin; Wackerlig, Judith; Roller, Alexander; Beryozkina, Tetyana; Radoman, Bojana; Saroja, Sivaprakasam R.; Lindner, Wolfgang; Gonzalez, Eduardo Perez; Bakulev, Vasiliy; Leban, Johann Jakob; Sitte, Harald H.; Urban, Ernst; Langer, Thierry; Lubec, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9330-9348</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modafinil is a wake promoting compd. with high potential for cognitive enhancement.  It is targeting the dopamine transporter (DAT) with moderate selectivity, thereby leading to reuptake inhibition and increased dopamine levels in the synaptic cleft.  A series of modafinil analogs have been reported so far, but more target-specific analogs remain to be discovered.  It was the aim of this study to synthesize and characterize such analogs and, indeed, a series of compds. were showing higher activities on the DAT and a higher selectivity toward DAT vs. serotonin and norepinephrine transporters than modafinil.  This was achieved by substituting the amide moiety by five- and six-membered arom. heterocycles.  In vitro studies indicated binding to the cocaine pocket on DAT, although mol. dynamics revealed binding different from that of cocaine.  Moreover, no release of dopamine was obsd., ruling out amphetamine-like effects.  The absence of neurotoxicity of a representative analog may encourage further preclin. studies of the above-mentioned compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxI4zZzeCZg7Vg90H21EOLACvtfcHk0liT2QnFIYcMNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGnu7fP&md5=f391cc57a70ae320ae11961b00575633</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01313%26sid%3Dliteratum%253Aachs%26aulast%3DKalaba%26aufirst%3DP.%26aulast%3DAher%26aufirst%3DN.%2BY.%26aulast%3DIlic%26aufirst%3DM.%26aulast%3DDragacevic%26aufirst%3DV.%26aulast%3DWieder%26aufirst%3DM.%26aulast%3DMiklosi%26aufirst%3DA.%2BG.%26aulast%3DZehl%26aufirst%3DM.%26aulast%3DWackerlig%26aufirst%3DJ.%26aulast%3DRoller%26aufirst%3DA.%26aulast%3DBeryozkina%26aufirst%3DT.%26aulast%3DRadoman%26aufirst%3DB.%26aulast%3DSaroja%26aufirst%3DS.%2BR.%26aulast%3DLindner%26aufirst%3DW.%26aulast%3DGonzalez%26aufirst%3DE.%2BP.%26aulast%3DBakulev%26aufirst%3DV.%26aulast%3DLeban%26aufirst%3DJ.%2BJ.%26aulast%3DSitte%26aufirst%3DH.%2BH.%26aulast%3DUrban%26aufirst%3DE.%26aulast%3DLanger%26aufirst%3DT.%26aulast%3DLubec%26aufirst%3DG.%26atitle%3DHeterocyclic%2520analogues%2520of%2520modafinil%2520as%2520novel%252C%2520atypical%2520dopamine%2520transporter%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9330%26epage%3D9348%26doi%3D10.1021%2Facs.jmedchem.7b01313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kristofova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radoman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragacevic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leban, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhau, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitte, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubec, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aradska, J.</span></span> <span> </span><span class="NLM_article-title">A daily single dose of a novel modafinil analogue CE-123 improves memory acquisition and memory retrieval</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2018.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.bbr.2018.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=29410048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Ogsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2018&pages=83-94&author=M.+Kristofovaauthor=Y.+D.+Aherauthor=M.+Ilicauthor=B.+Radomanauthor=P.+Kalabaauthor=V.+Dragacevicauthor=N.+Y.+Aherauthor=J.+Lebanauthor=V.+Korzauthor=L.+Zanonauthor=W.+Neuhauauthor=M.+Wiederauthor=T.+Langerauthor=E.+Urbanauthor=H.+H.+Sitteauthor=H.+Hoegerauthor=G.+Lubecauthor=J.+Aradska&title=A+daily+single+dose+of+a+novel+modafinil+analogue+CE-123+improves+memory+acquisition+and+memory+retrieval&doi=10.1016%2Fj.bbr.2018.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A daily single dose of a novel modafinil analogue CE-123 improves memory acquisition and memory retrieval</span></div><div class="casAuthors">Kristofova, Martina; Aher, Yogesh D.; Ilic, Marija; Radoman, Bojana; Kalaba, Predrag; Dragacevic, Vladimir; Aher, Nilima Y.; Leban, Johann; Korz, Volker; Zanon, Lisa; Neuhaus, Winfried; Wieder, Marcus; Langer, Thierry; Urban, Ernst; Sitte, Harald H.; Hoeger, Harald; Lubec, Gert; Aradska, Jana</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-94</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dopamine reuptake inhibitors have been shown to improve cognitive parameters in various tasks and animal models.  We recently reported a series of modafinil analogs, of which the most promising, 5-((benzhydrylsulfinyl)methyl) thiazole (CE-123), was selected for further development.  The present study aims to characterize pharmacol. properties of CE-123 and to investigate the potential to enhance memory performance in a rat model.  In vitro transporter assays were performed in cells expressing human transporters.  CE-123 blocked uptake of [3H] dopamine (IC50 = 4.606 μM) while effects on serotonin (SERT) and the norepinephrine transporter (NET) were negligible.  Blood-brain barrier and pharmacokinetic studies showed that the compd. reached the brain and lower elimination than R-modafinil.  The Pro-cognitive effect was evaluated in a spatial hole-board task in male Sprague-Dawley rats and CE-123 enhances memory acquisition and memory retrieval, represented by significantly increased ref. memory indexes and shortened latency.  Since DAT blockers can be considered as indirect dopamine receptor agonists, western blotting was used to quantify protein levels of dopamine receptors D1R, D2R and D5R and DAT in the synaptosomal fraction of hippocampal subregions CA1, CA3 and dentate gyrus (DG).  CE-123 administration in rats increased total DAT levels and D1R protein levels were significantly increased in CA1 and CA3 in treated/trained groups.  The increase of D5R was obsd. in DG only.  Dopamine receptors, particularly D1R, seem to play a role in mediating CE-123-induced memory enhancement.  Dopamine reuptake inhibition by CE-123 may represent a novel and improved stimulant therapeutic for impairments of cognitive functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprz2p5563B_bVg90H21EOLACvtfcHk0lhJk9kGle6zEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Ogsbw%253D&md5=0f3059aab891533f96b28d3529310a77</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2018.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2018.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DKristofova%26aufirst%3DM.%26aulast%3DAher%26aufirst%3DY.%2BD.%26aulast%3DIlic%26aufirst%3DM.%26aulast%3DRadoman%26aufirst%3DB.%26aulast%3DKalaba%26aufirst%3DP.%26aulast%3DDragacevic%26aufirst%3DV.%26aulast%3DAher%26aufirst%3DN.%2BY.%26aulast%3DLeban%26aufirst%3DJ.%26aulast%3DKorz%26aufirst%3DV.%26aulast%3DZanon%26aufirst%3DL.%26aulast%3DNeuhau%26aufirst%3DW.%26aulast%3DWieder%26aufirst%3DM.%26aulast%3DLanger%26aufirst%3DT.%26aulast%3DUrban%26aufirst%3DE.%26aulast%3DSitte%26aufirst%3DH.%2BH.%26aulast%3DHoeger%26aufirst%3DH.%26aulast%3DLubec%26aufirst%3DG.%26aulast%3DAradska%26aufirst%3DJ.%26atitle%3DA%2520daily%2520single%2520dose%2520of%2520a%2520novel%2520modafinil%2520analogue%2520CE-123%2520improves%2520memory%2520acquisition%2520and%2520memory%2520retrieval%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2018%26volume%3D343%26spage%3D83%26epage%3D94%26doi%3D10.1016%2Fj.bbr.2018.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors</span>. <i>Adv. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1016/S1054-3589(08)57007-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2FS1054-3589%2808%2957007-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=20230764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmt1OltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2009&pages=253-289&author=G.+Tandaauthor=A.+H.+Newmanauthor=J.+L.+Katz&title=Discovery+of+drugs+to+treat+cocaine+dependence%3A+behavioral+and+neurochemical+effects+of+atypical+dopamine+transport+inhibitors&doi=10.1016%2FS1054-3589%2808%2957007-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors</span></div><div class="casAuthors">Tanda, Gianluigi; Newman, Amy H.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Pharmacology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">Contemporary Aspects of Biomedical Research: Drug Discovery</span>),
    <span class="NLM_cas:pages">253-289</span>CODEN:
                <span class="NLM_cas:coden">ADPHEL</span>;
        ISSN:<span class="NLM_cas:issn">1054-3589</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Stimulant drugs acting at the dopamine transporter (DAT), like cocaine, are widely abused, yet effective medical treatments for this abuse have not been found.  Analogs of benztropine (BZT) that, like cocaine, act at the DAT have effects that differ from cocaine and in some situations block the behavioral, neurochem., and reinforcing actions of cocaine.  Neurochem. studies of dopamine levels in brain and behavioral studies have demonstrated that BZT analogs have a relatively slow onset and reduced maximal effects compared to cocaine.  Pharmacokinetic studies, however, indicated that the BZT analogs rapidly access the brain at concns. above their in vitro binding affinities, while binding in vivo demonstrates apparent assocn. rates for BZT analogs lower than that for cocaine.  Addnl., the off-target effects of these compds. do not fully explain their differences from cocaine.  Initial structure-activity studies indicated that BZT analogs bind to DAT differently from cocaine and these differences have been supported by site-directed mutagenesis studies of the DAT.  In addn., BZT analog-mediated inhibition of uptake was more resistant to mutations producing inward conformational DAT changes than cocaine analogs.  The BZT analogs have provided new insights into the relation between the mol. and behavioral actions of cocaine and the diversity of effects produced by dopamine transport inhibitors.  Novel interactions of BZT analogs with the DAT suggest that these drugs may have a pharmacol. that would be useful in their development as treatments for cocaine abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzP1lulUWR6LVg90H21EOLACvtfcHk0lhJk9kGle6zEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmt1OltA%253D%253D&md5=f168272f328f6fe2849b3c651e55d30e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS1054-3589%2808%2957007-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1054-3589%252808%252957007-4%26sid%3Dliteratum%253Aachs%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DDiscovery%2520of%2520drugs%2520to%2520treat%2520cocaine%2520dependence%253A%2520behavioral%2520and%2520neurochemical%2520effects%2520of%2520atypical%2520dopamine%2520transport%2520inhibitors%26jtitle%3DAdv.%2520Pharmacol.%26date%3D2009%26volume%3D57%26spage%3D253%26epage%3D289%26doi%3D10.1016%2FS1054-3589%2808%2957007-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstbrein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitte, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gether, U.</span></span> <span> </span><span class="NLM_article-title">Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">823</span>, <span class="refDoi"> DOI: 10.1124/mol.107.039800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fmol.107.039800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=17978168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1egs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=813-823&author=C.+J.+Lolandauthor=R.+I.+Desaiauthor=M.+F.+Zouauthor=J.+Caoauthor=P.+Grundtauthor=K.+Gerstbreinauthor=H.+H.+Sitteauthor=A.+H.+Newmanauthor=J.+L.+Katzauthor=U.+Gether&title=Relationship+between+conformational+changes+in+the+dopamine+transporter+and+cocaine-like+subjective+effects+of+uptake+inhibitors&doi=10.1124%2Fmol.107.039800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors</span></div><div class="casAuthors">Loland, Claus J.; Desai, Rajeev I.; Zou, Mu-Fa; Cao, Jianjing; Grundt, Peter; Gerstbrein, Klaus; Sitte, Harald H.; Newman, Amy Hauck; Katz, Jonathan L.; Gether, Ulrik</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">813-823</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cocaine exerts its stimulatory effect by inhibiting the dopamine transporter (DAT).  However, novel benztropine- and rimcazole-based inhibitors show reduced stimulant effects compared with cocaine, despite higher affinity and selectivity for DAT.  To investigate possible mechanisms, we compared the subjective effects of different inhibitors with their mol. mode of interaction at the DAT.  We detd. how different inhibitors affected accessibility of the sulfhydryl-reactive reagent [2-(trimethylammonium)ethyl]-methanethiosulfonate to an inserted cysteine (I159C), which is accessible when the extracellular transporter gate is open but inaccessible when it is closed.  The data indicated that cocaine analogs bind an open conformation, whereas benztropine and rimcazole analogs bind a closed conformation.  Next, we investigated the changes in inhibition potency of [3H]dopamine uptake of the compds. at a mutant DAT (Y335A) characterized by a global change in the conformational equil.  We obsd. a close relationship between the decrease in potencies of inhibitors at this mutant and cocaine-like responding in rats trained to discriminate cocaine from saline injections.  Our data suggest that chem. different DAT inhibitors stabilize distinct transporter conformations and that this in turn affects the cocaine-like subjective effects of these compds. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryV1skqbjuE7Vg90H21EOLACvtfcHk0lhJk9kGle6zEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1egs7Y%253D&md5=3371614fa985881d76d801d8d07442cf</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.039800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.039800%26sid%3Dliteratum%253Aachs%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DDesai%26aufirst%3DR.%2BI.%26aulast%3DZou%26aufirst%3DM.%2BF.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DGerstbrein%26aufirst%3DK.%26aulast%3DSitte%26aufirst%3DH.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DGether%26aufirst%3DU.%26atitle%3DRelationship%2520between%2520conformational%2520changes%2520in%2520the%2520dopamine%2520transporter%2520and%2520cocaine-like%2520subjective%2520effects%2520of%2520uptake%2520inhibitors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D73%26spage%3D813%26epage%3D823%26doi%3D10.1124%2Fmol.107.039800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tunstall, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendruscolo, J. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmeichel, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koob, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendruscolo, L. F.</span></span> <span> </span><span class="NLM_article-title">Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.neuropharm.2017.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=29217282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFykurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=96-103&author=B.+J.+Tunstallauthor=C.+P.+Hoauthor=J.+J.+Caoauthor=J.+C.+M.+Vendruscoloauthor=B.+E.+Schmeichelauthor=R.+D.+Slackauthor=G.+Tandaauthor=A.+J.+Gadianoauthor=R.+Raisauthor=B.+S.+Slusherauthor=G.+F.+Koobauthor=A.+H.+Newmanauthor=L.+F.+Vendruscolo&title=Atypical+dopamine+transporter+inhibitors+attenuate+compulsive-like+methamphetamine+self-administration+in+rats&doi=10.1016%2Fj.neuropharm.2017.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats</span></div><div class="casAuthors">Tunstall, Brendan J.; Ho, Chelsea P.; Cao, Jianjing; Vendruscolo, Janaina C. M.; Schmeichel, Brooke E.; Slack, Rachel D.; Tanda, Gianluigi; Gadiano, Alexandra J.; Rais, Rana; Slusher, Barbara S.; Koob, George F.; Newman, Amy H.; Vendruscolo, Leandro F.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">96-103</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Methamphetamine (METH) is a highly addictive drug, but no pharmacol. treatment is yet available for METH use disorders.  Similar to METH, the wake-promoting drug (R)-modafinil (R-MOD) binds to the dopamine transporter (DAT).  Unlike METH, R-MOD is not a substrate for transport by DAT and has low abuse potential.  We tested the hypothesis that the atypical DAT inhibitor R-MOD and compds. that are derived from modafinil would decrease METH intake by reducing the actions of METH at the DAT.  We tested the effects of systemic injections of R-MOD and four novel modafinil-derived ligands with increased DAT affinity (JJC8-016, JJC8-088, JJC8-089, and JJC8-091) on i.v. (i.v.) METH self-administration in rats that were allowed short access (ShA; 1 h) or long access (LgA; 6 h) to the drug.  ShA rats exhibited stable METH intake over sessions, whereas LgA rats exhibited an escalation of drug intake.  R-MOD decreased METH self-administration in ShA and LgA rats (in the 1st hour only).  JJC8-091 and JJC8-016 decreased METH self-administration in both ShA and LgA rats.  JJC8-089 decreased METH self-administration in LgA rats only, whereas JJC8-088 had no effect on METH self-administration in either ShA or LgA rats.  These findings support the potential of atypical DAT inhibitors for the treatment of METH use disorders and suggest several novel compds. as candidate drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovlYUD2STJo7Vg90H21EOLACvtfcHk0liead0O2gnWNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFykurrJ&md5=e5d4b83aa9093b918b490ee8dd1ac0bd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DTunstall%26aufirst%3DB.%2BJ.%26aulast%3DHo%26aufirst%3DC.%2BP.%26aulast%3DCao%26aufirst%3DJ.%2BJ.%26aulast%3DVendruscolo%26aufirst%3DJ.%2BC.%2BM.%26aulast%3DSchmeichel%26aufirst%3DB.%2BE.%26aulast%3DSlack%26aufirst%3DR.%2BD.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DGadiano%26aufirst%3DA.%2BJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DVendruscolo%26aufirst%3DL.%2BF.%26atitle%3DAtypical%2520dopamine%2520transporter%2520inhibitors%2520attenuate%2520compulsive-like%2520methamphetamine%2520self-administration%2520in%2520rats%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D131%26spage%3D96%26epage%3D103%26doi%3D10.1016%2Fj.neuropharm.2017.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keighron, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avelar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschumi, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckstead, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span> <span> </span><span class="NLM_article-title">Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1435</span>, <span class="refDoi"> DOI: 10.1038/s41386-019-0366-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fs41386-019-0366-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=30858517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyru7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=1435&author=A.+H.+Newmanauthor=J.+Caoauthor=J.+D.+Keighronauthor=C.+J.+Jordanauthor=G.+H.+Biauthor=Y.+Liangauthor=A.+M.+Abramyanauthor=A.+J.+Avelarauthor=C.+W.+Tschumiauthor=M.+J.+Becksteadauthor=L.+Shiauthor=G.+Tandaauthor=Z.+X.+Xi&title=Translating+the+atypical+dopamine+uptake+inhibitor+hypothesis+toward+therapeutics+for+treatment+of+psychostimulant+use+disorders&doi=10.1038%2Fs41386-019-0366-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders</span></div><div class="casAuthors">Newman, Amy Hauck; Cao, Jianjing; Keighron, Jacqueline D.; Jordan, Chloe J.; Bi, Guo-Hua; Liang, Ying; Abramyan, Ara M.; Avelar, Alicia J.; Tschumi, Christopher W.; Beckstead, Michael J.; Shi, Lei; Tanda, Gianluigi; Xi, Zheng-Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1435-1444</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Medication-assisted treatments are unavailable to patients with cocaine use disorders.  Efforts to develop potential pharmacotherapies have led to the identification of a promising lead mol., JJC8-091, that demonstrates a novel binding mode at the dopamine transporter (DAT).  Here, JJC8-091 and a structural analog, JJC8-088, were extensively and comparatively assessed to elucidate neurochem. correlates to their divergent behavioral profiles.  Despite sharing significant structural similarity, JJC8-088 was more cocaine-like, increasing extracellular DA concns. in the nucleus accumbens shell (NAS) efficaciously and more potently than JJC8-091.  In contrast, JJC8-091 was not self-administered and was effective in blocking cocaine-induced reinstatement to drug seeking.  Electrophysiol. expts. confirmed that JJC8-091 was more effective than JJC8-088 at inhibiting cocaine-mediated enhancement of DA neurotransmission.  Further, when VTA DA neurons in DAT-cre mice were optically stimulated, JJC8-088 produced a significant leftward shift in the stimulation-response curve, similar to cocaine, while JJC8-091 shifted the curve downward, suggesting attenuation of DA-mediated brain reward.  Computational models predicted that JJC8-088 binds in an outward facing conformation of DAT, similar to cocaine.  Conversely, JJC8-091 steers DAT towards a more occluded conformation.  Collectively, these data reveal the underlying mol. mechanism at DAT that may be leveraged to rationally optimize leads for the treatment of cocaine use disorders, with JJC8-091 representing a compelling candidate for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAa-KR-A2MpbVg90H21EOLACvtfcHk0liead0O2gnWNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyru7rI&md5=5105829a90c04a23b0406e8a209215e2</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fs41386-019-0366-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-019-0366-z%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DKeighron%26aufirst%3DJ.%2BD.%26aulast%3DJordan%26aufirst%3DC.%2BJ.%26aulast%3DBi%26aufirst%3DG.%2BH.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DAvelar%26aufirst%3DA.%2BJ.%26aulast%3DTschumi%26aufirst%3DC.%2BW.%26aulast%3DBeckstead%26aufirst%3DM.%2BJ.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26atitle%3DTranslating%2520the%2520atypical%2520dopamine%2520uptake%2520inhibitor%2520hypothesis%2520toward%2520therapeutics%2520for%2520treatment%2520of%2520psychostimulant%2520use%2520disorders%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D1435%26doi%3D10.1038%2Fs41386-019-0366-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisgaard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, M. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gether, U.</span></span> <span> </span><span class="NLM_article-title">The binding sites for benztropines and dopamine in the dopamine transporter overlap</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2010.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.neuropharm.2010.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=20816875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVaitLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=182-190&author=H.+Bisgaardauthor=M.+A.+B.+Larsenauthor=S.+Mazierauthor=T.+Beumingauthor=A.+H.+Newmanauthor=H.+Weinsteinauthor=L.+Shiauthor=C.+J.+Lolandauthor=U.+Gether&title=The+binding+sites+for+benztropines+and+dopamine+in+the+dopamine+transporter+overlap&doi=10.1016%2Fj.neuropharm.2010.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The binding sites for benztropines and dopamine in the dopamine transporter overlap</span></div><div class="casAuthors">Bisgaard, Heidi; Larsen, M. Andreas B.; Mazier, Sonia; Beuming, Thijs; Newman, Amy Hauck; Weinstein, Harel; Shi, Lei; Loland, Claus J.; Gether, Ulrik</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-190</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Analogs of benztropines (BZTs) are potent inhibitors of the dopamine transporter (DAT) but are less effective than cocaine as behavioral stimulants.  As a result, there have been efforts to evaluate these compds. as leads for potential medication for cocaine addiction.  Here we use computational modeling together with site-directed mutagenesis to characterize the binding site for BZTs in DAT.  Docking into mol. models based on the structure of the bacterial homolog LeuT supported a BZT binding site that overlaps with the substrate-binding pocket.  In agreement, mutations of residues within the pocket, including Val1523.46 to Ala or Ile, Ser4228.60 to Ala and Asn1573.51 to Cys or Ala, resulted in decreased affinity for BZT and the analog JHW007, as assessed in [3H]dopamine uptake inhibition assays and/or [3H]CFT competition binding assay.  A putative polar interaction of one of the Ph ring fluorine substituents in JHW007 with Asn1573.51 was used as a criterion for detg. likely binding poses and establish a structural context for the mutagenesis findings.  The anal. positioned the other fluorine-substituted Ph ring of JHW007 in close proximity to Ala47910.51/Ala48010.52 in transmembrane segment (TM) 10.  The lack of such an interaction for BZT led to a more tilted orientation, as compared to JHW007, bringing one of the Ph rings even closer to Ala47910.51/Ala48010.52.  Mutation of Ala47910.51 and Ala48010.52 to valines supported these predictions with a larger decrease in the affinity for BZT than for JHW007.  Summarized, our data suggest that BZTs display a classical competitive binding mode with binding sites overlapping those of cocaine and dopamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR-5LmnkQ4_7Vg90H21EOLACvtfcHk0ljoD2qpUxgkZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVaitLzM&md5=b601a5fa6abe86a35f84193ee45970a7</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2010.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2010.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DBisgaard%26aufirst%3DH.%26aulast%3DLarsen%26aufirst%3DM.%2BA.%2BB.%26aulast%3DMazier%26aufirst%3DS.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DGether%26aufirst%3DU.%26atitle%3DThe%2520binding%2520sites%2520for%2520benztropines%2520and%2520dopamine%2520in%2520the%2520dopamine%2520transporter%2520overlap%26jtitle%3DNeuropharmacology%26date%3D2011%26volume%3D60%26spage%3D182%26epage%3D190%26doi%3D10.1016%2Fj.neuropharm.2010.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanettini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthrie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship studies on a series of 3 alpha-[bis(4-fluorophenyl)methoxy]tropanes and 3 alpha-[bis(4-fluorophenyl)methylamino]tropanes as novel atypical dopamine transporter (DAT) inhibitors for the treatment of cocaine use disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10172</span>– <span class="NLM_lpage">10187</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01454</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01454" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCqt7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=10172-10187&author=M.+F.+Zouauthor=J.+Caoauthor=A.+M.+Abramyanauthor=T.+Kopajticauthor=C.+Zanettiniauthor=D.+A.+Guthrieauthor=R.+Raisauthor=B.+S.+Slusherauthor=L.+Shiauthor=C.+J.+Lolandauthor=A.+H.+Newman&title=Structure-activity+relationship+studies+on+a+series+of+3+alpha-%5Bbis%284-fluorophenyl%29methoxy%5Dtropanes+and+3+alpha-%5Bbis%284-fluorophenyl%29methylamino%5Dtropanes+as+novel+atypical+dopamine+transporter+%28DAT%29+inhibitors+for+the+treatment+of+cocaine+use+disorders&doi=10.1021%2Facs.jmedchem.7b01454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders</span></div><div class="casAuthors">Zou, Mu-Fa; Cao, Jianjing; Abramyan, Ara M.; Kopajtic, Theresa; Zanettini, Claudio; Guthrie, Daryl A.; Rais, Rana; Slusher, Barbara S.; Shi, Lei; Loland, Claus J.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10172-10187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of medications to treat cocaine use disorders has thus far defied success, leaving this patient population without pharmacotherapeutic options.  As the dopamine transporter (DAT) plays a prominent role in the reinforcing effects of cocaine that can lead to addiction, atypical DAT inhibitors have been developed that prevent cocaine from binding to DAT, but they themselves are not cocaine-like.  Herein, a series of novel DAT inhibitors were synthesized, and based on its pharmacol. profile, the lead compd. I was evaluated in phase I metabolic stability studies in mouse liver microsomes and compared to cocaine in locomotor activity and drug discrimination paradigms in mice.  A mol. dynamic simulation study supported the hypothesis that atypical DAT inhibitors have similar binding poses at DAT in a conformation that differs from that of cocaine.  Such differences may ultimately contribute to their unique behavioral profiles and potential for development as cocaine use disorder therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm08JwNTX1KbVg90H21EOLACvtfcHk0ljoD2qpUxgkZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCqt7fO&md5=e8f6fcbf17e227d9f5839049b6dd4dc5</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01454%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DM.%2BF.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DZanettini%26aufirst%3DC.%26aulast%3DGuthrie%26aufirst%3DD.%2BA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DStructure-activity%2520relationship%2520studies%2520on%2520a%2520series%2520of%25203%2520alpha-%255Bbis%25284-fluorophenyl%2529methoxy%255Dtropanes%2520and%25203%2520alpha-%255Bbis%25284-fluorophenyl%2529methylamino%255Dtropanes%2520as%2520novel%2520atypical%2520dopamine%2520transporter%2520%2528DAT%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cocaine%2520use%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D10172%26epage%3D10187%26doi%3D10.1021%2Facs.jmedchem.7b01454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolzenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">The isomeric preference of an atypical dopamine transporter inhibitor contributes to its selection of the transporter conformation</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1735</span>– <span class="NLM_lpage">1746</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.7b00094</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.7b00094" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXms1Wnt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1735-1746&author=A.+M.+Abramyanauthor=S.+Stolzenbergauthor=Z.+Liauthor=C.+J.+Lolandauthor=F.+Noeauthor=L.+Shi&title=The+isomeric+preference+of+an+atypical+dopamine+transporter+inhibitor+contributes+to+its+selection+of+the+transporter+conformation&doi=10.1021%2Facschemneuro.7b00094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The Isomeric Preference of an Atypical Dopamine Transporter Inhibitor Contributes to Its Selection of the Transporter Conformation</span></div><div class="casAuthors">Abramyan, Ara M.; Stolzenberg, Sebastian; Li, Zheng; Loland, Claus J.; Noe, Frank; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1735-1746</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cocaine, a widely abused psychostimulant, inhibits the dopamine transporter (DAT) by trapping the protein in an outward-open conformation, whereas atypical DAT inhibitors such as benztropine have low abuse liability and prefer less outward-open conformations.  Here, we use a spectrum of computational modeling and simulation approaches to obtain the underlying mol. mechanism in atomistic detail.  Interestingly, our quantum mech. calcns. and mol. dynamics (MD) simulations suggest that a benztropine deriv. JHW007 prefers a different stereoisomeric conformation of tropane in binding to DAT compared to that of a cocaine deriv., CFT.  To further investigate the different inhibition mechanisms of DAT, we carried out MD simulations in combination with Markov state modeling anal. of wild-type and Y156F DAT in the absence of any ligand or the presence of CFT or JHW007.  Our results indicate that the Y156F mutation and CFT shift the conformational equil. toward an outward-open conformation, whereas JHW007 prefers an inward-occluded conformation.  Our findings reveal the mechanistic details of DAT inhibition by JHW007 at the atomistic level, which provide clues for rational design of atypical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxNFlSEtAxMLVg90H21EOLACvtfcHk0ljoD2qpUxgkZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXms1Wnt7w%253D&md5=41117f8ff97f8c81d8e8bd9448bb72ed</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.7b00094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.7b00094%26sid%3Dliteratum%253Aachs%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DStolzenberg%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DNoe%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DThe%2520isomeric%2520preference%2520of%2520an%2520atypical%2520dopamine%2520transporter%2520inhibitor%2520contributes%2520to%2520its%2520selection%2520of%2520the%2520transporter%2520conformation%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D1735%26epage%3D1746%26doi%3D10.1021%2Facschemneuro.7b00094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Razavi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khelashvili, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span> <span> </span><span class="NLM_article-title">A Markov state-based quantitative kinetic model of sodium release from the dopamine transporter</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">40076</span>, <span class="refDoi"> DOI: 10.1038/srep40076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fsrep40076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=28059145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntlelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=40076&author=A.+M.+Razaviauthor=G.+Khelashviliauthor=H.+Weinstein&title=A+Markov+state-based+quantitative+kinetic+model+of+sodium+release+from+the+dopamine+transporter&doi=10.1038%2Fsrep40076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A Markov State-based Quantitative Kinetic Model of Sodium Release from the Dopamine Transporter</span></div><div class="casAuthors">Razavi, Asghar M.; Khelashvili, George; Weinstein, Harel</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40076</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The dopamine transporter (DAT) belongs to the neurotransmitter:sodium symporter (NSS) family of membrane proteins that are responsible for reuptake of neurotransmitters from the synaptic cleft to terminate a neuronal signal and enable subsequent neurotransmitter release from the presynaptic neuron.  The release of one sodium ion from the crystallog. detd. sodium binding site Na2 had been identified as an initial step in the transport cycle which preps. the transporter for substrate translocation by stabilizing an inward-open conformation.  We have constructed Markov State Models (MSMs) from extensive mol. dynamics simulations of human DAT (hDAT) to explore the mechanism of this sodium release.  Our results quantify the release process triggered by hydration of the Na2 site that occurs concomitantly with a conformational transition from an outward-facing to an inward-facing state of the transporter.  The kinetics of the release process are computed from the MSM, and transition path theory is used to identify the most probable sodium release pathways.  An intermediate state is discovered on the sodium release pathway, and the results reveal the importance of various modes of interaction of the N-terminus of hDAT in controlling the pathways of release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIuAYJ2vYiZrVg90H21EOLACvtfcHk0lhVyNGCOQbMFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntlelsg%253D%253D&md5=685a78ef27fb0588d16ebdbf4f52516b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fsrep40076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep40076%26sid%3Dliteratum%253Aachs%26aulast%3DRazavi%26aufirst%3DA.%2BM.%26aulast%3DKhelashvili%26aufirst%3DG.%26aulast%3DWeinstein%26aufirst%3DH.%26atitle%3DA%2520Markov%2520state-based%2520quantitative%2520kinetic%2520model%2520of%2520sodium%2520release%2520from%2520the%2520dopamine%2520transporter%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D40076%26doi%3D10.1038%2Fsrep40076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahar, I.</span></span> <span> </span><span class="NLM_article-title">Quantitative assessment of the energetics of dopamine translocation by human dopamine transporter</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">5336</span>– <span class="NLM_lpage">5346</span>, <span class="refDoi"> DOI: 10.1021/acs.jpcb.7b10340</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jpcb.7b10340" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOitbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2018&pages=5336-5346&author=M.+H.+Chengauthor=C.+Kayaauthor=I.+Bahar&title=Quantitative+assessment+of+the+energetics+of+dopamine+translocation+by+human+dopamine+transporter&doi=10.1021%2Facs.jpcb.7b10340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Assessment of the Energetics of Dopamine Translocation by Human Dopamine Transporter</span></div><div class="casAuthors">Cheng, Mary Hongying; Kaya, Cihan; Bahar, Ivet</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5336-5346</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-5207</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Computational evaluation of the energetics of substrate binding, transport, and release events of neurotransmitter transporters at the mol. level is a challenge, as the structural transitions of these membrane proteins involve coupled global and local changes that span time scales of several orders of magnitude, from nanoseconds to seconds.  Here, we provide a quant. assessment of the energetics of dopamine (DA) translocation through the human DA transporter (hDAT), using a combination of mol. modeling, simulation, and anal. tools.  DA-binding and -unbinding events, which generally involve local configurational changes, are evaluated using free-energy perturbation or adaptive biasing force methods.  The global transitions between the outward-facing state and the inward-facing state, on the other hand, require a dual-boost accelerated mol. dynamics simulation.  We present results on DA-binding/unbinding energetics under different conditions, as well as the conformational energy landscape of hDAT in both DA-bound and -unbound states.  The study provides a tractable method of approach for quant. evaluation of substrate-binding energetics and efficient estn. of conformational energy landscape, in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonsBnmjh64hLVg90H21EOLACvtfcHk0lhVyNGCOQbMFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOitbfP&md5=f6e825eed95c36287664349b3e176f36</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jpcb.7b10340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jpcb.7b10340%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%2BH.%26aulast%3DKaya%26aufirst%3DC.%26aulast%3DBahar%26aufirst%3DI.%26atitle%3DQuantitative%2520assessment%2520of%2520the%2520energetics%2520of%2520dopamine%2520translocation%2520by%2520human%2520dopamine%2520transporter%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2018%26volume%3D122%26spage%3D5336%26epage%3D5346%26doi%3D10.1021%2Facs.jpcb.7b10340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohut, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and Sigma receptors</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.185025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.111.185025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=21859929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFehtbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2011&pages=662-677&author=T.+Hiranitaauthor=P.+L.+Sotoauthor=S.+J.+Kohutauthor=T.+Kopajticauthor=J.+Caoauthor=A.+H.+Newmanauthor=G.+Tandaauthor=J.+L.+Katz&title=Decreases+in+cocaine+self-administration+with+dual+inhibition+of+the+dopamine+transporter+and+Sigma+receptors&doi=10.1124%2Fjpet.111.185025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and σ receptors</span></div><div class="casAuthors">Hiranita, Takato; Soto, Paul L.; Kohut, Stephen J.; Kopajtic, Theresa; Cao, Jianjing; Newman, Amy H.; Tanda, Gianluigi; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">662-677</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sigma receptor (σR) antagonists attenuate many behavioral effects of cocaine but typically not its reinforcing effects in self-administration procedures.  However, the σR antagonist rimcazole and its N-propylphenyl analogs, [3-(cis-3,5-dimethyl-4-[3-phenylpropyl]-1-piperazinyl)-propyl]diphenylamine hydrochloride (SH 3-24) and 9-[3-(cis-3,5-dimethyl-4-[3-phenylpropyl]-1-piperazinyl)-propyl]carbazole hydrobromide (SH 3-28), dose-dependently decreased the maximal rates of cocaine self-administration without affecting comparable responding maintained by food reinforcement.  In contrast, a variety of σR antagonists [N-phenethylpiperidine oxalate (AC927), N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine dihydrobromide (BD 1008), N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino) ethylamine dihydrobromide (BD 1047), N-[2-(3,4-dichlorophenyl) ethyl]-4-methylpiperazine dihydrochloride (BD 1063), and N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine monohydrochloride (NE-100)] had no effect on cocaine self-administration across the range of doses that decreased rates of food-maintained responding.  Rimcazole analogs differed from selective σR antagonists in their dual affinities for σRs and the dopamine transporter (DAT) assessed with radioligand binding.  Selective DAT inhibitors and σR antagonists were studied alone and in combination on cocaine self-administration to det. whether actions at both σRs and the DAT were sufficient to reproduce the effects of rimcazole analogs.  Typical DAT inhibitors [2β-carbomethoxy-3β-(4-fluorophenyl)tropane (WIN 35,428), methylphenidate, and nomifensine] dose-dependently shifted the cocaine dose-effect curve leftward.  Combinations of DAT inhibitor and σR antagonist doses that were behaviorally inactive alone decreased cocaine self-administration without effects on food-maintained responding.  In addn., whereas the DAT inhibitors were self-administered at rates similar to those of cocaine, neither rimcazole analogs nor typical σR antagonists (NE-100 and AC927) maintained responding above control levels across a wide range of doses.  These findings suggest that the unique effects of rimcazole analogs are due to dual actions at the DAT and σRs and that a combined target approach may have utility in development of medical treatments for cocaine abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs0gcxwJwV_LVg90H21EOLACvtfcHk0lhVyNGCOQbMFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFehtbvJ&md5=7be9d75e9be58be204e9f89e672f4a5a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.185025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.185025%26sid%3Dliteratum%253Aachs%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DSoto%26aufirst%3DP.%2BL.%26aulast%3DKohut%26aufirst%3DS.%2BJ.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DDecreases%2520in%2520cocaine%2520self-administration%2520with%2520dual%2520inhibition%2520of%2520the%2520dopamine%2520transporter%2520and%2520Sigma%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D339%26spage%3D662%26epage%3D677%26doi%3D10.1124%2Fjpet.111.185025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Sigma receptor effects of N-substituted benztropine analogs: implications for antagonism of cocaine self-administration</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.241109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.117.241109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=28442581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2017&pages=2-13&author=T.+Hiranitaauthor=W.+C.+Hongauthor=T.+Kopajticauthor=J.+L.+Katz&title=Sigma+receptor+effects+of+N-substituted+benztropine+analogs%3A+implications+for+antagonism+of+cocaine+self-administration&doi=10.1124%2Fjpet.117.241109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">σ receptor effects of N-substituted benztropine analogs: implications for antagonism of cocaine self-administration</span></div><div class="casAuthors">Hiranita, Takato; Hong, Weimin C.; Kopajtic, Theresa; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-13</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several N-substituted benztropine (BZT) analogs are atypical dopamine transport inhibitors as they have affinity for the dopamine transporter (DAT) but have minimal cocaine-like pharmacol. effects and can block numerous effects of cocaine, including its self-administration.  Among these compds., N-Me (AHN1-055), N-allyl (AHN2-005), and N-Bu (JHW007) analogs of 3α-[bis(4'-fluorophenyl)methoxy]-tropane were more potent in antagonizing self-administration of cocaine and d-methamphetamine than in decreasing food-maintained responding.  The antagonism of cocaine self-administration (0.03-1.0 mg/kg per injection) with the above BZT analogs was reproduced in the present study.  Further, the stimulant-antagonist effects resembled previously reported effects of pretreatments with combinations of std. DAT inhibitors and σ1-receptor (σ1R) antagonists.  Therefore, the present study examd. binding of the BZT analogs to σRs, as well as their in vivo σR antagonist effects.  Each of the BZT analogs displaced radiolabeled σR ligands with nanomolar affinity.  Further, self-administration of the σR agonist DTG (0.1-3.2 mg/kg/injection) was dose dependently blocked by AHN2-005 and JHW007 but potentiated by AHN1-055.  In contrast, none of the BZT analogs that were active against DTG self-administration was active against the self-administration of agonists at dopamine D1-like [R(+)-SKF 81297, (±)-SKF 82958 (0.00032-0.01 mg/kg per injection each)], D2-like [R(-)-NPA (0.0001-0.0032 mg/kg per injection), (-)-quinpirole (0.0032-0.1 mg/kg per injection)], or μ-opioid (remifentanil, 0.0001-0.0032 mg/kg per injection) receptors.  The present results indicate that behavioral antagonist effects of the N-substituted BZT analogs are specific for abused drugs acting at the DAT and further suggest that σR antagonism contributes to those actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUG3AyF6Z927Vg90H21EOLACvtfcHk0ljn3TPoGMuqLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsbvF&md5=148e6177caf110e0a158f8cfc0803e95</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.241109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.241109%26sid%3Dliteratum%253Aachs%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.%2BC.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DSigma%2520receptor%2520effects%2520of%2520N-substituted%2520benztropine%2520analogs%253A%2520implications%2520for%2520antagonism%2520of%2520cocaine%2520self-administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D362%26spage%3D2%26epage%3D13%26doi%3D10.1124%2Fjpet.117.241109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">The Sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">11250</span>– <span class="NLM_lpage">11261</span>, <span class="refDoi"> DOI: 10.1074/jbc.M116.774075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1074%2Fjbc.M116.774075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=28495886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCisL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=11250-11261&author=W.+C.+Hongauthor=H.+Yanoauthor=T.+Hiranitaauthor=F.+T.+Chinauthor=C.+R.+McCurdyauthor=T.+P.+Suauthor=S.+G.+Amaraauthor=J.+L.+Katz&title=The+Sigma-1+receptor+modulates+dopamine+transporter+conformation+and+cocaine+binding+and+may+thereby+potentiate+cocaine+self-administration+in+rats&doi=10.1074%2Fjbc.M116.774075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats</span></div><div class="casAuthors">Hong, Weimin Conrad; Yano, Hideaki; Hiranita, Takato; Chin, Frederick T.; McCurdy, Christopher R.; Su, Tsung-Ping; Amara, Susan G.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">11250-11261</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The dopamine transporter (DAT) regulates dopamine (DA) neurotransmission by recapturing DA into the presynaptic terminals and is a principal target of the psychostimulant cocaine.  The sigma-1 receptor (σ1R) is a mol. chaperone, and its ligands have been shown to modulate DA neuronal signaling, although their effects on DAT activity are unclear.  Here, the authors report that the prototypical σ1R agonist (+)-pentazocine potentiated the dose response of cocaine self-administration in rats, consistent with the effects of the σR agonists PRE-084 and DTG (1,3-di-o-tolylguanidine) reported previously.  These behavioral effects appeared to be correlated with functional changes of DAT.  Preincubation with (+)-pentazocine or PRE-084 increased the Bmax values of [3H]WIN35428 binding to DAT in rat striatal synaptosomes and transfected cells.  A specific interaction between σ1R and DAT was detected by co-immunopptn. and bioluminescence resonance energy transfer assays.  Mutational analyses indicated that the transmembrane domain of σ1R likely mediated this interaction.  Furthermore, cysteine accessibility assays showed that σ1R agonist preincubation potentiated cocaine-induced changes in DAT conformation, which were blocked by the specific σ1R antagonist CM304.  Moreover, σ1R ligands had distinct effects on σ1R multimerization.  CM304 increased the proportion of multimeric σ1Rs, whereas (+)-pentazocine increased monomeric σ1Rs.  Together these results support the hypothesis that σ1R agonists promote dissocn. of σ1R multimers into monomers, which then interact with DAT to stabilize an outward-facing DAT conformation and enhance cocaine binding.  The authors propose that this novel mol. mechanism underlies the behavioral potentiation of cocaine self-administration by σ1R agonists in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9IZLHbohe7rVg90H21EOLACvtfcHk0ljn3TPoGMuqLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCisL7F&md5=5366dbf409e7cbefeb52c79a3198023f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M116.774075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M116.774075%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DW.%2BC.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DAmara%26aufirst%3DS.%2BG.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520Sigma-1%2520receptor%2520modulates%2520dopamine%2520transporter%2520conformation%2520and%2520cocaine%2520binding%2520and%2520may%2520thereby%2520potentiate%2520cocaine%2520self-administration%2520in%2520rats%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26spage%3D11250%26epage%3D11261%26doi%3D10.1074%2Fjbc.M116.774075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohut, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.208264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.113.208264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=24194527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=174-191&author=T.+Hiranitaauthor=S.+J.+Kohutauthor=P.+L.+Sotoauthor=G.+Tandaauthor=T.+A.+Kopajticauthor=J.+L.+Katz&title=Preclinical+efficacy+of+N-substituted+benztropine+analogs+as+antagonists+of+methamphetamine+self-administration+in+rats&doi=10.1124%2Fjpet.113.208264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats</span></div><div class="casAuthors">Hiranita, Takato; Kohut, Stephen J.; Soto, Paul L.; Tanda, Gianluigi; Kopajtic, Theresa A.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-191, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Atypical dopamine-uptake inhibitors have low abuse potential and may serve as leads for development of cocaine-abuse treatments.  Among them, the benztropine (BZT) derivs., N-Bu (JHW007), N-allyl (AHN2-005), and N-Me (AHN1-055) analogs of 3α-[bis(4'-fluorophenyl)methoxy]-tropane dose-dependently decreased cocaine self-administration without effects on food-maintained responding.  Our study examd. selectivity by assessing their effects on self-administration of other drugs.  As with cocaine, each BZT analog (1.0-10.0 mg/kg i.p.) dose-dependently decreased maximal self-administration of d-methamphetamine (0.01-0.32 mg/kg/infusion) but was inactive against heroin (1.0-32.0 μg/kg/infusion) and ketamine (0.032-1.0 mg/kg/infusion) self-administration.  Further, std. dopamine indirect-agonists [WIN35,428 ((-)-3β-(4-fluorophenyl)-tropan-2-β-carboxylic acid Me ester tartrate), d-amphetamine (0.1-1.0 mg/kg i.p., each)] dose-dependently left-shifted self-administration dose-effect curves for d-methamphetamine, heroin, and ketamine.  Noncompetitive NMDA-glutamate receptor/channel antagonists [(+)-MK-801 (0.01-0.1 mg/kg i.p.), memantine (1.0-10.0 mg/kg i.p.)] also left-shifted dose-effect curves for d-methamphetamine and ketamine (but not heroin) self-administration.  The μ-agonists [dl-methadone and morphine (1.0-10.0 mg/kg i.p., each)] dose-dependently decreased maximal self-administration of μ-agonists (heroin, remifentanil) but not d-methamphetamine or ketamine self-administration.  The μ-agonist-induced decreases were similar to the effects of BZT analogs on stimulant self-administration and effects of food prefeeding on responding maintained by food reinforcement.  Radioligand-binding and behavioral studies suggested that inhibition of dopamine transporters and s receptors were crit. for blocking stimulant self-administration by BZT-analogs.  Thus, the present results suggest that the effects of BZT analogs on stimulant self-administration are similar to effects of μ-agonists on μ-agonist self-administration and food prefeeding on food-reinforced responding, which implicates behavioral mechanisms for these effects and further supports development of atypical dopamine uptake inhibitors as medications for stimulant abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoePjL_jLBq8LVg90H21EOLACvtfcHk0ljn3TPoGMuqLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKjur4%253D&md5=5a67df57fd903d92e17c313203d9aebe</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.208264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.208264%26sid%3Dliteratum%253Aachs%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DKohut%26aufirst%3DS.%2BJ.%26aulast%3DSoto%26aufirst%3DP.%2BL.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DPreclinical%2520efficacy%2520of%2520N-substituted%2520benztropine%2520analogs%2520as%2520antagonists%2520of%2520methamphetamine%2520self-administration%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D174%26epage%3D191%26doi%3D10.1124%2Fjpet.113.208264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hedges, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obray, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yorgason, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerasekara, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uys, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellinger, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffensen, S. C.</span></span> <span> </span><span class="NLM_article-title">Methamphetamine induces dopamine release in the nucleus accumbens through a Sigma receptor-mediated pathway</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1405</span>– <span class="NLM_lpage">1414</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fnpp.2017.291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=29185481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12it78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=1405-1414&author=D.+M.+Hedgesauthor=J.+D.+Obrayauthor=J.+T.+Yorgasonauthor=E.+Y.+Jangauthor=V.+K.+Weerasekaraauthor=J.+D.+Uysauthor=F.+P.+Bellingerauthor=S.+C.+Steffensen&title=Methamphetamine+induces+dopamine+release+in+the+nucleus+accumbens+through+a+Sigma+receptor-mediated+pathway&doi=10.1038%2Fnpp.2017.291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Methamphetamine Induces Dopamine Release in the Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway</span></div><div class="casAuthors">Hedges, David M.; Obray, J. Daniel; Yorgason, Jordan T.; Jang, Eun Young; Weerasekara, Vajira K.; Uys, Joachim D.; Bellinger, Frederick P.; Steffensen, Scott C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1405-1414</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Methamphetamine (METH) is a drug with a high addictive potential that is widely abused across the world.  Although it is known that METH dysregulates both dopamine transmission and dopamine reuptake, the specific mechanism of action remains obscure.  One promising target of METH is the sigma receptor, a chaperone protein located on the membrane of the endoplasmic reticulum.  Using fast-scan cyclic voltammetry, we show that METH-enhancement of evoked dopamine release and basal efflux is dependent on sigma receptor activation.  METH-induced activation of sigma receptors results in oxidn. of a cysteine residue on VMAT2, which decreases transporter function.  Unilateral injections of the sigma receptor antagonist BD-1063 prior to METH administration increased dopamine-related ipsilateral circling behavior, indicating the involvement of sigma receptors.  These findings suggest that interactions between METH and the sigma receptor lead to oxidative species (most likely superoxide) that in turn oxidize VMAT2.  Altogether, these findings show that the sigma receptor has a key role in METH dysregulation of dopamine release and dopamine-related behaviors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4t7gheuDT2rVg90H21EOLACvtfcHk0lgXlgC2YYUrOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12it78%253D&md5=2f8cc2b1b8ea906e9f40b2f73a4586eb</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.291%26sid%3Dliteratum%253Aachs%26aulast%3DHedges%26aufirst%3DD.%2BM.%26aulast%3DObray%26aufirst%3DJ.%2BD.%26aulast%3DYorgason%26aufirst%3DJ.%2BT.%26aulast%3DJang%26aufirst%3DE.%2BY.%26aulast%3DWeerasekara%26aufirst%3DV.%2BK.%26aulast%3DUys%26aufirst%3DJ.%2BD.%26aulast%3DBellinger%26aufirst%3DF.%2BP.%26aulast%3DSteffensen%26aufirst%3DS.%2BC.%26atitle%3DMethamphetamine%2520induces%2520dopamine%2520release%2520in%2520the%2520nucleus%2520accumbens%2520through%2520a%2520Sigma%2520receptor-mediated%2520pathway%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26spage%3D1405%26epage%3D1414%26doi%3D10.1038%2Fnpp.2017.291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sambo, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagnarine, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriquez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Febo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruijnzeel, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daws, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoshbouei, H.</span></span> <span> </span><span class="NLM_article-title">The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2228</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02087-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fs41467-017-02087-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=29263318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A280%3ADC%252BC1MzjslSitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2228&author=D.+O.+Samboauthor=M.+Linauthor=A.+Owensauthor=J.+J.+Lebowitzauthor=B.+Richardsonauthor=D.+A.+Jagnarineauthor=M.+Shettyauthor=M.+Rodriquezauthor=T.+Alongeauthor=M.+Aliauthor=J.+Katzauthor=L.+Yanauthor=M.+Feboauthor=L.+K.+Henryauthor=A.+W.+Bruijnzeelauthor=L.+Dawsauthor=H.+Khoshbouei&title=The+sigma-1+receptor+modulates+methamphetamine+dysregulation+of+dopamine+neurotransmission&doi=10.1038%2Fs41467-017-02087-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission</span></div><div class="casAuthors">Sambo Danielle O; Lin Min; Lebowitz Joseph J; Richardson Ben; Alonge Taiwo; Ali Mishaal; Khoshbouei Habibeh; Owens Anthony; Daws Lynette; Jagnarine Darin A; Febo Marcelo; Bruijnzeel Adriaan W; Shetty Madhur; Rodriquez Meghan; Henry L Keith; Katz Jonathan; Yan Long</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2228</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dopamine neurotransmission is highly dysregulated by the psychostimulant methamphetamine, a substrate for the dopamine transporter (DAT).  Through interactions with DAT, methamphetamine increases extracellular dopamine levels in the brain, leading to its rewarding and addictive properties.  Methamphetamine also interacts with the sigma-1 receptor (σ1R), an inter-organelle signaling modulator.  Using complementary strategies, we identified a novel mechanism for σ1R regulation of dopamine neurotransmission in response to methamphetamine.  We found that σ1R activation prevents methamphetamine-induced, DAT-mediated increases in firing activity of dopamine neurons.  In vitro and in vivo amperometric measurements revealed that σ1R activation decreases methamphetamine-stimulated dopamine efflux without affecting basal dopamine neurotransmission.  Consistent with these findings, σ1R activation decreases methamphetamine-induced locomotion, motivated behavior, and enhancement of brain reward function.  Notably, we revealed that the σ1R interacts with DAT at or near the plasma membrane and decreases methamphetamine-induced Ca(2+) signaling, providing potential mechanisms.  Broadly, these data provide evidence for σ1R regulation of dopamine neurotransmission and support the σ1R as a putative target for the treatment of methamphetamine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREMjSSm_naSEHdcurJClFcfW6udTcc2eZQ-r02gsWn5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzjslSitA%253D%253D&md5=37e54a2f26bec8d60459b42df2e10602</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02087-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02087-x%26sid%3Dliteratum%253Aachs%26aulast%3DSambo%26aufirst%3DD.%2BO.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DOwens%26aufirst%3DA.%26aulast%3DLebowitz%26aufirst%3DJ.%2BJ.%26aulast%3DRichardson%26aufirst%3DB.%26aulast%3DJagnarine%26aufirst%3DD.%2BA.%26aulast%3DShetty%26aufirst%3DM.%26aulast%3DRodriquez%26aufirst%3DM.%26aulast%3DAlonge%26aufirst%3DT.%26aulast%3DAli%26aufirst%3DM.%26aulast%3DKatz%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DFebo%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DL.%2BK.%26aulast%3DBruijnzeel%26aufirst%3DA.%2BW.%26aulast%3DDaws%26aufirst%3DL.%26aulast%3DKhoshbouei%26aufirst%3DH.%26atitle%3DThe%2520sigma-1%2520receptor%2520modulates%2520methamphetamine%2520dysregulation%2520of%2520dopamine%2520neurotransmission%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D2228%26doi%3D10.1038%2Fs41467-017-02087-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+Highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lgXlgC2YYUrOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520Highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchel, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberg, J. I.</span></span> <span> </span><span class="NLM_article-title">Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go-related gene channels</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1443</span>– <span class="NLM_lpage">1452</span>, <span class="refDoi"> DOI: 10.1124/mol.108.049056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fmol.108.049056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=18701618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCnt77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1443-1452&author=M.+J.+Perrinauthor=P.+W.+Kuchelauthor=T.+J.+Campbellauthor=J.+I.+Vandenberg&title=Drug+binding+to+the+inactivated+state+is+necessary+but+not+sufficient+for+high-affinity+binding+to+human+ether-a-go-go-related+gene+channels&doi=10.1124%2Fmol.108.049056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go-related gene channels</span></div><div class="casAuthors">Perrin, Mark J.; Kuchel, Philip W.; Campbell, Terence J.; Vandenberg, Jamie I.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1443-1452</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drug block of the human ether-a-go-go-related gene K+ channel (hERG) is the most common cause of acquired long QT syndrome, a disorder of cardiac repolarization that may result in ventricular tachycardia and sudden cardiac death.  We investigated the open vs. inactivated state dependence of drug block by using hERG mutants N588K and N588E, which shift the voltage dependence of inactivation compared with wild-type but in which the mutated residue is remote from the drug-binding pocket in the channel pore.  Four high-affinity drugs (cisapride, dofetilide, terfenadine, and astemizole) demonstrated lower affinity for the inactivation-deficient N588K mutant hERG channel compared with N588E and wild-type hERG.  Three of four low-affinity drugs (erythromycin, perhexiline, and quinidine) demonstrated no preference for N588E over N588K channels, whereas dl-sotalol was an example of a low-affinity state-dependent blocker.  All five state-dependent blockers showed an even lower affinity for S620T mutant hERG (no inactivation) compared with N588K mutant hERG (greatly reduced inactivation).  Computer modeling indicates that the reduced affinity for S620T compared with N588K and wild-type channels can be explained by the relative kinetics of drug block and unblock compared with the kinetics of inactivation and recovery from inactivation.  We were also able to calc., for the first time, the relative affinities for the inactivated vs. the open state, which for the drugs tested here ranged from 4- to 70-fold.  Our results show that preferential binding to the inactivated state is necessary but not sufficient for high-affinity binding to hERG channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaHugsuGVEULVg90H21EOLACvtfcHk0lgEZE7J6WAmTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCnt77E&md5=fc04e3e6bef06a9ca27a5ed388150ef0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.049056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.049056%26sid%3Dliteratum%253Aachs%26aulast%3DPerrin%26aufirst%3DM.%2BJ.%26aulast%3DKuchel%26aufirst%3DP.%2BW.%26aulast%3DCampbell%26aufirst%3DT.%2BJ.%26aulast%3DVandenberg%26aufirst%3DJ.%2BI.%26atitle%3DDrug%2520binding%2520to%2520the%2520inactivated%2520state%2520is%2520necessary%2520but%2520not%2520sufficient%2520for%2520high-affinity%2520binding%2520to%2520human%2520ether-a-go-go-related%2520gene%2520channels%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26spage%3D1443%26epage%3D1452%26doi%3D10.1124%2Fmol.108.049056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gintant, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sager, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockbridge, N.</span></span> <span> </span><span class="NLM_article-title">Evolution of strategies to improve preclinical cardiac safety testing</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fnrd.2015.34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=26893184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVCju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=457-471&author=G.+Gintantauthor=P.+T.+Sagerauthor=N.+Stockbridge&title=Evolution+of+strategies+to+improve+preclinical+cardiac+safety+testing&doi=10.1038%2Fnrd.2015.34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of strategies to improve preclinical cardiac safety testing</span></div><div class="casAuthors">Gintant, Gary; Sager, Philip T.; Stockbridge, Norman</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">457-471</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The early and efficient assessment of cardiac safety liabilities is essential to confidently advance novel drug candidates.  This article discusses evolving mechanistically based preclin. strategies for detecting drug-induced electrophysiol. and structural cardiotoxicity using in vitro human ion channel assays, human-based in silico reconstructions and human stem cell-derived cardiomyocytes.  These strategies represent a paradigm shift from current approaches, which rely on simplistic in vitro assays that measure blockade of the Kv11.1 current (also known as the hERG current or IKr) and on the use of non-human cells or tissues.  These new strategies have the potential to improve sensitivity and specificity in the early detection of genuine cardiotoxicity risks, thereby reducing the likelihood of mistakenly discarding viable drug candidates and speeding the progression of worthy drugs into clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-kYgmcNzy-bVg90H21EOLACvtfcHk0lgEZE7J6WAmTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVCju7s%253D&md5=0a6fa907a6d85fa0a3b42188a22165b9</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.34%26sid%3Dliteratum%253Aachs%26aulast%3DGintant%26aufirst%3DG.%26aulast%3DSager%26aufirst%3DP.%2BT.%26aulast%3DStockbridge%26aufirst%3DN.%26atitle%3DEvolution%2520of%2520strategies%2520to%2520improve%2520preclinical%2520cardiac%2520safety%2520testing%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D457%26epage%3D471%26doi%3D10.1038%2Fnrd.2015.34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalyaanamoorthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barakat, K. H.</span></span> <span> </span><span class="NLM_article-title">Binding modes of hERG blockers: an unsolved mystery in the drug design arena</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1080/17460441.2018.1418319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1080%2F17460441.2018.1418319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=29240515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVSmtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=207-210&author=S.+Kalyaanamoorthyauthor=K.+H.+Barakat&title=Binding+modes+of+hERG+blockers%3A+an+unsolved+mystery+in+the+drug+design+arena&doi=10.1080%2F17460441.2018.1418319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Binding modes of hERG blockers: an unsolved mystery in the drug design arena</span></div><div class="casAuthors">Kalyaanamoorthy, Subha; Barakat, Khaled H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-210</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8rGFUuQD4ObVg90H21EOLACvtfcHk0lgEZE7J6WAmTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVSmtrzF&md5=9d0ea3eb1d621d890b8aed4cb11922a4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1080%2F17460441.2018.1418319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2018.1418319%26sid%3Dliteratum%253Aachs%26aulast%3DKalyaanamoorthy%26aufirst%3DS.%26aulast%3DBarakat%26aufirst%3DK.%2BH.%26atitle%3DBinding%2520modes%2520of%2520hERG%2520blockers%253A%2520an%2520unsolved%2520mystery%2520in%2520the%2520drug%2520design%2520arena%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2018%26volume%3D13%26spage%3D207%26epage%3D210%26doi%3D10.1080%2F17460441.2018.1418319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fant, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duff, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noskov, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Toward reducing hERG affinities for DAT inhibitors with a combined machine learning and molecular modeling approach</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">562a</span>– <span class="NLM_lpage">562a</span>, <span class="refDoi"> DOI: 10.1016/j.bpj.2018.11.3021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.bpj.2018.11.3021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=562a-562a&author=A.+D.+Fantauthor=S.+Wackerauthor=J.+Jungauthor=J.+Q.+Guoauthor=A.+M.+Abramyanauthor=H.+J.+Duffauthor=A.+H.+Newmanauthor=S.+Y.+Noskovauthor=L.+Shi&title=Toward+reducing+hERG+affinities+for+DAT+inhibitors+with+a+combined+machine+learning+and+molecular+modeling+approach&doi=10.1016%2Fj.bpj.2018.11.3021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2018.11.3021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2018.11.3021%26sid%3Dliteratum%253Aachs%26aulast%3DFant%26aufirst%3DA.%2BD.%26aulast%3DWacker%26aufirst%3DS.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DJ.%2BQ.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DDuff%26aufirst%3DH.%2BJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DNoskov%26aufirst%3DS.%2BY.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DToward%2520reducing%2520hERG%2520affinities%2520for%2520DAT%2520inhibitors%2520with%2520a%2520combined%2520machine%2520learning%2520and%2520molecular%2520modeling%2520approach%26jtitle%3DBiophys.%2520J.%26date%3D2019%26volume%3D116%26spage%3D562a%26epage%3D562a%26doi%3D10.1016%2Fj.bpj.2018.11.3021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johannesen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanabria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waite-Labott, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumb, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blinova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stohlman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockbridge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, D. G.</span></span> <span> </span><span class="NLM_article-title">Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1002/cpt.205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1002%2Fcpt.205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=26259627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVylsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2016&pages=214-223&author=L.+Johannesenauthor=J.+Vicenteauthor=J.+W.+Masonauthor=C.+Eratoauthor=C.+Sanabriaauthor=K.+Waite-Labottauthor=M.+Hongauthor=J.+Linauthor=P.+Guoauthor=A.+Mutlibauthor=J.+Wangauthor=W.+J.+Crumbauthor=K.+Blinovaauthor=D.+Chanauthor=J.+Stohlmanauthor=J.+Florianauthor=M.+Uganderauthor=N.+Stockbridgeauthor=D.+G.+Strauss&title=Late+sodium+current+block+for+drug-induced+long+QT+syndrome%3A+Results+from+a+prospective+clinical+trial&doi=10.1002%2Fcpt.205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial</span></div><div class="casAuthors">Johannesen, L.; Vicente, J.; Mason, J. W.; Erato, C.; Sanabria, C.; Waite-Labott, K.; Hong, M.; Lin, J.; Guo, P.; Mutlib, A.; Wang, J.; Crumb, W. J.; Blinova, K.; Chan, D.; Stohlman, J.; Florian, J.; Ugander, M.; Stockbridge, N.; Strauss, D. G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">214-223</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced long QT syndrome has resulted in many drugs being withdrawn from the market.  At the same time, the current regulatory paradigm for screening new drugs causing long QT syndrome is preventing drugs from reaching the market, sometimes inappropriately.  In this study, we report the results of a first-of-a-kind clin. trial studying late sodium (mexiletine and lidocaine) and calcium (diltiazem) current blocking drugs to counteract the effects of hERG potassium channel blocking drugs (dofetilide and moxifloxacin).  We demonstrate that both mexiletine and lidocaine substantially reduce heart-rate cor. QT (QTc) prolongation from dofetilide by 20 ms.  Furthermore, all QTc shortening occurs in the heart-rate cor. J-Tpeak (J-Tpeakc) interval, the biomarker we identified as a sign of late sodium current block.  This clin. trial demonstrates that late sodium blocking drugs can substantially reduce QTc prolongation from hERG potassium channel block and assessment of J-Tpeakc may add value beyond only assessing QTc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqKnezvy6cALVg90H21EOLACvtfcHk0lhBuEhnOKeyXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVylsb0%253D&md5=b6f88fd121d50d4d32b1ab7ae6664d37</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fcpt.205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.205%26sid%3Dliteratum%253Aachs%26aulast%3DJohannesen%26aufirst%3DL.%26aulast%3DVicente%26aufirst%3DJ.%26aulast%3DMason%26aufirst%3DJ.%2BW.%26aulast%3DErato%26aufirst%3DC.%26aulast%3DSanabria%26aufirst%3DC.%26aulast%3DWaite-Labott%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DP.%26aulast%3DMutlib%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DCrumb%26aufirst%3DW.%2BJ.%26aulast%3DBlinova%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DD.%26aulast%3DStohlman%26aufirst%3DJ.%26aulast%3DFlorian%26aufirst%3DJ.%26aulast%3DUgander%26aufirst%3DM.%26aulast%3DStockbridge%26aufirst%3DN.%26aulast%3DStrauss%26aufirst%3DD.%2BG.%26atitle%3DLate%2520sodium%2520current%2520block%2520for%2520drug-induced%2520long%2520QT%2520syndrome%253A%2520Results%2520from%2520a%2520prospective%2520clinical%2520trial%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D99%26spage%3D214%26epage%3D223%26doi%3D10.1002%2Fcpt.205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolleddula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worboys, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassil, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdet, D. L.</span></span> <span> </span><span class="NLM_article-title">Biotransformation and bioactivation reactions of alicyclic amines in drug molecules</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.3109/03602532.2014.924962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.3109%2F03602532.2014.924962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=24909234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlagu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=379-419&author=J.+Bolleddulaauthor=K.+DeMentauthor=J.+P.+Driscollauthor=P.+Worboysauthor=P.+J.+Brassilauthor=D.+L.+Bourdet&title=Biotransformation+and+bioactivation+reactions+of+alicyclic+amines+in+drug+molecules&doi=10.3109%2F03602532.2014.924962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Biotransformation and bioactivation reactions of alicyclic amines in drug molecules</span></div><div class="casAuthors">Bolleddula, Jayaprakasam; DeMent, Kevin; Driscoll, James P.; Worboys, Philip; Brassil, Patrick J.; Bourdet, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">379-419</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Aliph. nitrogen heterocycles such as piperazine, piperidine, pyrrolidine, morpholine, aziridine, azetidine, and azepane are well known building blocks in drug design and important core structures in approved drug therapies.  These core units have been targets for metabolic attack by P450s and other drug metabolizing enzymes such as aldehyde oxidase and monoamine oxidase (MAOs).  The electron rich nitrogen and/or α-carbons are often major sites of metab. of alicyclic amines.  The most common biotransformations include N-oxidn., N-conjugation, oxidative N-dealkylation, ring oxidn., and ring opening.  In some instances, the metabolic pathways generate electrophilic reactive intermediates and cause bioactivation.  However, potential bioactivation related adverse events can be attenuated by structural modifications.  Hence it is important to understand the biotransformation pathways to design stable drug candidates that are devoid of metabolic liabilities early in the discovery stage.  The current review provides a comprehensive summary of biotransformation and bioactivation pathways of aliph. nitrogen contg. heterocycles and strategies to mitigate metabolic liabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgryPqDMy3f7Vg90H21EOLACvtfcHk0lhBuEhnOKeyXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlagu7jO&md5=f20339b5306805f531cbd22f0640e8b6</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.3109%2F03602532.2014.924962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602532.2014.924962%26sid%3Dliteratum%253Aachs%26aulast%3DBolleddula%26aufirst%3DJ.%26aulast%3DDeMent%26aufirst%3DK.%26aulast%3DDriscoll%26aufirst%3DJ.%2BP.%26aulast%3DWorboys%26aufirst%3DP.%26aulast%3DBrassil%26aufirst%3DP.%2BJ.%26aulast%3DBourdet%26aufirst%3DD.%2BL.%26atitle%3DBiotransformation%2520and%2520bioactivation%2520reactions%2520of%2520alicyclic%2520amines%2520in%2520drug%2520molecules%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2014%26volume%3D46%26spage%3D379%26epage%3D419%26doi%3D10.3109%2F03602532.2014.924962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlholm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacome, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Highly selective dopamine D3 receptor antagonists with arylated diazaspiro alkane cores</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9905</span>– <span class="NLM_lpage">9910</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9905-9910&author=S.+W.+Reillyauthor=S.+Griffinauthor=M.+Taylorauthor=K.+Sahlholmauthor=C.+C.+Wengauthor=K.+Xuauthor=D.+A.+Jacomeauthor=R.+R.+Luedtkeauthor=R.+H.+Mach&title=Highly+selective+dopamine+D3+receptor+antagonists+with+arylated+diazaspiro+alkane+cores&doi=10.1021%2Facs.jmedchem.7b01248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores</span></div><div class="casAuthors">Reilly, Sean W.; Griffin, Suzy; Taylor, Michelle; Sahlholm, Kristoffer; Weng, Chi-Chang; Xu, Kuiying; Jacome, Daniel A.; Luedtke, Robert R.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9905-9910</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aryldiazaspirocyclylpropyl phenyltriazolyl thioethers such as I (R = 2-MeOC6H4, 4-FC6H4, 4-MeOC6H4, 2-pyridinyl, 3-NCC6H4, 2,3-Cl2C6H3) were prepd. as selective dopamine D3 receptor (D3R) antagonists; their selectivities for D3R over D2R and for selected compds. over 5-HT1a, 5-HT2a, and 5-HT2c receptors and adenylyl cyclase were detd.  I (R = 2-MeOC6H4, 4-FC6H4) showed favorable D3R affinities (Ki = 12-25.6 nM) and were 264- to 905-fold selective for D3R vs D2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHLC1nn5_14LVg90H21EOLACvtfcHk0lhBuEhnOKeyXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsbjL&md5=a60ed8b0524189901b7155e11025d3c6</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01248%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DS.%2BW.%26aulast%3DGriffin%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DSahlholm%26aufirst%3DK.%26aulast%3DWeng%26aufirst%3DC.%2BC.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DJacome%26aufirst%3DD.%2BA.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DHighly%2520selective%2520dopamine%2520D3%2520receptor%2520antagonists%2520with%2520arylated%2520diazaspiro%2520alkane%2520cores%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9905%26epage%3D9910%26doi%3D10.1021%2Facs.jmedchem.7b01248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlholm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacome, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanicolas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Leveraging a low-affinity diazaspiro orthosteric fragment to reduce dopamine D3 receptor (D3R) ligand promiscuity across highly conserved aminergic G-protein-coupled receptors (GPCRs)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5132</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00412</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00412" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1Sntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5132&author=S.+W.+Reillyauthor=A.+A.+Riadauthor=C.+J.+Hsiehauthor=K.+Sahlholmauthor=D.+A.+Jacomeauthor=S.+Griffinauthor=M.+Taylorauthor=C.+C.+Wengauthor=K.+Xuauthor=N.+Kirschnerauthor=R.+R.+Luedtkeauthor=C.+Parryauthor=S.+Malhotraauthor=J.+Karanicolasauthor=R.+H.+Mach&title=Leveraging+a+low-affinity+diazaspiro+orthosteric+fragment+to+reduce+dopamine+D3+receptor+%28D3R%29+ligand+promiscuity+across+highly+conserved+aminergic+G-protein-coupled+receptors+%28GPCRs%29&doi=10.1021%2Facs.jmedchem.9b00412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D3 Receptor (D3R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs)</span></div><div class="casAuthors">Reilly, Sean W.; Riad, Aladdin A.; Hsieh, Chia-Ju; Sahlholm, Kristoffer; Jacome, Daniel A.; Griffin, Suzy; Taylor, Michelle; Weng, Chi-Chang; Xu, Kuiying; Kirschner, Nathan; Luedtke, Robert R.; Parry, Christopher; Malhotra, Shipra; Karanicolas, John; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5132-5147</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previously, we reported a 3-(2-methoxyphenyl)-9-(3-((4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propyl)-3,9-diazaspiro[5.5]undecane (I) compd. with excellent dopamine D3 receptor (D3R) affinity (D3R Ki = 12.0 nM) and selectivity (D2R/D3R ratio = 905).  Herein, we present derivs. of I with comparable D3R affinity (II, D3R Ki = 3.2 nM, D2R/D3R ratio = 60) and selectivity (III, D3R Ki = 21.0 nM, D2R/D3R ratio = 934).  Fragmentation of I revealed orthosteric fragment IV to express an unusually low D3R affinity (Ki = 2.7 μM).  Compared to piperazine congener V, which retains a high-affinity orthosteric fragment (VI, D3R Ki = 23.9 nM), I was found to be more selective for the D3R among D1- and D2-like receptors and exhibited negligible off-target interactions at serotoninergic and adrenergic G-protein-coupled receptors (GPCRs), common off-target sites for piperazine-contg. D3R scaffolds.  This study provides a unique rationale for implementing weakly potent orthosteric fragments into D3R ligand systems to minimize drug promiscuity at other aminergic GPCR sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0AsYC3qYsr7Vg90H21EOLACvtfcHk0lgyQDYJk2323Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1Sntrs%253D&md5=ce936e36f3007e1f5587edf9275479ff</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00412%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DS.%2BW.%26aulast%3DRiad%26aufirst%3DA.%2BA.%26aulast%3DHsieh%26aufirst%3DC.%2BJ.%26aulast%3DSahlholm%26aufirst%3DK.%26aulast%3DJacome%26aufirst%3DD.%2BA.%26aulast%3DGriffin%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DWeng%26aufirst%3DC.%2BC.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DKirschner%26aufirst%3DN.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DParry%26aufirst%3DC.%26aulast%3DMalhotra%26aufirst%3DS.%26aulast%3DKaranicolas%26aufirst%3DJ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DLeveraging%2520a%2520low-affinity%2520diazaspiro%2520orthosteric%2520fragment%2520to%2520reduce%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%2520ligand%2520promiscuity%2520across%2520highly%2520conserved%2520aminergic%2520G-protein-coupled%2520receptors%2520%2528GPCRs%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5132%26doi%3D10.1021%2Facs.jmedchem.9b00412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izenwasser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">4446</span>– <span class="NLM_lpage">4455</span>, <span class="refDoi"> DOI: 10.1021/jm9902943</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9902943" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK1MXmt12ltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=4446-4455&author=S.+M.+Husbandsauthor=S.+Izenwasserauthor=T.+Kopajticauthor=W.+D.+Bowenauthor=B.+J.+Vilnerauthor=J.+L.+Katzauthor=A.+H.+Newman&title=Structure-activity+relationships+at+the+monoamine+transporters+and+sigma+receptors+for+a+novel+series+of+9-%5B3-%28cis-3%2C+5-dimethyl-1-piperazinyl%29propyl%5Dcarbazole+%28rimcazole%29+analogues&doi=10.1021%2Fjm9902943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships at the Monoamine Transporters and σ Receptors for a Novel Series of 9-[3-(cis-3,5-Dimethyl-1-piperazinyl)- propyl]carbazole (Rimcazole) Analogues</span></div><div class="casAuthors">Husbands, Stephen M.; Izenwasser, Sari; Kopajtic, Theresa; Bowen, Wayne D.; Vilner, Bertold J.; Katz, Jonathan L.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4446-4455</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-[3-(Cis-3,5-Dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) has been characterized as a σ receptor antagonist that binds to the dopamine transporter with moderate affinity (Ki = 224 nM).  Although the binding affinities at the dopamine transporter of rimcazole and cocaine are comparable, rimcazole only depressed locomotor activity in mice and antagonized the stimulant effects produced by cocaine.  The neurochem. mechanisms underlying the attenuation of cocaine's effects are not understood, although interaction at a low affinity site/state of the dopamine transporter has been suggested.  To explore further this class of compds., a series of rimcazole analogs was designed and synthesized.  Displacement of [3H]WIN 35,428 binding at the dopamine transporter in rat caudate-putamen revealed that arom. substitutions on rimcazole were not well tolerated, generally, with significant redns. in affinity for a 3,6-dibromo deriv. (Ki = 3890 nM), 1,3,6-tribromo deriv.(Ki = 30300 nM), 3-amino deriv. (Ki = 2400 nM), and 3,6-dinitro deriv. (Ki = 174000 nM) analogs.  An N-phenylpropyl group was the only terminal piperazine nitrogen substituent that retained moderate affinity at the dopamine transporter (Ki = 263 nM).  Analogs in which the carbazole ring was replaced with a freely rotating diphenylamine moiety were also prepd.  Although the diphenylamino analog in which the terminal piperazine nitrogen was unsubstituted, as in rimcazole, demonstrated relatively low binding affinity at the dopamine transporter (Ki = 813 nM), an N-phenylpropyl analog was found to have the highest affinity for the dopamine transporter within the series (Ki = 61.0 nM).  All of the analogs that had affinity for the dopamine transporter inhibited [3H]dopamine uptake in synaptosomes, and potencies for these two effects showed a pos. correlation (r2 = 0.7731, p = 0.0018).  Several of the analogs displaced [3H]paroxetine from serotonin transporters with moderate to high affinity, with an N-phenylpropyl deriv. having the highest affinity (Ki = 44.5 nM).  In contrast, none of the analogs recognized the norepinephrine transporter with an affinity of <1.3 μM.  Binding affinities for σ1 and σ2 receptors were also detd., and several of the compds. were more potent than rimcazole with affinities ranging from 97 nM to >6 μM at σ1 sites and 145 to 1990 nM at σ2 sites.  A compd. with the highest affinity at σ1 sites was also the compd. with highest affinity at the dopamine transporter.  These novel rimcazole analogs may provide important tools with which to characterize the relationship between the low affinity site or state of the dopamine transporter, σ receptors, and their potential roles in modulating cocaine's psychostimulant actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC4bpCWt4m9bVg90H21EOLACvtfcHk0lgyQDYJk2323Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmt12ltrw%253D&md5=cd8d2b8c55f0387873714af4b18b99a5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm9902943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9902943%26sid%3Dliteratum%253Aachs%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DIzenwasser%26aufirst%3DS.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DStructure-activity%2520relationships%2520at%2520the%2520monoamine%2520transporters%2520and%2520sigma%2520receptors%2520for%2520a%2520novel%2520series%2520of%25209-%255B3-%2528cis-3%252C%25205-dimethyl-1-piperazinyl%2529propyl%255Dcarbazole%2520%2528rimcazole%2529%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D4446%26epage%3D4455%26doi%3D10.1021%2Fjm9902943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izenwasser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeloff, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Isothiocyanate derivatives of 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]-carbazole (rimcazole): Irreversible ligands for the dopamine transporter</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">4340</span>– <span class="NLM_lpage">4346</span>, <span class="refDoi"> DOI: 10.1021/jm9705519</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9705519" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFKlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=4340-4346&author=S.+M.+Husbandsauthor=S.+Izenwasserauthor=R.+J.+Loeloffauthor=J.+L.+Katzauthor=W.+D.+Bowenauthor=B.+J.+Vilnerauthor=A.+H.+Newman&title=Isothiocyanate+derivatives+of+9-%5B3-%28cis-3%2C5-dimethyl-1-piperazinyl%29propyl%5D-carbazole+%28rimcazole%29%3A+Irreversible+ligands+for+the+dopamine+transporter&doi=10.1021%2Fjm9705519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Isothiocyanate derivatives of 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]carbazole (Rimcazole): irreversible ligands for the dopamine transporter</span></div><div class="casAuthors">Husbands, Stephen M.; Izenwasser, Sari; Loeloff, Richard J.; Katz, Jonathan L.; Bowen, Wayne D.; Vilner, Bertold J.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4340-4346</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cocaine has been reported to bind to the dopamine transporter in a biphasic fashion, and the low-affinity component may play a modulatory role in cocaine's psychomotor stimulant effects.  To study this further, the authors have prepd. a series of irreversible ligands based on rimcazole [I; 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]carbazole], a compd. that has been postulated to bind only to the low-affinity site.  The alkylating moiety, isothiocyanate, is attached to the distal nitrogen of the piperazine ring via alkyl chains of varying lengths or directly attached to one of the arom. groups.  It was found that substitution on the piperazine nitrogen caused an initial decrease in affinity that was recovered as the alkyl chain length increased.  Isothiocyanate deriv. II of rimcazole, with the highest affinity for the dopamine transporter (DAT), binds in a monophasic and irreversible manner, as evidenced by the greatly diminished binding of [3H]WIN 35,428 in tissue that had been preincubated with the ligand and then thoroughly washed using centrifugation.  The dose-dependent redn. in Bmax was accompanied by a concn.-related decrease in KD values.  This shift in KD to a lower value suggests that the preincubation with isothiocyanate II produced a preferential irreversible binding to the low-affinity [3H]WIN 35,428 site on the dopamine transporter.  These ligands may prove to be important tools with which to study the significance of the low-affinity site on the DAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJm0uovk7Z7LVg90H21EOLACvtfcHk0liBWCvgOVy73A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFKlug%253D%253D&md5=b3d7f07a10569ea9be26b9bd324c4b31</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm9705519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9705519%26sid%3Dliteratum%253Aachs%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DIzenwasser%26aufirst%3DS.%26aulast%3DLoeloff%26aufirst%3DR.%2BJ.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DIsothiocyanate%2520derivatives%2520of%25209-%255B3-%2528cis-3%252C5-dimethyl-1-piperazinyl%2529propyl%255D-carbazole%2520%2528rimcazole%2529%253A%2520Irreversible%2520ligands%2520for%2520the%2520dopamine%2520transporter%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D4340%26epage%3D4346%26doi%3D10.1021%2Fjm9705519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Dual probes for the dopamine transporter and sigma(1) receptors: novel piperazinyl alkyl-bis(4′-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2589</span>– <span class="NLM_lpage">2598</span>, <span class="refDoi"> DOI: 10.1021/jm030008u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030008u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs12qt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2589-2598&author=J.+Caoauthor=S.+S.+Kulkarniauthor=S.+M.+Husbandsauthor=W.+D.+Bowenauthor=W.+Williamsauthor=T.+Kopajticauthor=J.+L.+Katzauthor=C.+Georgeauthor=A.+H.+Newman&title=Dual+probes+for+the+dopamine+transporter+and+sigma%281%29+receptors%3A+novel+piperazinyl+alkyl-bis%284%E2%80%B2-fluorophenyl%29amine+analogues+as+potential+cocaine-abuse+therapeutic+agents&doi=10.1021%2Fjm030008u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Probes for the Dopamine Transporter and σ1 Receptors: Novel Piperazinylalkylbis(4'-fluorophenyl)amine Analogues as Potential Cocaine-Abuse Therapeutic Agents</span></div><div class="casAuthors">Cao, Jianjing; Kulkarni, Santosh S.; Husbands, Stephen M.; Bowen, Wayne D.; Williams, Wanda; Kopajtic, Theresa; Katz, Jonathan L.; George, Clifford; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2589-2598</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Both dopamine uptake inhibitors and σ1 receptor antagonists have been implicated as potential pharmacotherapeutics for the treatment of cocaine abuse.  While the dopamine uptake inhibitors may share with cocaine neurochem. mechanisms underlying reinforcing properties, σ1 antagonists have been shown to attenuate some behavioral actions and toxic side effects assocd. with cocaine overdose.  Rimcazole, a σ1 receptor antagonist that binds to the DAT (Ki = 224 nM), is not behaviorally cocaine-like and attenuates some of the behavioral actions of cocaine.  To det. the roles of both DAT and σ1 receptors in the behavioral actions of rimcazole, a series of analogs was synthesized.  Initial studies identified two analogs that showed high to moderate affinities for both DAT and σ1 receptors and failed to show cocaine-like discriminative stimulus (DS) effects.  A second series of bis(4-fluorophenyl)amine analogs have now been prepd. in which the most potent DAT compd., I [R1 = CH2CH2CHPhOH, R2 = H] (Ki = 8.5 nM), was selective over serotonin transporter (SERT/DAT = 94), norepinephrine transporter (NET/DAT = 63), and σ1 receptor binding (σ1/DAT = 44).  In addn., I [R1 = CH2Ph, R2 = H; R1 = H, R2 = Me] showed superior selectivity for DAT over SERT (170- and 140-fold, resp.) and DAT over NET (219- and 190-fold, resp.) but were essentially equipotent at DAT and σ1 receptors (10; Ki = 77 and 124 nM, resp., 17; Ki = 28 and 13 nM, resp.).  CoMFA studies at both DAT and σ1 receptors were performed to examine structural requirements for optimal binding at these two targets as well as to assess differences between them.  Behavioral evaluation of analogs with varying affinities for both DAT and σ1 receptors may provide a novel approach toward designing medications for cocaine abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSk1ra5C_lfrVg90H21EOLACvtfcHk0liBWCvgOVy73A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs12qt78%253D&md5=f00a3f570eb7723594810dc343ba64bd</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm030008u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030008u%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DKulkarni%26aufirst%3DS.%2BS.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DDual%2520probes%2520for%2520the%2520dopamine%2520transporter%2520and%2520sigma%25281%2529%2520receptors%253A%2520novel%2520piperazinyl%2520alkyl-bis%25284%25E2%2580%25B2-fluorophenyl%2529amine%2520analogues%2520as%2520potential%2520cocaine-abuse%2520therapeutic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2589%26epage%3D2598%26doi%3D10.1021%2Fjm030008u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Dual DAT/sigma 1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl) amino) propyl) piperazin-1-yl)-1-phenylpropan-1-ol</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5238</span>– <span class="NLM_lpage">5241</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.08.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.bmcl.2008.08.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=18774292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFert7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5238-5241&author=J.+Caoauthor=T.+Kopajticauthor=J.+L.+Katzauthor=A.+H.+Newman&title=Dual+DAT%2Fsigma+1+receptor+ligands+based+on+3-%284-%283-%28bis%284-fluorophenyl%29+amino%29+propyl%29+piperazin-1-yl%29-1-phenylpropan-1-ol&doi=10.1016%2Fj.bmcl.2008.08.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Dual DAT/σ1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol</span></div><div class="casAuthors">Cao, Jianjing; Kopajtic, Theresa; Katz, Jonathan L.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5238-5241</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ester analogs of (±)3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol were synthesized and evaluated for binding at DAT, SERT, NET, and σ1 receptors, and compared to GBR 12909 and several known σ1 receptor ligands.  Most of these compds. demonstrated high affinity (K i = 4.3-51 nM) and selectivity for the DAT among the monoamine transporters.  S- and R-1-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-3-phenylpropan-2-ol were also prepd. wherein modest enantioselectivity was demonstrated at the DAT.  However, no enantioselectivity at σ1 receptors was obsd. and most of the ester analogs of the more active S-enantiomer showed comparable binding affinities at both DAT and σ1 receptors with a maximal 16-fold DAT/σ1 selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps-GGvWyuyvrVg90H21EOLACvtfcHk0liBWCvgOVy73A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFert7%252FL&md5=8a40cb7474dc768647f635535ea1b04b</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.08.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.08.065%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DDual%2520DAT%252Fsigma%25201%2520receptor%2520ligands%2520based%2520on%25203-%25284-%25283-%2528bis%25284-fluorophenyl%2529%2520amino%2529%2520propyl%2529%2520piperazin-1-yl%2529-1-phenylpropan-1-ol%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5238%26epage%3D5241%26doi%3D10.1016%2Fj.bmcl.2008.08.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">A role for sigma receptors in stimulant self-administration and addiction</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1097/FBP.0000000000000209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1097%2FFBP.0000000000000209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=26650253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=100-115&author=J.+L.+Katzauthor=W.+C.+Hongauthor=T.+Hiranitaauthor=T.+P.+Su&title=A+role+for+sigma+receptors+in+stimulant+self-administration+and+addiction&doi=10.1097%2FFBP.0000000000000209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">A role for sigma receptors in stimulant self-administration and addiction</span></div><div class="casAuthors">Katz, Jonathan L.; Hong, Weimin C.; Hiranita, Takato; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2 and 3</span>),
    <span class="NLM_cas:pages">100-115</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Sigma-1 receptors (σ1Rs) are structurally unique intracellular proteins that function as chaperones. σ1Rs translocate from the mitochondria-assocd. membrane to other subcellular compartments, and can influence a host of targets, including ion channels, G-protein-coupled receptors, lipids, and other signaling proteins.  Drugs binding to σRs can induce or block the actions of σRs.  Studies indicate that stimulant self-administration induces the reinforcing effects of σR agonists, because of dopamine transporter actions.  Once established, the reinforcing effects of σR agonists are independent of dopaminergic mechanisms traditionally thought to be crit. to the reinforcing effects of stimulants.  Self-administered doses of σR agonists do not increase dopamine concns. in the nucleus accumbens shell, a transmitter and brain region considered important for the reinforcing effects of abused drugs.  However, self-administration of σR agonists is blocked by σR antagonists.  Several effects of stimulants have been blocked by σR antagonists, including the reinforcing effects, assessed by a place-conditioning procedure.  However, the self-administration of stimulants is largely unaffected by σR antagonists, indicating fundamental differences in the mechanisms underlying these two procedures used to assess the reinforcing effects.  When σR antagonists are administered in combination with dopamine uptake inhibitors, an effective and specific blockade of stimulant self-administration is obtained.  Actions of stimulant drugs related to their abuse induce unique changes in σR activity and the changes induced potentially create redundant and, once established, independent reinforcement pathways.  Concomitant targeting of both dopaminergic pathways and σR proteins produces a selective antagonism of stimulant self-administration, suggesting new avenues for combination chemotherapies to specifically combat stimulant abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozieYVfrbwdLVg90H21EOLACvtfcHk0lh7tXFa3vdSbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOht7o%253D&md5=262279d7e148fade608c21d7c6f87704</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1097%2FFBP.0000000000000209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0000000000000209%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DHong%26aufirst%3DW.%2BC.%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DA%2520role%2520for%2520sigma%2520receptors%2520in%2520stimulant%2520self-administration%2520and%2520addiction%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2016%26volume%3D27%26spage%3D100%26epage%3D115%26doi%3D10.1097%2FFBP.0000000000000209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Redfern, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palethorpe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegl, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camm, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T. G.</span></span> <span> </span><span class="NLM_article-title">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/S0008-6363(02)00846-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=12667944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&author=W.+S.+Redfernauthor=L.+Carlssonauthor=A.+S.+Davisauthor=W.+G.+Lynchauthor=I.+MacKenzieauthor=S.+Palethorpeauthor=P.+K.+Sieglauthor=I.+Strangauthor=A.+T.+Sullivanauthor=R.+Wallisauthor=A.+J.+Cammauthor=T.+G.+Hammond&title=Relationships+between+preclinical+cardiac+electrophysiology%2C+clinical+QT+interval+prolongation+and+torsade+de+pointes+for+a+broad+range+of+drugs%3A+evidence+for+a+provisional+safety+margin+in+drug+development&doi=10.1016%2FS0008-6363%2802%2900846-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span></div><div class="casAuthors">Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discussing attempts to det. the relative value of preclin. cardiac electrophysiol. data (in vitro and in vivo) for predicting risk of torsades de pointes (TdP) in clin. use.  Published data on human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG) (or IKr) activity, cardiac action potential duration (at 90% repolarization; APD90), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.  These data were set against the free plasma concns. attained during clin. use (effective therapeutic plasma concns.; ETPCunbound).  The drugs were divided into five categories: (1) Class Ia and III antiarrhythmics; (2) withdrawn from market due to TdP; (3) measurable incidence/numerous reports of TdP in humans; (4) isolated reports of TdP in humans; (5) no reports of TdP in humans.  Data from hERG (or IKr) assays in addn. to ETPCunbound data were available for 52 drugs.  For Category 1 drugs, data for hERG/IKr IC50, APD90, QTc in animals and QTc in humans were generally close to or superimposed on the ETPCunbound values.  This relationship was uncoupled in the other categories, with more complex relationships between the data.  In Category 1 (except amiodarone), the ratios between hERG/IKr IC50 and ETPCunbound (max) ranged 0.1-31-fold.  Similar ranges were obtained for drugs in Category 2 (0.31-13-fold) and Category 3 (0.03-35-fold).  A large spread was found for Category 4 drugs (0.13-35,700-fold); this category embraced an assortment of mechanisms ranging from drugs which may well be affecting IKr currents in clin. use (e.g., sparfloxacin) to others such as nifedipine (35,700-fold) where channel block is not involved.  Finally, for the majority of Category 5 drugs there was a >30-fold sepn. between hERG/IKr activity and ETPCunbound values, with the notable exception of verapamil (1.7-fold), which is free from QT prolongation in man; this is probably explained by its multiple interactions with cardiac ion channels.  The dataset confirms the widely held belief that most drugs assocd. with TdP in humans are also assocd. with hERG K+ channel block at concns. close to or superimposed upon the free plasma concns. found in clin. use.  A 30-fold margin between Cmax and hERG IC50 may suffice for drugs currently undergoing clin. evaluation, but for future drug discovery programs, pharmaceutical companies should consider increasing this margin, particularly for drugs aimed at nondebilitating diseases.  However, interactions with multiple cardiac ion channels can either mitigate or exacerbate the prolongation of APD and QT that would ensue from block of IKr currents alone, and delay of repolarization per se is not necessarily torsadogenic.  Clearly, an integrated assessment of in vitro and in vivo data is required in order to predict the torsadogenic risk of a new candidate drug in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkpRDUH0rhyrVg90H21EOLACvtfcHk0lh7tXFa3vdSbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D&md5=a236c07febd2e05fe70e61604619bf2e</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%2BS.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BS.%26aulast%3DLynch%26aufirst%3DW.%2BG.%26aulast%3DMacKenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%26aulast%3DStrang%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DA.%2BT.%26aulast%3DWallis%26aufirst%3DR.%26aulast%3DCamm%26aufirst%3DA.%2BJ.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26atitle%3DRelationships%2520between%2520preclinical%2520cardiac%2520electrophysiology%252C%2520clinical%2520QT%2520interval%2520prolongation%2520and%2520torsade%2520de%2520pointes%2520for%2520a%2520broad%2520range%2520of%2520drugs%253A%2520evidence%2520for%2520a%2520provisional%2520safety%2520margin%2520in%2520drug%2520development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26spage%3D32%26epage%3D45%26doi%3D10.1016%2FS0008-6363%2802%2900846-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kniazeff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergmann, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raniszewska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gether, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span> <span> </span><span class="NLM_article-title">The binding sites for cocaine and dopamine in the dopamine transporter overlap</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">780</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1038/nn.2146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fnn.2146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=18568020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1Omsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=780-789&author=T.+Beumingauthor=J.+Kniazeffauthor=M.+L.+Bergmannauthor=L.+Shiauthor=L.+Graciaauthor=K.+Raniszewskaauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=H.+Weinsteinauthor=U.+Getherauthor=C.+J.+Loland&title=The+binding+sites+for+cocaine+and+dopamine+in+the+dopamine+transporter+overlap&doi=10.1038%2Fnn.2146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The binding sites for cocaine and dopamine in the dopamine transporter overlap</span></div><div class="casAuthors">Beuming, Thijs; Kniazeff, Julie; Bergmann, Marianne L.; Shi, Lei; Gracia, Luis; Raniszewska, Klaudia; Newman, Amy Hauck; Javitch, Jonathan A.; Weinstein, Harel; Gether, Ulrik; Loland, Claus J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">780-789</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Beuming and colleagues detd. that the binding site for cocaine overlaps with that of dopamine on the dopamine transporter.  Detailed modeling and mutagenesis expts. revealed that this site is deeply buried amongst several transmembrane domains.  Cocaine is a widely abused substance with psychostimulant effects that are attributed to inhibition of the dopamine transporter (DAT).  We present mol. models for DAT binding of cocaine and cocaine analogs constructed from the high-resoln. structure of the bacterial transporter homolog LeuT.  Our models suggest that the binding site for cocaine and cocaine analogs is deeply buried between transmembrane segments 1, 3, 6 and 8, and overlaps with the binding sites for the substrates dopamine and amphetamine, as well as for benztropine-like DAT inhibitors.  We validated our models by detailed mutagenesis and by trapping the radiolabeled cocaine analog [3H]CFT in the transporter, either by crosslinking engineered cysteines or with an engineered Zn2+-binding site that was situated extracellularly to the predicted common binding pocket.  Our data demonstrate the mol. basis for the competitive inhibition of dopamine transport by cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogCWenpzRZ47Vg90H21EOLACvtfcHk0lh7tXFa3vdSbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1Omsrw%253D&md5=7f96344e92478939540d84a37eaf3a70</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fnn.2146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.2146%26sid%3Dliteratum%253Aachs%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DKniazeff%26aufirst%3DJ.%26aulast%3DBergmann%26aufirst%3DM.%2BL.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DGracia%26aufirst%3DL.%26aulast%3DRaniszewska%26aufirst%3DK.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DGether%26aufirst%3DU.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520binding%2520sites%2520for%2520cocaine%2520and%2520dopamine%2520in%2520the%2520dopamine%2520transporter%2520overlap%26jtitle%3DNat.%2520Neurosci.%26date%3D2008%26volume%3D11%26spage%3D780%26epage%3D789%26doi%3D10.1038%2Fnn.2146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penmatsa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">Neurotransmitter and psychostimulant recognition by the dopamine transporter</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>521</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1038/nature14431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1038%2Fnature14431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=25970245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WltbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=521&publication_year=2015&pages=322-327&author=K.+H.+Wangauthor=A.+Penmatsaauthor=E.+Gouaux&title=Neurotransmitter+and+psychostimulant+recognition+by+the+dopamine+transporter&doi=10.1038%2Fnature14431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotransmitter and psychostimulant recognition by the dopamine transporter</span></div><div class="casAuthors">Wang, Kevin H.; Penmatsa, Aravind; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">521</span>
        (<span class="NLM_cas:issue">7552</span>),
    <span class="NLM_cas:pages">322-327</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Na+/Cl--coupled biogenic amine transporters are the primary targets of therapeutic and abused drugs, ranging from antidepressants to the psychostimulants cocaine and amphetamines, and to their cognate substrates.  Here we det. X-ray crystal structures of the Drosophila melanogaster dopamine transporter (dDAT) bound to its substrate dopamine, a substrate analog 3,4-dichlorophenethylamine, the psychostimulants D-amphetamine and methamphetamine, or to cocaine and cocaine analogs.  All ligands bind to the central binding site, located approx. halfway across the membrane bilayer, in close proximity to bound sodium and chloride ions.  The central binding site recognizes three chem. distinct classes of ligands via conformational changes that accommodate varying sizes and shapes, thus illustrating mol. principles that distinguish substrates from inhibitors in biogenic amine transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWbqTaT0RDD7Vg90H21EOLACvtfcHk0linI14dTHfzQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WltbbK&md5=1784d5fd0e7e1ddbe8346c96aaf98a00</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fnature14431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14431%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DK.%2BH.%26aulast%3DPenmatsa%26aufirst%3DA.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DNeurotransmitter%2520and%2520psychostimulant%2520recognition%2520by%2520the%2520dopamine%2520transporter%26jtitle%3DNature%26date%3D2015%26volume%3D521%26spage%3D322%26epage%3D327%26doi%3D10.1038%2Fnature14431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaaro-Peled, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strick, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engle, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2067</span>– <span class="NLM_lpage">2073</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.046482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fdmd.112.046482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=22837388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKkt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=2067-2073&author=R.+Raisauthor=A.+G.+Thomasauthor=K.+Wozniakauthor=Y.+Wuauthor=H.+Jaaro-Peledauthor=A.+Sawaauthor=C.+A.+Strickauthor=S.+J.+Engleauthor=N.+J.+Brandonauthor=C.+Rojasauthor=B.+S.+Slusherauthor=T.+Tsukamoto&title=Pharmacokinetics+of+oral+D-serine+in+D-amino+acid+oxidase+knockout+mice&doi=10.1124%2Fdmd.112.046482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice</span></div><div class="casAuthors">Rais, Rana; Thomas, Ajit G.; Wozniak, Krystyna; Wu, Ying; Jaaro-Peled, Hanna; Sawa, Akira; Strick, Christine A.; Engle, Sandra J.; Brandon, Nicholas J.; Rojas, Camilo; Slusher, Barbara S.; Tsukamoto, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2067-2073</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">D-Amino acid oxidase (DAAO) catalyzes the oxidative deamination of D-amino acids including D-serine, a full agonist at the glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor.  To evaluate the significance of DAAO-mediated metab. in the pharmacokinetics of oral D-serine, plasma D-serine levels were measured in both wild-type mice and transgenic mice lacking DAAO.  Although D-serine levels were rapidly diminished in wild-type mice (t1/2 = 1.2 h), sustained drug levels over the course of 4 h (t1/2 > 10 h) were obsd. in mice lacking DAAO.  Coadministration of D-serine with 6-chlorobenzo[d]isoxazol-3-ol (CBIO), a small-mol. DAAO inhibitor, in wild-type mice resulted in the enhancement of plasma D-serine levels, although CBIO seems to have only temporary effects on the plasma D-serine levels due to glucuronidation of the key hydroxyl group.  These findings highlight the predominant role of DAAO in the clearance of D-serine from the systemic circulation.  Thus, a potent DAAO inhibitor with a longer half-life should be capable of maintaining high plasma D-serine levels over a sustained period of time and might have therapeutic implications for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOnvR-tnwQ-rVg90H21EOLACvtfcHk0linI14dTHfzQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKkt73I&md5=c80a66d06d07cff75117790e0a927f84</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.046482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.046482%26sid%3Dliteratum%253Aachs%26aulast%3DRais%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DA.%2BG.%26aulast%3DWozniak%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DJaaro-Peled%26aufirst%3DH.%26aulast%3DSawa%26aufirst%3DA.%26aulast%3DStrick%26aufirst%3DC.%2BA.%26aulast%3DEngle%26aufirst%3DS.%2BJ.%26aulast%3DBrandon%26aufirst%3DN.%2BJ.%26aulast%3DRojas%26aufirst%3DC.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DTsukamoto%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520of%2520oral%2520D-serine%2520in%2520D-amino%2520acid%2520oxidase%2520knockout%2520mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D2067%26epage%3D2073%26doi%3D10.1124%2Fdmd.112.046482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keighron, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quarterman, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarco, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coggiano, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleaves, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanettini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span> <span> </span><span class="NLM_article-title">Effects of (R)-modafinil and modafinil analogues on dopamine dynamics assessed by voltammetry and microdialysis in the mouse nucleus accumbens shell</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2012</span>– <span class="NLM_lpage">2021</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00340</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00340" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVahtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2012-2021&author=J.+D.+Keighronauthor=J.+C.+Quartermanauthor=J.+Caoauthor=E.+M.+DeMarcoauthor=M.+A.+Coggianoauthor=A.+Gleavesauthor=R.+D.+Slackauthor=C.+Zanettiniauthor=A.+H.+Newmanauthor=G.+Tanda&title=Effects+of+%28R%29-modafinil+and+modafinil+analogues+on+dopamine+dynamics+assessed+by+voltammetry+and+microdialysis+in+the+mouse+nucleus+accumbens+shell&doi=10.1021%2Facschemneuro.8b00340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of (R)-Modafinil and Modafinil Analogues on Dopamine Dynamics Assessed by Voltammetry and Microdialysis in the Mouse Nucleus Accumbens Shell</span></div><div class="casAuthors">Keighron, Jacqueline D.; Quarterman, Juliana C.; Cao, Jianjing; De Marco, Emily M.; Coggiano, Mark A.; Gleaves, Apre; Slack, Rachel D.; Zanettini, Claudio; Newman, Amy Hauck; Tanda, Gianluigi</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2012-2021</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent discoveries have improved our understanding of the physiol. and pathol. roles of the dopamine transporter (DAT); however, only a few drugs are clin. available for DAT-implicated disorders.  Among those drugs, modafinil (MOD) and its (R)-enantiomer (R-MOD) have been used off-label as therapies for psychostimulant use disorders, but they have shown limited effectiveness in clin. trials.  Recent preclin. studies on MOD and R-MOD have led to chem. modified structures aimed toward improving their neurobiol. properties that might lead to more effective therapeutics for stimulant use disorders.  This study examines three MOD analogs (JJC8-016, JJC8-088, and JJC8-091) with improved DAT affinities compared to their parent compd.  These compds. were investigated for their effects on the neurochem. (brain microdialysis and FSCV) and behavior (ambulatory activity) of male Swiss-Webster mice.  Our data indicate that these compds. have dissimilar effects on tonic and phasic dopamine in the nucleus accumbens shell and variability in producing ambulatory activity.  These results suggest that small changes in the chem. structure of a DAT inhibitor can cause compds. such as JJC8-088 to produce effects similar to abused psychostimulants like cocaine.  In contrast, other compds. like JJC8-091 do not share cocaine-like effects and have a more atypical DAT-inhibitor profile, which may prove to be an advancement in the treatment of psychostimulant use disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOsciN_K_fZLVg90H21EOLACvtfcHk0linI14dTHfzQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVahtbw%253D&md5=8cf600df118f6a21c423e3b275007977</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00340%26sid%3Dliteratum%253Aachs%26aulast%3DKeighron%26aufirst%3DJ.%2BD.%26aulast%3DQuarterman%26aufirst%3DJ.%2BC.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DDeMarco%26aufirst%3DE.%2BM.%26aulast%3DCoggiano%26aufirst%3DM.%2BA.%26aulast%3DGleaves%26aufirst%3DA.%26aulast%3DSlack%26aufirst%3DR.%2BD.%26aulast%3DZanettini%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DTanda%26aufirst%3DG.%26atitle%3DEffects%2520of%2520%2528R%2529-modafinil%2520and%2520modafinil%2520analogues%2520on%2520dopamine%2520dynamics%2520assessed%2520by%2520voltammetry%2520and%2520microdialysis%2520in%2520the%2520mouse%2520nucleus%2520accumbens%2520shell%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D2012%26epage%3D2021%26doi%3D10.1021%2Facschemneuro.8b00340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl) methoxy]ethyl}-4-(3-phenylpropyl)piperazine], and benztropine analogs</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.091231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.105.091231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=16014753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOks7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=397-404&author=R.+I.+Desaiauthor=T.+A.+Kopajticauthor=D.+Frenchauthor=A.+H.+Newmanauthor=J.+L.+Katz&title=Relationship+between+in+vivo+occupancy+at+the+dopamine+transporter+and+behavioral+effects+of+cocaine%2C+GBR+12909+%5B1-%7B2-%5Bbis-%284-fluorophenyl%29+methoxy%5Dethyl%7D-4-%283-phenylpropyl%29piperazine%5D%2C+and+benztropine+analogs&doi=10.1124%2Fjpet.105.091231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between in Vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine],and benztropine analogs</span></div><div class="casAuthors">Desai, Rajeev I.; Kopajtic, Theresa A.; French, Dawn; Newman, Amy H.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">397-404</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Analogs of benztropine (BZT) bind to the dopamine (DA) transporter and inhibit DA uptake but often have behavioral effects that differ from those of cocaine and other DA-uptake inhibitors.  To better understand these differences, we examd. the relationship between locomotor-stimulant effects of cocaine, 1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)-piperazine (GBR 12909), and BZT analogs [(3α-[bis(4'-fluorophenyl)methoxy]-tropane) (AHN 1-055) and (N-allyl-3α-[bis(4'-fluorophenyl)methoxy]-tropane) (AHN 2-005)] and their in vivo displacement of the DA transporter ligand [125I]3β-(4-iodophenyl)-tropan-2β-carboxylic acid iso-Pr ester hydrochloride (RTI-121) in striatum.  Cocaine, GBR 12909, and BZT analogs each displaced [125I]RTI-121 and stimulated locomotor activity in a dose- and time-dependent manner.  The time course revealed a slower onset of both effects for AHN 1-055 and AHN 2-005 compared with cocaine and GBR 12909.  The BZT analogs were less effective than cocaine and GBR 12909 in stimulating locomotor activity.  Locomotor stimulant effects of cocaine were generally greater than predicted by the regression of displacement of [125I]RTI-121 and effect at short times after injection and less than predicted at longer times after injection.  This result suggests that the apparent rate of occupancy of the DA transporter, in addn. to percentage of sites occupied, contributes to the behavioral effects of cocaine.  The present results suggest that among drugs that act at the DA transporter, the slower apparent rates of occupancy with the DA transporter by the BZT analogs may contribute in an important way to differences in their effectiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjPuttHGNvq7Vg90H21EOLACvtfcHk0lhoy6HFFmvTRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOks7nI&md5=aa3d51cc833c446f5895f06bf1c28b99</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.091231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.091231%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DR.%2BI.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DFrench%26aufirst%3DD.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DRelationship%2520between%2520in%2520vivo%2520occupancy%2520at%2520the%2520dopamine%2520transporter%2520and%2520behavioral%2520effects%2520of%2520cocaine%252C%2520GBR%252012909%2520%255B1-%257B2-%255Bbis-%25284-fluorophenyl%2529%2520methoxy%255Dethyl%257D-4-%25283-phenylpropyl%2529piperazine%255D%252C%2520and%2520benztropine%2520analogs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D397%26epage%3D404%26doi%3D10.1124%2Fjpet.105.091231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmeichel, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zemlan, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berridge, C. W.</span></span> <span> </span><span class="NLM_article-title">A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2Fj.neuropharm.2012.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=22796428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFahsbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=321-328&author=B.+E.+Schmeichelauthor=F.+P.+Zemlanauthor=C.+W.+Berridge&title=A+selective+dopamine+reuptake+inhibitor+improves+prefrontal+cortex-dependent+cognitive+function%3A+potential+relevance+to+attention+deficit+hyperactivity+disorder&doi=10.1016%2Fj.neuropharm.2012.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: Potential relevance to attention deficit hyperactivity disorder</span></div><div class="casAuthors">Schmeichel, Brooke E.; Zemlan, Frank P.; Berridge, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">321-328</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Drugs used to treat attention deficit hyperactivity disorder (ADHD) improve prefrontal cortex (PFC)-dependent cognitive function.  The majority of ADHD-related treatments act either as dual norepinephrine (NE) and dopamine (DA) reuptake inhibitors (psychostimulants) or selective NE reuptake inhibitors (SNRIs).  Certain benztropine analogs act as highly selective DA reuptake inhibitors while lacking the reinforcing actions, and thus abuse potential, of psychostimulants.  To assess the potential use of these compds. in the treatment of ADHD, we examd. the effects of a well-characterized benztropine analog, AHN 2-005, on performance of rats in a PFC-dependent delayed-alternation task of spatial working memory.  Similar to that seen with all drugs currently approved for ADHD, AHN 2-005 dose-dependently improved performance in this task.  Clin.-relevant doses of psychostimulants and SNRIs elevate NE and DA preferentially in the PFC.  Despite the selectivity of this compd. for the DA transporter, addnl. microdialysis studies demonstrated that a cognition-enhancing dose of AHN 2-005 that lacked locomotor activating effects increased extracellular levels of both DA and NE in the PFC.  AHN 2-005 produced a larger increase in extracellular DA in the nucleus accumbens, although the magnitude of this was well below that seen with motor activating doses of psychostimulants.  Collectively, these observations suggest that benztropine analogs may be efficacious in the treatment of ADHD or other disorders assocd. with PFC dysfunction.  These studies provide a strong rationale for future research focused on the neural mechanisms contributing to the cognition-enhancing actions and the potential clin. utility of AHN 2-005 and related compds.This article is part of a Special Issue entitled 'Cognitive Enhancers'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcRRQhVm59OLVg90H21EOLACvtfcHk0lhoy6HFFmvTRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFahsbzJ&md5=02d22b902af8d4218bb0d228c2d5cc81</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DSchmeichel%26aufirst%3DB.%2BE.%26aulast%3DZemlan%26aufirst%3DF.%2BP.%26aulast%3DBerridge%26aufirst%3DC.%2BW.%26atitle%3DA%2520selective%2520dopamine%2520reuptake%2520inhibitor%2520improves%2520prefrontal%2520cortex-dependent%2520cognitive%2520function%253A%2520potential%2520relevance%2520to%2520attention%2520deficit%2520hyperactivity%2520disorder%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D64%26spage%3D321%26epage%3D328%26doi%3D10.1016%2Fj.neuropharm.2012.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izenwasser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Novel 3-alpha-(diphenylmethoxy) tropane analogs - Potent dopamine uptake inhibitors without cocaine-like behavioral profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2258</span>– <span class="NLM_lpage">2261</span>, <span class="refDoi"> DOI: 10.1021/jm00041a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00041a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK2cXkslejur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=2258-2261&author=A.+H.+Newmanauthor=A.+C.+Allenauthor=S.+Izenwasserauthor=J.+L.+Katz&title=Novel+3-alpha-%28diphenylmethoxy%29+tropane+analogs+-+Potent+dopamine+uptake+inhibitors+without+cocaine-like+behavioral+profiles&doi=10.1021%2Fjm00041a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 3α-(Diphenylmethoxy)tropane Analogs: Potent Dopamine Uptake Inhibitors without Cocaine-like Behavioral Profiles</span></div><div class="casAuthors">Newman, Amy Hauck; Allen, Andrew C.; Izenwasser, Sari; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2258-61</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The compd. I is the first tropane analog to be described that is structurally similar to cocaine and GBR 12909, binds with high affinity to the dopamine transporter, blocks the reuptake of dopamine, and yet is behaviorally distinct from all other compds. that share this structural and/or neurochem. profile.  Preliminary locomotor activity and drug discrimination data show that all of the compds. in this series appear to demonstrate the same behavioral profile as I.  The possibility that this compd. and others in this series may be potential cocaine antagonists is currently being investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsfTXfjcVNs7Vg90H21EOLACvtfcHk0lhoy6HFFmvTRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkslejur8%253D&md5=f817de033330e444c1aab347536f15db</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm00041a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00041a002%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DAllen%26aufirst%3DA.%2BC.%26aulast%3DIzenwasser%26aufirst%3DS.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DNovel%25203-alpha-%2528diphenylmethoxy%2529%2520tropane%2520analogs%2520-%2520Potent%2520dopamine%2520uptake%2520inhibitors%2520without%2520cocaine-like%2520behavioral%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D2258%26epage%3D2261%26doi%3D10.1021%2Fjm00041a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izenwasser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel 3 alpha-diphenylmethoxytropane analogs: Selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">315</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=9862785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK1MXisVyqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=1999&pages=302-315&author=J.+L.+Katzauthor=S.+Izenwasserauthor=R.+H.+Klineauthor=A.+C.+Allenauthor=A.+H.+Newman&title=Novel+3+alpha-diphenylmethoxytropane+analogs%3A+Selective+dopamine+uptake+inhibitors+with+behavioral+effects+distinct+from+those+of+cocaine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 3α-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine</span></div><div class="casAuthors">Katz, Jonathan L.; Izenwasser, Sari; Kline, Richard H.; Allen, Andrew C.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">302-315</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pharmacol. effects were assessed for a series of 3α-diphenylmethoxy-1αH,5αH-tropane analogs which have structural similarities to cocaine.  Like cocaine, these compds. displaced [3H]WIN 35,428 binding from rat caudate and had affinities ranging from approx. 10-fold greater than cocaine (Ki=11.8 nM) to relatively low affinity (Ki=2000 nM).  The compds. also inhibited dopamine uptake with potencies corresponding to their affinities for WIN 35,428 binding sites.  Like the parent compd., benztropine, the 3α-(diphenylmethoxy)tropane analogs displaced [3H]pirenzepine from muscarinic M1 receptors with affinities ranging from 2 to 120 nM.  Cocaine produced dose-related increases in locomotor activity (horizontal ambulation) in Swiss Webster mice, whereas the 3α-(diphenylmethoxy)tropane analogs generally had lower efficacy than cocaine.  Compds. with fluoro-substituents in the Ph rings generally were among those with efficacy approaching that of cocaine; those with chloro- and bromo-substituents were markedly less efficacious, despite having binding affinities comparable to those of the corresponding fluoro-substituted compds.  The 3α-(diphenylmethoxy)tropane analogs were also examd. in rats trained to discriminate saline from cocaine (10 mg/kg, i.p.).  Cocaine produced a dose-related increase in responding on the cocaine-appropriate lever, reaching 100% at 10 mg/kg.  Only the 4',4''-difluoro-substituted analog produced effects similar to those of cocaine; the other compds. showed markedly reduced efficacy compared to cocaine.  Drug interaction studies showed that the antimuscarinics, atropine and scopolamine, potentiated rather than attenuated the locomotor stimulant and cocaine-like discriminative-stimulus effects of cocaine, indicating that the antimuscarinic effects of the 3α-diphenylmethoxytropane analogs did not contribute to their diminished cocaine-like activity.  Studies of the time course of selected compds. indicated that their reduced cocaine-like efficacy was likely not due to behavioral observations being conducted at an inopportune time period.  Because none of the 3α-diphenylmethoxytropane analogs studied showed evidence that they were binding to more than one site, and because the structure activity relationships among these drugs are distinctly different from those obtained with cocaine, these data suggest that the 3α-diphenylmethoxytropane analogs are accessing a different binding domain than that accessed by cocaine.  Binding to this domain may produce a behavioral profile that is distinct from that of the cocaine-like dopamine uptake inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVv6SJkGAJDrVg90H21EOLACvtfcHk0lhohitZV5oz8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXisVyqug%253D%253D&md5=f2a3046324b849beee51eb2bd8bdac05</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DIzenwasser%26aufirst%3DS.%26aulast%3DKline%26aufirst%3DR.%2BH.%26aulast%3DAllen%26aufirst%3DA.%2BC.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%25203%2520alpha-diphenylmethoxytropane%2520analogs%253A%2520Selective%2520dopamine%2520uptake%2520inhibitors%2520with%2520behavioral%2520effects%2520distinct%2520from%2520those%2520of%2520cocaine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D288%26spage%3D302%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupica, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">2-Isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.212738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.113.212738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=24518035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVCmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2014&pages=297-309&author=T.+Hiranitaauthor=D.+S.+Wilkinsonauthor=W.+M.+C.+Hongauthor=M.+F.+Zouauthor=T.+A.+Kopajticauthor=P.+L.+Sotoauthor=C.+R.+Lupicaauthor=A.+H.+Newmanauthor=J.+L.+Katz&title=2-Isoxazol-3-phenyltropane+derivatives+of+cocaine%3A+molecular+and+atypical+system+effects+at+the+dopamine+transporter&doi=10.1124%2Fjpet.113.212738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">2-isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter</span></div><div class="casAuthors">Hiranita, Takato; Wilkinson, Derek S.; Hong, Weimin C.; Zou, Mu-Fa; Kopajtic, Theresa A.; Soto, Paul L.; Lupica, Carl R.; Newman, Amy H.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">297-309, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The present study examd. RTI-371 [3β-(4-methylphenyl)-2β-[3-(4-chlorophenyl)-isoxazol-5-yl]tropane], a phenyltropane cocaine analog with effects distinct from cocaine, and assessed potential mechanisms for those effects by comparison with its constitutional isomer, RTI-336 [3β-(4-chlorophenyl)-2β-[3-(4-methylphenyl)-isoxazol-5-yl]tropane].  In mice, RTI-371 was less effective than cocaine and RTI-336 in stimulating locomotion, and incompletely substituted (∼60% max. at 5 min or 1 h after injection) in a cocaine (10 mg/kg i.p.)/saline discrimination procedure; RTI-336 completely substituted.  In contrast to RTI-336, RTI-371 was not self-administered, and its pretreatment (1.0-10 mg/kg i.p.) dose-dependently decreased maximal cocaine self-administration more potently than food-maintained responding.  RTI-336 pretreatment dose-dependently left-shifted the cocaine self-administration dose-effect curve.  Both RTI-336 and RTI-371 displaced [3H]WIN35,428 [[3H](-)-3β-(4-fluorophenyl)-tropan-2β-carboxylic acid Me ester tartrate] binding to striatal dopamine transporters (DATs) with Ki values of 10.8 and 7.81 nM, resp., and had lower affinities at serotonin or norepinephrine transporters, or muscarinic and σ receptors.  The relative low affinity at these sites suggests the DAT as the primary target of RTI-371 with minimal contributions from these other targets.  In biochem. assays probing the outward-facing DAT conformation, both RTI-371 and RTI-336 had effects similar to cocaine, suggesting little contribution of DAT conformation to the unique pharmacol. of RTI-371.  The locomotor-stimulant effects of RTI-371 (3.0-30 mg/kg i.p.) were comparable in wild-type and knockout cannabinoid CB1 receptor (CB1R) mice, indicating that previously reported CB1 allosteric effects do not decrease cocaine-like effects of RTI-371.  DAT occupancy in vivo was most rapid with cocaine and least with RTI-371.  The slow apparent assocn. rate may allow compensatory actions that in turn dampen cocaine-like stimulation, and give RTI-371 its unique pharmacol. profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDwwGziyXAgbVg90H21EOLACvtfcHk0lhohitZV5oz8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVCmt7Y%253D&md5=0c4e7470799ae071011ab59b882e7165</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.212738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.212738%26sid%3Dliteratum%253Aachs%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DWilkinson%26aufirst%3DD.%2BS.%26aulast%3DHong%26aufirst%3DW.%2BM.%2BC.%26aulast%3DZou%26aufirst%3DM.%2BF.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DSoto%26aufirst%3DP.%2BL.%26aulast%3DLupica%26aufirst%3DC.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3D2-Isoxazol-3-phenyltropane%2520derivatives%2520of%2520cocaine%253A%2520molecular%2520and%2520atypical%2520system%2520effects%2520at%2520the%2520dopamine%2520transporter%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D349%26spage%3D297%26epage%3D309%26doi%3D10.1124%2Fjpet.113.212738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomenzo, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madura, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surratt, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudell, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">2-Substituted 3 beta-aryltropane cocaine analogs produce atypical effects without inducing inward-facing dopamine transporter conformations</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">624</span>– <span class="NLM_lpage">634</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.230722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.115.230722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=26769919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A280%3ADC%252BC28ngt1CitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2016&pages=624-634&author=W.+M.+C.+Hongauthor=T.+A.+Kopajticauthor=L.+F.+Xuauthor=S.+A.+Lomenzoauthor=B.+Jeanauthor=J.+D.+Maduraauthor=C.+K.+Surrattauthor=M.+L.+Trudellauthor=J.+L.+Katz&title=2-Substituted+3+beta-aryltropane+cocaine+analogs+produce+atypical+effects+without+inducing+inward-facing+dopamine+transporter+conformations&doi=10.1124%2Fjpet.115.230722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">2-Substituted 3β-Aryltropane Cocaine Analogs Produce Atypical Effects without Inducing Inward-Facing Dopamine Transporter Conformations</span></div><div class="casAuthors">Hong Weimin C; Kopajtic Theresa A; Xu Lifen; Lomenzo Stacey A; Jean Bernandie; Madura Jeffry D; Surratt Christopher K; Trudell Mark L; Katz Jonathan L</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">624-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Previous structure-activity relationship studies indicate that a series of cocaine analogs, 3β-aryltropanes with 2β-diarylmethoxy substituents, selectively bind to the dopamine transporter (DAT) with nanomolar affinities that are 10-fold greater than the affinities of their corresponding 2α-enantiomers.  The present study compared these compounds to cocaine with respect to locomotor effects in mice, and assessed their ability to substitute for cocaine (10 mg/kg, i.p.) in rats trained to discriminate cocaine from saline.  Despite nanomolar DAT affinity, only the 2β-Ph2COCH2-3β-4-Cl-Ph analog fully substituted for cocaine-like discriminative effects.  Whereas all of the 2β compounds increased locomotion, only the 2β-(4-ClPh)PhCOCH2-3β-4-Cl-Ph analog had cocaine-like efficacy.  None of the 2α-substituted compounds produced either of these cocaine-like effects.  To explore the molecular mechanisms of these drugs, their effects on DAT conformation were probed using a cysteine-accessibility assay.  Previous reports indicate that cocaine binds with substantially higher affinity to the DAT in its outward (extracellular)- compared with inward-facing conformation, whereas atypical DAT inhibitors, such as benztropine, have greater similarity in affinity to these conformations, and this is postulated to explain their divergent behavioral effects.  All of the 2β- and 2α-substituted compounds tested altered cysteine accessibility of DAT in a manner similar to cocaine.  Furthermore, molecular dynamics of in silico inhibitor-DAT complexes suggested that the 2-substituted compounds reach equilibrium in the binding pocket in a cocaine-like fashion.  These behavioral, biochemical, and computational results show that aryltropane analogs can bind to the DAT and stabilize outward-facing DAT conformations like cocaine, yet produce effects that differ from those of cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHUIt0a7sLpmx8TEN9K18QfW6udTcc2eaQWMpTWEj5b7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28ngt1CitA%253D%253D&md5=a21420fab70030162709440ede486173</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.230722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.230722%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DW.%2BM.%2BC.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DL.%2BF.%26aulast%3DLomenzo%26aufirst%3DS.%2BA.%26aulast%3DJean%26aufirst%3DB.%26aulast%3DMadura%26aufirst%3DJ.%2BD.%26aulast%3DSurratt%26aufirst%3DC.%2BK.%26aulast%3DTrudell%26aufirst%3DM.%2BL.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3D2-Substituted%25203%2520beta-aryltropane%2520cocaine%2520analogs%2520produce%2520atypical%2520effects%2520without%2520inducing%2520inward-facing%2520dopamine%2520transporter%2520conformations%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D356%26spage%3D624%26epage%3D634%26doi%3D10.1124%2Fjpet.115.230722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheffel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boja, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhar, M. J.</span></span> <span> </span><span class="NLM_article-title">Cocaine receptors - In vivo labeling with H-3 (−)cocaine, H-3 Win-35,065–2, and H-3 Win-35,428</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1002/syn.890040415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1002%2Fsyn.890040415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=2603151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaK3cXptFKhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1989&pages=390-392&author=U.+Scheffelauthor=J.+W.+Bojaauthor=M.+J.+Kuhar&title=Cocaine+receptors+-+In+vivo+labeling+with+H-3+%28%E2%88%92%29cocaine%2C+H-3+Win-35%2C065%E2%80%932%2C+and+H-3+Win-35%2C428&doi=10.1002%2Fsyn.890040415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Cocaine receptors: in vivo labeling with 3H-(-)cocaine, 3H-WIN 35065-2, and 3H-WIN 35428</span></div><div class="casAuthors">Scheffel, Ursula; Boja, John W.; Kuhar, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (New York, NY, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">390-2</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    </div><div class="casAbstract">The binding of tritiated (-)-cocaine and its 2 title analogs to the brain striatum and cerebellum was studied in mice.  The analogs WIN-35065-2 and WIN-35428 showed a stronger binding than cocaine to cocaine-binding sites in the striatum presumably assocd. with dopamine transports.  Both analogs are less prone to metab. than cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2UAERaB5xILVg90H21EOLACvtfcHk0lhJC0GNaRNsOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXptFKhtA%253D%253D&md5=eed1a9ec1ddf6a054b5fc81045289b37</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fsyn.890040415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.890040415%26sid%3Dliteratum%253Aachs%26aulast%3DScheffel%26aufirst%3DU.%26aulast%3DBoja%26aufirst%3DJ.%2BW.%26aulast%3DKuhar%26aufirst%3DM.%2BJ.%26atitle%3DCocaine%2520receptors%2520-%2520In%2520vivo%2520labeling%2520with%2520H-3%2520%2528%25E2%2588%2592%2529cocaine%252C%2520H-3%2520Win-35%252C065%25E2%2580%25932%252C%2520and%2520H-3%2520Win-35%252C428%26jtitle%3DSynapse%26date%3D1989%26volume%3D4%26spage%3D390%26epage%3D392%26doi%3D10.1002%2Fsyn.890040415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Stimulants as specific inducers of dopamine-independent Sigma agonist self-administration in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.207522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1124%2Fjpet.113.207522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=23908387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2ks7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=20-29&author=T.+Hiranitaauthor=P.+L.+Sotoauthor=G.+Tandaauthor=T.+A.+Kopajticauthor=J.+L.+Katz&title=Stimulants+as+specific+inducers+of+dopamine-independent+Sigma+agonist+self-administration+in+rats&doi=10.1124%2Fjpet.113.207522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulants as specific inducers of dopamine-independent σ agonist self-administration in rats</span></div><div class="casAuthors">Hiranita, Takato; Soto, Paul L.; Tanda, Gianluigi; Kopajtic, Theresa A.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-29</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A previous study showed that cocaine self-administration induced dopamine-independent reinforcing effects of σ agonists mediated by their selective actions at σ1 receptors (σ1Rs), which are intracellularly mobile chaperone proteins implicated in abuse-related effects of stimulants.  The present study assessed whether the induction was specific to self-administration of cocaine.  Rats were trained to self-administer the dopamine releaser, d-methamphetamine (0.01-0.32 mg/kg per injection), the μ-opioid receptor agonist, heroin (0.001-0.032 mg/kg per injection), and the noncompetitive N-methyl-D-aspartate receptor/channel antagonist ketamine (0.032-1.0 mg/kg per injection).  As with cocaine, self-administration of d-methamphetamine induced reinforcing effects of the selective σ1R agonists PRE-084 [2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate hydrochloride] and (+)-pentazocine (0.032-1.0 mg/kg per injection, each).  In contrast, neither self-administration of heroin nor ketamine induced PRE-084 or (+)-pentazocine (0.032-10 mg/kg per injection, each) self-administration.  Although the σ1R agonists did not maintain responding in subjects with histories of heroin or ketamine self-administration, substitution for those drugs was obtained with appropriate agonists (e.g., remifentanil, 0.1-3.2 μg/kg per injection, for heroin and (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine ((+)-MK 801; dizocilpine), 0.32-10.0 μg/kg per injection, for ketamine).  The σR antagonist N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine dihydrobromide (BD 1008; 1.0-10 mg/kg) dose-dependently blocked PRE-084 self-administration but was inactive against d-methamphetamine, heroin, and ketamine.  In contrast, PRE-084 self-administration was affected neither by the dopamine receptor antagonist (+)-butaclamol (10-100 μg/kg) nor by the opioid antagonist (-)-naltrexone (1.0-10 mg/kg), whereas these antagonists were active against d-methamphetamine and heroin self-administration, resp.  The results indicate that experience specifically with indirect-acting dopamine agonists induces reinforcing effects of previously inactive σ1R agonists.  It is further suggested that induced σ1R reinforcing mechanisms may play an essential role in treatment-resistant stimulant abuse, suggesting new approaches for the development of effective medications for its treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKYX262DkAL7Vg90H21EOLACvtfcHk0lhJC0GNaRNsOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2ks7zI&md5=3a6c50fc2758e9892cbe0c683b56b7d4</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207522%26sid%3Dliteratum%253Aachs%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DSoto%26aufirst%3DP.%2BL.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DStimulants%2520as%2520specific%2520inducers%2520of%2520dopamine-independent%2520Sigma%2520agonist%2520self-administration%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D20%26epage%3D29%26doi%3D10.1124%2Fjpet.113.207522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between inhibition constant (K1) and concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic-reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+inhibition+constant+%28K1%29+and+concentration+of+inhibitor+which+causes+50%25+inhibition+%28I50%29+of+an+enzymatic-reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lhJC0GNaRNsOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2525%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic-reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreassen, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span> <span> </span><span class="NLM_article-title">A conserved salt bridge between transmembrane segments 1 and 10 constitutes an extracellular gate in the dopamine transporter</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">35003</span>– <span class="NLM_lpage">35014</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.586982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=10.1074%2Fjbc.M114.586982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=25339174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVSgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=35003-35014&author=A.+V.+Pedersenauthor=T.+F.+Andreassenauthor=C.+J.+Loland&title=A+conserved+salt+bridge+between+transmembrane+segments+1+and+10+constitutes+an+extracellular+gate+in+the+dopamine+transporter&doi=10.1074%2Fjbc.M114.586982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">A conserved salt bridge between transmembrane segments 1 and 10 constitutes an extracellular gate in the dopamine transporter</span></div><div class="casAuthors">Pedersen, Anders V.; Andreassen, Thorvald F.; Loland, Claus J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">35003-35014, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Neurotransmitter transporters play an important role in termination of synaptic transmission by mediating reuptake of neurotransmitter, but the mol. processes behind translocation are still unclear.  The crystal structures of the bacterial homolog, LeuT, provided valuable insight into the structural and dynamic requirements for substrate transport.  These structures support the existence of gating domains controlling access to a central binding site.  On the extracellular side, access is controlled by the "thin gate" formed by an interaction between Arg-30 and Asp-404.  In the human dopamine transporter (DAT), the corresponding residues are Arg-85 and Asp-476.  Here, we present results supporting the existence of a similar interaction in DAT.  The DAT R85D mutant has a complete loss of function, but the addnl. insertion of an arginine in opposite position (R85D/D476R), causing a charge reversal, results in a rescue of binding sites for the cocaine analog [3H]CFT.  Also, the coordination of Zn2+ between introduced histidines (R85H/D476H) caused a ∼2.5-fold increase in [3H]CFT binding (Bmax).  Importantly, Zn2+ also inhibited [3H]dopamine transport in R85H/D476H, suggesting that a dynamic interaction is required for the transport process.  Furthermore, cysteine-reactive chem. shows that mutation of the gating residues causes a higher proportion of transporters to reside in the outward facing conformation.  Finally, we show that charge reversal of the corresponding residues (R104E/E493R) in the serotonin transporter (SERT) also rescues [3H](S)-citalopram binding, suggesting a conserved feature.  Taken together, these data suggest that the extracellular thin gate is present in monoamine transporters and that a dynamic interaction is required for substrate transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob2g8cE5ScPrVg90H21EOLACvtfcHk0ljCwH57IUYVCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVSgug%253D%253D&md5=8036920794dfc9fbf25a1f09f356cfaa</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.586982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.586982%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DA.%2BV.%26aulast%3DAndreassen%26aufirst%3DT.%2BF.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26atitle%3DA%2520conserved%2520salt%2520bridge%2520between%2520transmembrane%2520segments%25201%2520and%252010%2520constitutes%2520an%2520extracellular%2520gate%2520in%2520the%2520dopamine%2520transporter%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D35003%26epage%3D35014%26doi%3D10.1074%2Fjbc.M114.586982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i60"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01188">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_52731"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b01188">10.1021/acs.jmedchem.9b01188</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Microanalysis data on all final compounds, phase I metabolic stability data in mouse liver microsomes, metabolite ID, metabolic stability data in human liver microsomes, and off target binding data on selected compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_001.pdf">jm9b01188_si_001.pdf (320.13 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01188/suppl_file/jm9b01188_si_002.csv">jm9b01188_si_002.csv (3.37 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01188&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01188%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-5" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01188" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799a1ad8ff2248d","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
